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ABSTRACT OF DISSERTATION

DESIGN, SYNTHESIS AND PHYSICOCHEMICAL ANALYSIS OF
RUTHENIUM(II) POLYPYRIDYL COMPLEXES FOR APPLICATION IN
PHOTOTHERAPY AND NUCLEIC ACID SENSING

Current chemotherapeutics exhibit debilitating side effects as a result of their
toxicity to healthy tissues. Reducing these side effects by developing chemotherapeutics
with selectivity for cancer cells is an active area of research. Phototherapy is one
promising modality for selective treatment, where drug molecules are “turned on” when
irradiated with light, reducing damage to healthy tissues by spatially restricting the areas
exposed to irradiation. A second approach to improve selectivity is to exploit the
differences in cancerous versus healthy cells, such as increased metabolism and/or
upregulation of cell surface receptors. Ruthenium(II) polypyridyl complexes are
candidates for phototherapy due to their highly tunable photophysical and photochemical
properties. The addition of strain to the metal center is a general approach used to render
complexes susceptible to light-induced ligand loss. Upon ejection of a ligand, the Ru(II)
center is capable of covalently binding biomolecules within cells to produce a cytotoxic
effect. The ligands surrounding the metal center are amenable to chemical modification
through the incorporation of pendent functional groups as chemical “handles”, allowing
for different directing molecules to be attached.
Nucleic acids are important targets for drug discovery, and the development of
selective probes to either visualize or selectively damage nucleic acids within the cell is

an ongoing area of research. Specifically, G-rich regions are abundant in the human
genome, and the presence of G-quadruplexes in telomeres and promoter regions of
oncogenes make them potential therapeutic targets. Ru(II) complexes are known to bind
nucleic acids, and some have been shown to induce and/or stabilize G-quadruplex
Structures. Multiple series of Ru(II) compounds have been synthesized and tested to
improve the functional range for Ru(II) complexes for in vivo applications, where they
act as “light switches” for DNA. These molecules are “off” when in an aqueous
environment but turned “on” in the presence of DNA. Several hit compounds were
identified that showed selectivity for specific G-quadruplex structures.

KEYWORDS: Ruthenium(II) polypyridyl complexes, cancer, phototherapy, nucleic acid
sensing, G-quadruplexes
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Chapter 1. Introduction.

1.1 What is cancer and how is it treated?
Cancer is currently the second leading cause of death in the United States,
following heart disease. More than 1.7 million people are estimated to be diagnosed with
cancer in 2016.1 Additionally, in 2016 alone, 600,000 Americans will die from cancer,
which is more than 1,600 deaths per day.1 The most common cancers that occur in men
are prostate (26%), lung and bronchus (14%), and colon and rectum (8%). In women, the
most commonly diagnosed are breast (29%), lung and bronchus (13%), and colon and
rectum (8%). While prostate and breast cancers have higher incidence rates they have
high survival rates, where prostate cancer has a >94% chance of survival2 and breast
cancer, if detected in the early stages, has a >75% chance of survival.3 Unfortunately, the
5-year survival rate for lung and bronchus cancers is <20% and is estimated to lead
cancer deaths in men (28%) and woman (26%) in 2015.4 Data collected between 2007
and 2011 reveals that the state of Kentucky has one of the highest cancer-caused death
rates in the United States, with 257.5 deaths per 100,000 males and 172.2 deaths per
100,000 female. Likewise, Kentucky has the highest cancer incidence rate, with 604
incidences per 100,000 males and 464.2 incidences per 100,000 females. Breast (26%)
and prostate (21%) have higher incidence rates in Kentucky than lung (20% male and
17% females) but lung cancer has a much greater death rate (37% male and 32% female)
than breast (13%) and prostate (9%).5 These statistics alone make clear the need for
improved treatments.
Cancer is defined as a group of diseases that are characterized by the
uncontrollable growth of abnormal cells. Cancer cells are unable to follow the normal
regulatory signals to stop dividing or undergo apoptosis, programmed cell death. This
lack of regulation of rapidly dividing cells leads to the formation of tumors. Cancerous
tumors are malignant and will invade other tissues if left untreated. This process is called
metastasis, where cancer cells will spread to other parts of the body through the lymph
nodes and blood stream. Current methods of treatment for cancer include surgery, if the
tumor is operable, radiation, and chemotherapy. These therapies are commonly used in
combination to provide the most successful treatment. Typically, when the tumor is easily
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accessible, surgery will be used followed by chemotherapy and/or radiation therapy. A
few factors determine the combination that is used: accessibility/location of the cancer,
risk factors, and possibility for successful outcomes.6
Chemotherapy is used in most treatment regimens, and is defined as the treatment
of cancer with an antineoplastic drug or a combination of two or more drugs. When used
in combination with other forms of treatment, chemotherapeutics are either used as
neoadjuvant therapeutics, to shrink a tumor prior to surgery or radiation therapy, or as
adjuvant therapeutics, to kill any remaining cancerous cells following surgery or radiation
therapy. The unfortunate downside to traditional chemotherapeutics is the side effects
they cause for the patients undergoing treatment. Since chemotherapeutics are designed
to kill cells, they will not only kill the rapidly growing cancerous cells but also the
normal cells that divide quickly, which leads to unwanted side effects. Common side
effects that patients experience are fatigue, hair loss, and nausea; however, other more
serious side effects, such as neuropathy and hearing loss, may occur based on the
chemotherapeutics taken.

1.2 Metal-based anticancer agents.
Metal-based anticancer drug research is a growing field because nearly 50% of
patients being treated for cancer are given a platinum based drug, cisplatin (Figure 1.1).
Cisplatin, cis-diaminedichloroplatium(II), was clinically approved to treat a variety of
different types of solid tumors, such as ovarian (1978), bladder (1993), and testicular
(1978).7 It has been especially successful in treating testicular germ cell cancer, where
90% of the cases treated with cisplatin were curable.8
Following administration of cisplatin to patients by intravenous (IV) injection, the
chloride ligands stay coordinated to the platinum center due to the high chloride

Cisplatin

Carboplatin

Oxaliplatin

Figure 1.1: Structures of FDA approved platinum based chemotherapeutics.
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Figure 1.2: DNA base pairing to show hydrogen-bonding and atom numbering.
concentration (100 mM) in the bloodstream.7, 9 Since the chloride concentration inside a
cell is much lower (4–20 mM), when cisplatin is taken into the cell, the chloride ligands
are replaced with water ligands by a process called aquation, creating the active species.7,
9a

Inside the cell, platinum binding to DNA primarily occurs at the N7 position of

guanosine and to a lesser extent the N7 position of adenosine (Figure 1.2). The majority
of the DNA adducts formed by cisplatin are 1,2-intrastrand adducts with two adjacent
guanosines (60–65%) and 1,2-intrastrand adducts with an adjacent adenosine and
guanosine (20–25%).7 Other adducts that form approximately 2% of the time are 1,3intrastrand adducts with two guanosines separated by an additional base, 1,2-interstrand
adducts where the guanosines are on opposite strands, and monofunctional adducts.7
When cisplatin forms crosslinks with the DNA, it induces a 30–60° bend toward the
major groove.10 Additionally, the cisplatin adduct unwinds the helix up to 23°.10 The
distortion of DNA induces activation of DNA damage repair mechanisms. When DNA
repair mechanisms are unable to properly repair the DNA, it leads to apoptosis of the
cell.11 Apoptosis is triggered by the expression of proteins such as ATR, p53, and MAPK
through complex signaling pathways.12

3

The widespread treatment with cisplatin revealed two major clinical problems
associated with its use. Cisplatin has dose-limiting side effects, such as nephrotoxicity,
neurotoxicity, ototoxicity, and myelosuppression.13 Due to these severe side effects,
cisplatin has to be administered at concentrations that may not be lethal to tumor cells,
leading to development of drug resistance. There are a few different ways in which drug
resistance to cisplatin is developed; the upregulation of drug efflux pumps or decreased
uptake, deactivation of cisplatin by glutathione (a naturally occurring tripeptide found in
abundance, 16 mM, in the cytosol), and improved repair mechanisms for cisplatin-DNA
adducts.9a, 14 Since the discovery and clinical use of cisplatin, 23 different platinum based
compounds have entered clinical trials, with only two additional compounds becoming
FDA approved for clinical use, carboplatin and oxaliplatin (Figure 1.1).9a Carboplatin,
approved in 1989 is used to treat ovarian cancers. Oxaliplatin was approved to treat
colorectal cancer in 2002.7,

9a

These derivatives kill cancer cells using similar DNA

damage mechanisms as cisplatin but have features that reduce the dose-limiting side
effects. Carboplatin replaces the chloride ligands with a 1,1-cyclobutanedicarboxylate
bidentate ligand which slows the rate of aquation from 10-5 s-1 to 10-8 s-1, ultimately
lowering the reactivity and allowing for carboplatin to be administered at much higher
doses than cisplatin.15
In a continued effort to find a metal-based chemotherapeutic with reduced toxicity
and side effects, other metal centers are being explored. Current areas of research involve
the use of ruthenium, osmium, rhenium, rhodium, and iridium, among others.16
Ruthenium compounds are well suited for medical applications due to three main
properties: they can form multiple geometries with facile ligand exchange, they may have
multiple oxidation states at physiological pH, and they are capable of mimicking iron
binding for transportation.17 Ruthenium complexes can adopt either a tetrahedral or
octahedral geometry, creating opportunities to design compounds with structural
complementarity to a specific cellular target. Ligand exchange can occur similar to the
behavior of platinum based drugs, and can result in a similar mechanism of action. The
capability of ruthenium complexes to have multiple oxidation states, 2+ and 3+ at
physiological pH, can be exploited to design prodrugs. A prodrug is a derivative of a drug
molecule that undergoes an enzymatic or chemical transformation in vivo to produce the
4
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Figure 1.3: Structures of Ru(III) complexes developed for clinical trials.
active species.18 In the case of Ru(III) compounds, the 3+ complexes can be reduced to
2+, traditionally called “activation by reduction,” creating the active species and
biological effect. The reducing environment tumors possess can be attributed to the lower
oxygen level, higher glutathione concentration, and lower pH compared to healthy
tissues. Lastly, ruthenium complexes typically have enhanced uptake, compared to
platinum compounds, due to their ability to bind to the iron-binding protein transferrin.19
The combination of these key properties of ruthenium-based drugs alone allows for the
design of drug molecules with selective activation and reduced toxicity from currently
utilized platinum-based drugs.
The reducing environment of tumors has been the center of ruthenium-based
drugs developed for clinical trials, NAMI-A, KP1019, and KP1339 (Figure 1.3).20 The
first ruthenium compound to enter clinical trials was NAMI-A following impressive preclinical results against tumor metastases with metastasis reduction up to 100% in four
independent models.21 Upon uptake of NAMI-A into cancer cells, it is activated by
reduction from the prodrug, 3+ oxidation state, to active drug, 2+ oxidation state. When
NAMI-A was studied in a phase 1 clinical trial as a single agent, only 4% of the patients
with non-small cell lung cancer (NSCLC) experienced stable disease for 21 weeks.22
More recently, a phase I clinical trial with NSCLC patients ended featuring combination
therapy of NAMI-A and gemcitabine, a nucleoside analog typically used in combination
with cisplatin. Unfortunately, NAMI-A in combination with gemcitabine is only
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moderately tolerable by patients and the future of NAMI-A as a drug is uncertain.22a
KP1019, the second ruthenium based compound to enter clinical trials, showed reduction
of tumor volume to 8% and minimal toxicity in a pre-clinical cisplatin resistant murine
model closely resembling human colon cancer.23 KP1019 acts as a tumor-inhibiting drug
with a different mechanism of action from conventional platinum-based drugs, postulated
to be the reduction of Ru(III) to Ru(II) followed by reaction with DNA, and ultimately
activation of apoptosis through a mitochondrial pathway.23 In phase I clinical trials,
KP1019 showed minimal side effects and stable disease in 5 of 8 patients for up to 10
weeks.23 One downside to KP1019 is the poor solubility and in turn, KP1339 was
developed to improve solubility. KP1339 recently finished a phase I clinical trial with
promising results. Patients showed toxicity profiles that were manageable and two
patients with Stage IV neuroendocrine tumors having stable disease for 9 dosing cycles.24

1.3 Light-activated therapies.
While progress is being made toward the creation of new anticancer transition
metal complexes, they either lack selectivity or lack cytotoxicity. Of the compounds
previously described, none of them are able to discriminate between healthy and
cancerous tissues. The Ru(III) complexes are an improvement to conventional platinum
drugs with their selective activation in a reducing environment; however, they do not
prevent systemic toxicity that results in patient side effects. Improving the prodrug
strategy is an active area of drug discovery.18 Two types of stimuli can be used to activate
a prodrug: internal stimuli, including enzyme activation and the reducing cellular
environment, and external stimuli, such as heat or light. Using external stimuli to activate
a compound gives spatial control over where the compound is activated and will likely
result in reduced systemic toxicity. One active area of anticancer research is using light
irradiation to activate a prodrug molecule, either as photodynamic therapy (PDT) or
photoactivated chemotherapy (PACT). Both PDT and PACT requires two components: a
photosensitizer and the administration of light. For the most successful activation in vivo,
light activation should occur within the therapeutic window (620–850 nm).25 Light
penetration is dependent on tissue type; however generally irradiation with 600–700 nm
light 50–200% penetrates tissue deeper than irradiation with 400–500 nm light.25 The
6

Photofrin

Foscan

Figure 1.4: Porphyrin photosensitizers used in PDT.
main difference between PDT and PACT is their mechanism of cytotoxicity. PDT
requires the formation of singlet oxygen (1O2), a cytotoxic reactive oxygen species
(ROS). On the other hand, PACT creates a cytotoxic effect though a chemical
modification to the drug molecule, typically through ligand dissociation, protecting group
cleavage, or light induced DNA crosslinking.26
When a photosensitizer is designed, it must meet certain criteria. First, the
photosensitizer should be chemically inert in the absence of light and have high
phototoxicity. The difference in reactivity in the absence and presence of light is
described as the phototoxicity index (PI). Second, a photosensitizer should be selective
for cancerous tissues over healthy tissues. Enhanced uptake in cancer cells will provide
the greatest degree of spatial control. Lastly, activation of the photosensitizer should be
within the appropriate therapeutic window to maximize the depth of tissue penetration,
depending on the tumor site and size. Porphyrins are the most extensively studied
photosensitizers thus far. They contain four pyrrole rings that are connected by methene
bridges to form a cyclic structure. In 1976, the first clinical trial began with Photofrin, a
hematoporphyrin derivative, and gained FDA approval in 1995 for the treatment of
7

certain endobronchial NSCLC, where surgery and radiotherapy were not options (Figure
1.4). Another porphyrin example, Foscan, is EU (European Union) approved, not FDA
approved, for the treatment of head and neck squamous cell carcinomas (Figure 1.4). One
of the main benefits of porphyrins as PDT agents is the activation wavelength is within
the therapeutic window, 630 nm (Photofrin) and 652 nm (Foscan).
One major downside to conventional PDT agents is the requirement for oxygen.
In order for PDT agents to produce a cytotoxic effect they must produce ROS. The
formation of ROS can occur through two different types of reactions (Figure 1.5).
Initially, the absorption of light by a photosensitizer excites an electron from the singlet
ground state (1GS) to a singlet excited state (1ES). The electron in the 1ES is short lived
and will quickly transfer to a longer-lived triplet excited state (3ES). From the 3ES, the
excited state has two fates, either type I or type II reactions. A type I reaction is
characterized by the direct reaction of the triplet excited state electron with a substrate
and transfers an electron to form a radical, which then interacts with oxygen to produce
ROS, typically in the form of superoxide, hydroxyl radicals or peroxides.27 On the other
hand, type II reactions are characterized by the direct transfer of energy from the triplet
excited state to oxygen to form 1O2.27 Importantly, ROS are very short lived, with t1/2
<0.04 µs, and will only react with entities in a small radius, <0.02 µm, preventing ROS
from diffusing across more than one membrane, which ultimately causes less damage to
healthy tissues around the tumor.28 Unfortunately, PDT agents require the sensitization of
oxygen, so they do not work in low oxygen environments, such as hypoxic regions of
tumors.
Reaction with a
substrate or O2

ROS or radical
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1
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Figure 1.5: Mechanism of action for conventional photosensitizers.
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1.4 Photophysics/photochemistry of Ru(II) polypyridyl complexes for PDT and
PACT.
Many transition metal complexes have been reported that may be activated by UV
and/or visible light.29 Specifically, Ru(II) polypyridyl complexes have been studied quite
extensively for their photochemical, photophysical, electrochemical, chemiluminescence,
electrochemiluminescence, and electron and energy transfer properties.30 Ru(II)
polypyridyl complexes provide a versatile platform for the design of externally activated
prodrugs for use in PDT and PACT due to their tunable photophysical properties, strong
visible absorption, and kinetically inertness.30 Unstrained Ru(II) polypyridyl complexes
such as [Ru(bpy)3]2+ (bpy = 2,2’-bipyridine) contain ligands with σ donor orbitals
localized on the nitrogen atoms and π donor and π* acceptor orbitals delocalized on the
aromatic rings.30 The well-studied Ru(II) polypyridyl complex, [Ru(bpy)3]2+, absorbs
visible light with a λmax centered around 450 nm (Figure 1.6b).

In Figure 1.7a, a

A

2+

2+

[Ru(bpy)3]

[Ru(bpy)2dmbpy]

B

C

Figure 1.6: Absorption and emission properties of unstrained versus strained Ru(II)
complexes. (A) Structures of [Ru(bpy)3]2+ and [Ru(bpy)2dmbpy]2+. Overlay of the
absorption profiles (B) and emission profiles (C) of [Ru(bpy)3]2+ (black) and
[Ru(bpy)2dmbpy]2+ (red).
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Figure 1.7: Simplified Jablonski diagrams to show the electronic transitions of (A)
unstrained Ru(II) complexes and (B) strained Ru(II) complexes.
simplified Jablonski diagram for [Ru(bpy)3]2+ and other unstrained Ru(II) complexes is
shown. Following the absorption of a photon, an electron is excited from the 1GS to the
1

MLCT (metal-to-ligand charge transfer) state. Through intersystem crossing (ISC), the

electron is transferred to a lower energy 3MLCT excited state. Radiative relaxation from
the 3MLCT state to the 1GS results in an intense emission band centered around 600 nm
(Figure 1.6c). For unstrained complexes, the energy difference between the 3MLCT and
3

MC (metal centered) states is too large for an electron to populate the 3MC state at

physiological temperatures. When unstrained Ru(II) polypyridyl complexes are irradiated
with visible light and begin to populate the 3MLCT excited state, they can undergo a type
II reaction, if oxygen is present, to produce the cytotoxic 1O2. Like conventional PDT
agents, unstrained Ru(II) polypyridyl complexes are photostable and require oxygen to
produce a light activated cytotoxic effect.
In efforts to eliminate the oxygen requirement, PACT is becoming more widely
studied. Photoinduced DNA damage is one characteristic of PACT and is being studied
by many groups. In fact, there have been multiple transition metal complexes that are
10

Figure 1.8: Ligand dissociation of [Ru(bpy)2dmbpy]2+ occurs via a dissociative
mechanism.
capable of causing DNA damage following irradiation.31 To design and synthesize
oxygen independent Ru(II) PACT agents, distortion is introduced to the octahedral
geometry to form strained complexes, such as [Ru(bpy)2dmbpy]2+ (dmbpy = 6,6’dimethyl-2,2’-bipyridine).32 The addition of distortion creates a photochemically labile
Ru(II) complex that can chemically react with biomolecules to produce a cytotoxic effect
in the absence of oxygen. The absorption profile of [Ru(bpy)2dmbpy]2+ is almost
identical to [Ru(bpy)3]2+; however, the emission is diminished as a result of the
intramolecular strain induced by the two methyl groups of the dmbpy ligand (Figure 1.6).
Distortion lowers the 3MC state, which can now be thermally accessed from the 3MLCT
state (Figure 1.7b).33 Thermal population of the 3MC state allows for radiationless
deactivation to the 1GS through ligand dissociation. Most octahedral metal complexes
will undergo a ligand loss via a dissociative mechanism from the 3MC state.30 In the case
of Ru(II) polypyridyl complexes, a dissociative mechanism is characterized by the
sequential or simultaneous breaking of the Ru–N bonds to the bidentate ligand, followed
by, or in conjunction with, the coordination of the incoming ligand (Figure 1.8). In each
case, the incoming ligands will either be solvent molecules or coordinating counter-ions,
such as Cl-. Dissociative substitution rates are typically independent of the concentration
or identity of the incoming ligand, where the breaking of an existing Ru–N bond is the
rate limiting step. If an incoming ligand binds following the first Ru–N bond cleavage,
re-chelation of the bidentate ligand may occur; however, re-chelation of strained
complexes is unlikely. The loss of a bidentate ligand creates a Ru(II) complex that is now
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capable of covalently binding to biomolecules in vivo, such as nucleic acids, to induce a
cytotoxic effect.

1.5 Targeted approaches for cancer treatment and detection.
Light activated chemotherapeutics can be controlled spatially, but they do not
necessarily have selective uptake into cancer cells over healthy cells. The non-selective
nature of these compounds may result in unwanted toxicities toward healthy cells even in
the absence of light. One way to overcome this potential issue is to design compounds
that specifically target cancer cells. Luckily, cancer cells have numerous characteristics
that set them apart from healthy cells. One major difference between cancer cells and
healthy cells is the enhanced metabolism and altered oxidative phosphorylation of cancer
cells. In contrast to healthy cells, where mitochondria synthesize the majority of ATP
used by the cell through oxidative phosphorylation, cancer cells suppress mitochondrial
metabolism and rely on fermentation metabolism for ATP generation.34 The suppression
of oxidative metabolism by cancer cells occurs regardless of the presence of oxygen and
has been termed “anaerobic glycolysis” or the “Warburg effect”.35 Many hypotheses have
been developed to explain why cancer cells adopted this mechanism of metabolism, such
as adaptation to proliferate even under a hypoxic environment,36 allowing cancer cells to
circumvent apoptosis by repressing oxidative metabolism,37 and allowing for tumor cells
to adopt the invasive characteristic.38 The upregulation of glycolysis is accompanied by
the overexpression of glucose transporters.39 Specifically, Glut1 and Glut3 have been
shown to be overexpressed in different cancer cell lines.40 One goal is to design
molecules that take advantage of the increased rate of glycolysis and upregulation of
glucose transporters in efforts to increase uptake into cancer cells.
Another targeting approach is to design compounds that have a higher affinity to
different DNA sequences and structures. Guanosine-rich (G-rich) regions capable of
forming G-quadruplex structures are abundant in the human genome, and their presence
in telomeres and promoter regions makes them appealing therapeutic targets.41 Many
proto-oncogenes have G-quadruplex forming regions within their promoter sequence,
such as c-myc,42 c-kit,43 and bcl-2,44 and agents that bind the G-quadruplex could affect
regulation of gene transcription. G-rich regions are also present at the ends of telomeres
12

that have the ability to form G-quadruplexes, and stabilization of these G-quadruplexes
inhibits the ability of the enzyme telomerase to lengthen the telomeres.45 As a result, the
identification of small molecules that demonstrate selectivity for biologically relevant Gquadruplexes is an active area in drug discovery.41c
G-quadruplex binding ligands are generally comprised of polyaromatic systems in
order to take advantage of the large π surface of the G-tetrad, enhancing π-π
interactions.46 These molecules usually carry a positive charge to increase electrostatic
interactions with the negatively charged DNA.46 One challenge in the design of Gquadruplex binding ligands is their lack of selectivity for quadruplex over duplex DNA.
In recent years, selectivity has been accomplished with several small organic molecules,47
with binding affinities typically at least 10x greater for G-quadruplex DNA when
compared to duplex DNA. An elegant approach to sensing has been achieved using
fluorogenic ligands, where the ligands brightly fluoresce upon binding to G-quadruplex
DNA, allowing for selective visualization of G-quadruplex structures.48 An emerging
area of research aims to combine DNA sequence and structure selectivity with agents that
can be triggered with external stimuli.49
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Chapter 2. Determining the structure-photoactivity relationship of Ru(II)
polypyridyl complexes.

2.1 Introduction.
PDT is an approved cancer treatment that utilizes visible light as the trigger for
the generation of singlet oxygen by organic sensitizers.1 However, PDT efficacy is
limited due to both this oxygen-dependent mechanism and the poor chemical
characteristics of the currently available photosensitizers. The reliance on oxygen
precludes activity in hypoxic tumors, and the standard porphyrin-type organic
photosensitizers used in PDT suffer from photobleaching, poor solubility, and retention
in tissues, causing protracted photosensitivity. In light of these drawbacks, several groups
are investigating photoactive metal complexes as alternative PDT agents.2 Ruthenium
polypyridyl complexes have tunable absorption properties,3 and they have long been
known to induce 1O2-mediated DNA photocleavage when exposed to UV to visible
light.4 Some ruthenium agents have been reported to act via oxygen-independent
mechanisms, allowing for activity in hypoxic tissues.5
In 2012, the activity of three light-activated Ru(II) complexes were reported by
the Glazer research group, in comparison to cis[Pt(NH3)2Cl2] (cisplatin) (Figure 2.1).6
The compounds were synthesized and characterized as racemic mixtures and tested to
determine their light activated DNA damaging capabilities, as well as their cytotoxicity.
The unstrained complex, [Ru(bpy)2phen]2+ (1,10-phenanthroline (phen), 2b), was used as
a control, as it does not undergo photochemical ligand dissociation upon irradiation.

2b

2e

2g

Figure 2.1: Structures of Ru(II) complexes initially synthesized and tested.
[Ru(bpy)2phen]2+ (2b), [Ru(bpy)2dmbpy]2+ (2e), and [Ru(bpy)2dmdpq]2+ (2g).

19

[Ru(bpy)2dmbpy]2+ (2e) and [Ru(bpy)2dmdpq]2+ (3,6-dimethyl-dipyrido[3,2-f:2’,3’-h]quinoxaline (dpq), 2g) have two methyl groups directed toward the Ru(II) center,
inducing distortion to the octahedral geometry. This distortion creates steric clash that
renders the complexes photochemically labile and prime candidates for PACT. These
Ru(II) complexes were found to be unreactive in the dark but when irradiated with visible
light undergo photochemical ligand loss. Upon ligand dissociation the Ru(II) complexes
have two open binding sites for potential covalent interaction with DNA and/or other
biomolecules within the cell. These complexes were able to damage DNA following
irradiation similar to the activity of cisplatin. Additionally, these strained complexes
showed high phototoxicity indices (PI), the ratio of dark cytotoxicity to light cytotoxicity,
in which they were unable to kill cancer cells until irradiated with light, whereupon a
highly cytotoxic species was produced.
In an effort to understand the structure-photoactivity relationship of Ru(II)
polypyridyl complexes, we investigated multiple features. 1) Does increasing the π
surface of the polypyridyl ligands have an effect on the photocytotoxicity? 2) Will
increasing the intramolecular strain provide optimal photochemistry, and what effect does
it have on the photocytotoxicity? 3) Can the light activation wavelength be tuned to
within the therapeutic window for PDT and PACT? 4) Are light activatable
monofunctional Ru(II) complexes equally active as bifunctional Ru(II) complexes? 5)
Does the geometry of the open binding sites for reaction of biomolecules with the metal
center matter?
2.2 Effects of increasing the ligand π surface and increasing intramolecular strain.
Modulation of photochemical activity can be achieved through manipulation of
the Ru(II) scaffold in different ways. First, extension of the π system of the polypyridyl
ligands away from the metal center enhances the DNA affinity.7 Second, the introduction
of intramolecular strain results in light induced ligand dissociation creating a reactive
species capable of causing cell death.6, 8 A family of complexes with different structural
properties were synthesized and characterized for their ability to act as PDT or PACT
agents. The compounds can be broken into three main classes based on the ligands
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Co-ligands

π surface

π surface

Strain

Series 1 (2a–2d): no strain
Series 2 (2e–2h): strain

Series 3 (2i–2l)

Figure 2.2: Structures of the three series of Ru(II) complexes studied for the importance
of π surface and intramolecular strain.

incorporated (Figure 2.2, Table 2.1). Series 1, compounds 2a–2d, are unstrained
[Ru(bpy)2L]2+ scaffolds, capable of producing 1O2 and do not undergo ligand ejection
upon visible light irradiation. Series 2 is composed of compounds 2e–2h, which
maintains the [Ru(bpy)2L]2+ scaffold but incorporates the addition of two methyl groups
on L to induce strain to the Ru(II) center. With the introduction of strain, series 2 can
undergo ligand dissociation when activated with visible light. Lastly, series 3, compounds
2i–2l, utilizes the [Ru(dmphen)2L]2+ (dmphen = 2,9-dimethyl-1,10-phenanthroline)
scaffold for additional strain compared to series 2. Within each series, the π system of
ligand L is increased away from the metal center. The sequence of ligands include: bpy or
dmbpy, or dmphen, dpq (dipyrido[3,2-f:2′,3′-h]-quinoxaline) or dmdpq, and dppz
(dipyrido[3,2-a:2′,3′-c]phenazine)

or

dmdppz

(3,6-dimethyl-dipyrido[3,2-a:2′,3′-

c]phenazine).
Each complex was synthesized, characterized, and studied to determine the
relationship between incorporation of strain and extension of the π surface on the
photochemistry, DNA damage, and cytotoxicity induced by the compounds. Complexes
2a–2l were prepared as PF6- salts under low ambient light (see Chapter 6 for experimental
details). Prior to in vitro and in vivo testing each complex was fully characterized by 1HNMR, 13C-NMR, ESI-MS and HPLC. Crystals were obtained from the PF6- salts and the
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Table 2.1: Compound codes and ligand identification for structures studied for
increasing π surface and intramolecular strain.a
Compound

a

Ru(L1)2L2

Glazer Lab

Code

L1

L2

Code

2a

Bpy

Bpy

GL-024

2b

Bpy

Phen

GL-004

2c

Bpy

Dpq

GL-021

2d

Bpy

Dppz

GL-009

2e

Bpy

Dmbpy

GL-002

2f

Bpy

Dmphen

GL-007

2g

Bpy

Dmdpq

GL-003

2h

Bpy

Dmdppz

GL-010

2i

Dmphen

Bpy

GL-022

2j

Dmphen

Phen

GL-048

2k

Dmphen

Dpq

GL-039

2l

Dmphen

Dppz

GL-040

Table 6.2 contains structures and full names of ligands.

structures were fully analyzed in order to determine correlations between the degree of
distortion and the photoactivation process. Crystal structure analysis of the complexes
provided information about the degree of distortion required for the light activated ligand
ejection of the strained Ru(II) complexes (see Appendix 1 for full data tables and crystal
structure figures). Each strained complex exhibited varying degrees of structural changes
that facilitate light induced ligand dissociation. Comparison of each series revealed three
types of distortion induced upon the addition of methyl groups directed toward the Ru(II)
center. The three types of distortion included: elongated bond lengths, bending from the
normal plane, and twisting about the 2,2’ bond in complexes containing a bpy ligand
(Figure 2.3). Elongated bond lengths to the ejected ligand ranged from 2.11–2.12 Å,
while the non-ejecting ligands maintain a bond length between 2.06–2.07 Å, similar to
those of the unstrained series. Many of the strained systems developed an out of plane
bend of the methylated ligand(s), with minimal bending to non-methylated ligand(s). The
last type of distortion induced was twisting about the 2,2’ C-C bond of the bpy ligand.
22

Figure 2.3: Cartoon representation of the different types of distortion created with the
addition of strain.

Compounds 2a–2d (series 1) showed little distortion from octahedral as nonmethylated ligands were incorporated in the complex.9 The average Ru-N bond length
was maintained at around 2.06–2.07 Å for all six bonds. The bite angle for each ligand
remained constant at ~78°. However, complex 4 showed slight deviation with a 6° bend
out of plane of the dppz ligand resulting in the bpy-dppz bond angles increasing by 6–7°.
The addition of methyl groups to the third ligand induced differing degrees of distortion
to compounds of series 2 (2e–2h). With the extension of the π system, the degree of bend
decreased for the methylated ligand, Figure 2.4 and Table 2.2. Compound 2e had the
largest degree of bend at 23° for dmbpy. The two bpy co-ligands also deviated from
planarity by an average of 7.6°. One bpy (N3-N4) showed twisting by 6° orienting half
the ligand evenly between the methyl groups of the dmbpy. This twisting increased
A

B

N7

N3

N3
N4
N5

C

N1
Ru
N6

N2

N5

N1

N4

Ru N2
N6

N8
N
5

N1

N3

Ru N2

N4

N6

Figure 2.4: The degree of bend caused by the methyl group correlates with the size of
the ligand’s π system. (A) 2e, (B) 2f, (C) 2g. Note: ellipsoids are at 50% probability
with H atoms and PF6- counter-ions omitted for clarity.
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the bond angle between the dmbpy and bpy (N3-N4) to 94.08(9)° compared to the bond
angles between the other two ligands, an average of 83.7°.The more rigid dmphen ligand
in 2f showed less distortion with only a 12° bend. The two bpy co-ligands were also less
distorted with an average bend of 4° and an average twist of 4°. The twisting increased
the axial angle between the dmphen and bpy to 92.77(9)°, compared to the average angle
of 84.1° for the other two sets of angles. Unlike 2e and 2f, the dmdpq ligand of 2g
remained planar. To accommodate for the planar dmdpq, the two bpy co-ligands are bent
by an average of 4° and both experience a twist between 5–8°. The axial angles between
the bpy ligands and the dmdpq are also increased to maximize the space around the
methyl groups.
Changing the backbone from [Ru(bpy)2L]2+ to [Ru(dmphen)2L]2+ for series 3
(compounds 2i–2l) resulted in increased distortion of the octahedral geometry.
Compound 2i showed substantial distortion of the two dmphen co-ligands, where both
were bent by an average of 19.9°, while the bpy ligand remained planar. This resulted in
the angle between the two dmphen co-ligands increasing to 101.7°, from the average
angle of [Ru(bpy)3]2+ of 89.2°.9a For 2j, the bend for the dmphen co-ligands was slightly
less then 2i, with an average of 16.4°. This deviation is not accommodated with an
increase or decrease in bond angles between the axial bonds, but rather through slight
decreases in equatorial bond angles. The dmphen-phen equatorial bond angle is 6°
smaller than the dmphen-dmphen equatorial bond angle. Increasing the π system further
with the dpq ligand, the dmphen ligands are even less distorted, with an average of a
13.9° bend, while the dpq ligand is bent slightly (4.7°). Compound 2l has similar
distortions to that of 2k, where both dmphen co-ligands are bent significantly by an
average of 20.8° and the dppz ligand by ~8°.10 These ligands move to maximize the space
around them by increasing their equatorial bond angles by 5-7° from octahedral.
The ligand dissociation for series 2 and 3 was followed by UV/Vis spectroscopy
and the ejection products were analyzed by ESI-MS (Figure 2.5 and Table 2.3).
Although the solid state distortion observed in the crystal structures represents the lowest
energy state and may not necessarily reflect the distribution of states in solution, upon
detailed analysis of the crystal structures a correlation was observed between the
distortion of the bpy co-ligands and the t1/2 (Table 2.3). The overall distortion was
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Table 2.2: Average bond lengths (Å), twist/rotation (°) and bend (°) for 2e–2l.
Bond Length (Å)

Twist or Rotation (°)

Bend (°)

Unstrained

Strained

Unstrained

Strained

Unstrained

Strained

2e

2.06

2.11

3.9

2.9

7.6

22.2

2f

2.06

2.12

2.4

0.7

4.1

11.7

2g

2.07

2.12

6.7

1.0

3.8

1.2

2h

2.06

2.10

0.6

1.9

2.2

15.7

2i

2.07

2.10

0.0

2.2

2.3

19.9

2j

2.08

2.11

4.2

3.5

3.1

16.6

2k

2.09

2.12

0.8

1.7

4.7

13.9

2l

2.10

2.11

1.0

1.2

8.0

20.8

calculated from the bend out of plane and the twisting about the 2,2’ C-C bond to give a
14.5° (2e), 6.4° (2f), and 10.5° (2g) of distortion. The order of the t1/2 was 2f>2g>2e,
matching the order of the degree of distortion. The further extension of the π system to
the dppz ligand appears to stabilize the structure through increased π stacking interaction
between different molecules in solution. Not only does the distortion to the metal center
decrease but the rigidity of L increases with the extension of the π system, which could
increase the probability for re-coordination of the ligand, ultimately slowing the ejection
process through the commonly accepted stepwise bond breaking of chelating ligands.11
The presence of isosbestic points in the absorption spectra indicates the conversion of the
starting complex to a single product, followed by the onset of a second isosbestic point
for each complex except 2e and 2h. This second process suggests decomposition occurs
following the initial ligand dissociation event. To further analyze the light induced
products all strained complexes were subjected to ESI-MS analysis for determination of
the ligand ejected. Each complex ejected the methylated ligand with the exception of 2i,
which had a mixture of ejected ligands and resulting complexes.
Different types of DNA interaction and damage were identified by agarose gel
electrophoresis, where supercoiled pUC19 plasmid was incubated with increasing
concentration of each complex in the dark or after one hour of blue (>400 nm) light
exposure (Figure 2.6, 2.7 and Table 2.4) Two controls were utilized to identify the
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D

E

F

G

H

Figure 2.5: Photoejection kinetics followed by UV/Vis. Inset shows the change in
absorbance as a function of time and fit to a one phase decay equation (black = 550–450
nm and blue = 500 nm). (A) 2e, (B) 2f, (C) 2g, (D) 2h, (E) 2i, (F) 2j, (G) 2k, (H) 2l.
different types of damage to the plasmid DNA; copper(II) phenanthroline (Cu(OP)2) to
create relaxed circle DNA, and the restriction enzyme, EcoRI, to generate linear DNA.
The Ru(II) complexes displayed light activated DNA damage through the production of
1

O2 and/or photobinding, with a few showing interaction through intercalation in the

absence of light. Series 1 induced single strand breaks to the DNA when irradiated with
light. This was visualized by the conversion between supercoiled DNA to relaxed circle
(Figure 2.6a and 2.7).6 As unstrained complexes, 2a–2d are unable to promote an
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Table 2.3: t1/2 for photoejection and ejected ligand analysis
Compound

a

Ejected Ligand

t1/2 (min)

2e

Dmbpy

0.2

2f

Dmphen

13.5 and 85

2g

Dmdpq

7.7 and 88

2h

Dmdppz

>8 hrs

2i

Dmphen and Bpy

0.5 and 191a

2j

Dmphen

3.0 and 237a

2k

Dmphen

2.9 and 47a

2l

Dmphen

23 and 292a

two distinct processes were identified.

electron from the 3MLCT to 3MC state for ligand ejection upon light activation but
instead the energy is transferred from the 3MLCT to 3O2 producing 1O2, the active
species. Complex 2d, containing a ligand with high DNA affinity, dppz, intercalates into
the DNA base stack.12 Intercalation is evident from the smearing of the DNA between the
supercoiled and relaxed circle form (Figure 2.6b).
On the other hand, ligand loss produces a reactive Ru(II) complex capable of
covalently binding DNA. Covalent adducts are visualized by the reduced mobility on the
agarose gel with increasing concentration of Ru(II) complex, as well as loss of EtBr
signal due to its inability to intercalate in the base stack (Figure 2.6c). Complexes 2e and
2f produce covalent adducts when irradiated, whereas complexes 2g and 2i–2k create
single strand breaks in addition to covalent adducts (Figure 2.7).6 Complexes 2h and 2l,
include the dppz/dmdppz ligand and therefore show intercalation as well as light-induced
covalent adducts (Figure 2.7).
The DNA damage assay provided information on the in vitro activity of each
series of complexes as potential PDT or PACT agents. Series 1 caused light induced
activity in the form of single strand breaks, while the addition of strain for series 2 and 3
resulted in covalent modification of the DNA. Single strand breaks are easier to repair
than covalent adducts. Unfortunately, in vitro assays do not directly relate to the in vivo
cell cytotoxicity of these complexes. In order to determine the potency of 2a–2l on cancer
cells, cytotoxicity was determined using HL60 (human promyelocytic leukemia) cells
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Table 2.4: Description of each type of DNA damage observed.
Type of Damage

Description
Single strand breaks create relaxed circle DNA, which

Single strand breaks

has reduced mobility than supercoiled and are typically
1

O2 generated. The Cu(OP)2 reaction control generates
relaxed circle DNA.
Double strand breaks create linear DNA, which runs

Double strand breaks

between relaxed circle and supercoiled DNA. The
EcoRI control generates linear DNA.
DNA “smears” between the upper migrating relaxed

Intercalation

circle and the lower migrating supercoiled and no
longer shows a sharp supercoiled band.
Covalent binding of the complexes to DNA is

Photobinding

visualized by the increasingly reduced mobility of the
DNA with increasing complex concentration, “stair
stepping”.

A

1 2 3 4 5 6 7 8 9 10 11 12

B

1 2 3 4 5 6 7 8 9 10 11 12

C

1 2 3 4 5 6 7 8 9 10 11 12

dark

1hr

Figure 2.6: Agarose gels showing the interaction and damage to 40 μg/mL pUC19
plasmid with and without irradiation of >400 nm. (A) 2a (1O2 induced DNA damage),
(B) 2d (intercalation), (C) 2f (photobinding). Lane 1 and 12: DNA ladder; Lane 2:
EcoRI; Lane 3: Cu(OP)2; Lanes 4–11: 0–500 μM. EcoRI and Cu(OP)2 are used as
controls for linear and relaxed circular DNA, respectively. Gels were stained with
ethidium bromide (EtBr) for visualization of the plasmid.
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C
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dark

1hr
D

E

F

dark
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Figure 2.7: Agarose gels showing the interaction and damage to 40 μg/mL pUC19
plasmid with and without irradiation of >400 nm. (A) 2c, (B) 2h, (C) 2i, (D) 2j, (E)
2k, (F) 2l, Lane 1 and 12: DNA ladder; Lane 2: EcoRI; Lane 3: Cu(OP)2; Lanes 4–
11: 0–500 μM. EcoRI and Cu(OP)2 are used as controls for linear and relaxed circular
DNA, respectively. Gels were stained with ethidium bromide (EtBr) for visualization
of the plasmid.
and A549 (adenocarcinomic human alveolar basal epithelial) cells in the presence and
absence of light. In brief, cells were incubated with the compound (0–300 μM) in the
dark overnight followed by 3 min of blue light activation (>400 nm). Cell survival was
assayed using Alamar Blue after an additional 72 hours of incubation.
As expected, cisplatin did not exhibit light induced cytotoxicity, however,
noteworthy differences between the three series of Ru(II) complexes occurred. Not
surprisingly, series 1, the unstrained, photochemically inert complexes, showed very little
light induced toxicity as evident by the low PI values in both cell lines (Table 2.5). Series
1 requires the production of 1O2 to provide the cytotoxic effect under the conditions used
in this experiment; this requirement has a deleterious effect on the activity of these
complexes. On the other hand, series 2 and 3, the strained, photochemically active
complexes, had significant light induced toxicity in both cell lines, with PI values up to
833 in HL60 cells and 633 in A549 cells.
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Table 2.5: Cell cytotoxicity for 2a–2l in HL60 and A549 cells.
Compound

HL60 IC50 [μM]

A549 IC50 [μM]

Dark

Light

PI

Dark

Light

PI

3.1

3.1

1.0

1.5

1.5

1.0

2a

>300

250

>1.2

>300

110

>2.7

2b

240

81

3.0

250

40

6.3

2c

>300

73

>4.1

70

30

2.3

2d

>300

125

>2.4

30

20

1.5

2e

>300

1.6

>188

150

1.1

136

2f

11.9

1

11.9

6

0.4

15

2g

108

2.6

41.5

250

1.2

208

2h

100

68

1.5

40

15

2.7

2i

150

1.7

88.2

44.1

2.4

18.4

2j

102

0.3

340

57.8

1.1

52.5

2k

>250

0.3

833

75.9

0.12

633

2l

150

0.5

300

113.7

7.1

16.0

Cisplatin

The unstrained compounds acted as controls for light induced cytotoxicity.
Compounds 2a–2c caused light induced single strand breaks through the production of
1

O2 in vitro, while in vivo they were only slightly more potent upon irradiation.6

Likewise, compound 2d, a known DNA intercalator, did not show any significant light
induced toxicity. In general, comparison of light and dark activities for series 1 showed
significantly different light induced activity in vitro from light induced activities in vivo.
With the introduction of strain, with series 2 and 3, there was an increase in light
activated cytotoxicity resulting in larger PI values compared to series 1. Series 2
complexes ranged in activity in both the dark and following irradiation, where 2e had the
largest difference between dark and light IC50 values, with PI values >130. Similarly, 2g
had minimal dark toxicity and high light induced toxicity, with PI values >40. On the
other hand, complex 2f showed high dark toxicity in both cell lines and a PI value of only
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11.9 in HL60s and 15 in A549s was obtained. Compound 2h behaved similarly to the
unstrained complexes in series 1, which could be attributed to the extremely slow ligand
ejection process (t1/2 >8 hours in water). The complexes that eject a dmphen ligand (Table
2.3), 2f and 2i–2l, showed light induced toxicities < 2.4 μM, with many <1 μM. The
series 3 complexes (2i–2l) had minimal dark toxicity and their PI values ranged from 88–
833, where 2k had the largest window in HL60 cells. When series 3 compounds were
tested in A549 cells the dark toxicity was 1.3–3.4x greater but the complexes maintained
the light induced toxicity. Many of the complexes resulted in light induced toxicities
superior to cisplatin (3.1 μM in HL60 cells and 1.5 μM in A549 cells, Table 2.4). Series 3
compounds and 2e exhibited ideal behavior as PACT agents, with minimal dark toxicity
and significant light toxicity, resulting in a large PI value.
Light activated Ru(II) complexes are of interest as possible PACT agents for the
treatment of cancer because of their easily manipulated structural properties and tunable
photophysical/photochemical properties. Visible light activation of the complexes
presented in this section reveal that increasing the distortion around the metal center leads
to faster ligand dissociation. Also, as determined through crystal structure analysis of the
strained complexes, the extension of the π system minimizes distortion and results in
longer half-lives of ligand ejection. Unfortunately, the distortion and rate of ligand
ejection did not directly correlate to the cytotoxicity.
In summary, the results of this section have given insight on future structural
changes to incorporate to maximize the efficacy of Ru(II) complexes for PACT.
Additionally, tuning the rate of ligand loss is important for the activation time used for
cell studies in order to create enough active species to provide the intended cytotoxic
effect. One major drawback to these complexes is their activation wavelength in
relationship to current PDT agent’s therapeutic window is too low.

2.3 Shifting the absorption profile for enhanced therapeutic relevance.
Currently, organic PDT sensitizers have retained one key advantage over metal
complexes: the ability to be activated by light in the “therapeutic window” for PDT,
using red and near IR light from 600–1100 nm. Very recently, metal complexes were
reported that were able to damage DNA when activated with low energy light.13 In this
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Table 2.6: Compound codes and ligand identification for structures studied for
shifting the absorption profile.a
Compound
Code

a

Ru(L1)2L2

Glazer Lab

L1

L2

Code

2m

Phen

Biq

GL-011

2n

Biq

Phen

GL-054

2o

Phen

Bnap

GL-083

2p

Dmphen

Bnap

GL-148

2q

Biq

Bnap

GL-101

2r

Bnap

Bnap

GL-092

Table 6.2 contains structures and full names of ligands.

section, two series of complexes are discussed and represent the next step towards
functional PACT agents. These simple ruthenium polypyridyl complexes can be activated
in the therapeutic window, and many demonstrate both photo-activated DNA binding and
potent cytotoxicity in cancer cells (Table 2.6).

2.3.1 First generation red light activated complexes using the 2,2’-biquinoline
ligand.14 (Reproduced from Ref. 14 with permission from the Royal Society of
Chemistry.)
The photoactivity of the ruthenium complexes can be regulated by a single key
feature; the induction of distortion into the octahedral geometry around the metal.
Distortion is known to lower the energy of a dissociative 3MC (metal centered) state,
allowing for its thermal population following photoexcitation to the 3MLCT (metal to
ligand charge transfer) state.15 The structure of the ruthenium complex is conveniently
deformed by the incorporation of ligands that clash with one another when assembled
around the metal center. The 2,2’-biquinoline (biq) ligand possesses an extended πsurface around the Ru(II) center and generates strain when they clash with other ligands
upon incorporation into a Ru(II) complex,

combining light-activated photochemical

reactivity16 with a sufficiently red-shifted absorption to allow for activity in the PDT
therapeutic window.
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2m

2n

Figure 2.8: Structures and UV/Vis absorption spectra of 2m (black) and 2n (red).
Inset shows the absorption in the PDT window.
Two complexes were synthesized containing one or two biquinoline ligands, and
one or two smaller, non-strained phen ligands, as shown in Figure 2.8. The addition of
the biquinoline ligands resulted in bathochromic shifts in the absorption spectra, as
compared to [Ru(phen)3]2+, a prototypical Ru(II) polypyridyl complex with a λmax = 450
nm for the low energy MLCT absorption. Addition of one biquinoline ligand in 2m shifts
the MLCT to lower energies, with λmax = 525 nm. Incorporation of two biquinoline
ligands further shifts the λmax to 550 nm for 2n. Expansion of the region from 600-900
nm shows that there is some absorption at 700 nm for 2m, while 2n is able to absorb light
> 800 nm.
Crystal structures for the biq complexes show the extent of distortion in the
ground state structures. The deformation of the octahedral geometry is manifest in
lengthening of the bonds between the metal and the biq ligand(s) as well as twisting of
the ligands (Figure 2.9). In comparison with [Ru(phen)3]2+, an undistorted octahedral
complex with average Ru-N bond lengths of 2.064 Å,17 compound 2n is slightly distorted
with the Ru-N bonds lengthened to 2.08–2.10 Å, as shown in Figure 2.9. In compound
2m, shown in Figure 2.9, one of the phenanthroline ligands maintains an average length
similar to that of [Ru(phen)3]2+ at about 2.060 Å, and the other two ligands’ Ru-N bonds
are lengthened to an average of 2.11 and 2.09 Å.16c The biquinoline in 2m is twisted by
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A

B

Figure 2.9: Crystal structure figures to show the distortion of the biq ligand in (A) 2m
and (B) 2n where in white the N(3)-N(4) biquinoline is horizontal and in blue the
N(1)-N(2) biquinoline is horizontal to show that both biquinoline ligands have a 20°
bend from the ideal octahedral plane but the N(3)-N(4) ligand has a 12° twist about
the C-C bond between the two quinolines where the N(1)-N(2) does not have this
degree of twist.
5° about the C-C bond between the two quinoline systems. In contrast, the two
biquinoline ligands show different distortions in compound 2n, with biq(2) exhibiting a
12.1(4)° twist, while biq(1) has a 2.7(4)° rotation. The biquinoline ligands are also bent
out of the normal plane by approximately 20° in both complexes, while the
phenanthroline ligands stay in the plane. This bend out of plane tips the biquinoline
toward the phenanthroline ligand for 2n, creating a 7° increase in the angle between the
biquinoline ligands, as well as an 8° and 10° compression in the biquinolinephenanthroline angle. In contrast, the biquinoline ligand in compound 2m pushes the two
phenanthroline ligands toward each other by 8o. In both structures the biquinoline ligands
maximize the space around them, which induces the distortion in complexes 2n and 2m.
The complexes all undergo photosubstitution reactions upon exposure to visible
light. The kinetics of the ejection process were followed by UV/Vis absorption
spectroscopy, as shown in Figures 2.10 and 2.11. The number of sterically hindered
ligands and the corresponding distortion in the complex affects the rate of the
photosubstitution reaction, with an order of magnitude variation in t1/2 for the different
structures. The wavelength dependence of the photochemical process also correlated well
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A

B

C

Figure 2.10: Plots of photoejection kinetics of compound 2m in dH2O followed by
UV/Vis. The kinetic fit is shown in the inset. (A) photoejection with blue optical cast
plastic filter; (B) photoejection with green optical cast plastic filter; (C) photoejection
with red optical cast plastic filter.
with the absorption spectra, with rapid reaction observed with blue and green light and
slower ejection with irradiation using red and near-IR light. The most rapid ejection was
observed with blue light for 2n, with a t1/2 of 53 seconds, while a t1/2 of 8.7 minutes was
measured for 2m. The presence of isosbestic points in the absorption spectra indicated the
direct conversion from starting material to a single product. Samples of each complex
after light activation were subjected to analytical HPLC as shown in Figure S2.1.1. The
tris-polypyridyl compounds are converted to bis-polypyridyl complexes with the
selective ejection of a biquinoline ligand in all cases, as indicated by the peak with a
retention time of 32.15 minutes (identified as the free biquinoline ligand). The
phenanthroline ligand was not observed in any of the chromatograms, and the only free
ligand that was detected in the mass spectra for all samples was biquinoline.
The ability of the ruthenium complexes to damage DNA upon light activation was
determined by gel electrophoresis with supercoiled pUC19 plasmid, as shown in Figure
2.12. All complexes induced a dose-dependent effect on the DNA mobility, with
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A

B

C

D

Figure 2.11: Plots of photoejection kinetics of compound 2n in dH2O followed by
UV/Vis. The kinetic fit is shown in the inset. (A) photoejection with blue optical cast
plastic filter; (B) photoejection with green optical cast plastic filter; (C) photoejection
with red optical cast plastic filter; (D) photoejection with IR optical cast plastic filter.
increasing retention indicating photobinding of the complex to the plasmid DNA. The
decreased migration on the gel with increasing concentration of complex is consistent
with a DNA crosslinking effect, the same as observed with cisplatin.18 Intercalation also
causes decreased migration in agarose gels, but no effect was observed for 2m and 2n in
the absence of light, making intercalation unlikely. Also, very similar results were
obtained for the gel electrophoresis of the chemically synthesized [Ru(phen)2(H2O)2]2+,
which covalently modifies DNA. The aqua complexes of ruthenium form covalent
adducts with DNA and nucleosides upon thermal activation. The compounds do not
appear to photocleave DNA, as no increase in the linear or relaxed circle forms of DNA
were observed. A significant loss of the ethidium bromide (EtBr) signal was observed for
the light activated 2m, 2n, and [Ru(phen)2(H2O)2]2+ at concentrations >15 µM. To
determine if this was due to degradation of the DNA, bands were excised and purified.
The majority of the DNA was recovered intact, suggesting that the Ru(II) adducts
interfere with EtBr-DNA binding or EtBr emission. The purified DNA exhibited the
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Figure 2.12: Agarose gel showing the dose response of 2m (left) and 2n (right) with 40
µg/mL pUC19 plasmid in the dark and after irradiation with various wavelengths of light.
(A) Dark, (B) Blue (> 400 nm), (C) Green (> 450 nm), (D) Red (> 600 nm), and (E) nearIR (> 650 nm). Lane 1: DNA ladder; Lane 2: EcoRI; Lane 3: Cu(OP)2; Lane 4–11: 0–
1000 µM; Lane 12: DNA Ladder. EcoRI and Cu(OP)2 are used as controls for linear and
relaxed circular DNA, respectively.

same decreased gel mobility on a second agarose gel, supporting a covalent,
photobinding mechanism for 2m and 2n. The photobinding mechanism of 2m and 2n
may be advantageous in contrast to DNA photocleavage mediated by most metal
complexes, which requires oxygen and generates single strand breaks, which may be
readily repaired.19
The photoreactivity of 2m and 2n was dependent on the wavelength of light used,
with blue light producing the greatest potency, followed by green light. Significant
activity was retained upon shifting to both red and near-IR light, as indicated by gel shift.
The activity decreased approximately 4-fold using a >600 nm cut-off filter, and was
further diminished under near- IR irradiation. It should be noted, however, that the light
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intensity is significantly attenuated by these long wavelength cut-off filters; this is
combined with the effect of diminished molar absorptivity for the compounds in the red
and near-IR region. The use of a more intense red or near-IR light source is expected to
improve the apparent potency of the compounds; this is supported by the fact that
irradiation for longer times induces greater DNA photobinding. Finally, all complexes
showed negligible reactivity with the DNA in the dark.
Cytotoxicity studies were performed to determine if the light-induced DNA
damage translated to biological activity in cancer cells. The complexes exhibited dose
dependent cytotoxicity in the HL60 human leukemia cell line. The activity of the
compounds was also dependent on the light dose, indicating that light-activation is
directly correlated with cytotoxicity. The compounds were incubated with the cells for 12
hours prior to irradiation with blue (>400 nm), red (>600 nm), and near-IR (>650 nm)
light. In all cases, the compounds demonstrated light-mediated toxicity, with IC50 values
of 1–2 µM observed with blue light, as shown in Table 2.7. The activity decreased as redand near-IR cut-off filters were used to eliminate the higher energy activation light.
Increasing the light dose increased the observed potency, and decreased the IC50 value,
similar to the enhanced activity observed with increased light dose in the DNA
photobinding experiments. For example, compound 2n showed a 2-fold enhancement in
potency upon increasing the irradiation time from 3 to 6 minutes with red light,
recovering the activity measured under irradiation with blue light. The superior activity
of 2n compared to 2m with red and near-IR light irradiation is consistent with the

Table 2.7: Cytotoxicity of 2m and 2n in HL60 cells.
Phototoxicity

IC50 [μM]

Compound

Dark

Index, PI

Blue

Red

Red

IR

(3 min)

(3 min)

(6 min)

(25 min)

Blue

IR

2m

52.5

1.22

13.8

7.63

15.8

43

3.32

2n

47.3

2.4

4.54

2.29

5.14

19.7

9.2

Cisplatin

2.6

2.6

N.D.

N.D.

N.D.

1

N.D.
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presence of a longer wavelength absorption feature extending past 700 nm. A maximal PI
of 43 was found with blue light for compound 2m. Compound 2n was more potent than
2m with red- and near-IR light, exhibiting a PI of 20 and 9.2, respectively. To the best of
our knowledge, this was the first report of light-activated metal complexes producing
cytotoxic responses in cancer cells using direct irradiation with red and near-IR light.
While transition metal complexes have long been studied due to their combined
DNA binding and photocleavage properties, very few metal compounds have been
identified that show promise as PDT and PACT agents in cell studies. Direct DNA
photobinding may cause more toxic lesions in cells than single strand DNA cleavage, but
nearly all of the metal complexes previously reported in the literature that are capable of
DNA covalent modification require UV or higher energy blue light.20 This study shows
that strained Ru(II) biquinoline complexes exhibit sensitive light-mediated reactivity, and
act as DNA photobinding agents for PACT. These compounds take advantage of an
intrinsic photodecomposition pathway that is regulated by the distortion of the metal
complex, and the extended π-surface of the biquinoline ligands allow for absorption of
red to near-IR light. Furthermore, the compounds described in this section are the first
examples of light-activated metal complexes that kill cancer cells upon activation in the
PACT therapeutic window.

2.3.2 Second generation red light activated complexes using the 2,2’-bi-1,8naphthyridine ligand.
We showed that the complexes containing the biquinoline ligand can be activated
in the therapeutic window and are successful at killing cancer cells by activation with
near-IR light. The MLCT is between 530 and 550 nm, falling short of the ideal activation
range for PACT between 600–800 nm. The promise of these complexes as PACT agents
has led to the exploration of other ligands to shift the absorption even further, with the
goal of attaining low energy MLCT >700 nm. Specifically, the 2,2’-bis-1,8-naphthyridine
(bnap) has been reported to have a λmax = 574 nm when combined with Ru(bpy)2.21 This
red shift from the biquinoline system is due to the lowering of the π* orbital associated
with the increased delocalizing ability of this ligand.49
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Figure 2.13: Structures of the bnap containing complexes. [Ru(phen)2bnap]2+ (2o),
[Ru(dmphen)2bnap]2+ (2p), [Ru(biq)2bnap]2+ (2q), and [Ru(bnap)3]2+ (2r).
A

B

Figure 2.14: UV/Vis absorption profile for each bnap complex (A) Full spectrum and
(B) MLCT region for 2o (black), 2p (blue), 2q (red), and 2r (green).
In order to study the impact the bnap ligand has on the MLCT a series of
complexes were synthesized using different co-ligand (Figure 2.13). The addition of the
bnap ligand provides at least an additional 25 nm shift in λmax to around 575 nm. When
the bnap ligand is combined with Ru(phen)2 (2o) and Ru(dmphen)2 (2p) there is tailing
absorption to 625 nm. With combination with Ru(biq)2 (2q) the absorption extends past
650 nm. Surprisingly, with [Ru(bnap)3]2+ (2r) the MLCT peak is broad and shows
significant absorption to 625 nm with tailing absorption past 675 nm (Figure 2.14).
The photoejection kinetics of each complex was tested using 470 nm and 660 nm
LEDs. Surprisingly, complex 2o is not photoactive, even though its analogous compound
2m was photoactive. The main difference between the bnap and biq ligands is at the 8
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N8

Figure 2.15: (A) UV/Vis absorption profile of 2o before irradiation (blue) and after 8
hours of irradiation with a 470 nm LED (red). (B) Side view of the crystal structure of
2o showing minimal distortion created due to the bnap ligand.
position, where the carbon and hydrogen of biq ligand are replaced with nitrogens in the
bnap ligand. The loss of the hydrogen at this position significantly reduces the degree of
distortion in the structure, as seen in the crystal structure (Figure 2.15). The bnap ligand
has similar Ru-N bond elongation to that of the biq ligand in 2m (2.1Å). Unlike the biq
ligand, the bnap ligand is only slightly distorted with a 5° twist about the 2,2’ C-C bond,
compared to a 5° twist and a 20° bend of the biq ligand (Table 2.8).
In efforts to synthesize a photoactive compound, the bnap ligand was complexed
with strained backbones, Ru(dmphen)2Cl2 to give 2p and Ru(biq)2Cl2 to give 2q. Both
complexes were photoactive with a 470 nm LED, as well as a 660 nm LED (Figure 2.16
and Table 2.9). The presence of isosbestic points in the UV/Vis spectrum of 2p reveales
the direct conversion of the starting complex to a single product. The photoejection t1/2 of
2p was 6.8x slower using the 660 nm LED versus the 470 nm LED. On the other hand,
the photoejection process of 2q seems to go through an intermediate, where there is an
extremely rapid conversion from a broad MLCT centered at 550 nm to a sharp MLCT
band centered at 550 nm. Following the initial conversion, the peak shifts to a λmax = 580
nm. The initial phase is too rapid to to accurately determine a t1/2 using our techniques
and the overall photoejection process for 2q was only 18 seconds slower with the 660 nm
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A

B

C

D

Figure 2.16: Photoejection kinetics of (A) 2p with the 470 nm LED, (B) 2p with the
660 nm LED, (C) 2q with the 470 nm LED, and (D) 2q with the 470 nm LED. Insets
show the change in absorbance versus time.
Table 2.8: Average bond lengths (Å), twist/rotation (°) and bend (°) for 2m–2o and
2q.
Bond Length (Å)

Twist or Rotation (°)

Bend (°)

Unstrained

Strained

Unstrained

Strained

Unstrained

Strained

2m

2.08

2.10

0.3

19.2

4.4

5.6

2n

2.10

2.09

0.4

7.4

1.6

21.5

2o

2.07

2.10

1.1

4.1

2.2

5.0

2q

2.15

2.10

21.1

18.0

5.7

18.6

LED versus the 470 nm LED. This can be explained by the absorption profiles of both
complexes, where 2p has little to no absorption at 660 nm but 2q has significant
absorption.
Crystals of 2p were not successfully grown but the crystal structure of 2q
revealed significant distortion in the bnap ligand as well as the biq co-ligands (Figure
2.17). The average bond length of the Ru-N bonds to the two biq co-ligands was 2.096 Å
and the bnap ligand was 2.149 Å. Additionally, the biq ligands had a 19° bend out of
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Table 2.9: t1/2 of ligand ejection for bnap complexes.

t1/2 (min)

t1/2 (min)

470 nm

660 nm

2o

No ejection

N/A

2p

3.1 ± 0.2

21 ± 2

2q

0.35 ± 0.02

0.65 ± 0.4

2r

>8 hr

N/A

Compound

A

B

N1
N6

N8

N5 N7

N2

N8

N1

N2
N3

N3

N6

N4
N5

N4
N7

Figure 2.17: Thermal ellipsoid plot of 2q to show the distortion of (A) the bnap ligand
and (B) the biq ligand.
plane with an 18° twist about the 2,2’ C-C bond. Likewise, the banp ligand had a 21°
twist about the 2,2’ C-C bond but only a 5° bend. The distortion associated with this
complex renders it extremely photolabile, where the t1/2 using blue light was less than
30s. Given the highly photochemically reactive nature of 2q, making a more stable
complex with absorption at 660 nm was ideal. While trying to synthesize Ru(bnap)2Cl2,
the major product was [Ru(bnap)3]2+ under every experimental condition attempted and
Ru(bnap)2Cl2 was never successfully synthesized. Interestingly, with the addition of three
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Figure 2.18: UV/Vis absorption of 2r following 8 hours of irradiation with 470 nm
light. The blue line represents t = 0 min and the red line represents t = 8 hours.
1 2 3 4 5 6 7 8 9 10 11 12

1 2 3 4 5 6 7 8 9 10 11 12
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C

D
dark

470 nm

660 nm

Figure 2.19: Agarose gel showing the dose response of (A) 2o, (B) 2p, (C) 2q and (D)
2r with 40 µg/mL pUC19 plasmid in the dark and after irradiation with 470 nm and
660 nm light. Lane 1: DNA ladder; Lane 2: EcoRI; Lane 3: Cu(OP)2; Lane 4–11: 0–
500 µM; Lane 12: DNA Ladder. EcoRI and Cu(OP)2 are used as controls for linear
and relaxed circular DNA, respectively.
bnap ligands, complex 2r only undergoes slow photoejection and only minimal change is
observed after 8 hours of irradiation (Figure 2.18).
The ability of each complex to induce DNA damage was determined using gel
electrophoresis with plasmid DNA (Figure 2.19). Each of the complexes show minimal
interaction with the plasmid DNA at various concentrations in the absence of light; this is
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likely through an electrostatic interaction as these complexes do not have significant π
surface to successfully intercalate into the DNA. Not surprisingly, the non-ejecting
complexes 2o and 2r showed no light induced DNA damage following irradiation with
470 nm light. Given the inactivity of 2o and 2r using 470 nm light they were not
irradiated with 660 nm light. In contrast, 2p and 2q have significant light induced DNA
damage using both 470 nm and 660 nm light. Compound 2p seems to produce single
strand breaks beginning at 15 μM with 470 nm light and 30 μM with 660 nm light. The
damaging concentration difference can be attributed to the different rates of ligand loss
when using lower energy light. In contrast, 2q provides evidence of photobinding
beginning at 15 μM for both 470 and 670 nm light, as visualized by the reduced mobility
of the DNA. The loss of EtBr signal at higher concentrations is caused by the binding of
the Ru(II) complex preventing the intercalation of the EtBr to visualize the DNA signal.
To investigate the potential for these complexes to act as PACT agents,
cytotoxicity studies were completed in HL60 cells in the dark and following irradiation
with 470 and 660 nm light (Table 2.10). Surprisingly, the non-ejecting complexes, 2o and
2r exhibited increased activity following irradiation with 470 nm light, with PI values of
4.4 and 3.6, respectively. It may be possible for these complexes to form 1O2 as their
cytotoxic species, however, this was not visualized in the DNA damage assay. The light
activated cytotoxicity was lessened using 660 nm light for 2o and completely diminished
for 2r. The photoejecting complexes, 2p and 2q, showed enhancement similar to 2o when
irradiated with 470 nm light, having PI values of 3.5 and 3, respectively. Unfortunately,
all of these complexes have significant dark toxicities, rendering them not useful as
PACT agents.
The addition of the bnap successfully gave Ru(II) complexes with a red-shifted
MLCT compared to the biq complexes. The bnap ligand introduced less strain to the
Ru(II) complex than the biq ligand due to the loss of a hydrogen at the 8 position. This
change in distortion required the complexation of the bnap ligand with already strained
starting materials (Ru(dmphen)2Cl2 and Ru(biq)2Cl2) for photoactivatable complexes.
Complex 2q was not only photoactive but had a desirable activation wavelength and
maintained its t1/2 with lower energy light. While the wavelength shift and photoactivity
for these complexes was promising, the dark toxicity is problematic and modifications
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Table 2.10: Cell cytotoxicity of 2o–2r in HL60 cells.
IC50 [μM]

Compound
Dark

470 nm

PI

660 nm

PI

2o

18.8

4.3

4.4

10.7

1.8

2p

6.3

1.8

3.5

6.3

1

2q

1.5

0.5

3

1.2

1.3

2r

6.4

1.8

3.6

6.4

1

need to be made to minimize the dark toxicity while maintaining the wavelength of
activation.

2.4 Exploring the differences between mono- and di-adduct forming complexes.
The photoactive Ru(II) complexes discussed in the previous sections consist of
bidentate ligands, where the phototriggered release of one ligand leaves two open binding
sites for the covalent adducts to form between the Ru(II) complex and different
biomolecules in vivo, similar to cisplatin. With the increase of mono-functional Pt(II)
agents, such as phenanthriplatin, we were interested in studying the effect that mono- and

Mono

2s

2t

2u

2v

2w

2x

Di

Figure 2.20: Structures of monofunctional and bifunctional complexes studied.
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Table 2.11: Compound codes and ligand identification for structures studied for
shifting the absorption profile.a
Ru(L1)2LL’

Compound

Glazer Lab

Code

L1

L

L’

Code

2s

Bpy

Imidazole

Cl

GL-289

2t

Bpy

Pyridine

Cl

GL-286

2u

Bpy

Quinoline

Cl

GL-097

2v

Bpy

Isoquinoline

Cl

GL-278

2w

Bpy

Imidazole

Imidazole

GL-288

2x

Bpy

Pyridine

Pyridine

GL-084

a

Table 6.2 contains structures and full names of ligands.

bifunctional Ru(II) polypyridyl complexes have on the photochemical reactivity, DNA
damaging activity and cytotoxicity. The question we aimed to address was, are Ru(II)
monoadducts as effective as Ru(II) diadducts? In efforts to answer this question, six
Ru(bpy)2LL’ (L = monodentate ligand, L’ = Cl or L) complexes were synthesized and
studied, where four were monofunctional (L’ = Cl) and two were bifunctional (L = L’,
Figure 2.20 and Table 2.11).
Initially, the thermal stabilities of the monofunctional complexes, 2s–2v, were
studied to determine if the Cl- or monodentate ligand exchanges in the presence of
different nucleophiles. The thermal exchange rates were studied in different aqueous
media (water, 1 x PBS, and opti-mem supplemented with 1% FBS) and in the presence of
CT DNA. None of the complexes showed complete thermal exchange after 15 hour
incubation at 37 °C under any condition; therefore only overall absorption changes will
be discussed (Table 2.12). Surprisingly, each of the complexes had similar absorption
changes in the aqueous media, despite the differences associated with each aqueous
solution. Complex 2s had the largest change in absorbance at the MLCT in 1 x PBS (Δabs
= 0.24–0.295, Figure 2.21 and S2.1.2). On the other hand, complex 2v had the smallest
change in absorbance (Δabs = 0.042–0.049, Figure 2.21 and S2.1.4). Complexes 2t and 2u
were in the middle with Δabs = 0.14–0.17 and Δabs = 0.11–0.129, respectively (Figure
2.21, S2.1.3, and S2.1.4). Interestingly, none of the complexes showed significant
spectroscopic changes in the presence of CT DNA, suggesting that either the complexes
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A

B

C

D

Figure 2.21: Thermal exchange of 2s – 2v in 1 x PBS incubated at 37 °C. (A) 2s, (B)
2t, (C) 2u, and (D) 2v.
Table 2.12: Δabs of thermal exchange and DNA binding for 2s–2v.
Δabs
Compound

Water

1 x PBS

Opti-mem

CT DNA

1% FBS
2s

0.25 ± 0.01

0.295 ± 0.005

0.24 ± 0.04

0.019 ± 0.004

2t

0.17 ± 0.02

0.16 ± 0.01

0.14 ± 0.02

0.004 ± 0.003

2u

0.117 ± 0.002

0.11 ± 0.01

0.129 ± 0.005

0.006 ± 0.003

2v

0.044 ± 0.004

0.049 ± 0.002

0.042 ± 0.003

0.02 ± 0.01

do not covalently bind to CT DNA or the monoadduct does not result in a spectral shift at
the MLCT for these complexes (Figures S2.1.2–S2.1.4). Complex 2s showed the greatest
overall absorption change with an absorbance increase and MLCT peak broadening
following 15 hrs incubation with CT DNA.
Since these complexes only undergo slow thermal exchange in aqueous media
and show little to no interaction with CT DNA, we were interested in their potential as
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PACT agents. Therefore, the photochemical reactivity of both the monofunctional and
bifunctional complexes was investigated. Aqueous photoejection studies were completed
under the same conditions as the thermal exchange studies, where each complex was
irradiated with 470 nm light and scans were taken after set time points for a total of 7
hours. None of the complexes showed complete photoejection; therefore, the change in
absorbance was determined (Table 2.13). Each aqueous medium gave similar
photoejection profiles; therefore, the 1 x PBS data is shown for simplicity (Figures S2.1.6
and S2.1.7).

Given the minimal photoejection that occurs in aqueous media, the

photochemical reactivity of each complex as the PF6- salt was tested in acetonitrile, where
acetonitrile acts as the incoming ligand (Figure S2.1.8 ad Table 2.14). All of the
complexes, except 2s, undergo a two phase transition, where one ligand is exchanged
rapidly followed by a slower exchange of the second ligand. Complex 2s does not
undergo a complete photochemical reaction over 8 hours of irradiation. Complexes 2t–
2w have similar t1/2 values for the initial fast phase, ranging from 0.34–2 min.
Additionally, they have much slower second phases, where 2t and 2u do not go to
completion within 8 hours. Complex 2x is an outlier, where both ligand exchange
processes are finished rapidly. The initial phase occurs within the first time point and the
t1/2 cannot be accurately measured using our techniques. The second, slower phase occurs
with a t1/2 of 1.9 min. Two major conclusions can be drawn from these results: 1) the
Table 2.13: Δabs values for the photoejection of 2s–2x in 1 x PBS and CT DNA.
Compound

Δabs
1 x PBS

CT DNA

2s

0.021 ± 0.003

0.042 ± 0.006

2t

0.032 ± 0.002

0.103 ± 0.008

2u

0.05 ± 0.01

0.11 ± 0.01

2v

0.047 ± 0.005

0.069 ± 0.003

2w

0.017 ± 0.005

0.056 ± 0.007

2x

0.097 ± 0.006

0.12 ± 0.01
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Table 2.14: t1/2 values for the photoejection of 2s–2x in acetonitrile.
t1/2 (min)

Compound
Fast

Slow

2s

>480

2t

0.34 ± 0.02

>480

2u

0.59 ± 0.01

>480

2v

0.45 ± 0.01

127 ± 4

2w

2.0 ± 0.5

81 ± 26

2x

0.05 ± 0.01

1.9 ± 0.2

imidazole ligand is more tightly coordinated than the pyridyl ligands and causes the
photoejection process to be much slower and 2) the presence of one Cl- ligand has a
negative effect on the rate of ligand ejection.
Additional analysis was completed to determine if one or two ligands were
exchanged for solvent molecules during the photochemical reaction (Figure 2.22). In
aqueous conditions, 2t and 2x were further analyzed using the UV/Vis profiles at
different time points of the reaction. We hypothesize that the initial phase of 2x is the
formation of 2t, as evident by the overlapping spectra (blue and red lines) in Figure 2.22.
Once 2t is formed, the second phase is extremely slow and does not correspond to the
formation of Ru(bpy)2Cl2; therefore, we hypothesize that the second phase is the aquation
of the Ru(bpy)2(L)Cl complex (Scheme 2.1). On the other hand, in acetonitrile two
different processes can be pulled from the data presented in Figure 2.22. For
monosubsituted 2s, the initial phase is the replacement of the imidazole ligand with an
acetontrile ligand and the second phase would be the replacement of the Cl- ligand,
however, this occurs extremely slowly (Scheme 2.2). When the disubstituted 2w, is
irradiated in acetonitrile, we predict the ligand exchange occurs sequentially and the
second exchange event is less favored and therefore much slower (Scheme 2.2). Over the
course of 8 hours, the final spectrum of 2w is approaching the spectrum of
[Ru(bpy)2(CH3CN)2]2+ as evidenced by the near overlapping purple and pink lines in
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A

B

Figure 2.22: UV/Vis spectra overlay for determination of photoproduct in (A) 1 x PBS
and (B) acetonitrile. For 1 x PBS, complexes 2t (blue line) and 2x (black dashed line)
were overlaid with the intermediate from the reaction of 2x (red dashed line), the final
product for 2t (black line), the final product for 2x (red line), and Ru(bpy)2Cl2 (blue
dashed line). For acetonitrile, complexes 2s (black line) and 2w (blue line) were
overlaid with the intermediate from the reaction of 2w (blue dashed line), the final
product for 2s (black dashed line), the final product for 2w (red dashed line), and
[Ru(bpy)2(CH3CN)2]2+ (red line).

Fast Phase

Very Slow Phase

Scheme 2.1: Hypothesized reaction scheme for 2t and 2x in an aqueous environment.
Figure 2.22B.
The photochemical reactivity was also investigated in the present of CT DNA
(Figure S2.1.6 and S2.1.7). Surprisingly, none of the complexes showed complete
photochemical reactions in 1 x PBS or in the presence of CT DNA, except 2x in 1 x PBS.
However, each complex showed a greater change in the MLCT region in the presence of
CT DNA. The larger change may be a result of adducts forming with the CT DNA.
To further test the interaction these complexes had with DNA, the DNA damage
assay was completed in the dark and following 1 hr irradiation with 470 nm light (Figure
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Very Slow Phase

Fast Phase

Slow Phase

B

Scheme 2.2: Hypothesized reaction scheme for (A) 2s and (B) 2w in an acetonitrile.
2.23). In the dark, none of the complexes showed interaction with the plasmid DNA.
These results were expected, given the low thermal interaction with CT DNA of the
monofunctional complexes. Based on the DNA gels in the dark, the monofunctional
complexes do not perturb the supercoiled plasmid and it can be hypothesized that these
compounds are likely not interacting strongly with the plasmid DNA, this data is
supported by the lack of spectroscopic change in the thermal binding studies. Despite the
slow ejection kinetics in aqueous media, following irradiation in the presence of plasmid
DNA, each of the complexes show increased interaction with the plasmid DNA and the
reduced mobility of the DNA is indicative of covalent adducts. The two imidazole
complexes, 2s and 2w show less activity in comparison to the other 4 complexes. This is
likely due to the slower photochemical reactivity. Complexes 2t, 2u, and 2x show
interaction with the plasmid DNA at the lowest dose point (7.8 μM) following irradiation.
To quickly test the potential of these complexes as PACT agents, an E. Coli based
assay using BL21 cells was developed by Yang Sun, where the IC50 can be determined
before and after irradiation in comparison to cisplatin (Figure S2.1.9 and Table 2.15).
Each complex, except 2u, showed minimal cytotoxicity in the absence of light. Following
irradiation the complexes showed an increase in cytotoxicity with PI values ranging from
1.9–7.3. Compound 2u had a similar IC50 to cisplatin following irradiation. Interestingly,
there were major differences between 2u and 2v where the only difference is the position
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Figure 2.23: Agarose gel electrophoresis showing the dose response of (A) 2s, (B) 2t,
(C) 2u, (D) 2v, (E) 2w, and (F) 2x with 40 μg mL-1 pUC19 DNA before and after 1
hour irradiation and incubation at 37 °C. Lanes 1 and 12: DNA ladder; Lane 2: EcoRI;
Lane 3: Cu(OP)2; Lane 4–11: 0–500 μM compound. EcoRI and Cu(OP)2 were used as
controls to represent linear DNA and relaxed circle DNA, respectively.
of the nitrogen atom of the quinoline ligand. Additionally, differences were seen for the
monosubstituted and disubstituted pairs, where 2s and 2w had the same PI value (3.4) yet
had radically different dark and light toxicities.
Given the differences in isomers and number of ligands, we hypothesized that the
cellular accumulation could be different for both sets of complexes. Atomic absorption
spectroscopy was completed for 2s and 2u–2w in BL21 cells in the absence and presence
of light (Figure 2.24). Interestingly, very little difference was seen for the
monosubstituted imidazole complex (2s) compared to the disubstituted imidazole
complex (2w). Only a slight increase in intracellular accumulation was seen for 2s. On
the other hand, 2u had a much greater increase in intracellular metal accumulation than
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Table 2.15: IC50 values in BL21 cells before and after irradiation.
Compound

IC50 [μM]
Dark

Light

PI

2.3

2.3

1

2s

>300

87.8

>3.4

2t

100

36.6

2.7

2u

14.0

4.2

3.3

2v

141

19.2

7.3

2w

51.8

15.4

3.4

2x

>300

52.6

>1.9

Cisplatin

2v, which may explain the increased dark toxicity of 2u.
These complexes show promise as PACT agents due to multiple factors. First, the
thermal exchange that occurs does not result in dark reactivity with DNA and in E. Coli
cells. Second, even with slow photochemical reactivity in aqueous environments, the
complexes are able to covalently damage DNA, as visualized by the agarose gels. Lastly,
some of these complexes have low dark toxicity, and presence of moderate light induced
cytotoxicity in E. Coli resulted in PI values >2. The PI values are much lower than other
complexes tested previously in mammalian cells, suggesting that these complexes will

Figure 2.24: Percent intracellular metal for 2s and 2u–2w by atomic absorption
spectroscopy.
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not have significant light induced activity in mammalian cells. Additional studies still
need to be conducted in mammalian cells to determine the overall activity of these
complexes as PACT agents.

2.5 Does geometry matter?
The last question we aimed to address was, does the geometry of Ru(II)
polypyridyl complexes have an effect on the in vitro and in vivo behavior? Cisplatin, cis[PtCl2(NH3)2], has received worldwide acceptance as a clinical drug for the treatment of
various neoplastic diseases,22 while its isomer transplatin, trans-[PtCl2(NH3)2], was found
to be therapeutically inactive.23 This observation was considered a paradigm for the
structure-activity relationships (SAR) of Pt-based antitumor compounds, according to
which the antitumor activity requires a neutral square-planar platinum center with two
ammine ligands in cis-geometry and two leaving groups.23 The lack of antitumor activity
in transplatin has been associated with the formation of intrastrand cross-links between
purine-pyrimidine24 residues instead of purine-purine (major DNA adducts formed by
cisplatin)25 due to stereochemical constraints.
In addition to Pt based compounds, other metal complexes have been shown to
have biological activity in vitro, including potency in cisplatin-resistant tumor cells.26
Ruthenium has received particular attention in the present search for therapeutic agents,
and ruthenium compounds exhibit antitumor effects as well as antibacterial, antiviral, and
antimalarial activity.26b Two anionic Ru(III) coordination compounds, NAMI-A and
KP1019, possess a strong ability to inhibit metastases of solid invasive cancers and
successfully completed phase I clinical trials, but ultimately failed in phase II clinical
trials.27 Generally, antitumor Ru(II) complexes can be divided in two primary families,
i.e. the half-sandwich “piano-stool” and polypyridyl-types.26b The later family has been
gaining attention due to their appealing physicochemical properties, which offer the
possibility to use them in PDT and PACT.28 However, all the Ru(II) compounds able to
form covalent bonds to biomolecules exhibit a cis geometry, and no examples of trans
polypyridyl Ru(II) isomers with biological activity are yet known, in spite of their
interesting photophysical and catalytic properties.29 But, does geometry matters in the
design of anticancer Ru(II) complexes? This section describes the first polypyridyl Ru(II)
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Cisplatin

Transplatin 2y: R = Cl
2x: R =

2z: R = Cl
2aa: R =

Figure 2.25: Structures of Cisplatin, Transplatin, cis-Ru(bpy)2Cl2 (2y),

cis-

[Ru(bpy)2py2]2+ (2x), trans-Ru(qpy)Cl2 (2z), and trans-[Ru(qpy)py2]2+ (2aa).

complex with trans geometry exhibiting in vitro anticancer activity.
In order to determine the behavior of trans Ru(II) polypyridyl complexes, we
synthesized

trans-Ru(qpy)Cl2 (2z,

qpy

=

2,2’:6’,2”:6”,2’”-quaterpyridine)

and

-

investigated the Cl ligand exchange rate, DNA binding, and cytotoxicity in comparison
to cis-Ru(bpy)2Cl2 (2y) (Figure 2.25). The qpy ligand was synthesized via a modified
Ullman coupling reaction with 6-chloro-2,2’-bipyridine followed by coordination to
RuCl3 to yield 2z.29d The qpy ligand has been reported to act as a bridging ligand in
dinuclear Ru(II) complexes,30 as well as a tetradentate ligand in mononuclear Ru(II)
complexes.29d,

31

To confirm 2z was mononuclear and compare the DNA binding

behavior and cytotoxicity of 2z to a complex unable to undergo thermal exchange, we
synthesized and characterized trans- [Ru(qpy)(py)2]2+ (2aa, py = pyridine).29d
Additionally, cis-[Ru(bpy)2(py)2]2+ (2y) was used as a nonexchangeable control for the
cis geometry.
To determine the efficacy of 2y–aa in cancer cells, cytotoxicity studies were
performed in HL60 leukemia cells and A549 lung cancer cells. Figure 2.26 and Table
2.16 show the cytotoxicity of 2y–aa compared to cisplatin and transplatin. For square
planar platinum based compounds with exchangeable Cl- ligands, the cis geometry is
cytotoxic with IC50 values of 1.5 and 1.7 μM when incubated with HL60 and A549 cells..
As anticipated, the trans geometry has no effect on either cell line. Surprisingly, for
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A

B

Figure 2.26: Cytotoxicity of cisplatin (black, ), transplatin (blue, ), 2y (red, ), 2x
(purple, ), 2z (green, ), and 2aa (grey, Δ) in (A) HL60 and (B) A549.
Table 2.16: Cytotoxicity IC50 values for HL60 and A549 cell lines.
HL60

A549

IC50 (µM)

IC50 (µM)

1.5 ± 0.1

1.7 ± 0.5

Transplatin

>100

>100

2y

96 ± 1

73 ± 1

2x

>100

98 ± 1

2z

10.1 ± 1.1

10.3 ± 1.2

2aa

>100

93 ± 1

Compound
Cisplatin

octahedral ruthenium complexes with exchangeable Cl- ligands, the trans geometry is
7.1–9.5x more cytotoxic than the cis geometry. For compounds that are incapable of
ligand exchange, 2y and 2aa, where py ligands replace the Cl- ligands, the cytotoxicity is
eliminated in HL60 cells, and only minimal toxicity was observed at 100 μM in A549
cells. Our hypotheses for the differences in cytotoxicity for the complexes are: 1) the
trans geometry interacts with different in vivo targets from the cis geometry; and 2)
thermally exchangeable ligands are required for the cytotoxic effect to occur.
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Figure 2.27: Agarose gel electrophoresis showing the dose response of (A) cisplatin,
(B) transplatin, (C) 2y, (D) 2z, (E) 2x, and (F) 2aa with 40 μg mL-1 pUC19 DNA
incubated at 37 °C. Lanes 1 and 12: DNA ladder; Lane 2: EcoRI; Lane 3: Cu(OP)2;
Lane 4–11: 0–500 μM compound. EcoRI and Cu(OP)2 were used as controls to
represent linear DNA and relaxed circle DNA, respectively.
The DNA binding behavior for each compound was assessed using agarose gel
electrophoresis, in order to compare cis and trans Pt(II) versus Ru(II). Dose responses
were performed with cisplatin, transplatin, 2y–ad with pUC19 plasmid DNA after
reaction at 37 °C for 12 hours (Figure 2.27). Cisplatin interacts with plasmid DNA at
very low concentrations (15 μM) and effectively crosslinks the DNA. The adducts are
visualized by the reduced mobility of the DNA at low concentrations, followed by
increased mobility of the DNA at higher concentrations of cisplatin. In contrast,
transplatin has minimal interaction with the DNA, even at high concentrations, where the
migration of the DNA is only effected starting at 125 μM transplatin. Surprisingly, when
incubated with plasmid DNA, 2y or 2z only showed minimal perturbation of DNA
mobility, suggesting that either they do not interact strongly with plasmid DNA or the
interaction does not cause significant changes to the supercoiled plasmid structure.
Replacement of the Cl- ligands for py ligands resulted in even less of an effect, where
there was a slight decrease in mobility at the highest concentration (500 µM) of 2y, and
2aa had no impact on the plasmid DNA.
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Given that both 2y and 2z contain thermally labile chloride ligands, their ligand
exchange rates were monitored using UV/Vis absorption spectroscopy. Compounds 2y
and 2aa, containing pyridine ligands, were expected to be less susceptible to thermal
exchange, and were also studied. Initially, the thermal exchange of 2y–aa was
determined under different buffer and media conditions (Figures 2.28 and S2.1.10–13).
Full spectrum absorbance was measured in 96 well plates incubated at 37 °C over the
course of 15 hours. To determine the t1/2 of ligand exchange, the change in absorbance
was plotted as a function of time. While the t1/2 could be determined for 2x, compound 2z
underwent a very slow ligand exchange and the reaction never reached completion;
therefore, the half-life could not be accurately determined. Not surprisingly, 2y and 2aa
only show very minimal changes in UV/Vis spectra following 15 hour incubation in
aqueous solutions confirming that they are essentially kinetically inert.
To compare the rates of ligand exchange under different conditions for 2x–aa, the
spectral change at 500, 450, 345 and 325 nm, respectively, was determined. These
wavelengths represent where the majority of conditions tested resulted in maximal signal
change for each complex. Striking differences were seen for 2y and 2z, where 2y has the
fastest exchange in opti-mem supplemented with 1% FBS (fetal bovine serum, t1/2 = 12.8
min; used as a control for the cell cytotoxicity experiments), and slowest in water (t1/2 =
53 min, Figures 2.28 and S2.1.10, Table S2.1.1). On the other hand, 2z had the largest
spectral change in water (Δabs = 0.19) yet the smallest change in opti-mem with 1% FBS
(Δabs = 0.011, Figure 2.28 and S2.1.12, Table S2.1.4).
The fast exchange for 2y and minimal exchange for 2z in opti-mem with 1% FBS
may help to explain the drastic differences in cytotoxicity. The slow/minimal reaction of
2z with cell culture media would allow the complex to enter the cell without reaction
with media components, whereas the fast reaction of 2y essentially deactivates the
complex prior to entering the cell. One of the causes for transplatin’s inactivity is its high
chemical reactivity, where it becomes deactivated through reactions with plasma and
tissue proteins before entering a cell.32 In a recent publication, transplatin was
successfully internalized as the inactive molecule by encapsulation into nanocapsules,
essentially preventing deactivation; following intracellular release it was able to induce a
cytotoxic effect.33 Likewise, we have previously reported Ru(II) complex prodrugs that
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A

B

C

D

Figure 2.28: Thermal exchange studies of 2y and 2z at 37 °C showing rapid exchange
for 2y and slow exchange for 2z. (A) 2y in water, (B) 2z in water, (C) 2y in opti-mem,
1% FBS, and (D) 2z in opti-mem, 1% FBS. Insets show the change in absorbance fit to
a one phase decay equation. Note: 2z undergoes incomplete conversion over the course
of 15 hours.
are inactive but when irradiated with light produce a cis-Ru(bpy)2L2 (L = H2O or Cl) and
are quite cytotoxic.34 Clearly, caging the “inactive” compound to allow uptake into
cancer cells before a trigger renders these compounds “active”.
Once inside the cell, cisplatin is known to crosslink DNA, primarily through
intrastrand adducts to the N7 of guanosine, creating a cytotoxic effect, whereas
transplatin is unable to form the same crosslinks to DNA, resulting in a non-toxic
molecule. To determine if cis and trans Ru(II) complexes behave similarly to cis and
trans Pt(II) complexes, the DNA binding ability of 2y and 2z was tested. The kinetics of
both Ru(II) complexes were monitored in the presence of each DNA nucleoside, CT
DNA, and four oligonucleotides. The oligonucleotides, poly A poly T, poly G poly C,
poly AT, and poly GC were chosen to determine if the compounds have any base or
sequence preference.
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A

B

Figure 2.29: Final product overlay of (A) 2y and (B) 2z with each nucleoside. Buffer
(black), dA (blue), dT (red), dG (green), and dC (purple).
Both 2y and 2z exhibited similar responses in the presence of each nucleoside. It
is clear that an exchange takes place given the spectroscopic changes, however, the
nucleosides alone are not exchanging with the chloride ligands. Instead, the product
formed in each case is nearly identical to that formed in buffer alone, confirming the
exchange is likely with a component in the buffer rather than the nucleoside (Figure
2.29).
When 2y was incubated in the presence of duplex DNA some differences began
to arise. First, the interaction with the oligonucleotides exhibited two phase kinetics,
suggesting a different ligand exchange with DNA was occurring compared to in buffer
alone. Second, 2y had longer initial half-lives (t1/2 = 25 and 24.8 min) with poly A poly T
and poly AT than with poly G poly C and poly GC (t1/2 = 14.9 and 17 min, Table S2.1.1).
Lastly and most importantly, there were major spectroscopic differences in the products
of 2y, where poly G poly C and poly GC products are quite different from the products
A

B

Figure 2.30: Final product overlay of (A) 2y and (B) 2z with DNA. Buffer (black), CT
DNA (blue), poly A poly T (red), poly G poly C (green), poly AT (purple), and poly
GC (orange).
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formed with poly A poly T and poly AT (Figure 2.30). These results suggest there is a
base pair preference for GC over AT, like cisplatin. In contrast 2z did not exhibit
significant reaction with the DNA sequences and only show slightly higher absorbance
changes from the reaction in buffer over the 15 hour incubation (Table S2.1.3). However,
2z did have some spectroscopic differences between the DNA sequences, where the
product of 2z with poly G poly C and poly GC had slightly different spectra compared to
the other DNA sequences (Figure 2.29). This may indicate that 2z has a similar
preference for the GC base pair as 2y, though to a much lower extent.
In addition to examining the DNA binding behavior of 2y and 2z, the thermal
exchange in the presence of protein was explored. Interestingly, the thermal exchange
half-life of 2y is faster in the presence of BSA (t1/2 = 30 min) compared to buffer (t1/2 =
48 min, Figure 2.31). Likewise, 2z has 1.8x more change in the presence of BSA
compared to buffer only. In order to probe what amino acids are the likely site for
reaction with the metal complexes, small organic molecules that are structural mimics of
reactive amino acid side chains were tested. Only imidazole and β-mercaptoethanol
(BME) enhanced the ligand exchange of 2y, where the half-life was 2x and 1.2x faster,
respectively. Ethanol, imidazole, and acetic acid enhanced ligand exchange for
compound 2z, with 1.2–1.7x greater changes in absorbance. Therefore, we hypothesis
that 2y will likely bind proteins that have accessible histidine or cysteine residues,
whereas 2z has the possibility to interact through histidine, aspartic acid, glutamic acid,
serine, or threonine. These differences may play a role in the behavior of 2y and 2z in
A

B

Figure 2.31: Final product overlay of (A) 2y and (B) 2z with small molecules. Buffer
(black), BSA (brown), BME (blue), EtOH (red), imidazole (green), phenol (purple),
cysteamine (orange), acetic acid (pink), and acetonitrile (grey).
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vivo. Compounds 2y and 2aa were studied under the same conditions, but once more only
showed minimal change (Δabs < 0.08) over the course of 15 hrs due to the thermally
stable pyridine ligands.
It is possible that the number of exchangeable ligands differed for the cis and
trans complexes, and this also could contribute to the biological activity. As both 2y and
2z react with imidazole, the complexes were incubated with this heterocycle until there
was no further change in the absorption spectra, and then samples were analyzed by
HPLC and mass spectrometry. Both complexes react with imidazole and produce new
species with longer retention times than the products that form in buffer alone. The
reaction

of

complex

2y

with

imidazole

resulted

in

full

conversion

to

[Ru(bpy)2(imidazole)2]2+ with the same retention time and absorption spectra of the
molecule produced by chemical synthesis (Figure 2.32). Mass spectrometry also
confirmed that both Cl- ligands exchange for imidazole. The trans complex 2z also
exchanged both Cl- ligands for imidazole and the HPLC confirms that a different
chemical species is produced from that in buffer alone (Figure 2.32). Thus, both the cis
and trans complexes can form biadducts, and should be capable of crosslinks, either
between DNA bases, DNA and proteins, or within a protein.
SAR studies for cytotoxic metal compounds rarely investigate the impact of
geometry. The history of platinum compound research and the inactivity of transplatin
was interpreted to demonstrate that a particular geometric arrangement was required for
efficacy. However, replacement of the NH3 ligand in ineffective transplatin by planar Nheterocyclic amines produced trans-platinum complexes with significantly improved
cytotoxicity due to enhanced rate of bifunctional interstrand adducts formation and
altered sequence specificity.35 Not only the geometry requirements for platinum species
have been overcome; many compounds with “non-conventional” structures, including
polynuclear,36 monofunctional,37 Pt(IV)38 and organometallic39 complexes have displayed
anticancer potential. This highlights that more chemical space is available for exploration
among platinum compounds than previously thought. The same appears to be true for
ruthenium compounds, or, alternatively, different geometries should be investigated than
are currently reflected in the literature.
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2+

A

cis-[Ru(bpy)2(imidazole)2]

B

2+

C

trans-[Ru(qpy)(imidazole)2]

D

Figure 2.32: HPLC analysis for the thermal reaction of 2y and 2z with imidazole. (A)
HPLC traces for cis-[Ru(bpy)2(imidazole)2]2+ (black), the thermal reaction of 2y with
imidazole (blue), and the thermal reaction of 2y in buffer only (red). (B) UV/Vis profiles
of the peak at 8.4 min for cis-[Ru(bpy)2(imidazole)2]2+ (black), the peaks for the thermal
reaction of 2z with imidazole at 8.4 min (blue solid; overlays with the black line,
indicate the major product of the thermal reaction of 2y with imidazole resulted in the
formation of cis-[Ru(bpy)2(imidazole)2]2+) and 8.8 min (blue dashed), and the peaks for
the thermal reaction of 2z in buffer only at 7.7 min (red solid, overlaying with the blue
dashed, indicating the minor product formed in the thermal reaction of 2y with imidazole
is identical to the major product formed in buffer only) and 6.3 min (red dashed, a minor
product). (C) HPLC traces for the thermal reaction of 2z with imidazole (blue) and the
thermal reaction of 2z in buffer only (red). (D) UV/Vis profiles of the peaks for the
thermal reaction of 2z with imidazole at 8.2 min (blue solid), and 4.3 min (blue dashed)
and the peak for the thermal reaction of 2z in buffer only at 7 min (red, overlays with the
blue dashed line indicating the minor product formed in the thermal reaction of 2z with
imidazole is identical to the major product formed in buffer only).
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In conclusion, we have synthesized two trans Ru(II) complexes and studied their
binding interactions and cytotoxicities in comparison to their cis analogues. The trans
complex containing exchangeable ligands is 7.1–9.5x more potent than the cis compound,
depending on cell line. In addition, there are major differences in the DNA binding
behavior of the two compounds, and their interactions with amino acid mimics. We
hypothesize that the different rates of reactivity of 2y and 2z are crucial for their anticancer behavior. The fast and highly reactive cis complex, 2y, can easily react with media
and biomolecules, becoming inactive before it is able to enter the cancer cell, or is
quickly deactivated upon entering the cell, leaving an “inactive” compound. On the other
hand, the slow exchange of the trans complex, 2z, allows it to avoid side reactions and
reach a vulnerable target within the cell. Lastly, the ability of the Cl- ligands of 2z to
exchange is crucial to the biological activity, as evidenced by the absence of activity for
the complex incapable of ligand exchange. To the best of our knowledge, this is the first
report of the cytotoxic behavior of a trans polypyridyl Ru(II) complex. These results have
the potential to open up a new area of research to develop a metal-based
chemotherapeutic.

2.6 Summary – What structural features are most important for biological activity?
Five different questions were asked and answered over the course of the research
presented in this chapter. Structure-activity relationships have been identified and provide
a nice foundation for optimizing simple Ru(II) polypyridyl complexes as PACT agents.
Does increasing the π surface of the polypyridyl ligands have an effect on the
photocytotoxicity? Overall, increasing the π surface had a negative impact on the
photocytotoxicity. The larger π surface ligands, dppz/dmdppz significantly slowed the
ligand ejection process, where 2h and 2l had t1/2 values >8 hours and 23 min,
respectively. This ultimately resulted in minimal light induced cytotoxicity, giving small
PI values and rendering these complexes not ideal for PACT.
Will increasing the intramolecular strain provide optimal photochemistry
and what effect does it have on the photocytotoxicity? Two series of Ru(II) complexes
were synthesized and tested, where one series had one strain-inducing methylated ligand
and the other series had two strain-inducing methylated ligands. In series one, 2e–2g,
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there was a direct correlation between the strain added to the two bpy co-ligands by the
presence of the two methyl groups on the third ligand and the t1/2 of photoejection. The
greater the distortion of the bpy co-ligands the faster the photoejection occurred when
irradiated with 470 nm light. The second series did not have the same relationship, where
the two dmphen ligands were equally strained in all four complexes and the t1/2 was
similar for three of the four complexes. Additionally, when the ejected ligand is dmphen,
as with complexes 2e and 2i–2k, fast photoejection occurs (t1/2 = 0.5–3 min) and large PI
values in both HL60 and A549 cells are obtained, creating optimal activity for PACT.
Can the light activation wavelength be tuned to within the therapeutic
window for PDT and PACT? The addition of ligands that red-shift the absorption
profile of the Ru(II) complex were used to gain activation with red to near-IR light. The
first set of complexes incorporated biq ligands that extend the π surface around the Ru(II)
center and generated strain by clashing with the other ligands. With two biq ligands, 2n
was cytotoxic following activation by red and near-IR light, and was the first light
activated metal complex to be reported for activation in the therapeutic window.
Unfortunately, the dark toxicity of 2n was high and the complex only had a PI value of
9.2 with near-IR light. In efforts to further shirt the absorption profile and reduce the dark
toxicity, the bnap ligand was used and gave a nice 25 nm shift to 575 nm for the MLCT.
Two of the four complexes synthesized were not photoactive due to the lack of strain
created by the bnap ligand. Additionally, the two photoactive complexes were highly
dark toxic toward HL60 cells and only gave a maximal PI value of 3.5. While the bnap
ligand gave a close to ideal absorption profile, the in vivo activity was not promising.
Therefore, the activation wavelength can indeed be tuned, but other factors, such as dark
toxicity or photochemistry, may be negatively impacted. Further optimization of these
red-shifted Ru(II) complexes is needed.
Are light-activatable monofunctional Ru(II) complexes equally active as
bifunctional Ru(II) complexes? The photochemical and biological activity of four
monofunctional and two bifunctional Ru(II) complexes were compared. The presence of
a Cl- ligand for the monofunctional complexes slowed the ligand ejection process
significantly, compared to the more rapid photoejection of the bifunctional complexes. In
vitro DNA damage studies showed no interaction of any complex with plasmid DNA in
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the absence of light, but following irradiation showed significant binding. The degree of
binding was directly related to the t1/2 of ligand ejection, i.e. the slow ejecting complexes
had less binding than the fast ejecting complexes. The cytotoxicity was tested in E. Coli,
where many of the complexes had little to no dark toxicity and PI values up to 7.3.
Overall, these complexes did not have activities similar to the bidentate complexes
discussed previously and their activity needs to be significantly improved to be used for
PACT.
Does the geometry matter? Geometry is important for the thermal activity of
Ru(II) polypyridyl complexes. Thermally labile cis and trans Ru(II) polypyridyl
complexes showed significantly different behaviors in vivo, where cis was inactive on
HL60 cells and trans was very active. A series of in vitro studies showed drastic
differences in the rates of thermal exchange for cis versus trans. The cis complex
exchanged rapidly and could easily be deactivated in vivo, whereas trans was very slow
and would be able to reach its intended target. The in vitro studies also suggested that
there may be different in vivo targets for cis versus trans Ru(II) complexes. Overall, these
results have opened a new area of research for metal-based chemotherapeutics, and light
activated studies are ongoing.
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Chapter 3. Exploiting differences in cancer cells to improve uptake and light
induced cytotoxicity.

3.1 Introduction.
As discussed extensively in the previous chapter, PDT and PACT are medical
treatments where drug molecules are “turned on” by light and have the potential to reduce
off-target damage by spatially restricting the areas exposed to radiation. The wavelength
of activation is very important and affects the depth of tissue penetrance; therefore,
designing molecules that can be activated using different wavelengths of light increases
the versatility of phototherapeutics.1 Ru(II) polypyridyl complexes have tunable
photophysical and photochemical characteristics that can be exploited to design
complexes for PDT and PACT that are inert until activated with different wavelengths of
light, as shown in Chapter 2. Expanding on traditional Ru(II) complexes, we aimed to
create a synthetic “building block” to rapidly synthesize different functionalized Ru(II)
complexes.

The

addition

of

a

chemically

reactive

ligand,

5,6-epoxy-5,6-

dihydro[1,10]phenanthroline (phenepoxide), renders the Ru(II) complex as a synthetic
intermediate or “building block” containing a point of attachment for nucleophilic groups
that can be used to enhance uptake,2 target specific receptors, or direct subcellular
localization (Figure 3.1).
One downside to traditional chemotherapeutics is their inability to differentiate
between cancer cells and healthy cells. One major difference between cancer cells and
Tuning the MLCT Energy

Reactive Substituents

Modulating Strain

Environmental Sensitivity

Modifying Charge
Improving Uptake
Increasing Hydrophilicity

Specific Receptor Targeting

Increasing Hydrophobicity

Subcellular Localization

Figure 3.1: Depiction of the diversity in properties that can be explored through coligands and a chemically reactive ligand.
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healthy cells that can be exploited is the enhanced metabolic requirement of cancer cells.
The suppression of the oxidative metabolism pathway by cancer cells is known as the
“Warburg effect”.3 The “Warburg effect” is characterized by the upregulation of
glycolysis as the primary source of ATP. Our goal is to design light activated Ru(II)
complexes that take advantage of the increased rate of glycolysis and upregulation of
glucose transporters in efforts to increase uptake into cancer cells over healthy cells.
Additionally, using different co-ligands, we can modulate the behavior of the Ru(II)
complex (Figure 3.1). For example using ligands that introduce strain around the metal
center, such as dmphen or biq, results in light induced ligand dissociation using different
wavelengths of light, creating reactive species that covalently bind biomolecules, in vivo,
creating a cytotoxic effect.

3.2 Functionalizing Ru(II) polypyridyl complexes for PDT and PACT.
In effort to study the impact different functional groups, targeting molecule, and
co-ligands have on the photoejection kinetics, cytotoxicity, off-target toxicity, and
cellular uptake, four sets of complexes were synthesized and tested (Figure 3.2).

3a (bpy)
3b (biq)
3c (dmphen)

3d (bpy)
3e (biq)
3f (dmphen)

3g (biq)
3h (dmphen)

3i (bpy)
3j (biq)

Figure 3.2: Structures of the four sets of Ru(II) complexes studied for increasing
synthetic diversity and targeting cancer cells.
73

Phenepoxide was complexed with Ru(bpy)2Cl2, Ru(biq)2Cl2, and Ru(dmphen)2Cl2 to give
complexes 3a–3c. The phenepoxide ligand undergoes nucleophilic substitution in the
presence of different nucleophiles, and for the purpose of this study, primary thiols were
used as the nucleophile. For complexes 3d–3h, ligands were synthesized prior to
complexation with Ru(L)2Cl2, in order to optimize the nucleophilic substitution reaction
conditions. Complexes 3i and 3j were synthesized from 3a and 3b, respectively. Overall,
three co-ligands and three functionalized phenanthroline ligands were explored.
[Ru(bpy)2L]2+

The

complexes

are

photochemically inert,

whereas

the

[Ru(biq)2L]2+ and [Ru(dmphen)2L]2+ complexes are photolabile. As discussed in Chapter
2, the addition of biq and dmphen co-ligands induces distortion and results in light
activated ligand dissociation. The photoejection process was followed using UV/Vis
absorption spectroscopy, where aqueous solutions of 3e–3j were irradiated with a 470 nm
LED and scans were taken after select irradiation time points. Compounds 3e, 3g, and 3j,
were also irradiated with a 660 nm LED due to their red-shift absorption
A

B

C

Figure 3.3: Photoejection process for 3e. (A) UV/Vis profile, with tinitial (orange line)
and tfinal (green line), (B) kinetic analysis of the change in absorption as a function of
time when 3e is irradiated with the 470 nm LED (blue line) and the 660 nm LED (red
line), and (C) reaction scheme showing the photoejection products of 3e.
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Table 3.1: t1/2 values and identity of ligand ejected for 3e–3j.
t1/2 (min)

Compound
470 nm

660 nm

Ligand ejected

3e

2.22 ± 0.04

16.9 ± 0.3

Biq

3f

4.4 ± 0.1

N.D.

Dmphen

3g

2.1 ± 0.1

16 ± 2

Biq

3h

10.3 ± 1.2

N.D.

Dmphen

3j

2.53 ± 0.04

20.1 ± 0.5

Biq

profiles (Figure 3.3). The t1/2 of ligand ejection was determined using the change is
absorption as a function of time (Table 3.1). The ligand ejection process is dependent on
the degree of distortion induced by the strained co-ligands, where the biq co-ligands
create more distortion; therefore, 3e, 3g, and 3j had shorter t1/2 values 3f and 3h when
irradiated. Additionally, 3e, 3g, and 3j exhibited 7.6–7.9x slower ligand ejection when
irradiated with 660 nm light compared to 470 nm light. The products of ligand ejection
were determined by ESI-MS, and each complex was found to eject the strained ligand,
biq or dmphen, not the functionalized ligand (Table 3.1).

3.3 Testing for off-target toxicity.
Ru(II) complexes, such as [Ru(phen)3]2+, have been previously reported to bind
acetylcholinesterase at low μM concentration.4 Acetylcholinesterase (AChE) is an
enzyme that breaks down the neurotransmitter acetylcholine. Irreversible inhibition of
AChE can result in deleterious side effects, such as bradycardia (slowing of the heart
rate), hypotension (low blood pressure), bronchoconstriction (constriction of the airways
in the lungs), intraocular pressure (fluid pressure inside the eye), seizures, or even death.
For example, Paraoxon, an organophosphate cholinesterase inhibitor, is primarily used as
a pesticide and is a potent irreversible inhibitor that has been shown to lead to seizures,
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A

B

C

Figure 3.4: Percent inhibition of AChE with 10 μM Ru(II) complexes.
cardiac arrest, and death. Reversible AChE inhibitors are used medicinally but are fully
regulated.5 Testing the inhibition of AChE prior to in vivo testing could provide important
information on the promise of the Ru(II) complex as a potential drug. In order to
investigated AChE inhibition, Ellman’s standard colorimetric assay was used to detect
the break down of acetylthiocholine, where the product, thiocholine, reacts with 5,5dithio-bis-2-nitrobenzoic)acid (DNTB) to produce a yellow product. The turnover of
acetylthiocholine was monitored in the absence and presence of 10 μM Ru(II) complexes
by absorption in a 96-well plate over the course of 10 min. The percent inhibition was
determined for each complex, in comparison to their [Ru(L)2phen]2+ derivatives (Figure
3.4). When thioglucose is added to the phenanthroline ligand, the % inhibition is
decreased by 8.4–25.6%. These results are extremely promising for the use of thioglucose
functionalized complexes for future mouse studies, as these complexes may result in less
off-target toxicity.

3.4 Cytotoxicity in HL60 cells.
Ru(II) polypyridyl complexes display a wide range of activities in the absence of
light and following light activation. To determine the efficacy, cytotoxicity studies were
performed in HL60 cells in the dark and following irradiation. All complexes tested were
activated with 470 nm light. Additionally, 3d–3f, 3i, and 3j were irradiated with 660 nm
light. IC50 values show a broad range of activity for these complexes (Table 3.2).
Complexes 3g–3i have significant dark toxicity and only slight light induced toxicity,
whereas 3j has no dark toxicity and very little light induced toxicity. In general, the
addition of the thioglucose to the phenanthroline ligand reduced the dark toxicity for each
backbone. Interestingly, 3e had no activity in the dark or after irradiation. On the other
hand, 3f has very little dark toxicity (72.4 μM) and following blue light irradiation is
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Table 3.2: IC50 values in HL60 cells for 3d–3j.
IC50 [μM]

Compound

a

Dark

470 nm

PI

660 nm

PI

3d

>100

11.6 ± 0.9

>8.8

>100

1

3e

>100

>100

1

>100

1

3f

80 ± 20

0.28 ± 0.07

286

8.3 ± 1.7

9.6

3g

31 ± 9

10.2 ± 0.3

3

8.9 ± 0.7

3.5

3h

36 ± 3

1.3 ± 0.2

28

2.2 ± 1.0

16.4

3ia

>100

50 ± 5

>2

80 ± 2

>1.25

3j

22.9 ± 0.1

6.6 ± 0.5

3.5

19.9 ± 0.8

1.2

Only 50% cell death occurs.

extremely cytotoxic (0.3 μM), giving a PI value of 240. We hypothesized the difference
between 3e and 3f is based on the uptake of the two complexes, where 3e does not get
into cells but 3f does.

3.5 Cellular uptake in HL60 cells.
Atomic absorption spectroscopy (AA) was used to determine the Ru content in
HL60 cells following the incubation in the absence of light and following irradiation with
the 470 nm LED. The biq and dmphen complexes were compared to their phenanthroline
derivatives 2m and 2j, respectively. In general, minimal ruthenium is taken into cells in
the dark, where 2j, 3e, and 3h had levels below the detection limit of the instrument.
Following irradiation, the uptake is increased for each complex. In contrast to our
original hypothesis, the least cytotoxic molecules from the [Ru(biq)2L]2+series, showed
the greatest uptake into HL60 cells. Additionally, the two thioglucose complexes, 3e and
3f have the least uptake in comparison to the other complexes in their series.
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Table 3.3: Percent uptake into HL60 cells determined by AA for 2j, 2m, and 3e–3h.

a

Compound

Dark

Light

2m

0.45 ± 0.03

3.8 ± 0.3

3e

0.0a

1.6 ± 0.1

3g

0.34 ± 0.02

3.80 ± 0.02

2j

0.0a

1.00 ± 0.02

3f

0.09 ± 0.1

0.53 ± 0.03

3h

0.0a

1.1 ± 0.1

Ruthenium content is below the detection limits of the instrument.

A

B

Figure 3.5: Cellular uptake of 2j, 2m, and 3e–3h into HL60 cells in the absence of light
(black) and following irradiation (blue).

3.6 Conclusions.
A single step approach was developed to modify Ru(II) complexes and increase
the synthetic diversity by using phenanthroline epoxide as a reactive center, allowing for
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divergent synthesis through the incorporation of moieties to modulate uptake and
reactivity. Biq and dmphen co-ligands induced distortion in the Ru(II) complex, allowing
for light-activated ligand loss. Thioglucose was added to 3 Ru(II) complexes in order to
increase uptake into cancer cells, and resulted in a complex, 3f, with a PI of 240. The
addition of thioglucose reduces the inhibition of AChE, a possible target that induces
deleterious side effects. Unexpectedly, the cellular uptake did not directly relate to the
cytotoxicity of these Ru(II) complexes. Modifications to the Ru(II) complexes
successfully reduced dark toxicity, and light induced toxicity was dependent on the
ligands present. Additional studies need to be completed to determine the uptake
mechanism of the thioglucose complexes to determine why those complexes have the
lowest uptake into HL60 cells, yet the most promising in vivo results.
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Chapter 4. Developing “light switches” for nucleic acids

4.1 Introduction to the “light switch” effect.
Small molecules have been utilized with great success to investigate DNA
sequences and structures.1 Typical interactions that may result in specific sequence and
structure recognition include groove binding2 and intercalation.3 Metal complexes3-4, as
well as organic small molecules, have been reported to demonstrate preferential binding
for different types of DNA, such as duplex5 and G-quadruplex DNA.6 Compounds have
also been designed to recognize different DNA sequences, including DNA defects, such
as mismatch DNA7 and abasic sites.7b Certain DNA defects and structures are more
prevalent in human diseases, and as a result designing molecules with increasingly
selective DNA recognition is an active area in drug discovery research.6a, 8 Two important
areas of research are utilizing molecules that luminesce upon binding to specific DNA
sequences or structures9 and assay development for rapid identification of compounds
that selectively bind biologically relevant DNA targets.10
Luminescent Ru(II) polypyridyl complexes are of interest as photophysical probes
because they are kinetically inert, absorb and emit visible to near-IR light, are
photostable, and have tunable photophysical properties.11 Ru(II) complexes containing
the dipyridylphenazine (dppz) ligand act as unusual environmentally sensitive “light
switch” compounds. Unlike most Ru(II) polypyridyl complexes, [Ru(LL)2dppz]2+ (LL =
bpy or phen) are non-luminescent in aqueous solutions but brightly emit in non-aqueous
environments, making them sensitive probes for molecular-level surroundings. Multiple
theories have been proposed to explain the behavior of these compounds.12 Similar to
other Ru(II) polypyridyl complexes, the Ru(II) center undergoes a metal-to-ligand charge
transfer (MLCT) upon visible light excitation, where an electron is transferred from a
Ru(II) d-orbital into a π* orbital of the dppz ligand. Population of this 1MLCT state is
followed by quantitative intersystem crossing, where the electron relaxes into lower
energy 3MLCT excited state(s). In contrast to many luminescent Ru(II) complexes,
however, localization of the electron on different portions of the dppz ligand results in
different behavior. If the excited state is localized on the bpy portion, this results in a
luminescent “bright” state, while localization on the phenazine portion yields a non80

luminescent “dark” state (Figure 4.1).12d In some environments these two states are in
thermal equilibrium, and the differential partitioning between the 3MLCT states and/or
increasing the energy gap between them has been theorized to lead to the
environmentally sensitive “light switch” effect.12a Greater population of the “bright” state
is seen in non-polar aprotic solvents, while the “dark” state is favored in aqueous
environments.12a
1

MLCT

BS
3

4a

Absorption

N

N

N

N

bpy

MLCT
DS

NR
Decay

Emission

phenazine
GS

dppz fragments

Photophysics

Figure 4.1: Structures of 4a, dppz fragments and a Jablonski diagram.
Interestingly, complexes containing the dppz ligand have been shown to exhibit
DNA and RNA sensing capabilities, including sequence and tertiary structure selectivity,
making them useful as selective probes for DNA damage.7c,

13

Luminescent Ru(II)

polypyridyl complexes have been used to detect duplex DNA as well as different DNA
sequences, such as DNA mismatches or abasic sites.5,

7

Several compounds have also

been shown to exhibit selectivity for G-quadruplex structures.14 These complexes are
typically

[Ru(bpy)2L]2+

imidazophenanthroline.14a-c,

or

[Ru(phen)2L]2+,

14g-l

As with the organic systems, the compounds interact

where

L

is

a

derivative

of

primarily through π-stacking, which both induces the formation of G-quadruplexes and
stabilizes these structures. Given the sensitivity of Ru(II) complexes containing the dppz
ligand and its derivatives as biological sensors we were interested in exploring this
phenomenon in relationship to our photoactive Ru(II) complexes.
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4.2 Discovery of a photochemical “light switch”.15 (Reproduced from Ref. 15 with
permision from the Royal Society of Chemistry.)
In 2014, we reported a new type of DNA “light-switch”: a ruthenium complex
containing a dppz derivative that undergoes photochemical ligand substitution reactions
in the presence of DNA. This is in marked contrast to the extensively described
photophysical processes that have previously defined dppz complexes, and indeed most
other biological probes. This unusual system exhibits selective photochemistry to
generate a ligand-deficient and reactive metal center, along with a free coordinating
ligand, in the presence of nucleic acids and organic solvents. Furthermore, the compound
is sensitive to the DNA tertiary structure, displaying different reactivities in duplex and
G-quadruplex DNA. This feature could provide the basis for the development of DNA
structure-selective probes and effectors.
We have previously developed strained ruthenium complexes that undergo
phototriggered ligand ejection reactions in order to generate highly potent cytotoxic

A

4b

B

Figure. 4.2: Selective photoejection of 4b occurs in the presence of DNA. (A) Scheme
for the selective photoejection of dmdppz from 4b with λ > 400 nm light. (B) UV/Vis
monitoring of photoejection in the presence of CT DNA (10:1 nucleotide:Ru(II)). The
kinetic fit for the photochemical reaction is shown in the inset.
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species that are only activated when exposed to visible or near-IR light.16 This new lightresponsive agent adds sensing functionality, giving a DNA-selective “photochemical
light-switch”. The ligand dissociation proceeds through reactions of high-energy, liganddissociative 3MC excited states.17 Direct excitation to the 3MC state is forbidden, but
intramolecular strain lowers the energy of the 3MC state to allow for thermal population
from lower energy MLCT excited states, which are accessible with visible light.18 Thus,
to transform the light-switch 4a into a probe that combines DNA sensing with ligand
ejection photochemistry, as shown in Figure 4.2, strain-inducing methyl groups were
incorporated at the 3 and 6 positions of the dppz ligand (3, 6-dimethyl
dipyridylphenazine, dmdppz) to make 4b.

Figure 4.3: Crystal structure of racemic 4a and 4b show the bend of the dmdppz ligand.
4a side view (A) and full atom labeling (B); 4b side view (C) and full atom labeling
(D). Ellipsoids are drawn to 50% probability and hydrogen atoms are excluded for
clarity. Note: the crystal structures contain two independent but structurally similar
cations; only one is shown for clarity.
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The crystal structures of racemic 4a and 4b confirmed that addition of the methyl
groups induced distortion about the metal center, as shown in Figure. 4.3. The Ru-N
bonds are lengthened in the strained ligand, with an average of 2.10 Å for the Ru-N
bonds in dmdppz, in contrast to 2.07 Å for dppz. The main distortion in 4b is a 15°
bending of the dmdppz ligand from the normal plane of the octahedral complex, due to
the clash of the methyl group with the auxiliary ligands. The distortion is limited to the
misdirected19 and extended metal-ligand bonds to the dmdppz ligand; the bpy ligands in
either compound do not experience significant distortions.
Based on our previous work with analogous methylated, strained bipyridine or
phenanthroline complexes,16a, 20 one might expect 4b to undergo rapid photosubstitution
reactions in water and other nucleophilic solvents. However, 4b is quite unreactive in

A

B

Figure 4.4: Photochemical reaction of 4b is selective for DNA over protein.
Photoejection of 4b in the presence of (A) bovine serum albumin (BSA) and (B)
TGGT

duplex

DNA.

The

lack

of

isosbestic

points

for

(A)

indicates

photodecomposition in the presence of BSA; where as the presence of isosbestic
points for (B) indicate a selective photochemical process when bound to duplex DNA.
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Table 4.1: Photophysical and photochemical properties for 4a and 4b for various
reaction conditions.
λmax (nm),

t1/2 (min),

4a

4b

H2O

-

> 480

D2O

605 (weak)

140 ± 10

CH2Cl2

596

0.5 ± 0.05

DMF

638

25 ± 2

CT DNA

619

41 ± 2

TGGT duplex

615

31 ± 0.5

K+ G-Quadruplex

613

13.5 ± 1

-

154 ± 8

Conditions[a]

BSA

[a] See Chapter 6 for details.
water, exhibiting only very slow photodecomposition when exposed to visible light (λ >
400 nm; t1/2 > 8 hours), hinting at a more discerning switch that could exploit triggers in
concert with light. Indeed, the photoreactivity is increased by more than an order of
magnitude in the presence of duplex DNA oligonucleotides and CT DNA, with t1/2 values
of 31–41 minutes, as shown in Table 4.1. The photoejection process is characterized by
both a red shift in the absorption spectra and decreased extinction coefficient. Ligand
ejection is highly selective, as indicated by the presence of isosbestic points in the
UV/Vis spectra taken as a function of irradiation time (Figure 4.2 and 4.4). Only the
dmdppz ligand is ejected, and the photoreaction leads to covalent metalation of the DNA
(Figure 4.5).
The distortion of 4b does not appear to significantly affect the DNA binding
affinity, as similar Kb values of 1 x 107 and 3 x 107 M-1 were determined for racemic
mixtures of 4a and 4b with CT DNA.21 Intercalation of both complexes is also consistent
with the reduced mobility of supercoiled plasmid DNA in agarose gels, and the
modulation of the absorption spectra in the presence of DNA, characterized by
hypochromism of both the π-π* of the dppz ligand and the MLCT transitions, with
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A

B

C

D

DNA
dmdppz
Unreacted Ru(II)

Figure 4.5: HPLC chromatograms show the covalent attachment of 4b to the TGGT
duplex following irradiation. For all graphs: DNA only (black); DNA:Ru(II) in the
dark (blue); DNA: Ru(II) after irradiation (red); dmdppz ligand (green). (A) Left:
Expansion of chromatograms for DNA-containing peaks; right: UV/Vis spectra of
peaks from 7–7.5 min. demonstrates that Ru(II) is only retained with the DNA when
irradiated. (B) Left: Elution of unreacted Ru(II); the area decreases following
irradiation; right: UV/Vis spectra of peaks from 14–18 min. show the absorption
profile of Ru(II). (C) Left: Elution of ejected dmdppz only upon light activation of
Ru(II) with DNA; right: UV/Vis spectra of the peak at 35 min. show pure dmdppz and
ejected dmdppz. (D) Overlay of full HPLC chromatograms.
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maximal effect at a ratio of 2:1 DNA base pairs to metal center.22 Thus, the strained
complex retains the key DNA-sensing capabilities of other Ru(II) “light-switch”
molecules with the added facet of photochemical reactivity. Alternative tertiary structures
of DNA are intriguing targets for small molecule probes and therapeutics as they provide
potential for greater selectivity in gene and cellular regulation than double stranded
motifs. G-quadruplex structures are stacked tetrads of guanine bases found in both
telomere regions of chromosomes and promoter regions of specific oncogenes,23 making
them medically significant targets for cancer research and therapies.24 It has been shown
that Ru(II) complexes containing the dppz ligand bind to G-quadruplexes and exhibit
enhanced emission,25 so 4b was tested as a photochemical probe for the telomeric Gquadruplex structure using the sequence [AGGG(TTAGGG)3]. As anticipated, upon
binding the quadruplex, the photoejection rate for 4b increased 3-fold compared to
standard double helix CT DNA, giving a t1/2 of 13.5 minutes.26 This greatly enhanced
reactivity offers promise for 4b in potential applications in sensing and perturbing Gquadruplexes,21 and suggests it may show other sequence or structure discrimination
abilities.
The selectivity of the probe for DNA was compared to protein by testing the
ejection with BSA, a model non-selective small molecule binding protein.22 In contrast to
the nucleic acids, there was no observable emission for 4a in the presence of BSA, and
4b appeared to photo-decompose, with no isosbestic points in the absorption spectra
(Figure 4.4) and a t1/2 of 146 minutes. The poor reactivity with a hydrophobic protein is
similar to the behavior in water, and highlights the selectivity of the photochemistry for
the environment provided to the probe by intercalation in DNA.
Overall, the photochemical behavior of 4b parallels the photophysical
characteristics of unstrained Ru(II) complexes containing the dppz ligand. For example,
the emission intensity of 4a and other dppz complexes increases significantly in
nonpolar, aprotic solvents such as dichloromethane;23 similarly, the photoejection rate of
4b increases markedly as well (t1/2 > 8 hrs in water, t1/2 = 0.5 min in CH2Cl2, providing
>1,000-fold increase in ejection rate). As CH2Cl2 is a non-coordinating solvent, ligand
ejection is likely followed by coordination to the Cl- counter-ion, producing the
distinctive red-shift in the absorption spectra (Figure 4.6). The luminescence of Ru(II)
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A

B

C

Figure 4.6: Photoejection of 4b in CH2Cl2. (A) Cl- counter-ions, (B) PF6- counterions, and (C) PF6- counter-ions with 10x Bu4N+Cl-. The addition of a Cl- source
provides evidence that the Cl- acts as a ligand upon photoejection, and the final
UV/Vis absorbance profile is dependent on the identity of the incoming ligand in
solution.
dppz complexes is greater in D2O than H2O;24 the ejection of 4b also shows a similar
isotope effect of >3.4.25 These results are consistent with the interpretation of quenching
of the excited state photoejection process through vibrational deactivation processes
mediated via H-bonding.
The current model that describes the enhanced emission of the Ru(II) dppz
complex when bound to DNA or dissolved in non-polar solvents is based upon a
competition between a lower energy “dark” state that arises from the Ru(II) MLCT to the
phenazine portion of the dppz ligand and a higher energy “bright” state that is the result
of an MLCT to the bipyridine portion of the dppz ligand. The relative energies of these
two states are sensitive to the environment about the complex.26 Polar, protic
environments stabilize the “dark” state, lowering its energy and preventing the thermal
population of the higher energy “bright” state, thereby quenching emission.27 In contrast,
in DNA or aprotic solvents the “dark” state is close enough in energy to the “bright” state
to allow for its thermal population, resulting in enhanced emission. The

photochemical

behavior of 4b in DNA and select solvents is well explained by this model, augmented by
a tunable and energetically accessible 3MC state. A proposed Jablonski diagram is shown
in Figure 4.7, illustrating the interplay between these states. The “bright” and “dark”
states are in thermal equilibrium as a function of the environment, and the dissociative
3

MC state can be accessed only from the “bright” state. Population of the “dark” state is

enhanced in solvents such as water, and results in alternative non-radiative decay
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1

MLCT

3

MC

BS
3

Absorption

MLCT
DS
Ligand
Loss
Emission

GS

NR
Decay

Photophysics

Photochemistry

Figure 4.7: Jablonski diagram for the photophysics and photochemistry showing the
response of the different excited states to environment and strain.
pathways that reduce the yield of photoejection. A correlation can also be drawn between
the energy of the “bright” state (reflected by the emission wavelength of the unstrained
4a; Table 4.1) and the ejection rate of the strained system 4b. This is consistent with
enhanced population of the 3MC state from the “bright” state when the “bright” state is
elevated in energy. Studies in non-aqueous solvents provide additional support for this
explanation. Two aprotic solvents with similar ET(30) values were chosen to compare
emission and photoejection properties; the ET(30) scale provides an empirical measure of
the microscopic polarity of the solvent.27 The emission quantum yields of 4a are similar
in DMF and CH2Cl2, (DMF ET(30) = 43.8; λem = 0.011; CH2Cl2 ET(30) = 41.1; λem =
0.012).23 However, a 50-fold difference in t1/2 values was found for 4b (see Table 4.1) in
CH2Cl2 and DMF. Emission in the slightly more polar DMF is red-shifted, with λmax =
638 nm, reflecting a stabilization of the “bright” state, and thus reducing population of
the ligand dissociative 3MC state. In contrast, the emission in CH2Cl2 is characterized by
λmax = 596 nm, and much more facile ligand loss. This data suggests that the complex
will undergo ligand ejection photochemistry most efficiently under conditions that
destabilize polar charge transfer states and reduce population of the “dark” state MLCT
and it associated non-radiative decay pathways.
To the best of our knowledge, this strained Ru(II) dmdppz compound was the first
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metal complex shown to act as a dual photochemical DNA sensor and metalating agent.
For this molecule, strain is necessary but not sufficient to induce photoejection, as
environmental factors affect other nonradiative decay processes. In efforts to determine
the mechanism of the photochemical reaction 4b undergoes, we studied, in detail, the
environmental influence.
4.3 Investigating the photochemical “light switch” mechanism.28 (Reproduced with
permission from J. Phys. Chem. A, 2014, 118, 10474–10486. Copyright 2014 American
Chemical Society)
Compound 4a acts as a photophysical “light switch” but with the addition of two
methyl groups on the dppz ligand that are directed toward the Ru(II) center results in 4b,
a photochemical “light switch”. As previously discussed, this structural modification
induces distortion in the Ru(II) complex, which renders the complex photo-labile.15 The
two methyl groups clash with the bpy co-ligands, which results in the Ru-N bond lengths
of the dmdppz ligand being extended from 2.07 Å to 2.10 Å.15 In addition, the dmdppz
ligand is bent out of the normal plane by 15°.15 Results from this initial study revealed
that 4b undergoes rapid photo-induced ligand dissociation of the dmdppz in CH2Cl2 and
other organic solvents, but is very unreactive in an aqueous environment, where
photodecomposition is up to 1000x slower.15 In addition, 4b selectively ejects the
dmdppz ligand when intercalated into duplex or G-quadruplex DNA, and the Ru(II)
center covalently binds to the DNA bases. However, it is far less photoreactive in BSA, a
hydrophobic protein, suggesting that the complex exhibits significant photochemical
sensitivity and is able to discriminate between different hydrophobic environments.13c, 15
Our initial hypothesis was that ligand ejection photochemistry was favored under
conditions that lead to destabilization of the 3MLCT states, and greater population of the
“bright” state closest in energy to the dissociative 3MC state.29 The in vitro biological
behavior of 4b shows promise for use in detection and metalation of different DNA
structures, but in order to fully understand the biological behavior of 4b, we first need to
understand the fundamental photophysical and photochemical pathways that result in its
environmental selectivity. This is complicated by the fact that the only direct observable
comparison for both compounds 4a and 4b, at room temperature using steady-state
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spectroscopy, is the energy difference between the ground state and the initial 1MLCT,
which is the same (as illustrated by their essentially identical absorption spectra and
absorption solvatochromism). The 3MLCT state cannot be directly detected for 4b, as the
compound is non-luminescent in all solvents tested at room temperature, and observation
of the population of the 3MC state without the use of transient absorption spectroscopy is
only possible by indirect means, by following photoinduced ligand loss.30 Thus, to
elaborate on the photophysical processes that precede the final ligand loss step, we
studied the photochemical ligand loss behavior of 4b under different environmental
conditions in conjunction with studying the photophysical (emission) behavior of 4a.

4.3.1 ET(30) dependence.
In aqueous environments, hydrogenn -onding to both of the phenazine nitrogens
of the dppz ligand cause both [Ru(phen)2dppz]2+ and 4a to be non-luminescent due to
stabilization of the “dark” state relative to the “bright” state.12a, 12b, 12d This stabilization
increases population of the “dark” state, thus decreasing emission. The “dark” state is
associated with a 3MLCT localized on the more distant phenazine portion of dppz and the
luminescent “bright” state is a 3MLCT localized on the bpy portion of dppz.12e Therefore,
the dipole moment of the “dark” state is greater than that of the “bright” state, resulting in
increased sensitivity of the “dark” state to solvent polarity, in addition to the hydrogenbonding ability of the solvent.12c Various reports suggest that solvent polarity, expressed
using the ET(30) scale, an empirical measurement of solvent polarity, plays a vital role on
the photophysics of 4a.12e, 31 Studies measuring the luminescence lifetime, quantum yield
and λem of [Ru(phen)2dppz]2+ in solvents with different ET(30) values showed that there is
a reasonably linear relationship between solvent polarity and lifetimes and quantum
yields.31a In general, as the polarity of the solvent increases, the luminescent lifetimes
shorten and quantum yields decrease, but the λem does not correlate well with solvent
polarity.31a
To determine the extent to which the photophysics of 4a relates to the
photochemistry of 4b, photoejection studies of 4b were performed in a series of solvents
with a wide range of ET(30) values. The half-lives for ligand photoejection, with Clcounter-ions unless otherwise noted, were compared to the luminescent properties of 4a
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Table 4.2: Selected photophysical data for 4a and photochemical data for 4b with
solvents of different ET(30) values.
ET(30)
(kcal/mol)[b]

λem (nm),
4a[c]

Area,
4a[c]

t1/2 (min),
4b

CH2Cl2

40.7

596

7.08 x 107

0.5 ± 0.05

DMF

43.2

638

1.20 x 107

25 ± 2

CH3CN

45.6

618

2.63 x 107

1.6 ± 0.1[d]

CH3CH2OH

51.9

611

2.71 x 107

1.23 ± 0.01

CH3OH

55.4

614

3.22 x 106

5.8 ± 0.1

Water

63.1

-

-

>480[e]

Solvent[a]

[a] Cl- counter-ions was used unless otherwise noted. [b] See reference 32b. [c]
Luminescence data reported are uncorrected values. [d] PF6- counter-ions used to
simplify the photoejection process, as Cl- counter-ions can compete with solvent as
incoming ligands. [e] t1/2 of water was estimated for the photodecomposition of 4b.
(Table 4.2). As previously stated, the most non-polar solvent, CH2Cl2 (ET(30) = 40.7
kcal/mol), exhibited the fastest ligand ejection t1/2 of 0.5 min, but another solvent with
similar polarity, DMF (ET(30) = 43.2 kcal/mol), is 50-fold slower (t1/2 = 25 min).15
Further increasing solvent polarity with acetonitrile (PF6- counter-ions, ET(30) = 45.6
kcal/mol) and ethanol (ET(30) = 51.9 kcal/mol) increased the rate of ligand ejection, with
t1/2 of 1.6 and 1.23 min, respectively. Photoejection was slower when irradiated in
methanol (ET(30) = 55.4 kcal/mol) with a t1/2 of 5.8 min, and there was no selective
photoejection of the dmdppz ligand observed in water. These results show a surprising
range of t1/2 values for the protic solvents methanol, ethanol, and water, which will be
discussed later. In some cases, increasing the polarity of organic solvents was associated
with a decrease in the rate of photoejection of 4b, and in others the rates compared well
to the luminescence intensities of 4a. These data show that solvent polarity often does not
accurately predict the photochemical behavior of 4b, necessitating exploration of other
environmental factors that may provide better correlations.
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4.3.2 Effect of decreasing polarity in aprotic solvents.
As discussed in the previous section, DMF has a similar ET(30) value to CH2Cl2
but a nearly 50-fold difference in t1/2 is observed in the two solvents.15 We attributed the
slowed photoejection in DMF to the stabilization of the “bright” 3MLCT state, which is
manifest in a red-shift in the emission of 4a, (λem = 596 nm in CH2Cl2; λem = 638 nm in
DMF). We hypothesized that stabilization in DMF increases the energy gap between the
“bright” 3MLCT state and the dissociative 3MC excited state, decreasing the thermal
population of the 3MC state. In CH2Cl2, the dmdppz ligand is replaced by the two Clcounter-ions, producing Ru(bpy)2Cl2 as a final product, but in DMF the final product is
[Ru(bpy)2(DMF)Cl]1+. An alternative explanation for this behavior could be the
formation of an Eigen-Wilkins reactant preassociation encounter complex.32 An
encounter complex is formed by association of the outer-sphere incoming ligand with the
inner-sphere Ru(II) complex.32 In CH2Cl2, the more non-polar solvent, an encounter
complex would be favored between the outer-sphere Cl- with the inner-sphere Ru(II)
complex prior to photoactivation. In contrast, in DMF, solvation of the Cl- may occur,
preventing the formation of an encounter complex, and slowing the photoejection
process.
To determine if systematically decreasing the polarity in solvent mixtures had a
direct effect on the λem of 4a and the photoejection rate of 4b, the behavior of the two
complexes was analyzed in DMF:ether mixtures. The addition of ether decreases the
Table 4.3: Photophysical and photochemical data for 4a and 4b in DMF:ether
mixtures.
λem (nm),

Area,

t1/2 (min),

4a[a]

4a[a]

4b

0

638

1.20 x 107

25 ± 2

10

636

1.37 x 107

17.0 ± 0.1

50

636

1.67 x 107

4.9 ± 0.4

639

7

% Ether

70

1.75 x 10

2.13 ± 0.03

[a] Luminescence data reported are uncorrected values.
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polarity of the solvent mixture, and therefore increasing the fraction of ether was
anticipated to increase the rate of photoejection. If our prior hypothesis were accurate,
this would occur by destabilizing the “bright” 3MLCT state, resulting in a blue shift in the
emission of 4a. In contrast to our expectations, there was no change in the λem of 4a with
the addition of ether, but the emission intensity increased by a factor of 1.5 (Table 4.3).
Since the λem is unchanged the “bright” state is remaining at the same energy level, but is
becoming increasingly populated with increasing % ether. Presumably, in order for the
“bright” state to increase in population the “dark” state must be destabilized enough to
enhance the population of the “bright” state, unless the % ether has some affect on the
partitioning from the initial 1MLCT state into the two 3MLCT states, the solvent
composition effects non-radiative decay rate constants.
The photochemistry of 4b was more consistent with our predictions, as increasing
the percentage of ether from 0 to 70% decreased the t1/2 of photoejection by a factor of
12, from 25 min (100% DMF) to 2.13 min (70% ether) (Table 4.3). This result could be
explained by one of two hypotheses. First, the addition of ether destabilizes the “dark”
state and decreases the energy gap between the “bright” and “dark” state, allowing for
enhanced population of the “bright” state from the “dark”. This would then allow for
greater thermal population of the 3MC dissociative state, leading to ligand ejection. This
argument relies on different modulations in the energies of the 3MLCT excited states
under different environmental conditions, with the more polarized “dark” state having the
greater environmental sensitivity. Second, DMF has a greater dipole moment (3.82 D)
than CH2Cl2 (1.60 D) and ether (1.15 D). This higher dipole moment of DMF results in
greater solvation of the incoming Cl- ligands, inhibiting the formation of an encounter
complex. Reducing the strength of the ion-pair or formation of an encounter complex
between the Cl- counter-ions with cationic 4b would thus slow the rate of the
photoejection process. Adding ether should strengthen the ion-pairing, as with CH2Cl2,
facilitating formation of an encounter complex, and thus increase the rate of ligand
ejection. This second hypothesis would require that the observed ejection rate
dependence be connected to the properties of the incoming ligand, rather than the
behavior of the preceding photophysical states. The effect the incoming ligand identity
has on ligand ejection will be discussed in more detail later in this report.33
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4.3.3 Effect of polarity and viscosity in protic solvents.
The photophysical properties of [Ru(phen)2dppz]2+ and 4a have been studied in
various alcohols.12d,

34

Unlike with water, complete quenching of the emission due to

hydrogen-bonding to the phenazine nitrogens is not seen with other protic solvents. The
luminescent lifetimes of [Ru(phen)2dppz]2+ in methanol or ethanol are shorter than in
other organic solvents, where reported lifetimes in moderately polar solvents, such as
acetonitrile or DMSO, are at least 2x longer than ethanol. In contrast, lifetimes in nonpolar solvents, such as pyridine (ET(30) = 40.5 kcal/mol) or CH2Cl2, are up to 3.5x longer
than ethanol. This observation has been accredited to the polarity of the solvent.31a
Additional studies have explored the alcohol chain length dependence of the emission
intensity of 4a. The emission increases from methanol to 1-propanol, with a large
difference seen between methanol and ethanol.34b It was suggested that this behavior is
due to the decrease in acidity of the alcohol as the alkyl chain lengthens. However,
increasing the chain length past 4 carbons results in a decrease in intensity. The
explanation for this decrease in emission is uncertain.34b
When 4b is irradiated in linear chain alcohols the slowest photoejection t1/2 was
seen in methanol (5.8 min). Photoejection becomes more rapid when the chain length is
increased to ethanol, 1-propanol, and 1-butanol. However, in 1-hexanol, ligand ejection
slows, and continues to decline for the more viscous 1-octanol and 1-decanol.
Importantly, the ejection in 1-decanol (t1/2 = 3.9 min) is still markedly faster than in
methanol. The rate of ligand ejection of 4b closely parallels the effect of the chain length

Figure 4.8: Rate of ligand ejection of 4b versus emission area of 4a is dependent on
linear alcohol chain length. Blue (): t1/2 (min) of 4b. Black (): emission area of 4a.
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Table 4.4: Solvent parameters used for alcohol correlations
ET(30)

Viscosity
[a]

(kcal/mol)

2 [b]

(mNs/m )

α value[c]

Water

63.1

0.89

1.17

Methanol

55.4

0.544

0.93

Ethanol

51.9

1.027

0.83

1-propanol

50.7

1.722

0.78

1-butanol

49.7

2.948

0.79

1-hexanol

48.8

3.872

-

1-octanol

48.1

9.125

-

1-decanol

47.7

10.9

-

[a] Reichardt, C.; Chem. Rev., 1994, 94, 2319-2358. [b] Dean, J. A. Lange’s
Handbook of Chemistry; McGraw-Hill, INC: New York, NY, 1999. [c] Kamlet, M. J.,
Abboud, J -L. M., Abraham, M. H., Taft, R. W. J. Org. Chem. 1983, 48, 2877-2887.
on the emission intensity of 4a: greater emission intensity of 4a is correlated with faster
ligand ejection of 4b (Figure 4.8). The rapid photochemistry of 4b in these protic alcohol
solvents suggests that the hydrogen-bonding ability of these solvents has little effect on
the activity, as the hydrogen bond donating ability (α scale) of these alcohols ranges from
67–79% (α = 0.79–0.93) of the value of water (α = 1.17) (Table S2.2.1).35
For the alcohols, the photoejection t1/2 only correlates to the solvent polarity for
the series from ethanol through 1-butanol before it begins to deviate (Figure 4.9A). The
rate of photoejection slows by 4-fold from the fastest alcohol, 1-butanol (t1/2 = 0.96 min)
to the slowest, 1-decanol (t1/2 = 3.9 min). An alternative solvent parameter that could
have an impact on these t1/2 values is the viscosity. Indeed, the relationship of t1/2 to
viscosity provides a more linear correlation (r2 = 0.7793) than polarity (r2 = 0.5724)
(Figure 4.9B). As the alcohol chain length increases from 1 to 10 carbons there is a 17x
increase in viscosity. One potential explanation for this effect could be that increasing the
viscosity results in reduced mobility of the Cl- counter-ions, which are likely to act as the
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B

A

Figure 4.9: Relationship of the rate of ligand ejection of 4b to alcohol chain length
based on (A) ET(30) and (B) viscosity. Ethanol (black, ), 1-propanol (blue, ), 1butanol (red, ), 1-hexanol (green, ), 1-octanol (purple, ), 1-decanol (orange, ).
Note: methanol is an outlier and was excluded from these graphs. See Table S2.2.1 for
the complete data set and Table 4.4 for solvent parameters. The fits to the data are
provided to demonstrate the poor correlation.

Table 4.5: Photophysical and photochemical data for butanol isomers.
ET(30)

Viscosity
[a]

(kcal/mol)

[b]

(mPas)

λem (nm),
[c]

4a

Area,
[c]

4a

t1/2 (min),
4b

n-butanol

49.7

2.57

613

3.15 x 107

0.96 ± 0.03

iso-butanol

48.6

3.00

610

9.16 x 106

2.1 ± 0.1

sec-butanol

47.1

3.33

614

1.19 x 107

2.3 ± 0.1

tert-butanol

43.3

4.44

624

7.95 x 106

2.3 ± 0.1

[a] See reference 32b. [b] Farhan, A. M., Awwad, A. M.; J. Chem. Eng. Data, 2009, 54,
2095-2099. [c] Luminescence data reported are uncorrected values.
incoming ligands. This hypothesis is supported by the photoejection behavior of 4b in the
more viscous solvents ethylene glycol (13.35 mPA•s, t1/2 = 110 ± 20 min) and glycerol
(934 mPa•s, no photoejection observed). Again, this suggests that the availability of the
incoming ligand has an impact on the rate-determining step for the observed
photochemistry.13e
To gain additional evidence that polarity is not the sole feature dictating the
photochemistry of 4b, we studied a series of branched alcohol isomers of butanol that
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exhibit a 6 unit decrease in polarity on the ET(30) scale (Table 4.5). For these solvents,
the emission of 4a presented a different effect from what was observed with the linear
chain alcohols, where the emission change was non-linear with the more nonpolaralcohols. Very little change was observed in the t1/2 values when 4b was
photoejected with each butanol isomer. The photoejection slowed slightly from 1-butanol
(n-butanol; 0.96 min) to iso-butanol (2.1 min; a 2.4-fold increase) but then remained
constant for the other two isomers despite the changes in both polarity and viscosity. This
data confirms again that one parameter is not sufficient to describe the photophysical
behavior of 4a or photochemical behavior of 4b.
While there was an extraordinary effect on the photochemistry when ejection
studies were performed in the high viscosity solvents, ethylene glycol and glycerol, a
second parameter was varied moving from the alcohol series to these solvents, as
ethylene glycol contains two hydrogen-bonding alcohols and glycerol contains three. To
attempt to distinguish between the effects of viscosity versus the number of hydrogenbonding groups, studies were performed in a non-viscous solvent (DMF) with various
sugars added that are capable of providing multiple hydrogen-bonding interactions with
the dmdppz ligand of the Ru(II) complex. Photoejection studies were performed in DMF
in the presence of 1,000x glucose, mannose, and ribose in order to probe the effect of the
number and arrangement of the hydrogen-bonding groups.
It was found that the presence of the sugars had little effect on the luminescence
properties of 4a compared to pure DMF (Table 4.6), but had a large impact on the
photochemistry of 4b. The t1/2 of ligand ejection of 4b was slowed by 6.2–7.4-fold in the
presence of each sugar compared to pure DMF (Table 4.6), and was 1.4–1.7-fold slower
than in ethylene glycol. The number and arrangement of the hydroxyls on each sugar did
not appear to be an important feature. The photoejection of 4b, though slowed in the
presence of sugars with 4 or 5 hydrogen-bonding groups, compared favorably to the
complete abrogation of reactivity in glycerol, with 3 hydrogen-bonding groups,
suggesting that the number and arrangement of hydrogen bond donors is not a key feature
reducing the reactivity.
While it is clear that the presence of the sugars significantly reduced the rate of
the photochemical reaction, the cause once again was unclear. One possible explanation
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Table 4.6: The effect of sugars on the photophysical and photochemical data of 4a and
4b in DMF.
Area,

λem (nm),

t1/2 (min),

4a

4a

4b

DMF only

1.20 x 107

638

25 ± 2

+ glucose

1.00 x 107

639

156 ± 4

+ glucose and Cl-

7.67 x 106

642

14.5 ± 0.5

+ mannose

1.28 x 107

639

184 ± 1

6

638

15.3 ± 0.2

+ ribose

7

1.04 x 10

634

162 ± 2

+ ribose and Cl-

9.23 x 106

638

15 ± 0.4

+ mannose and Cl

-

6.23 x 10

for the behavior is that in high viscosity environments such as glycerol, the Cl- counterions are restricted from migrating into the inner sphere of the complex as is required for
coordination to the Ru(II) center. The presence of sugar in DMF solutions produces a less
viscous solution, while maintaining high numbers of hydrogen-bonding groups, and
enables the reaction to proceed but at a slowed rate compared to single hydrogen-bonding
organic solvents. To test if the availability of Cl- anions as incoming ligands played a
significant role, the experiments were repeated with 1,000x excess Cl-. Remarkably,
under these conditions, the reaction proceeds as if no sugar had been added (Table 4.6).
Either the concentration of the incoming ligand is a major factor in the kinetics of the
photochemical reaction, or the excess Cl- could alternatively be acting as a solvating
agent for the sugars in solution, preventing the hydrogen-bonding to the phenazine
nitrogens and the resulting enhancement of non-radiative decay pathways.36

4.3.4 Effect of increasing percent water in acetonitrile.
While the “dark” state of 4a is quite sensitive to solvent polarity and hydrogenbonding ability, the importance of hydrogen-bonding to the rate of photoejection of 4b
remained unclear. Thus, we explored the comparative impacts of increasing hydrogenbonding ability in solvent mixtures on the emission of 4a and the photochemistry of 4b.
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A

B

Figure 4.10: Effect of water on the photophysics of 4a and the photochemistry of 4b.
(A) Emission area of 4a with increasing % water; (B) t1/2 of ligand ejection of 4b
with increasing % water. Note: 99% and 100% water values are estimated due to the
slow photodecomposition of 4b.
This was accomplished by utilizing mixtures of acetonitrile (ET(30) = 45.6 kcal/mol) with
water (ET(30) = 63.1 kcal/mol). Acetonitrile is known to be a good incoming ligand for
the ligand-deficient Ru(II) center, and for these studies the product in each reaction
containing this solvent is [Ru(bpy)2(CH3CN)2]2+, in contrast to the earlier studies, where
Cl- anions acted as incoming ligands.
Following the model described in literature, the less polar and aprotic acetonitrile
should destabilize the “dark” state allowing for greater population of the “bright” state.12c
It is known that 4a is non-emissive in water and emits brightly in acetonitrile (Table
4.2).12b, 31a The addition of as little as 1% water to acetonitrile significantly decreases the
emission of 4a (Figure 4.10A and Table 4.7), with emission being fully quenched
between 10 and 50% water. This data is consistent with the accepted theory that
hydrogen-bonding to the phenazine nitrogens of 4a plays a significant role in the
emission properties.
Photoejection of 4b results in rapid ligand loss in 100% acetonitrile, with a t1/2 of
1.6 min (Figure 4.11B), but in 100% water 4b showed only slow photodecomposition,
evident by the absence of isosbestic points in the absorbance spectra (Figure 4.11A).15
There is a non-linear impact on the t1/2 observed for ligand ejection with increasing water
percentage in acetonitrile (Figure 4.10B). Surprisingly, there was no significant change
(<2-fold) in the rate of ligand ejection until 70% water was added. Selective
photoejection occurred even with 90% water, and while slower than in 100% acetonitrile,
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B

Figure 4.11: Comparison of photochemical behavior of 4b in (A) water
(photodecomposition) and (B) acetonitrile (t1/2 = 1.6 ± 0.1 min).
the t1/2 is still approximately 10-fold faster than the photodecomposition in 99% and
100% water. In addition, the final UV/Vis spectrum after photoreaction is equivalent to
that of [Ru(bpy)2(CH3CN)2]2+, confirming the identity of the final product.37
Thus, the photoejection data shows that the presence of just 10% acetonitrile is
enough to facilitate relatively efficient and selective ligand loss. This demonstrates that
hydrogen-bonding to the phenazine nitrogens is not the sole, or even primary, feature
dictating the photochemical process of 4b. The presence of a better coordinating solvent,
acting as the incoming ligand, facilitates the photoejection process in an aqueous
environment where water is a poor incoming ligand for 4b. This result renders the
hydrogen-bonding theory inadequate to explain the photochemical behavior of 4b. If the
luminescent behavior of 4a accurately reflects the energy levels and/or populations of the
“bright” and “dark” states of 4b, two possibilities exist to explain the observed disparity
with the photochemical behavior. First, the presence of a small amount of a good
incoming ligand facilitates chemical reactions that occur directly from either the “bright”
or “dark” 3MLCT states. Second, the acetonitrile alters the energy level of the 3MC state,
allowing for its population from both the “bright” and “dark” 3MLCT states. This
argument seems unlikely, as the 3MC state is not particularly sensitive to the solvent due
to the absence of significant electronic reorganization between the 3MC state and the
ground state, as previously described.38
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Table 4.7: Photophysics of 4a and photochemistry of 4b in acetonitrile/water
mixtures.
λem (nm),

Area,

t1/2 (min),

4a[a]

4a[a]

4b

618

2.63 x 107

1.6 ± 0.1

1% water

624

6.85 x 106

1.87 ± 0.08

10% water

-

1.03 x 106

1.74 ± 0.02

50% water[b]

-

1.91 x 105

2.28 ± 0.05

60% water[b]

-

2.29 x 105

3.18 ± 0.08

70% water[b]

-

1.78 x 105

6.3 ± 0.3

80% water[b]

-

2.29 x 105

18.1 ± 0.2

90% water[b]

-

1.37 x 105

49 ± 2

99% water[b]

-

1.35 x 105

>480[c]

[a] Uncorrected values. [b] Negligible emission with ≥ 50% water, where area values
reported were used for comparison purposes in Figure 4.10. [c] t1/2 of 99% water was
estimated in the same manner as for 100% water because photodecomposition was
incomplete after 12 hours of irradiation.
4.3.5 Summary of solvent effects and the possible fates of the 3MC state.
The results from these solvent studies can be summarized into a proposed
Jablonski diagram illustrating the environmental sensitivity of the excited states (Figure
4.12). When 4a or 4b is photoexcited, an electron is promoted into the 1MLCT state,
followed by intersystem crossing to one of the solvent dependent 3MLCT states.
Depending on the solvent, a thermal equilibrium exists between the higher energy
“bright” and lower energy “dark” states, and their energy gap is solvent dependent.12a In
contrast to the 3MLCT states, the energy of the dissociative 3MC state is known to be
relatively insensitive to solvent for other unstrained Ru(II) polypyridyl complexes38, and
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Figure 4.12: Jablonski diagrams illustrating the different photophysical and
photochemical pathways that are sensitive to environment and distortion. A thermal
equilibrium exists between the 3MLCT states under some, but not all environmental
conditions. The energy of the 3MC state is generally insensitive to environment but
sensitive to distortion. Population of the 3MC directly from the “dark” state may be
possible under some conditions (green line). Non-radiative decay that does not result
in ligand loss (black wavy lines) can occur from each of the excited states. Nonradiative decay processes that result in ligand loss may be possible from both the
3

MLCT and 3MC states (wavy lines). GS = ground state; MLCT = metal to ligand

charge transfer; BS = “bright” state; DS = “dark” state; NR = non-radiative; MC =
metal centered.

we assume it would be similar for strained systems. For 4a, relaxation from the “bright”
state to the ground state (GS) results in emission of a photon, while relaxation from the
“dark” state results in non-radiative decay. For 4b, when a good incoming ligand is
absent or its availability is reduced, either ligand loss or non-radiative decay can occur
through thermal population of the dissociative 3MC state from either 3MLCT state. When
a good incoming ligand is present and readily available, we propose that ligand loss can
occur through an additional pathway. This second process would follow an associative or
interchange associative mechanism directly from the 3MLCT states. The 3MC state of
Ru(II) polypyridyl complexes that is responsible for dissociative photosubstitution has
been reported to show no significant solvent dependence because there is no radial
redistribution of election density.38 The highly solvent dependent nature of the
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Scheme 4.1: Dissociative substitution pathway 1.

photoejection process for 4b thus supports the hypothesis of a pathway through an
associative mechanism from the 3MLCT states, rather than a purely dissociative
mechanism from the 3MC state.
It has been reported that population of the 3MC state results in ligand loss through
dissociative substitution if an intermediate is detectable.11 The dissociative (D) pathway 1
mechanism is illustrated in Scheme 4.1. A dissociative mechanism proceeds through
sequential (or simultaneous) breaking of the Ru-N bonds to the bidentate ligand, followed
by coordination of incoming ligands to form the product, [Ru(bpy)2L2]2+ (L =
monodentate ligand). The incoming ligands can either be two solvent molecules, two Clligands, or one of each. Dissociative substitution rates are typically independent of
incoming ligand identity and concentration, as the breaking of the existing bonds between
the Ru(II) center and the bidentate ligand are rate limiting.
If an incoming ligand binds prior to complete dissociation of the bidentate
dmdppz ligand, then the Ru(II) complex proceeds through pathway 2 (Scheme 4.2),
which is initiated by breaking one of the Ru-N bonds of dmdppz, forming a 5-coordinate
Scheme 4.2: Dissociative substitution pathway 2.
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Scheme 4.3: Associative substitution mechanism.

square pyramidal structure, containing a monodentate intermediate of the chelating
ligand. This leaves an open coordination site for the incoming ligand to bind, or
alternatively, re-chelation of the dmdppz can occur. If ligand binding occurs, a 6coordinate intermediate is formed. The fate of the 6-coordinate intermediate is either rechelation or breaking of the final Ru-N bond, liberating the dmdppz ligand. Ejection of
the dmdppz ligand allows for the incoming ligand to bind the open coordination site,
forming the photoproduct, [Ru(bpy)2L2]2+. Incoming ligand effects could be seen for
dissociative pathway 2 due to competition between the re-chelation and the binding of the
second incoming ligand.
If thermal population of the 3MC state is slow or the 3MC state is inaccessible,
ligand loss could also occur from the 3MLCT states through an associative (A)
substitution mechanism, illustrated in Scheme 4.3. While A type mechanisms are most
common in square planar complexes, due to steric factors, they have also been reported
for octahedral metal complexes.39 An A mechanism begins with the coordination of the
incoming ligand, forming a 7-coordinate intermediate. Donation of an electron pair from
the incoming ligand into the LUMO of the Ru(II) (the formally anti-bonding eg orbital)
results in lengthening of the Ru-N bond, leading to the initial Ru-N bond of dmdppz
breaking. The formation of a 7-coordinate intermediate may be expected to be more
favored from the 3MLCT rather than the 3MC because the lifetime of the 3MLCT (50-900
ns for 4a)26 is longer lived than the 3MC (<5 ns for [Ru(bpy)2py2]2+).31a, 40 In addition, the
metal center is in a +3 oxidation state in the 3MLCT state, as opposed to a +2 oxidation
state for the 3MC state, increasing the attraction between the metal and the incoming
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Scheme 4.4: Associative and dissociative-coupled substitution mechanism.

ligand. With the initial bond breaking, a monodentate dmdppz is formed that is capable of
re-chelation. If re-chelation does not occur, another incoming ligand binds to form the
second 7-coordinate intermediate, followed by the second Ru-N bond breaking to form
the [Ru(bpy)2L2]2+ final product. Associative mechanism rates are dependent on incoming
ligand identity and concentration.
Ligand loss proceeding through an A mechanism from the 3MLCT exited state via
a 7-coordinate intermediate could be mixed with dissociative-like steps following the first
Ru-N bond breaking, as shown in Scheme 4.4. This A and D-coupled substitution begins
with the formation of a 7-coordinate intermediate. After the first Ru-N bond is broken the
second Ru-N bond is broken before another incoming ligand is coordinated. This type of
mechanism may be dependent on the concentration and identity of the incoming ligand
but ultimately results in the same photoproduct, [Ru(bpy)2L2]2+.
Substitutions through either a D or an A mechanism are difficult to characterize
because they require the detection of an intermediate. When an intermediate is not
directly detected the term interchange (I) is used. An I reaction involves the existence of
an intermediate state where bonds are beginning to be formed between the incoming
ligand while the Ru-N bonds are broken, producing either an ion-pair or a loosely bonded
molecule.41 An I reaction can either be associative or dissociative in character.32, 42 When
the transition state favors the formation of a bond but does not go directly through a
detected 7-coordinate intermediate, the reaction is interchange associative (Ia). An Ia
reaction is sensitive to the identity of the incoming ligand and the formation of a new
bond.32,

42

If the transition state favors the breaking of a bond but a 5-coordinate
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intermediate cannot be isolated, the reaction is interchange dissociative (Id). Id reactions
are dependent on the breaking of a metal-ligand bond prior to the formation of a new
bond and are not sensitive to the incoming ligand.32, 42

4.3.6 Differentiating between A, D, Ia or Id mechanism for photosubstitution of 4b.
The photosubstitution of most Ru(II) polypyridyl complexes proceed through D
or Id mechanisms.11, 43 For [Ru(bpy)2L2]2+, containing monodentate ligands (L), literature
reports show that photosubstitution quantum yields are independent of the identity and
concentration of the incoming ligand.43a However, the identity of the final products of the
photosubstitution of [Ru(bpy)2(py)2]2+ are dependent on the strength of incoming ligand
coordination.43a The photoproducts that form in the presence of a weakly coordinating
anion (X-), such as NO3- or ClO4-, are mono-substituted (Ru(bpy)2(py)X).43a In contrast,
di-substituted photoproducts (Ru(bpy)2Y2) form in the presence of stronger coordinating
anions (Y-), such as F-, Cl-, Br-, or SCN-.43a
In contrast, when ligand loss occurs via the ejection of a bidentate ligand, for
[Ru(bpy)3]2+, entering group and solvent dependence is seen.38, 43b The photochemistry of
[Ru(bpy)3]2+ is still considered dissociative and proceeds through a 5-coordinate,
monodentate bpy intermediate, which is followed by incoming ligand coordination via a
6-coordinate, monodentate intermediate.43b The incoming ligand dependence for
[Ru(bpy)3]2+ is suggested to be due to the favorability of chelate ring closure over ligand
loss from the 6-coordinate intermediate, as the leaving bpy is held close to the recoordination site.43b While the behavior is complicated by this chelate effect, other
reports on Ru(II) polypyridyl complexes also suggest a D mechanism for
photosubstitution.43c-e

4.3.6.1 Effect of counter-ions and incoming ligand identity.
Our results indicate that for 4b, the availability of an incoming ligand with good
coordinating ability (i.e. Cl- or CH3CN) has a major impact on the t1/2 of ligand ejection.
When the availability is low, as in viscous solvents or in the presence of chloridesolvating species, the photoejection is slow. In contrast, when there is excess Cl-, the
solvent has a low viscosity, and the environment is non-polar, such as with CH2Cl2,
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Figure 4.13: Counter-ion dependence on the rate of ligand exchange in CH2Cl2. (A)
PF6- counter-ions of 4b (t1/2 = 26.0 ± 0.1 min), (B) Cl- counter-ions of 4b (t1/2 = 0.5 ±
0.05 min), (C) PF6- counter-ions of 4b with 1,000x Cl- added (t1/2 = 1.3 ± 0.1 min). The
final spectra after photoejection with the Cl- counter-ions or 1,000x Cl- is the same as
the spectrum of Ru(bpy)2Cl2. (Note: some absorption due to the liberated dmdppz
ligand is observed).
ligand loss is rapid. To further study the effect of the incoming ligand we examined the
photochemical process of 4b with the PF6- counter-ion, a poor ligand for Ru(II), in
CH2Cl2, a weakly coordinating, non-polar solvent that is unlikely to compete with the
binding of the counter-ions to the metal center. The ligand exchange was found to be 50
times slower (t1/2 (PF6-) = 26.0 ± 0.1 min, t1/2 (Cl-) = 0.5 ± 0.05 min), indicating again that
the presence of a coordinating counter-ions facilitates this ligand exchange (Figure 4.13).
Additionally, three other solvents (methanol, DMF, and DMSO) were also tested for
counter-ion dependence (Table 4.8). Photoejection in each solvent displayed 1.4–4.8 fold
decreases in the rate of ligand exchange when the counter-ions were PF6- compared to Cl-.
It was surmised that the presence of Cl- accelerates the photoejection process because it
Table 4.8: Counter-ion dependence of photoejection t1/2 in select solvents.[a]
CH2Cl2

CH3OH

DMF

DMSO

11 ± 2

119 ± 6

110 ± 20

5.8 ± 0.1

25 ± 2

80 ± 10

PF6- 26.0 ± 0.1
Cl-

0.5 ± 0.05

[a] t1/2 values in min.
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acts as the incoming ligand. When PF6- is present, ligand loss is disfavored due to the
weak- or non-coordinating nature of the selected solvents, showing that the identity of the
incoming ligand play a significant role in the photochemistry of 4b.

4.3.6.2 Effect of incoming ligand concentration.
The slow ligand loss in DMF and DMSO, even in the presence of stoichiometric
amounts of Cl-, may be due to increased solvation of the Cl- in these solvents compared
to methanol and CH2Cl2. This would prevent formation of an encounter complex and in
turn reduce the availability of the Cl- to act as the incoming ligand. Therefore, we tested
the concentration dependence of Cl- in CH2Cl2, methanol, DMF, and DMSO. Irradiation
of 4b (as the salt with PF6- counter-ions) with 2x, 100x, and 1,000x Cl- showed a clear
concentration dependence for the rate of ligand exchange (Figure 4.14 and Table 4.9).
Addition of 2x Cl- had little effect, but addition of 100x Cl- facilitated ligand loss give the
same t1/2 as 4b tested as the salt containing Cl- counter-ions. Increasing the Clconcentration to 1,000x further increased the rate of ligand exchange. The Clconcentration dependence for the photochemistry of 4b provides additional evidence that
the ligand dissociation may be proceeding through an A or Ia pathway, where the rate of
ligand substitution is dependent on availability and concentration of the incoming ligand.
Interestingly, a similarly strained Ru(II) complex, 2e was studied and showed little to no

Table 4.9: Counter-ion and concentration effect on the t1/2 of photoejection of 4b. [a]
PF6-

PF6- +
2x Cl

-

PF6- +
100x Cl

PF6- +
-

1,000x Cl

-

Cl-

CH2Cl2

26.0 ± 0.1

0.6 ± 0.1

1.0 ± 0.1

1.3 ± 0.1

0.5 ± 0.05

CH3OH

11 ± 2

7.7 ± 0.4

5.5 ± 0.2

3.4 ± 0.1

5.8 ± 0.1

DMF

119 ± 6

117 ± 1

28.5 ± 0.4

10.5 ± 0.8

25 ± 2

DMSO

110 ± 20

110 ± 30

73 ± 3

33 ± 2

80 ± 10

[a] t1/2 values in min.
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Figure 4.14: Incoming ligand concentration dependence of t1/2 of photoejection.
Tetrabutylammonium chloride was used as the Cl- source. (A) Cl- counter-ions, (B) PF6counter-ions, (C) PF6- counter-ions with 2x Cl-, (D) PF6- counter-ions with 100x Cl-, and
(E) PF6- counter-ions with 1,000x Cl-.
Table 4.10: t1/2 values for 2e in DMF under different conditions.
t1/2 (min)
PF6-

1.2 ± 0.1

Cl-

1.1 ± 0.1

PF6- + 2x Cl-

1.1 ± 0.1

PF6- + 100x Cl-

0.8 ± 0.1

PF6- + 1,000x Cl-

0.8 ± 0.1

counter-ion identity or concentration dependence in DMF, and thus likely proceeds via
the more standard D mechanism for ligand substitution (Table 4.10).

4.3.6.3 Effect of temperature on reaction rate.
Temperature dependent studies were performed to determine the activation
energy (Ea). The Ea for different conditions would reveal if the rate-determining steps
(RDS) were the same under different experimental conditions that give drastically
different t1/2 values. Accordingly, photosubstitution reactions of 4b were performed in
DMF and DMSO with 1,000x Cl- at 25, 60, and 85 °C. DMF and DMSO have similar
polarities (ET(30) = 43.2 and 45.1 kcal/mol, respectively), are both aprotic, non-hydrogen
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Table 4.11: Rate of photoejection of 4b as a function of temperature in DMF and
DMSO.
k (sec-1),

k (sec-1),

k (sec-1),

25 °C

60 °C

85 °C

4b, DMF

1.07 x 10-3

1.75 x 10-3

2.64 x 10-3

13.2

4b, DMSO

4.01 x 10-4

7.46 x 10-4

9.53 x 10-4

13.0

2e, DMF

1.39 x 10-2

1.50 x 10-2

1.71 x 10-2

3.0

Ea (kJ/mol)

bond donating solvents, and solvate ions well, reducing the possibility of forming an
encounter complex. Both DMF and DMSO stabilize the “bright” state of 4a, as evidenced
by the red shift in λem (Table S2.2.1). The “dark” state of 4a is likely stabilized further in
DMSO than in DMF, given the 2-fold reduction in emission in DMSO compared to
DMF. As might be anticipated from the enhanced emission of 4a in DMF, the
photosubstitution of 4b in DMF with 1,000x Cl- at room temperature (25 °C) is 2.7x
faster than DMSO under the same conditions (Table 4.11). Increasing the temperature to
60 °C accelerates the photosubstitution by a factor of 1.6–1.8, and increases again by a
factor of 1.3–1.5 when the temperature was increased to 85 °C. Using equation 1 and a
1

plot of 𝑙𝑙𝑙𝑙(𝑘𝑘) versus 𝑇𝑇, the activation energy (Ea) was calculated for both solvents (Table
4.11 and Figure 4.15). The activation energies for DMF and DMSO were essentially
equal (13.2 and 13.0 kJ/mol, respectively), suggesting the RDS for these two solvents is
the same. A detailed kinetic analysis was not attempted due to the complexity caused by
the appearance of different products at higher temperature that potentially are formed
through different reaction pathways.
𝑘𝑘

Equation 4.1: ln 𝑘𝑘2 = −
1

𝐸𝐸𝑎𝑎
𝑅𝑅

1

1

�𝑇𝑇 − 𝑇𝑇 � where 𝑘𝑘 = 𝑠𝑠𝑠𝑠𝑠𝑠 −1
2

1

The effect of temperature on the kinetics of photochemical ligand substitution of
2e was also investigated, and this compound exhibited very little temperature dependence
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(Table 4.11 and Figure 4.15). This complex also was found to have a much lower energy
barrier in the rate-determining step (Ea = 3.0 kJ/mol), supporting the conclusion that 2e
and 4b likely proceed through different photosubstitution mechanisms.

Figure 4.15: Arrhenius plot for determination of Ea. Black () 4b in DMF; Blue () 4b
in DMSO, Red () 2e in DMF.

4.3.6.4 Effect of incoming ligand size.
Since an A mechanism proceeds through a 7-coordinate intermediate, the size of
the incoming ligand should have an effect on the rate, which would be absent or
diminished with a D mechanism. Accordingly, we tested a series of nitrile solvents that
increase in size (acetonitrile, butyronitrile, and benzonitrile) to determine if incoming
ligand size played a role in determining the rate of ligand exchange. As each of these
solvents contains a nitrile group, they all serve as good ligands for the Ru(II) center, and
the di-nitrile species was formed in each case. As would be expected for an A or Ia
mechanism, the t1/2 of ligand ejection of 4b increased with increasing bulk of the
incoming ligand from 1.6 min (acetonitrile) to 10.9 min (benzonitrile). Interestingly,
there was no corresponding size effect on two similarly strained Ru(II) complexes, 2e and
2f (Table 4.12). Thus, the size dependence of the incoming ligand for 4b once again
suggests that the ligand exchange of 4b proceeds through a different mechanism than 2e
and 2f with 4b having associative character and the other compounds having dissociative
character.
This data shows that ligand substitution for 4b is dependent on the identity, size
and concentration of the incoming ligand, suggesting an alternative mechanism for
photosubstitution through an A or Ia pathway, in contrast to other literature reports on the
behavior of Ru(II) polypyridyl complexes. 43 The A mechanism for substitution proceeds
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Table 4.12: Effect of size of incoming ligand on t1/2 of ligand exchange.[a]
2e

2f

4b

Acetonitrile

0.35 ± 0.02

3.4 ± 0.5

1.6 ± 0.1

Butyronitrile

0.43 ± 0.02

3.9 ± 0.1

6.4 ± 0.2

Benzonitrile

0.42 ± 0.02

3.6 ± 0.8

10.0 ± 0.6

[a] t1/2 values in min.
through a 7-coordinate intermediate and is highly dependent on the identity and
concentration of the incoming ligand. Similarly, for the Ia mechanism, although an
intermediate is not detected, the process is dependent on the incoming ligand forming a
new Ru-ligand bond. The ligand exchange of 4b slows with increasing bulk of the
incoming ligand, but this behavior is not seen for two structurally similar complexes.
This suggests that some unfavorable incoming ligand interactions occur for 4b, which
could be due to steric clash created with the formation of a 7-coordinate intermediate
rather than a 5-coordinate intermediate. The incoming ligand concentration dependence
provides additional evidence to support an A or Ia mechanism. Increasing the chloride
concentration in four different solvents results in an increase in rate of photosubstitution
for 4b but did not have an effect for a similar ejecting system 2e, providing further
support for the hypothesis that 4b is undergoing an A or Ia mechanism of
photosubstitution.

4.3.7 Summary.
We performed a detailed photochemical study of a strained Ru(II) polypyridyl
complex, 4b, which was investigated for its solvent, incoming ligand, and temperature
dependence of ligand substitution in comparison to the photophysics of 4a. The results of
this study provided data to propose that 4b undergoes either an A or Ia mechanism for
photosubstitution, which is unusual for octahedral metal complexes. The experiments
demonstrated that the identity as well as the concentration of the incoming ligand played
a significant role in the rate of ligand exchange of 4b, a hallmark of an A or Ia
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mechanism. These results provide us with a better understanding of the environmental
sensitivity of this compound and how it compares to the well-known photophysical “light
switch”, 4a, and another strained Ru(II) complex, 2e. One possible explanation for the
distinct photochemical differences between the behavior of 4b and 2e may be the
increased charge separation of the excited state for 4b. A greater charge separation would
potentially provide time for an incoming ligand to bind and add an electrostatic attraction
for ligand substitution to proceed through an A or Ia mechanism. Photochemical studies
of a strained Ru(II) complex with a larger charge separations and extended excited state
lifetimes may provide additional data to support an A or a D mechanism of
photosubstitution for these types of Ru(II) complexes.
This study also provides an explanation for the surprising sensitivity the complex
exhibits in discriminating between hydrophobic proteins, duplex DNA, and G-quadruplex
DNA. If the photochemistry of the complex is subject to an A type mechanism, then the
reaction would be promoted in host environments that provide functional groups that can
act as incoming ligands. This would not be the case within a hydrophobic protein, as
very few amino acids possess strongly nucleophilic side-chains, but the base stack of
DNA would provide access to nitrogenous bases, and G-quadruplex DNA offers a high
local concentration of accessible guanine bases. Given the evidence to support an A type
mechanism, we aimed to introduce substituents that facilitate reaction from the 3MLCT
state rather than the dissociative 3MC state.
4.4 A single substituent can create highly selective “light switch” compounds.44
(Reproduced with permission from Chem. Eur. J. 2016, 22, 550–559. Copyright 2016
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)

While making modifications to the dppz ligand, we developed two Ru(II)
polypyridyl complexes that contain a bromine at the 11-position of the intercalating dppz
and dmdppz ligands, [Ru(bpy)2dppz-Br]2+ and [Ru(bpy)2dmdppz-Br]2+ (4c and 4b;
Figure 4.16). Complex 4c and 4b are derivatives of the photophysical “light switch” 4a,
and our photochemical “light switch”, 4b, respectively.12a, 15,

28

As seen in the crystal

structures of 4c and 4d (Figures 4.17, and Tables S1.17 and S1.18), the addition of a
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4c

4d

Figure 4.16. Structures of [Ru(bpy)2dppz-Br]2+ (4c) and [Ru(bpy)2dmdppz-Br]2+ (4d).

A

B

C

D

Figure 4.17. Crystal structures of 4c and 4d. Ellipsoid plots of 4c (A) side view and (B)
full atom labeling and 4d (C) side view and (D) full atom labelling showing the
difference in distortion of the dppz-Br ligand and the dmdppz-Br ligand. Ellipsoids are
drawn at 50% probability. The hydrogen atoms and minor disorder were omitted for
clarity. Note: the dppz-Br and dmdppz-Br ligand was disordered such that the plane of
the ligand is flipped by ~180°, resulting in a minor component fraction.
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B

Figure 4.18: Overlays of the crystal structures of 4a–4d. (A) 4a (black) and 4c (grey),
and (B) 4b (black) and 4d (grey) showing deviations in planarity of the dppz ligands
(left) and the differences in the bpy co-ligands (right). Complexes 4c and 4d clearly
exhibit increased distortion in the bpy co-ligands, and the overall orientation of the dppz
ligands is quite different.
bromo substituent has little to no effect on the dppz-Br and dmdppz-Br ligands within the
complex compared to their analogous parent ligands, dppz and dmdppz. The average RuN bond distance deviates slightly on the dppz ligand (2.073 Å)15 compared to the dppz-Br
ligand (2.068 Å). Likewise, the average Ru-N bond distance on the dmdppz ligand (2.104
Å)15 is similar to the dmdppz-Br ligand (2.115 Å). The intramolecular strain in 4d is
apparent from the 13° bend of the dmdppz-Br ligand out of plane, which is similar to
the15° bend seen for the dmdppz ligand.15 Interestingly, however, the bpy co-ligands in
both complexes 4c and 4d experience increased distortion compared to the complexes 4a
and 4b (Figure 4.18). This distortion is manifest through bending of the bpy out of plane
as well as by twisting about the 2-2’ C-C bond. In 4c, the bpy co-ligands have an average
bend and twist of 5.1° and 5.0°, respectively, which is approximately double the
distortion seen for 4a.15 Furthermore, the bpy co-ligands of 4d are bent by 6.7° and
twisted by 4.0° on average, which is 3x the distortion in 4b.15 Comparing the orientation
of the dppz/dmdppz ligands to the dppz-Br/dmdppz-Br ligands shows a drastic difference
in the overall planarity of the ligand (Figure 4.18). The dppz-Br and the dmdppz-Br
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ligands are more planar than the dppz and dmdppz ligands, likely due to the lack of πstacking interactions for 4c and 4d in the crystal lattice as a result of the addition of a
bromo substituent. The changes in distortion of 4c and 4d may play a role in imparting
selectivity for binding and reacting with specific nucleic acid structures.
A high throughput screening (HTS) assay was developed to evaluate the
interactions of the four complexes with 32 different biomolecules, including BSA,
nucleosides, duplex DNA, DNA sequences with mismatched bases, abasic sites, and
bulges, as well as triplex DNA and G-quadruplex DNA. Conditions were optimized to
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B

C

D

Figure 4.19. The luminescence fold change of 4c in different biomolecules in
comparison to (A) buffer alone and (B) in CT DNA. The t1/2 fold change of 4d in
comparison to (C) buffer alone and (D) in CT DNA. Experimental conditions from left
to right are in the order of Table 6.4. Compound 4c is most selective for the
intermolecular G-quadruplex (blue) and 4d is most selective for the telomeric Gquadruplex folded in the presence of K+ ions (green). Neither compound shows a
response when incubated with the telomeric G-quadruplex folded in the presence of Na+
ions (orange).
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Figure 4.20: Luminescence of 4a and t1/2 of 4b in different biomolecules in comparison
to buffer and duplex DNA. The luminescence fold change of 4a in comparison to (A)
buffer alone and (B) CT DNA. The t1/2 fold change of 4b in comparison to (C) buffer
alone and (D) CT DNA. The experimental conditions from left to right are in the order
of Table 6.4. The intermolecular (blue), K+ folded (green), and Na+ folded (orange) Gquadruplexes are highlighted for comparison to Figure 4.19.

minimize the amount of material used without compromising the data quality. Each
ruthenium complex was screened under saturating DNA conditions (1:5 [Ru]:[DNA bp])
so that the complexes would be fully bound and could be compared independent of their
binding affinities. The photophysical “light switch”, 4c, was tested in triplicate in a 384well plate, where luminescence was monitored by measuring full spectra. The
photochemical “light switch”, 4d, was tested under the same conditions, but in a 96-well
format. The spectral changes associated with photochemical reactions were determined
by measuring full absorbance spectra. For each experiment, compound 4d was irradiated
with a 470 nm LED array for set times, and the absorbance was measured after each light
exposure. The half-life (t1/2) of ligand loss was then determined, and the presence of
isosbestic points in the absorption spectra were used as an indication of a single
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photochemical reaction product. Both 4c and 4d exhibited enhanced behavior when
incubated with the different DNA sequences when compared to buffer, and showed
remarkable enhancement with G-quadruplex DNA over duplex DNA (Figure 4.19).
While compound 4a did not display a marked selectivity for any biomolecules
(Figure 4.20), when 4c was incubated with the different biomolecules, a significant
preference for the intermolecular G-quadruplex was observed. This was manifest in an
82-fold luminescence enhancement over buffer alone (Figure 4.21, Tables 4.13 and
S2.2.2). This selectivity for DNA secondary structure was also observed in a 14-fold
increase in luminescence compared to CT DNA. Additionally, 4c was able to
discriminate between different G-quadruplex sequences, as shown by the 2.7–11-fold
increase in luminescence when bound to the intermolecular G-quadruplex compared to
the other G-quadruplex sequences and structures (Tables 4.13 and S2.2.2). Furthermore,

Table 4.13: Photophysical and photochemical properties of 4c and 4d with different
G-quadruplex structures.

Condition[a]

Area
4c

Ratio to Ratio to
Buffer

Duplex

4c[b]

4c[c]

t1/2 (min)
4d

Ratio to Ratio to
Buffer Duplex
4d[b]

4d[c]

Buffer

81 ± 10

1.0

0.2

330 ± 80[d]

1.0

0.3

Inter

6600 ± 100

81.5

14.1

74 ± 8

4.5

1.2

c-myc

2440 ± 50

30.1

5.2

60 ± 4

5.5

1.5

Na+ [e]

620 ± 10

7.7

1.3

215 ± 3

1.5

0.4

K+ [e]

1990 ± 70

24.6

4.2

27 ± 2

12.2

3.2

[a] For full experimental details see Chapter 6 and Table 6.4. [b] The luminescence
area or t1/2 fold change compared to buffer only. [c] The luminescence area or t1/2 fold
change compared to CT DNA. [d] Estimated t1/2 for photodecomposition rather than
photoejection of the dmdppz-Br ligand; the reaction was not complete after 8 hours of
light exposure. [e] Human telomeric sequence folded in the presence of the indicated
cation.
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Intermolecular Antiparallel Basket Mixed-Hybrid
G-quadruplex
G-quadruplex
G-quadruplex

D

E

Anti

F
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H

Figure 4.21: Selectivity of 4c and 4d for different G-quadruplex structures. (A)
Cartoon representation of the intermolecular G-quadruplex, (B) telomeric (Na+)
antiparallel basket G-quadruplex, and (C) telomeric (K+) mixed-hybrid G-quadruplex,
colored boxes represent nucleotides in the anti conformation. (D) anti and syn
orientation of guanosine. (E) Hoogsteen base pairing of guanines in a G-quadruplex.
(F) Luminescence of 4c in buffer (black line), in the presence of the intermolecular Gquadruplex (blue line), the K+ G-quadruplex (green line), and the Na+ G-quadruplex
(orange line) demonstrating increased sensitivity for the intermolecular G-quadruplex.
(G) Photoejection kinetics of 4d when irradiated in buffer (black line, ), in the
presence of the intermolecular G-quadruplex (blue line, ), the K+ G-quadruplex
(green line, ), and the Na+ G-quadruplex (orange line, ) showing the fastest
reactivity with the K+ G-quadruplex. (H) Ligand loss reaction scheme for 4d when
irradiated in the presence of DNA.
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4c was also able to differentiate between the same telomeric G-rich sequence,
[AGGG(TTAGGG)3], under different conditions. When the DNA was folded in the
presence of K+ ions, the luminescence of 4c was 3x greater than when the DNA was
folded in the presence of Na+ ions (Tables 4.13 and S2.2.2).
The human telomeric sequence has been studied in the presence of Na+ and K+
ions and has been shown to form different structures depending on the cation, though
some question remains as to the nature of these structures. When folded in the presence
of Na+, the G-quadruplex takes on an antiparallel basket structure.45 In the presence of K+
ions, however, the structure has been reported to be either parallel46 or [3+1] mixed
hybrid.47 Multiple publications suggest that the structure of the telomeric sequence is
dependent not only on the identity of the metal cations, but also DNA concentration and
flanking nucleotide sequence.48 Under our experimental conditions, we have tentatively
assigned the telomeric sequence in the presence of K+ ions as the mixed-hybrid structure,
and as an antiparallel basket structure when folded with Na+ ions.49
The photoreactivity of 4d was assessed when incubated with different
biomolecules, and similar to the luminescent analogue 4c, it also exhibited a preference
for G-quadruplexes. The complex was most reactive in the presence of the telomeric Gquadruplex folded in the presence of K+ ions, with the rate of reaction increased 12x over
buffer alone and a 3.2x over CT DNA (Figures 4.20 and 4.21, Tables 4.13 and S2.2.3).
Complex 4d showed a 1.5–5.4x increase in the rate of ligand ejection with the other Gquadruplex structures compared to buffer, making it 2–8x more sensitive to the K+ Gquadruplex (Tables 4.13 and S2.2.3).
To determine if compounds 4c and 4d were selective for G-quadruplex structure,
their sensing ability or reactivity was tested with duplex DNA with similar G content. A
polyG•polyC duplex and a polyGC duplex were evaluated, and both complexes showed
minimal activity with the sequences. Complex 4c had a 5.2–12.3x luminescence
enhancement with various duplex sequences compared to buffer, while 4d was 1.5–3.7x
more reactive with duplex DNA compared to buffer. Remarkably, these compounds are
very selective for nucleic acids, as there was no enhancement in emission or reactivity for
4c and 4d with the hydrophobic protein BSA and neither complex was active with the
nucleosides alone. Thus, the three-dimensional arrangement of the nucleic acids appears
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Table 4.14: Binding constants and χRu for 4a–4d.
Compound

Mixed-Hybrid

Intermolecular

G-quadruplex

G-quadruplex

CT DNA

Kb/105 M-1

χRu

Kb/105 M -1

χRu

Kb/105 M -1

χRu

4a

6.7 ± 0.6

0.81

2.1 ± 0.5

0.81

8.2 ± 0.9

0.38/0.88

4b

3.7 ± 0.9

0.56

1.9 ± 0.3

0.63

1.1 ± 0.2

0.50

4c

2.0 ± 0.3

0.88

19 ± 1.0

0.81

1.5 ± 0.1

0.68

4d

6.1 ± 0.3

0.81

2.0 ± 0.2

0.63

1.2 ± 0.2

0.50

to mediate the selective photophysical and photochemical behavior of the complexes, as
neither the individual components of a nucleic acid nor a hydrophobic protein elicit a
response.
The sensitivity of 4c and 4d is pronounced compared to their parent complexes,
4a and 4b. When 4b was investigated for reactivity toward varying G-quadruplex
structures, the complex was not able to discriminate between changes in folding or
overall sequence, having only a 1–2x difference between G-quadruplex structures (Table
S2.2.4, Figure 4.20). Additionally, the enhancement when compared to CT DNA was
only at most a 4.4x increase. Similarly, 4a only exhibited an average of 2.6-fold
improvement compared to other G-quadruplex structures and with a maximum of 1.4x
increase over CT DNA (Table S2.2.3, Figure 4.20).
To discern what the major contributing factor for the sensitivity of 4c and 4d is,
binding constants were determined with CT DNA, the mixed-hybrid G-quadruplex and
the intermolecular G-quadruplex (Table 4.14, Figure 4.22). Complex 4c had the highest
binding affinity for the intermolecular G-quadruplex (1.9 x 106 M-1), whereas complex 4d
had a greater binding affinity for the K+ G-quadruplex (6.1 x 105

-1

M

). The binding

affinities paralleled the photophysical response of 4c and photochemical reactivity of 4d.
In addition, the binding stoichiometries were determined for 4a–4d using the Job plot
continuous variation method (Table 4.14, Figure 4.22).50 The complexes showed higher
binding stoichiometries for G-quadruplex DNA over duplex DNA. Complexes 4a–4d had
>1:1 ratios of Ru:DNA when bound to the mixed-hybrid and intermolecular G122
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Figure 4.22: DNA binding titrations and continuous variation analysis for 4a–4d.
Compound 4a (A–C), 4b (D–F), 4c (G–I), and 4d (J–L). Representative UV/Vis
titration with CT DNA (A, D, G, and H). Binding constant graphs (B, E, H, and K)
where the normalized change in extinction coefficient versus [DNA]/[Ru] ratio; black:
CT DNA, blue: K+ G-quadruplex, and red: intermolecular G-quadruplex. Job plots for
the binding stoichiometries (C, F, I, and L) to CT DNA (black), mixed-hybrid Gquadruplex (blue), intermolecular G-quadruplex (red). where the total concentration (Ru
+ DNA) was kept constant at 80 µm. The normalized absorbance change at 450 nm was
plotted versus the mol fraction of Ru(II) (χRu) and fit using linear regression analysis
with Prism software.
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Figure 4.23: Circular dichroism of the intermolecular (blue), K+ folded (green), and
Na+ folded (orange) G-quadruplexes.
quadruplexes as evident by inflection points at χ > 0.5. This unusual binding
stoichiometry has been hypothesized to be caused by ruthenium complexes stacking on
the DNA surface but does not give information on the binding mode of the complex to
DNA.50a Along with high binding stoichiometries, 4b and 4d had broad Job plots, which
may suggest multiple binding events or modes are occurring. Given the unusual binding
stoichiometries of 4c and 4d to the intermolecular and mixed-hybrid G-quadruplex,
respectively, it appears that the sensitivity of these complexes may be also influenced by
the binding orientation within different DNA sequences and structures.
In order to further probe the role the nucleic acid secondary structure played in the
binding behavior of the complexes, CD was used to understand the interaction of 4c and
4d with the telomeric mixed-hybrid G-quadruplex and intermolecular G-quadruplex. The
intermolecular G-quadruplex has four identical strands (5’-TAGGGTTA-3’) bound in a
parallel orientation, and is characterized by a positive ellipticity at 260 nm (Figure
4.23).48b Alternatively, the telomeric mixed-hybrid G-quadruplex is folded as an
intramolecular G-quadruplex with 3 antiparallel strands and 1 parallel strand, as evident
from the broad positive ellipticity at 290 nm (Figure 4.23).48b, 51
Thermal CD melting points (Tm) for both G-quadruplexes were determined in the
absence of compound, following incubation with each compound in the dark, and with 4b
and 4 after irradiation (Figure 4.24 and Table S2.2.6). Surprising differences were
observed when the strained compounds 4b and 4d were incubated with the telomeric
mixed-hybrid G-quadruplex in the dark compared to the unstrained molecules, 4a and 4c.
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Figure 4.24: CD melting curves for 4a–4d with different G-quadruplex structures. (A)
Mixed-hybrid G-quadruplex DNA only (black, ), with 4c (blue, ), 4d in the dark (red,
), and 4d following irradiation (dark green, ). (B) Mixed-hybrid G-quadruplex DNA
only (black, ), with 4a (blue, ), 4b in the dark (red, ), and 4b following irradiation
(dark green, ). (C) Intermolecular G-quadruplex DNA only (black, ), with 4c (blue,
), 4d in the dark (red, ), and 4d following irradiation (dark green, ). (D)
Intermolecular G-quadruplex DNA only (black, ), with 4a (blue, ), 4b in the dark
(red, ), and 4b following irradiation (dark green, ).

Both strained molecules appeared to induce the formation of an intermediate DNA
structure as the quadruplex melted, with greatest formation observed between 60 and
65 °C (Figure 4.25). This intermediate structure is characterized by a decrease in the
positive ellipticity at 295 nm and an increase in the positive ellipticity at 260 nm. It has
been proposed that this reflects the formation of a stable G-triplex intermediated in the
melting process, with maximal signal at ~65 °C.52 Based on our results, we hypothesize
that the Ru(II) complexes 4b and 4d are only interacting with and stabilizing one side of
the mixed-hybrid structure, allowing for partial unfolding from the strand reversal loop
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Figure 4.25 In the absence of irradiation, compounds 4b and 4d induce the formation
of a semi-stable intermediate G-triplex at ~65 °C during thermal melting, as visualized
by circular dichroism. (A) Cartoon representation of the proposed unfolding pathway
for the mixed-hybrid G-quadruplex. (B) The CD spectra of 4b and (C) 4d at 25 °C
(representing the mixed-hybrid, blue); at 65 °C (representing the triplex intermediate
formed, green); and at 95 °C (representing the fully unfolded strand, black).
side to form a G-triplex structure, as shown in Figure 4.25. This theory is further
supported by analysis of the different G-quadruplex structures.
In general, all four Ru(II) compounds have a stabilizing effect on both Gquadruplex structures, except when 4b and 4d are irradiated in the presence of the
telomeric mixed-hybrid G-quadruplex. This difference would be consistent with a distinct
binding mode of the strained complexes with this G-quadruplex compared to the
intermolecular G-quadruplex. In the telomeric mixed-hybrid G-quadruplex, the
guanosines are oriented with alternating syn and anti configurations as well as a strand
reversal loop resulting in increased molecular crowding of the phosphate backbone that
may inhibit intercalation (Figure 4.21 and 4.26).51 Therefore, the Ru(II) complex may
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Figure 4.26: Orientation of the guanosine bases in the different G-quadruplex
structures. (A) intermolecular parallel G-quadruplex (PDB: 1NZM), (B) telomeric
mixed-hybrid G-quadruplex (PDB: 2HY9), and (C) telomeric antiparallel basket Gquadruplex (PDB: 2MCC). The guanosines are shown in blue.

only bind as an end-capping molecule on either lateral loop faces, similar to other reports
of Ru(II) polypyridyl complexes with duplex and G-quadruplex DNA.7a, 51, 53 In this type
of binding mode, the dmdppz or dmdppz-Br ligand would only interact with one set of
guanosines, rather than two sets in an intercalating binding mode, and facilitate the
melting process through a triplex.
One question that was raised by this hypothesis of an end capping binding mode
was the effect of the environment on the photochemistry of the complexes. Neither of the
two molecules undergoes photoejection in an aqueous environment, suggesting that the
photochemical “light switch” effect relates to exposure of the phenazine nitrogens to
hydrogen-bonding solvents, just as the photochemical “light switch” effect is controlled
by exposure of these groups to water. However, when irradiated, both the dmdppz or
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dmdppz-Br ligands are photoejected from the Ru(II) complex, allowing the Ru(II) to
metalate the DNA (Figures S2.2.1 and S2.2.2).15 This would require a binding mode
where the dmdppz or dmdppz-Br ligands are shielded from the aqueous environment by
the bases in the lateral loop(s), thereby allowing photoejection to occur. Upon the
photoreaction, though, these end-capping dmdppz ligands could freely dissociate and
would no longer provide a stabilizing effect for the G-quadruplex; therefore the Tm is
comparable to DNA in the absence of complex. An alternative argument would be that
when Ru(II) metalation occurs it results in a destabilizing effect, which balances the
stabilization induced by the dmdppz ligand, with the end result of a Tm comparable to
DNA only.
The intramolecular antiparallel basket G-quadruplex also experiences irregular
spacing of the phosphate backbone (Figure 4.26), and the Ru(II) complexes will likely
bind through an end-capping mechanism. However, when 4a–4d are incubated with the
Na+ folded telomeric sequence they show diminished activity compared to the K+
structure. If the complexes bind through a similar end-capping mechanism through the
diagonal or lateral loops of the antiparallel basket structure, the loops must not be
shielding the phenazine nitrogens to the same extent as in the mixed-hybrid structure.
This may be due to the loop bases being flipped out in the antiparallel basket structure
and unable to shield the phenazine nitrogens properly. If these Ru(II) complexes are
binding via an end-capping mechanism, the loop regions seem to be important for
determining the activity of these molecules.
In the intermolecular G-quadruplex, in contrast, all of the guanosines are in an
anti configuration, resulting in a regular molecular spacing of the phosphate backbone
(Figure 4.26), allowing for potential intercalation of the dmdppz or dmdppz-Br ligand.46
Additionally, there are no loops in the intermolecular G-quadruplex which allows for
stacking of an intercalating ligand between two individual G-quadruplexes. Independent
of which binding mode occurs, 4b and 4d stabilize the intermolecular G-quadruplex,
likely through π-stacking interactions with the dmdppz or dmdppz-Br ligand, as
demonstrated by the 13–18° shift in the Tm. When irradiated with light, the stabilization
of the G-quadruplex is maintained and metalation of the DNA occurs (Figure S2.2.2).
This suggests that a stronger, longer lived stabilizing interaction is taking place in the
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Figure 4.27: Circular dichroism comparison of 4a (blue) and 4c (black) bound to the
telomeric G-quadruplex (red).
intermolecular structure. Based on the fact that the Tm remains unchanged upon
irradiation, we predict that either the dmdppz or dmdppz-Br ligand is unable to dissociate
from its intercalated position following DNA metalation, or alternatively, the metalation
stabilizes the structure.
Interestingly, 4c induces a structural change when bound to the mixed-hybrid Gquadruplex that we hypothesize is either from a change in folding or through ion
displacement upon Ru(II) binding. This change is visualized by an increased positive
ellipticity at 250 nm while maintaining a positive ellipticity at 295 nm. This spectral shift
and degree of stabilization is not seen for its parent complex 4a (Figure 4.27). This may
provide additional evidence that the substitution at the 11-position is a key feature in
directing activity of these molecules to specific DNA sequences and structures.
Complexes 4c and 4d are “light switches” that show significant selectivity
towards the parallel intermolecular G-quadruplex and telomeric mixed-hybrid Gquadruplex, respectively. Subtle changes in the structures of the complexes, caused by
intramolecular strain, resulted in dissimilar interactions with the G-quadruplexes. These
changes have an effect on the binding affinity, and we hypothesize that they induce
differences in the binding modes for the two G-quadruplex structures that result in
photophysical and photochemical selectivity. Complex 4c has a planar dppz-Br ligand
that is more likely to interact through intercalative binding, whereas distortion of
complex 4d may lead to the non-planar dmdppz-Br ligand interacting through endcapping at the lateral loop end. Since the phosphate backbone of the intermolecular Gquadruplex is equally spaced and lacks loops, the planar dppz ligand of 4c can intercalate
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more easily within the G-quadruplex or between two G-quadruplexes, compared to the
crowded backbone and loop containing telomeric mixed-hybrid G-quadruplex. This could
result in the heightened selectivity for the intermolecular G-quadruplex. Compound 4d,
in contrast, with a distorted planar dppz ligand, would interact more favorably in an endcapping binding mode where the loop regions shield the phenazine nitrogens, and the
compound exhibits greater selectivity for the telomeric mixed-hybrid G-quadruplex.
These differences give rise to two complexes with different modes of activation, and may
prove to be useful for rational design of G-quadruplex targeting molecules for in vivo
applications.54

4.5 Designing and testing a small library for structure activity relationship related
to selectivity for different DNA sequences.
Given the highly selective nature of 4c, we aimed to develop a library of
luminescent light switch derivatives to determine the role of the substituent identity, the
substituent position, and number of substituents on the selectivity for different DNA
structures. In order to rapidly generate a small library, a Ru(II) “building block” was
utilized for creation of dppz derivatives in a single step.55 Additionally, we applied a
rapid screening approach to evaluate the luminescent enhancement and selectivity of each
Ru(II) complex for different biologically relevant DNA sequences and structures
simultaneously.
A library of luminescent light switch derivatives were synthesized through a
condensation reaction of [Ru(bpy)2phendione]2+, the Ru(II) building block, with halogen
substituted o-phenylenediamines

(Figure 4.28). As demonstrated by Hartshorn and

Barton,55 the Ru(II) complex is a synthetic intermediate that provides for the convenient
synthesis of dppz derivatives in a single step. The complexes were purified via flash
chromatography and obtained in 60–82% yield.
In order to identify compounds that exhibited selectivity for different biological
molecules, the rapid screening approach was used to include BSA, nucleosides, single
strand DNA, duplex DNA, duplex DNA containing mismatches, abasic sites, and bulges,
triplex DNA, and G-quadruplex DNA.44 The assay was designed to test the impact of a
variety of factors on light switch response. The questions we posed include: 1) do the
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R1 = F (4e), Cl (4f), Br (4c);
Ru(II) building block

R3 = F (4g), Cl (4h), Br (4i);
R1 & R2 = F (4j), Cl (4k), Br (4l)

Figure 4.28: A library of Ru(II) dppz complexes was synthesized through a
condensation reaction using a common Ru(II) building block.

Unless otherwise

designated, R = H.
complexes behave the same in any hydrophobic environment? 2) do the number of DNA
strands/π stacking surface area alter luminescence? 3) does the nucleic acid base
composition matter? 4) does the specific three-dimensional structure have an impact? 5)
do sequential G-quadruplexes enhance the luminescence response? To answer these
questions, the response of compounds 4c, 4e–4l was examined by measuring full
spectrum luminescence in the presence of the 37 different biomolecules. Each complex
was screened under saturation conditions where the Ru(II) complexes were incubated at a
1:5 ratio of [Ru]:[biomolecule] for nucleosides and BSA. The concentration of DNA was
determined as [nucleotide (NP)] in order to remain independent of the number of strands.
The [Ru]:[NP] was 1:5 for single strand and G-quadruplex DNA, 1:10 for double strand
DNA, and 1:15 for triplex DNA. Working under saturating conditions allows for the
direct comparison of all compounds independent of the Ru(II) complex binding affinities
for the different biomolecules. To confirm we were working at saturating conditions,
binding titrations of 4c were performed and exhibited saturation around a 1:4 [Ru]:[NP]
ratio.44
In order to test if the Ru(II) complexes’ luminescent responses were selective for
nucleic acids rather than any hydrophobic environment, the behavior with BSA was
investigated, as BSA is commonly used as a model hydrophobic protein. In addition, each
individual nucleoside was tested to confirm the requirement of polymeric nucleic acid
structures for the light switch effect. The DNA sequences and structures that were tested
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Figure 4.29: Experimental set up of the 384-well plate screening assay, where 4
compounds can be evaluated simultaneously under 32 different conditions in triplicate.
Example data set for 38 different conditions shows the luminescence response of 4a in
the presence of different biomolecules. (A) Buffer, (B) BSA, (C) nucleosides, (D)
single strand DNA, (E) duplex DNA, (F) damaged duplex DNA (G) triplex DNA, and
(H) i-motif and G-quadruplex DNA. Note: biomolecules are ordered as they appear in
Table 6.4.
were designed to determine the importance of base composition and number of DNA
strands present. Base composition was also examined through the use of different single
strand and double strand DNA sequences, specifically, poly G, poly C, poly GC, poly A,
poly T, and poly AT sequences. Damaged DNA was tested, including mismatches, abasic
sites and bulges. Single, double, triplex and g-quadruplex structures were used to
determine the impact of increasing the number of strands and π stacking surface area on
the luminescence response. Lastly, different G-quadruplex structures were tested to
determine selectivity for the particular three-dimensional fold.
In order to probe for the selectivity to subtle differences in the three-dimensional
folding, 7 different G-quadruplex structures and 2 corresponding G-triplexes were
examined. The biological significance of the G-quadruplexes chosen for the study stem
from either forming from the human telomeric sequence or the promoter region of c-myc,
an oncogene. The different telomeric structures include the mixed-hybrid 1/2 (K+),
antiparallel basket (Na+), mixed-hybrid 1 (Tel26), and mixed-hybrid 2 (wtTel26). The imotif, the complementary sequence for the K+/Na+ G-quadruplexes, was also tested. In
addition, a double G-quadruplex was used to better mimic telomeres, which contain
132

A

B

Figure 4.30: Normalized ellipticity of the different G-quadruplexes. (A) K+ (orange),
intermolecular (dark blue), c-myc (light blue), and Na+ (dark red); (B) K+ (orange) and
double (purple).
repeating G-quadruplex structures connected by a short, 3 nucleotide strand that forms a
cleft between the two folded tetrads.56 The double quadruplex contained a sequence with
8 repeating G-rich regions that has a near identical structure to the K+ G-quadruplex (as
seen in the CD spectra in Figure 4.30). Thus, the primary difference between the two
structures is the presence of the cleft between the two quadruplexes.

4.5.1 Effect of hydrophobic environment.
Most of the complexes were non-luminescent in the buffer solution, which was
used as the control. However, compounds 4e, 4f, and 4g showed slight luminescence in
buffer. None of the complexes were luminescent in the presence of BSA, indicating that
the hydrophobic surfaces provided by this protein are not sufficient to induce switching
of the excited states. Individual nucleosides also were not able to induce emission.

4.5.2 Importance of number of DNA strands.
All of the complexes exhibited enhanced luminescence responses in the presence
of DNA (Figure 4.29 and Figures S2.2.3–S2.2.5). A common trend emerged where
increasing the number of DNA strands increased the brightness of 4c, 4e–4l (Figure 4.31
and Table S2.2.7). While single stranded DNA induced an average fold change in
emission of 7.1x, relative to buffer, duplex (11.8x), triplex (29.6x) and quadruplex
(44.7x) DNA structures were sequentially brighter. Only compound 4c was an outlier in
that it was more emissive in the presence of single stranded DNA (average of 12.8x) than
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Figure 4.31: Increasing the number of DNA strands increases the luminescence area.
(A–C) Plots of the average luminescence area versus number of DNA strands for (A)
11-substituted dppz complexes; (B) 10-substituted dppz complexes; (C) 11,12substituted dppz complexes; 4a (black, ), F substituent (blue, ), Cl substituent (red,
), and Br substituent (green, ). (D–F) Plots of the average luminescence area
versus the number of DNA strands for (D) F-substituted, (E) Cl-substituted, (F) Brsubstituted; 11-position (black, ), 10-position (blue, ), and 11,12-positions (red,
).
duplex (average of 7.7x). The emission behavior was also dependent on DNA sequence.
Figure 4.31 plots the luminescence intensity of each of the 9 dppz compounds versus the
number of DNA strands. Graphs A–C reflect the importance of the halogen identity (F,
Cl, Br) at a single position, and graphs D–F represent the impact of the substituent
position and number for each halogen. The identity of the halogen is important for the
overall behavior when comparing the luminescence to the number of DNA strands. This
is evident in the differences in the slopes of each data set (Figure 4.31 A–C and Table
S2.2.7), where the data set is defined as the average luminescence area of a compound
versus the number of DNA strands and the slope represents the change in luminescence
as the number of DNA strands increases. When the substituent is F or Cl, the position or
the number of substituents does not seem to matter, as apparent by the overlapping data
sets (Figure 4.31 D, E).
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Figure 4.32: Standard deviation of luminescence area versus the number of DNA
strands. (A) 11-substituted series; 4a (black), 4e (blue), 4f (green), and 4c (red); (B)
10-substituted series; 4a (black), 4g (blue), 4h (green), and 4i (red); (C) 11,12substituted series; 4a (black), 4j (blue), 4k (green), and 4l (red).

Both the position and quantity of Br substituent(s) is important for the average
response in relation to the number of DNA strands. Compound 4i, 10-Br, gives the
largest degree of change (greatest slope). In contrast, compound 4l 11,12-Br, shows the
most shallow slope, due to the minimal enhancement when bound to G-quadruplexes
versus single or double strand DNA. Interestingly, the Br substituted compounds for each
series show the lowest R2 value for improved luminescence to increasing DNA strands
(Table S2.2.7). This can be attributed to the fact that compounds 4c, 4i, and 4l have a
large signal increase when bound to higher order structures, but is dependent on the
specific quadruplex structure.
Interestingly, the luminescence response of the compounds in single strand,
duplex, and triplex DNA have low standard deviations, ranging from 0.1–9%, where the
standard deviation represents the variability of the luminescence response within each
category

(Figure 4.32). Conversely, the standard deviations in luminescent response

range from 15–43% when in the presence of the G-quadruplex sequences and structures.
A small standard deviation shows that the complex has little to no selectivity for one
sequence over another for DNA with equal number of strands, where a large standard
deviation is due to the selectivity for one or two specific structures over the others. The
high standard deviation for G-quadruplex DNA is likely due to the drastic differences in
how each G-rich sequence folds into its respective G-quadruplex structure.
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Figure 4.33 shows the luminescence fold change of each complex when bound to
triplex or G-quadruplex DNA as compared to the luminescence when bound to duplex
DNA (CT DNA). The results indicate that many of these compounds have a distinct
preference for specific DNA structures to a greater extent than the parent complex, 4a as
evident by the larger fold changes. Compounds 4c, 4e–4i had similar luminescence fold
changes when bound to the different triplex structures tested, but had enhanced changes
compared to the parent complex. On the other hand, the 11,12-substituted compounds,
4j–4l, had larger differences amongst the triplex sequences, where 4l had a significant
preference for the T-A-T triplex (>3.5x).
Compound 4l’s selectivity for T-A-T must be related to the DNA structure rather
than the sequence, as it showed little luminescence enhancement when bound to poly A
poly T and poly AT duplexes. In fact, the enhancement in the T-A-T triplex was 34x
greater than in the two AT-rich duplexes. We hypothesize that the two large Br groups at
the 11- and 12-positions of 4l prevent full intercalation into duplex DNA, causing the
phenazine nitrogens to be partially water exposed, resulting in only a 2.6–3.6x
luminescence enhancement as compared to buffer. In contrast, the larger surface area of
the T-A-T triplex aids in shielding the phenazine nitrogens, allowing for 89x
luminescence enhancement when compared to buffer. This hypothesis is further
supported by the behavior of compounds 4j and 4k. Compound 4j, with two small
A

B

Figure 4.33: Comparison of the fold change in luminescence as compared to duplex
DNA. (A) Triplex DNA; T-A-T triplex (black, ), 5’-triplex (blue, ), and 3’-triplex
(red, ). (B) G-quadruplex DNA; inter (black, ), c-myc (blue, ), Na+ (red, ), and
K+ (green, ).

136

fluorine substituents at the 11- and 12-positions has only a slight luminescence
enhancement (average of 2.5x) in the T-A-T triplex compared to the AT rich duplexes.
Increasing the size of the substituents to chlorines, as in compound 4k, increases the
luminescence differences in the T-A-T triplex to the AT rich duplexes with a 3.2x
enhancement. Similarly, the complexes showed varying selectivity for G-quadruplex
DNA, having up to a 64-fold luminescence enhancement compared to duplex DNA
(Figure 4.33 and Figures S2.2.3–S2.2.5). The most selective compound was 4l, which
exhibited the largest luminescence increase when bound to the parallel intermolecular Gquadruplex.
In addition to size, the polarizability of the halogen substituents may be important
for the behavior of these complexes in the presence of duplex, triplex and G-quadruplex
DNA. Highly polarizable atoms increase the London dispersion interactions and therefore
could have an enhanced interaction with the π system of the DNA base stack. The
fluorine substituents have the lowest polarizability (3.76 a.u.)57 and have the smallest
luminescence enhancement as the number of DNA strands increases, whereas the
bromine substituents are highly polarizable (21.9 a.u.)58 and have the largest
luminescence enhancement when increasing the number of DNA strands. To distinguish
if polarizability is a more important feature than size, [Ru(bpy)2dppz-11-CH3]2+ was
tested. The CH3 group is a non-polarizing substituent but is larger in size that a Br
substituent, 1.12 Å (Br) versus 2.05 Å (CH3).59 The addition of a 11-CH3 substituent
results in a complex that has little to no selectivity for G-quadruplex DNA. The complex
has a 62 ± 12 fold luminescence enhancement in the presence of duplex DNA over buffer
alone and a 84 ± 37- fold luminescence enhancement in the presence of G-quadruplex
DNA over buffer. This data suggests that polarizability may be an important feature for
designing complexes that have selectivity for G-quadruplex DNA over duplex DNA.
For this series of complexes, the highest luminescence response was observed for
the intermolecular G-quadruplex, as exhibited for compounds 4c, 4e, 4f, 4j, and 4l. In this
intermolecular quadruplex the complexes have at least a 1.2-fold increase over other Gquadruplex DNA sequences, with a 14–160-fold change over buffer alone. This selective
response is not observed for the [Ru(bpy)2dppz]2+ or [Ru(bpy)2dppz-11-CH3]2+.
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Interestingly, 4g exhibited selectivity for the i-motif, the complementary strand to the
telomeric G-quadruplex sequence, and 4k has slight selectivity for the wtTel26 sequence.

4.5.3 Impact of nucleic acid base composition.
Since complexes 4c, 4e–4l have an overall higher luminescence response when
associated with G-quadruplex DNA, we tried to distinguish between the impacts of base
composition vs. specific topology by correlating the luminescence area to the number of
guanosines (Figure 4.34). Similar sequences folded under identical conditions were
chosen to simplify the analysis. These sequences were (TGGT fwd (2 Gs), TGGT rev (6
Gs), 5’-triplex (9 Gs), Tel26 (12 Gs), and the double G-quadruplex (24 Gs) (Table 6.4)).
The parent complex, 4a and the 10-substituted series exhibited a near linear correlation
(R2 > 0.95) between emission enhancement and the number of guanosines in the DNA
sequences. Additionally, the slope (luminescence area versus number of guanosines) of
A
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Figure 4.34: Comparison of the luminescence area in the presence of different G-rich
sequences. (A) 11-substituted; (B) 10-substituted; (C) 11,12-substituted; where 4a
(black, ), F substituent (blue, ), Cl substituent (red, ), and Br substituent (green,
). (D) F-substituted; (E) Cl-substituted; (F) Br-substituted; where 11-position
(black, ), 10-position (blue, ), and 11,12-position (red, ). Sequences plotted are
TGGT fwd (2 Gs), TGGT rev (6 Gs), 5’-triplex (9 Gs), Tel26 (12Gs), and double (24
Gs). Full sequence information is available in Table 6.4.
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the 10-substituted series resulted in a linear correlation to the atomic diameter of the
halogen substituent (R2 = 0.94, Figure S2.2.6).
The 10-position is important as substituents at this position can shield the
phenazine nitrogen. In addition, recent crystal structures of [Ru(phen)2dppz]2+,
[Ru(bpy)2dppz]2+ and [Ru(TAP)2dppz-10-CH3]2+ (TAP = 1,4,5,8-tetraazaphenanthrene),
demonstrated that the angle of intercalation changed with the addition of the 10-CH3
substituent.7a,

13k, 60

The unsubstituted complexes bind DNA with two modes of

intercalation: symmetrically perpendicular and angled. The symmetric intercalation
occurs at a AT step and the phenazine nitrogens were able to hydrogen bond with water
molecules, whereas the angled intercalation occurs at a GC step and prevented hydrogenbonding to one of the phenazine nitrogens.13k The addition of a 10-CH3 substituent to the
dppz ligand results in an angled intercalation mode at a TC/AG step and prevented the
phenazine nitrogen on the non-methylated side from hydrogen-bonding with water.
Additionally, the angled intercalation caused by the 10-CH3 group prevents the adjacent
phenazine nitrogen from hydrogen-bonding.60 Given this structural information, we
hypothesize that the size of the substituent at the 10-position is extremely important for
how the dppz ligand binds to the different DNA structures, and in turn, the extent of
luminescence enhancement. On the other hand, the 11-substituted series and the 11, 12substituted series ranged in linearity from R2 = 0.40–0.92 and no clear correlation was
present (Table S2.2.8). This suggests that the 11- and 12- positions do not necessarily
dictate how the dppz ligand is binding to the different DNA structures. In addition to
increasing the number of guanosines, we also examined different damaged DNA
duplexes, such as mismatched bases, base bulges, and abasic sites. Unfortunately, none of
the complexes showed noteworthy emission enhancement in these sequences over the
parent duplex sequence.

4.5.4 Impact of three-dimensional structure.
As the luminescence of the complexes increased with the number of DNA strands
and with the number of guanosines in the DNA sequence, further analysis was completed
to determine if the complexes were able to detect differences in structure and folding
direction. Initially, we looked at the luminescence response when interacting with two G139
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Figure 4.35: Discriminating between G-rich triplex and G-quadruplex DNA with
similar three-dimensional structures. Cartoon representation of the different triplex and
G-quadruplex structures (A) 5’-Triplex; (B) Tel26; (C) 3’-Triplex; (D) wtTel26. (E)
Luminescence ratio when bound to the G-quadruplex versus its respective triplex
(Tel26:5’-triplex (blue), wtTel25:3’-triplex (green)). (F) Normalized ellipticity of the
different DNA sequences (5’-triplex (black), Tel26 (blue), 3’-triplex (red), and
wtTel26 (green)). (G) Ratio of the average response from Tel26 and wtTel26 to K+ Gquadruplex. (H) Normalized ellipticity of the different mixed-hybrid G-quadruplex
structures (Tel26/hybrid 1 (blue), wtTel26/hybrid 2 (green), and K+/hybrid 1 and 2
(orange)).
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quadruplexes and their analogous triplexes (Figure 4.35). The G-quadruplexes have the
same G-rich repeating sequence but differ by two bases at both the 5’ and 3’ ends of the
sequence. Substituting the two 5’ and two 3’ adenosines for thymidines inverts the
folding direction of the G-quadruplex.47b, 61 Since the only base composition difference is
at the 3’ or 5’ end of the triplexes versus the G-quadruplexes in this case, the analysis is
solely driven by structural differences, rather than sequence changes.
The solution structures of Tel26 and wtTel26 sequences have been previously
reported as the hybrid 1 and hybrid 2 G-quadruplexes, respectively.61-62 Additionally, it
has been proposed that substitution of one set of guanosines with thymidines on either the
5’ end of Tel26 or 3’ end of wtTel26 results in the G-triplex folding intermediate.63 The
analogous structural features of the Tel26 and wtTel26 were visualized by the similarities
in the CD spectra (Figure 4.35F). Similarly, the two triplex sequences have near identical
CD signals. However, comparison of the Tel26 quadruplex versus the 5’ triplex and
wtTel26 quadruplex versus the 3’-triplex demonstrated that there are notable differences
in their CD spectra. These structural differences allow for the Ru(II) complexes to
differentiate the G-quadruplex from the G-triplex. In general, the complexes have greater
luminescence enhancement when bound to a G-quadruplex over a G-triplex, with up to a
2.8x increase in luminescence. The preference for the G-quadruplex over the G-triplex
suggests that it is either the presence of a G-tetrad or the specific loop region that is
unfolded in the G-triplex that is essential for the response of 4c, 4e–4l.
As expected given the similarity in the structure, there was not a major preference
for the hybrid 1 versus hybrid 2 structures or the 5’-triplex versus the 3’-triplex in
reference to the number of halogens, the halogen identity, or the position. Indeed, 8 had
the highest fold change, which was only 1.7x when bound to wtTel26 over Tel26 (Figure
4.36). Similarly, 4l had the largest luminescence enhancement of 1.4x when bound to the
5’-triplex over the 3’-triplex (Figure 4.36).
Additionally, we analyzed the data for three different G-quadruplex structures
with similar sequences and folded under identical conditions, where each of the Gquadruplexes is associated with K+ ions. The K+ folded G-quadruplex is a mixture of the
hybrid 1 and hybrid 2 structures.48c The structures, by CD, have major differences at 270
nm, where the hybrid 1 structure has a larger positive ellipticity than the other sequences
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Figure 4.36: Luminescence response of 4a, 4c, and 4e–4l with respect to the folding
direction. Fold change when bound to Tel26 as compared to wtTel26 (black) and 5’triplex as compared to 3’-triplex (blue).
and the K+ G-quadruplex has the lowest positive ellipticity (Figure 4.35H). As none of
the complexes showed significant preference for the hybrid 1 or hybrid 2 structures, we
expected the complexes to have a similar light switch response with the K+ G-quadruplex
as the average response from Tel26 and wtTel26. All complexes exhibited luminescence
with the K+ G-quadruplex within 2-fold of the average luminescence of the hybrid 1 and
hybrid 2 G-quadruplexes (Figure 4.35G).
Next, we screened each complex against four G-quadruplexes that fold into quite
different structures. The four structures examined were the parallel intermolecular Gquadruplex (inter), the parallel propeller G-quadruplex (cmyc), the antiparallel basket
telomeric G-quadruplex (Na+), and the mixed-hybrid telomeric G-quadruplex (K+). The
major differences between the four G-quadruplexes are the presence and positioning of
loop regions which affects the accessibility of the G-tetrad. In recent reports, the loop
regions have been essential for the binding of certain metal complexes, specifically Zn2+,
where they interact with the thymidines within the loop region rather than with the Gtetrad.64 We hypothesize that the loop regions are also important for recognition by the
Ru(II) dppz complexes by either preventing binding to the G-tetrad or by shielding the
phenazine nitrogens. The inter G-quadruplex lacks loops, whereas the cmyc, K+, and Na+
G-quadruplexes each have 3 loop regions. For the inter G-quad, the G-tetrad is readily
accessible and the dppz ligands can easily π stack within one G-quadruplex or between
two G-quadruplex. The parallel propeller folding of the cmyc G-quadruplex results in
tight loops spanning each G-tetrad on 3 of 4 sides of the G-quadruplex. The placement of
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Figure 4.37: Distinguishing different G-quadruplex structures. Intermolecular (dark
blue), cmyc (light blue), Na+ (dark red), K+ (orange). Luminescence area in the
presence of the different G-quadruplex structures for the (A) F-substituted series; (B)
Cl-substituted series; (C) Br-substituted series. Fold change (luminescence area in the
presence of the different G-quadruplex structures in comparison to CT DNA) for the
(D) F-substituted series; (E) Cl-substituted series; (F) Br-substituted series
these loops significantly restricts the access of the dppz to π stack within one Gquadruplex, but the top and bottom face do not have loops so the dppz ligand can π stack
between two different G-quadruplexes. For the K+ G-quadruplex, the loops are placed in
a way that the dppz ligand would likely bind by threading through one of the lateral loops
and π stack as an end cap. Likewise, the Na+ G-quadruplex has lateral loops and a
diagonal loop that the dppz ligand has to thread through to π stack with one of the end Gtetrad.
Interestingly, none of the complexes have a large luminescence response with the
Na+ G-quadruplex. In fact, they only show up to an 8.4-fold enhancement in comparison
to CT DNA. The 10-substituted complexes, 4g–4i, do not have a strong preference for
any of the 4 G-quadruplexes (Figure 4.37). Instead, this series of complexes has some
selectivity for either the i-motif (4g) or the double G-quadruplex (4h and 4i). The 11substituted and 11, 12-substituted series prefer the inter G-quadruplex. The number of
substituents is important for the degree of selectivity for the inter G-quadruplex (Figure
143

A

B

Figure 4.38: Sensitivity to sequential G-quadruplexes. (A) Luminescence area of
+

each complex in the presence of K (orange), and double quadruplex (purple); (B)
+

Ratio of the double G-quadruplex to the K G-quadruplex.
4.37). The 11-substituted series shows a higher luminescence bound to the inter Gquadruplex when the substituent is either Cl or Br. On the other hand, for the 11, 12substituted series, the F-substituted complex gives a larger luminescence when bound to
the inter G-quadruplex than Cl or Br substituents. The position is also important for the
selectivity, as the 10-subsituted series do not have a preference for the inter Gquadruplex.
When comparing the luminescence response of each complex when bound to the
inter G-quadruplex compared to duplex DNA, the larger substituents

(Cl and Br)

consistently have a greater fold change compared to the F substituent. This is likely due
to the increase in size, causing complexes with the Cl and Br substituents to be more
sensitive to the increased π surface. Similarly, the 11,12-substituted series has an
enhanced fold change over the 11- and 10-substituted series. The double substitution may
force the dppz into one orientation when bound to the inter G-quadruplex that prevents
either phenazine nitrogen from being exposed to water, increasing the luminescence.

4.5.5 Impact of sequential G-quadruplexes.
Lastly, we were interested in the impact sequential G-quadruplexes have on the
luminescence response. The K+ and double G-quadruplex have near identical CD spectra,
confirming they both have a mixture of the hybrid 1 and hybrid 2 folding (Figure 4.30).
The double G-quadruplex has 2 G-quadruplexes separated by a short 3 nucleotide
sequence, introducing 2x the binding sites as well as a cleft region between the G144

quadruplexes. Since the experiments were completed using equal [Ru] and identical
[Ru]:[DNA (NP)], the difference in the number of binding sites between the K+ and
double G-quadruplexes is not a contributing factor to the response.
When comparing the response of each compound when bound to the double Gquadruplex DNA, the parent complex, 4a, along with 4h and 4i, showed pronounced
selectivity. As shown in Figure 4.38, the most selective compounds for the double Gquadruplex DNA were 4h and 4i, with 46-fold and 64-fold luminescence enhancement
when compared to CT DNA. Compounds 4h and 4i were 4.8 and 4.2x more selective for
the double G-quadruplex over the K+ G-quadruplex. Given the results for 4h and 4i, we
hypothesize that the >4x enhancement is due to selective binding orientation with the
double G-quadruplex, where the cleft region between quadruplexes may be important,
rather than the increased number of binding sites. From these results, complexes 4h and
4i are the most biologically relevant hit complexes for future in vivo applications where
repeating G-quadruplexes are prevalent, i.e. in telomeres (Figure 4.38).
Based on the selectivity of compound 4c to the intermolecular parallel Gquadruplex, a series of halogenated dppz Ru(II) complexes were synthesized using a
Ru(II) “building block” containing reactive functional groups. This series aimed to reveal
the importance of the substituent identity, the substituent position, and the number of
substituents on the “light switching” ability. Each dppz derivative was tested using a
rapid screening approach to determine the luminescence response against a series of
biomolecules. The biomolecules tested were selected to probe biologically relevant DNA
sequences and structures. Combining both approaches allowed for the rapid identification
of hit compounds that can be improved for future biological applications. Compound 4l
showed selectivity for T-A-T triplex DNA and interstrand G-quadruplex DNA.
Compounds 4h and 4i showed the greatest selectivity for the double G-quadruplex, a
more biologically relevant mimic of the G-quadruplexes formed in telomeres. These two
complexes not only had the greatest luminescence area but they also had the largest fold
change over duplex DNA, and may prove to be important for detection of Gquadruplexes in vivo.
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4.6 Conclusions.
The discovery of a photochemical “light switch”, 4b, a derivative of the wellknown photophysical “light switch” 4a, that had selective ligand loss in the presence of
DNA and acted as a dual photochemical DNA sensor and metalating agent lead to a
detailed photophysical and photochemical study to determine the mechanism of
photochemical substitution. This extensive study revealed the unique behavior of 4b, in
comparison to 2e and 2f. Unlike 2e and 2f, which undergo a dissociative mechanism for
ligand loss, the results of 4b suggest it undergoes an associative or interchange
associative mechanism for ligand loss. Associative mechanisms are incoming ligand
dependent and we hypothesized the distinct photochemical differences between the
behavior of 4b and 2e may be a result of the increased charge separation of the excited
state for 4b. A greater charge separation would potentially provide time for an incoming
ligand to bind and add an electrostatic attraction for ligand substitution to proceed
through an A or Ia mechanism. Additionally, this study also provided an explanation for
the surprising sensitivity the complex exhibits in discriminating between hydrophobic
proteins, duplex DNA, and G-quadruplex DNA, where the base stack of DNA provides
access to nitrogenous bases, and G-quadruplex DNA offers a high local concentration of
accessible guanine bases.
Given the evidence to support an A type mechanism, we aimed to introduce
substituents that facilitate reaction from the 3MLCT state rather than the dissociative 3MC
state. Our initial modification was the introduction of a Br substituent at the 11-position
of the dppz and dmdppz ligands to give complexes 4c and 4d, respectively. Each
complex was tested using a rapid screening approach to determine the luminescence
response against a series of biomolecules. The biomolecules tested were selected to probe
biologically relevant DNA sequences and structures. These complexes showed significant
“light switches” selectivity towards different G-quadruplex structures. Subtle changes in
the structures of the complexes, caused by intramolecular strain, resulted in dissimilar
interactions with the G-quadruplexes and we hypothesize these differences lead to
distinct binding modes for unstrained dppz complexes over strained dmdppz complexes
to G-quadruples DNA.
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Based on the selectivity of compound 4c for the intermolecular parallel Gquadruplex, a series of halogenated dppz Ru(II) complexes were synthesized to determine
the importance of the substituent identity, the substituent position, and the number of
substituents on the “light switching” ability. Compound 4l showed selectivity for T-A-T
triplex DNA and interstrand G-quadruplex DNA. Compounds 4h and 4i showed the
greatest selectivity for the double G-quadruplex, a more biologically relevant mimic of
the G-quadruplexes formed in telomeres. These studies resulted in a few complexes,
both photophysical and photochemical “light switches”, that will be useful for rational
design of G-quadruplex targeting molecules for in vivo applications.
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Chapter 5. Conclusions.

The first major goal of this research was to combine two current approaches in
cancer treatment: metal-based and light-activated chemotherapeutics. Metal-based
chemotherapeutics, such as cisplatin, are known for their ability to covalently damage
DNA, ultimately leading to cell death; however, their non-selective damage leads to
deleterious side effects for the patients undergoing treatment. On the other hand, lightactivated chemotherapeutics allow for spatially restricted activation and a reduction of
systemic toxicities, ultimately reducing side effects experienced by the patient; however,
current photoactive drugs require the presence of oxygen to create cytotoxic singlet
oxygen, reducing their efficacy in the hypoxic core of tumors. Both approaches have their
unique benefits, and if coupled together could provide a promising modality for treating
cancers.
Multiple series of ruthenium (II) polypyridyl complexes were designed and
synthesized to address key questions about what is driving the biological behavior.
Photophysical/photochemical studies, as well as in vitro and in vivo activity assays were
performed based on the overall goal of each series of complexes. The first set of
complexes aimed to determine the importance of the π surface and addition of
intramolecular strain on the photochemically induced cytotoxicity. The complexes with
the largest π surface ligands, dppz/dmdppz, gave the slowest photochemistry and resulted
in minimal light induced cytotoxicity. On the other hand, when increased intramolecular
strain was added, [Ru(dmphen)2L]2+, gave complexes with the largest PI values in both
HL60 and A549 cells, making them hit compounds for future structural modifications
and biological testing.
The next series of complexes were designed to improve the versatility of Ru(II)
complexes for PACT by creating complexes that can be activated by lower energy red or
near-IR light. With the incorporation of the biq or bnap ligand, the λmax was successfully
shifted to >525 nm and many complexes had some absorption >650 nm. Photoejection
studies in conjunction with crystal structures revealed the rapid photoejection for biq
complexes is due to extreme intramolecular strain induced by the bulky ligands. With the
addition of the bnap ligand the intramolecular stain is significantly reduced and renders
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the complexes photochemically inert. Unfortunately, many of these red-shifted
complexes were quite cytotoxic in the absence of light and further optimization to reduce
the dark toxicity is needed.
The third series of complexes aimed to determine if diadducts are necessary for
the photocytotoxic effect to occur. The photochemical activity of four monofunctional
and two bifunctional complexes showed that the presence of a covalently attached Clligand significantly slowed the photoejection process compared to the bifunctional
complexes. In turn, the slow photoejection process had a detrimental effect on the light
induced cytotoxicity toward E. coli cells, where the largest PI value was only 7.3.
Additionally, the bifunctional complexes do not appear to undergo complete
photochemical ligand exchange in aqueous solutions to open up two binding sites.
Overall, these complexes were much less active than complexes that contained three
bidentate ligands, and the presence of two open binding sites upon photoejection is
necessary for the cytotoxicity to occur.
The last set of complexes was synthesized in order to determine if geometry has
an impact of the cytotoxicity similar to that of cisplatin versus transplatin. Interestingly,
major differences were seen between cis-Ru(II) and trans-Ru(II), where the thermal
exchange was rapid for cis-Ru(II) but slow for trans-Ru(II). Additionally, the cis-Ru(II)
complex was not cytotoxic, whereas the trans-Ru(II) showed significant cytotoxicity. We
hypothesize this difference to be due to the rapid deactivation of the cis-Ru(II) complex
prior to entering the cell or immediately upon entering the cell. These results opened a
new area of research for metal-based chemotherapeutics. Additional studies are ongoing
to determine the photochemical activity of different trans-Ru(II) complexes.
The light activated complexes describe above can control spatial activation, but
they do not necessarily provide selective uptake into cancer cells over healthy cells.
Therefore, the second major goal of this research was to create Ru(II) polypyridyl
complexes that could target specific aspects of cancer cells. Gaining selectivity for cancer
cells would reduce the off-target toxicities generated by metal complexes in the absence
of light. Two different characteristics of cancer cells were exploited: increased
metabolism and the presence of guanosine-rich regions in telomeres and promoter
regions.
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One way to address the selective uptake of Ru(II) complexes into cancer cells is
to take advantage of the enhanced metabolism, or the Warburg effect, where cancer cells
require a larger amount of glucose metabolism to produce ATP. Three sets of complexes
were studied where one compound in each series had a pendant glucose molecule to act
as a “guide” to cancer cells. One complex was identified as a hit compound,
[Ru(dmphen)2phenTG]2+, due to its large PI window, 240. Unfortunately, the attachment
of glucose did not significantly improve uptake; however, it did reduce the inhibition of
AChE, a possible target that leads to unwanted side effects in vivo. Additional studies
need to be completed to determine the uptake mechanism of these complexes, as well as
additional complexes need to be designed to test if the proximity of the glucose molecule
has an impact on uptake.
The second area we explored was targeting therapeutically relevant DNA
sequences and structures. Unstrained Ru(II) dppz complexes are known photophysical
“light switches” for DNA, where the luminescence is quenched in an aqueous
environment due to hydrogen-bonding to the phenazine portion of the dppz ligand, but
when intercalated into the DNA base stack and sufficiently shielded from hydrogenbonding, these complexes brightly luminescence. We discovered that we can create a
photochemical “light switch”, [Ru(bpy)2dmdppz]2+, with the addition of two methyl
groups directed toward the metal center. This complex was shown to only slowly
photodecompose in an aqueous environment but when in the presence of DNA it not only
undergoes selective visible light induced ligand loss, but is capable of metalating the
DNA. Additionally, this complex showed selectivity for the telomeric G-quadruplex
structure. Through an extensive photophysical and photochemical study, we believe this
complex is undergoing ligand loss via an associative mechanism rather than a
dissociative mechanism, which is far more common for octahedral metal complexes. This
difference allows us to potentially tune the environmental selectivity due to the
importance of the incoming ligand for the photochemical process to occur.
In efforts to increase the rate of hit compound identification, a rapid screening
approach was developed using 96- and 384-well plates to test the photochemical and
photophysical complexes, respectively. Using this screening approach, each new complex
synthesized can be tested in triplicate under 32 different conditions simultaneously. In
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our initial attempts to design a more selective photochemical and photophysical “light
switch”, the 11-Br-substituted dppz complexes yielded the highest selectivity for
structurally distinct G-quadruplex structures. Given this striking selectivity, a series of
unstrained halogen derivatives were synthesized and tested using the rapid screening
approach. This series of complexes resulted in two complexes, 11,12-Cl and 11,12-Brsubsituted dppz, that had enhanced response when bound to a double telomeric Gquadruplex. These two complexes show the most therapeutically relevant results and are
classified as hit compounds. The current set of compounds has not been tested in vivo but
we predict that additional structural modifications need to be made prior to in vivo testing
to improve the uptake of Ru(II) complexes for imaging of different DNA structures
(photophysical series) or selective DNA damage (photochemical series).
There are still many experiments to be completed to fully understand these
projects, but overall each of these projects has answered many of the outstanding
questions within the field. A few key complexes have been identified and future structure
photoactivity relationship studies should be completed to improve the efficacy and
selectivity of these complexes. Assays and procedures have been developed and
optimized

to

rapidly

screen

new

complexes

for

thermal

exchange

and

photochemical/photophysical behavior. Additionally, a few new areas of research have
been opened: the importance of Ru(II) geometry on the cytotoxic behavior and the
discovery of the first photochemical “light switch” that is selective for G-quadruplex
DNA.
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Chapter 6. Experimental.

6.1 Materials.
Chemicals used for synthesis were purchased from suppliers and used without
further purification. cis-Dichlorobis(2, 2’-bipyridine)ruthenium(II) dehydrate (2y) was
purchased from Strem Chemicals All solvents used for photochemical analysis were
purchased from Sigma-Aldrich, VWR, or Fisher Scientiﬁc with >99% purity. Calf
thymus (CT) DNA was purchased from Sigma-Aldrich, re-suspended in buffer (50
mM NaCl, 5 mM Tris buffer, pH 7.0) and sonicated (bath sonicator for 40 min
followed by 10–15 1 sec pulses with a Branson Sonifier 250 (duty cycle = 90% and
output control = 2) to provide shorter strands for these studies. Custom DNA sequences
were purchased from Eurofins, resuspended and annealed according to Table 6.3. Table
6.3 also provides detailed information of the different protein, nucleoside and DNA
sequences tested. In brief, DNA sequences were resuspended in buffer, incubated at room
temperature for 15 minutes, vortexed, and annealed prior to testing. Following heating to
the specified annealing temperature, the DNA was cooled slowly to room temperature
then stored at 4 °C overnight. Bovine serum albumin (BSA), deoxyadenosine (dA),
deoxyguanosine (dG), thymidine (dT), and deoxycytosine (dC) were resuspended in
buffer to give a 1 mM stock. All biomolecules were stored long term at -20 °C.

6.2 Instrumentation.
All 1 H-NMR and

13

C-NMR were obtained on a Varian Mercury spectrometer

(400, 100 MHz). The 1H chemical shifts are reported relative to the residual solvent peak
of CD3CN (δ 1.94), CDCl3 (δ 7.24) or CD3OD (δ 3.31). The

13

C chemical shifts are

referenced to CD3CN at δ 1.39. Electrospray ionization (ESI) mass spectra were
obtained on a Varian 1200L mass spectrometer at the Environmental Research
Training Laboratory (ERTL) at the University of Kentucky. Absorption spectra were
obtained on an Agilent 8453 Diode Array spectrophotometer, an Agilent Cary 60
spectrophotometer or a BMG Labtech FLUOstar Omega microplate reader. Photoejection
experiments were performed using a Dell 200 Watt 1410X projector or 470 nm LED
array from Elixa (for in vitro photoejection experiments) or 410 Watt 955 Model 900 AJH
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projector (for cell cytotoxicity studies). The more intense light source was used for the
cell cytotoxicity studies in order to minimize the time the samples would be removed
from the incubation chamber in order to reduce cell death due to temperature and
atmosphere alterations. When using either projector, Edmund Optics filters (item number
NT43-941, NF49-935, NT43-947, and NT43-954, Figure 6.1) was used to cut off the
appropriate sections of the UV and visible spectrum.

UV/Vis experiments were

performed in either a 1-cm pathlength quartz cuvette placed 12 inches from the
projector/LED or a Greiner 96-well UV clear microplate placed 12 inches from the LED.
Luminescence spectra were obtained using a Horiba Jobin Yvon Fluorolog-3
spectroﬂuorometer equipped with a Hamamatsu type R928P photomultiplier tube or a
Molecular Devices Spectramax M5 microplate reader. Circular dichroism (CD)
experiments were performed on a Jasco J-815 CD Spectrometer equipped with a MPTC490S/15 temperature controller. HPLC experiments were run on an Agilent 1100 Series
HPLC equipped with a model G1311A quaternary pump, G1315B UV diode array
detector and Chemstation software version B.01.03. Chromatographic conditions were
optimized on a Column Technologies Inc. C18 120 Å column (for purity analysis) and
a Grace Davison Discovery Science (Vydac 218TP C18 5 μm) C18 column (for adduct
formation analysis) fitted with a Phenomenex C18 guard column. The gradient used
for all samples is shown in Table 6.1. The Prism software package was used to analyze
kinetic data with a single exponential equation, luminescence spectra with area under the

Figure 6.1: Plot of transmittance of Edmond Optics filters used in all light activated
experiments. Blue: blue filter; green: green filter; red: red filter; black: near-IR cutoff
filter.
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curve, and melting temperature using a sigmoidal dose response equation. Cell survival
was quantified using a TecanSpectraFluor Plus Microplate Reader.

Table 6.1: Gradient used for HPLC analysis.
Time (min)

0.1% formic acid in dH2O

0.1% formic acid in CH3CN

0

98

2

2

95

5

5

70

30

15

70

30

20

40

60

30

5

95

35

98

2

40

98

2

6.3 Synthesis and characterization.

Table 6.2: Structures of ligands used for Ru(II) complex formation.

Structure

Chemical Name

Abbreviation

Monodentate

imidazole

imid

pyridine

py

quinoline

quin
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isoquinoline

isoquin

Bidentate

2,2’-bipyridine

6,6’-dimethyl-2,2’bipyridine

1,10-phenanthroline

1,10-phenanthroline-5,6dione

5,6-epoxy-5,6-dihydro1,10-phenanthroline

5-(2-aminoethanethiol)1,10-phenanthroline
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bpy

dmbpy

phen

phendione

phenepoxide

phenamine

5-(2-sulfanylethan-1-ol)1,10-phenanthroline

5-thioglucose-1,10phenanthroline

2,9-dimethyl-1,10phenanthroline

2,9-dimethyl-1,10phenanthroline-5,6-dione

dipyrido[3,2-f:2′,3′-h]quinoxaline

3,6-dimethyl-dipyrido[3,2f:2′,3′-h]-quinoxaline
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phenBME

phenTG

dmphen

dmphendione

dpq

dmdpq

dipyrido[3.2-a:2’,3’c]phenazine

3,6-dimethyl-dipyrido[3,2a:2’,3’-c]phenazine

dppz

dmdppz

2,2’-biquinoline

biq

2,2’-bi-1,8-naphthyridine

bnap

Tetradentate

2,2′:6′,2′′:6′′,2′′′quaterpyridine

163

qpy

Table

6.3:

Structures

of

diamine

used

for

condensation

reactions

[Ru(bpy)2phendione]2+.
Structure

Chemical Name
4-fluoro-1,2phenylenediamine

4-chloro-1,2phenylenediamine

4-bromo-1,2phenylenediamine

3-fluoro-1,2phenylenediamine

3-chloro-1,2phenylenediamine

3-bromo-1,2phenylenediamine

4,5-difluoro-1,2phenylenediamine
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Complex Code

4e

4f

4c

4g

4h

4i

4j

with

4,5-dichloro-1,2phenylenediamine

4,5-dibromo-1,2phenylenediamine

4k

4l

6.3.1 Chapter 2 compounds.
Compounds 2b, 2e, and 2g were reported previously.1 Compounds 2d and 2h are cross
referenced as 4a and 4b.
2,2’-bi-1,8-naphthyridine (bnap) was prepared by literature method.2 1H NMR (CDCl3,
400 MHz): δ 9.13 (dd, J = 4.3, 1.9 Hz, 2H), 9.03 (d, J = 8.6 Hz, 2H), 8.61 (d, J = 8.6 Hz,
2H), 8.53 (dd, J = 8.2, 1.8 Hz, 2H), 7.70 (dd, J = 8.1, 4.3 Hz, 2H).ESI MS calcd for
C16H10N4 [L•H]+ 258.09, found 259.1 [L•H]+.
2,2′:6′,2′′:6′′,2′′′-quaterpyridine (qpy): A mixture of K2CO3 (176 mg, 1.28 mmol),
Pd(OAc)2 (43 mg, 0.64 mmol), NBu4Br (206.3 mg, 0.64 mmol) and 6-bromobipyridine
(300 mg, 1.28 mmol) in DMF (2 mL) was stirred under N2 atmosphere for a few minutes
at 115 ºC. Then, isopropanol (8 mL) was added to the orange solution and the final
mixture was remained at 115 ºC for 3h. After cooling to R.T., water and ether were added
and the organic phase was extracted and dried over MgSO4. The solvent was removed
under vacuum to obtain a pale yellow solid. Yield: 242 mg (61%). 1H NMR (CDCl3, 400
MHz): δ = 8.75–8.72 (m, 2H), 8.70–8.66 (m, 4H), 8.51 (dd, J = 8.0, 1.2 Hz, 2H), 8.01 (t,
J = 8.0 Hz, 2H), 7.91 (td, J = 8.0, 1.6 Hz, 2H), 7.39–7.35 (m, 2H). ESI MS calcd for
C20H14N4 [L•H]+ 310.12, found 311.1 [L•H]+.
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Figure 6.2: Example reaction scheme for the synthesis of Ru(L)2Cl2.
The synthesis of Ru(phen)2Cl2, Ru(dmphen)2Cl2, and Ru(biq)2Cl2 was performed as
described in the literature (Figure 6.2).3 Briefly, RuCl3 3Η2Ο (1 eq), L (2.5 eq), and LiCl
(12 eq) were added to 100 mL of DMF in a round bottom flask. The mixture was
refluxed, allowed to cool precipitated with acetone, filtered and washed with acetone. The
precipitate was dissolved in hot DMF, re-precipitated with acetone, filtered and washed
with acetone. Typical yields around 60%.

Figure 6.3: Example reaction scheme for the complexation of L’ to Ru(L)2Cl2.

Most of the Ru(II) complexes were prepared by either Method 1 or Method 2 (Figure
6.3).

Method 1: Ru(L)2Cl2 (1 eq) and L’ (1.1 eq) were added to 5 mL of a 4:1 ethanol and
water in a 10 mL round bottom. The mixture was heated to reflux in the dark, where the
reaction progress was followed by TLC. Upon completion the reaction was allowed to
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cool to room temperature and poured into 50 mL of deionized water and extracted with
CH2Cl2 to remove unreacted starting material. Addition of a saturated KPF6 solution to
the aqueous phase produced a precipitate that was then extracted into CH2Cl2. Solvent
was removed under reduced pressure and further purified by flash chromatography (SiO2,
MeCN/H2O/KNO3).
Method 2: Ru(L)2Cl2 (1 eq) and L’ (1.1 eq) were added to 5 mL degassed ethylene glycol
in a 15 mL pressure tube. The mixture was heated at 160 °C in the dark and the reaction
progress was followed by TLC. Upon completion of the reaction it was allowed to cool
and transferred into 50 mL of distilled water. Addition of a saturated KPF6 solution
produced a precipitate that was collected by vacuum filtration. The solid was washed
with deionized water and diethyl ether. The purification of the solid was carried out by
flash chromatography (SiO2, MeCN/H2O/KNO3).
[Ru(bpy)3](PF6)2 (2a): Complex 2a was prepared by literature methods.4 1H NMR
(CD3CN, 400 MHz): δ 8.50 (d, J = 8.2 Hz, 6H), 8.05 (t, J = 8.0 Hz, 6H), 7.73 (d, J = 5.5
Hz, 6H), 7.40 (t, J = 6.3 Hz);

13

C NMR (CD3CN, 100 MHz): δ 158.03, 152.73, 138.84,

128.61, 125.30; ESI MS calcd for C30H24N6Ru [M2+•PF6-]+ 715.07, [M]+ 570.11 [M]2+
285.06; found 715.1 [M2+•PF6-]+, 570.3 [M]+, 284.9 [M]2+. Purity by HPLC: 99.9% by
area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 452 (14600).5
[Ru(bpy)2dpq](PF6)2 (2c): Complex 2c was prepared by literature methods.6 1H NMR
(CD3CN, 400 MHz): δ 9.55 (d, J = 8.2 Hz, 2H), 9.23 (s, 2H), 8.56 (dd, J = 7.8, 7.8 Hz,
6H), 8.22 (dd, J = 5.3, 0.6 Hz, 2H), 8.14 (t, J = 7.8 Hz, 2H), 8.03 (t, J = 7.6 Hz, 2H),
7.92–7.87 (m, 4H), 7.68 (d, J = 5.6 Hz, 2H), 7.49 (t, J = 6.8 Hz, 2H), 7.26 (t, J = 6.8 Hz,
2H);

13

C NMR (CD3CN, 100 MHz): δ 158.31, 158.05, 154.79, 153.17, 153.08, 150.34,

147.82, 140.90, 139.05, 138.94, 134.38, 131.28, 128.68, 128.53, 128.19, 125.39, 125.33;
ESI MS calcd for C34H24N8Ru [M2+•PF6-]+ 791.08, [M]2+ 323.06; found 791.2 [M2+•PF6]+, 322.9 [M]2+. Purity by HPLC: 95.4% by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1)
256 (53600), 289 (55900), 449 (15100).
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[Ru(bpy)2dmphen](PF6)2 (2f): Complex 2f was prepared by literature methods.7 1H NMR
(CD3CN, 400 MHz): δ 8.57 (d, J = 8.0 Hz, 2H), 8.50 (d, J = 7.8 Hz, 2H), 8.09 (td, J =
8.0, 1.4 Hz, 2H), 8.05 (s, 2H), 8.02 (td, J = 8.2, 1.5 Hz, 2H), 7.82 (d, J = 5.8 Hz, 2H),
7.77 (d, J = 5.8 Hz, 2H), 7.78–7.59 (m, 4H), 7.34 (td, J = 9.0, 1.4 Hz, 2H), 7.31 (td, J =
9.0, 1.4 Hz, 2H), 2.0 (s, 6H);

C NMR (CD3CN, 100 MHz): δ 168.14, 158.70, 158.57,

13

153.93, 152.98, 149.67, 138.87, 138.70, 138.67, 130.57, 128.69, 128.42, 128.24, 128.14,
125.50, 125.48, 26.26; ESI MS calcd for C34H28N6Ru [M2+•PF6-]+ 767.1 [M]2+ 311.07;
found 767.1 [M2+•PF6-]+, 311.0 [M]2+. Purity by HPLC: 99.9% by area. UV/Vis
(CH3CN): λmax nm (ε M-1cm-1) 287 (60200), 452 (12800).
[Ru(dmphen)2bpy](PF6)2 (2i): Was prepared by method 2, where purification of the solid
was carried out by flash chromatography (SiO2, MeCN and elution with 1% KNO3 and
9% H2O) to give the pure complex. Yield: 120 mg (49%). 1H NMR (CD3CN, 400 MHz):
δ 8.66 (d, J = 8.2 Hz, 2H), 8.32 (d, J = 8.4 Hz, 2H), 8.24 (d, J = 8.8 Hz, 2H), 8.18 (d, J =
7.9 Hz, 2H), 8.11 (d, J = 8.8 Hz, 2H), 7.8 (td, J = 1.5, 8.0 Hz, 2H), 7.75 (d, J = 8.4 Hz,
2H), 7.41 (d, J = 8.4 Hz, 2H), 7.06–7.01 (m, 2H), 7.95 (td, J = 1.3, 7.5 Hz, 2H), 1.90 (s,
6H), 1.88 (s, 6H).

13

C NMR (CD3CN, 100 MHz): δ 169.68, 167.74, 158.96, 153.04,

150.42, 149.39, 138.98, 138.86, 137.82, 131.06, 130.96, 128.51, 128.37, 128.23, 127.96,
127.62, 124.90, 26.85, 25.77; ESI MS calcd for C38H32N6Ru [M2+•PF6-]+ 820.13, [M]2+
337.09; found 819.3 [M2+•PF6-]+, 337.0 [M]2+. Purity by HPLC: 94.0% by area. UV/Vis
(CH3CN): λmax nm (ε M-1cm-1) 270 (52100), 290 (29500), 457 (9000).
[Ru(dmphen)2phen](PF6)2 (2j): Was prepared by method 2, where purification of the
solid was carried out by flash chromatography (SiO2, MeCN and elution with 0.5%
KNO3 and 8% H2O) to give the pure complex. Yield: 150 mg (88.9%). 1H NMR
(CD3CN, 400 MHz): δ 8.72 (d, J = 8.6 Hz, 2H), 8.39 (dd, J = 7.9, 1.4 Hz, 2H), 8.26 (q, J
= 8.8 Hz, 4H), 8.11 (d, J = 8.8 Hz, 2H), 8.05 (s, 2H), 7.82 (d, J = 8.5 Hz, 2H), 7.37–7.31
(m, 4H), 7.21 (d, J = 8.2 Hz, 2H), 2.18 (s, 6H), 1.65 (s, 6H).13C NMR (CD3CN, 100
MHz): δ 169.80, 167.90, 154.07, 150.50, 149.35, 149.31, 139.00, 138.19, 137.62, 131.49,
131.09, 130.99, 129.00, 128.50, 128.22, 127.52, 126.16, 26.87, 25.87; ESI MS calcd for
C40H32N6Ru [M2+•PF6-]+ 842.17, [M]+ 698.17, [M]2+ 349.09; found 843.4 [M2+•PF6-]+,
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698.16 [M]+, 349.0 [M]2+. Purity by HPLC: 99.9 % by area. UV/Vis (CH3CN): λmax nm (ε
M-1cm-1) 270 (92,300), 460 (15,100).
[Ru(dmphen)2dpq](PF6)2 (2k): Complex 2k was prepared by literature methods.8 1H
NMR (CD3CN, 400 MHz): δ 9.33 (td, J = 4.9, 1.4 Hz, 2H), 9.12 (s, 2H), 8.74 (d, J = 8.2
Hz, 2H), 8.28 ( dd, J = 8.7, 8.2 Hz, 4H), 8.13 ( d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.4 Hz,
2H), 7.47 (d, J = 4.9 Hz, 4H), 7.23 (d, J = 8.3 Hz, 2H), 1.99 (s, 6H), 1.76 (s, 6H);

13

C

NMR (CD3CN, 100 MHz): δ 169.86, 168.06, 155.09, 151.08, 150.41, 149.18, 147.68,
140.88, 139.14, 137.65, 134.55, 131.07, 130.67, 128.54, 128.41, 128.37, 12826, 127.80,
127.15, 27.05, 25.88; ESI MS calcd for C42H32N8Ru [M2+•PF6-]+ 895.14, [M]+ 750.18,
[M]2+ 375.09; found 895.0 [M2+•PF6-]+, 748.9 [M]+, 375.1 [M]2+. Purity by HPLC: 98.1%
by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 224 (79900), 268 (79400), 459 (14900).
[Ru(dmphen)2dppz](PF6)2 (2l): Complex 2l was prepared by literature methods.9 1H
NMR (CD3CN, 400 MHz): δ 9.46 (dd, J = 7.6, 1.2 Hz, 2H), 8.74 (d, J = 8.4 Hz, 2H), 8.39
(q, J = 3.5 Hz, 2H), 8.29 (2d, J = 8.8 Hz, 4H), 8.14 (d, J = 8.6 Hz, 2H), 8.10 (q, J = 3.3
Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.49–7.43 (m, 4H), 7.25 (d, J = 8.4 Hz, 2H), 1.99 (s,
6H), 1.94 (s, 6H);

13

C NMR (CD3CN, 100 MHz): δ 169.88, 168.08, 155.06, 152.34,

150.48, 149.22, 143.70, 140.96, 139.16, 137.72, 132.78, 133.56, 131.35, 131.16, 131.06,
130.61, 128.56, 128.40, 128.30, 127.88, 128.47, 27.13, 25.90; ESI MS calcd for
C46H34N8Ru [M2+•PF6-]+ 945.15, [M]+ 800.19, [M]2+ 400.10; found 944.8 [M2+•PF6-]+,
799.5 [M]+, 400.1 [M]2+. Purity by HPLC: 98% by area. UV/Vis (CH3CN): λmax nm (ε M1

cm-1) 270 (82700), 370 (14500), 450 (11100).

[Ru(phen)2biq](PF6)2 (2m): Complex 2m was prepared by method 2, where purification
of the solid was carried out by precipitation from acetone with diethyl ether to give the
pure complex. Yield: 722.4 mg (92.6%). 1H NMR (CD3OD, 400 MHz): δ 8.96 (d, J = 8.8
Hz, 2H), 8.78 (dd, J = 8.4, 1.1 Hz, 2H), 8.72 (d, J = 8.8 Hz, 2H), 8.65 (dd, J = 8.2, 1.1
Hz, 2H), 8.39 (dd, J = 5.3, 1.1 Hz, 2H), 8.29 (q, J = 8.9 Hz, 4H), 8.01–7.98 (m, 4H), 7.91
(d, J = 5.3 Hz, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.64 (d, J = 5.5 Hz, 1H), 7.62 (d, J = 5.5 Hz,
1H), 7.47 (td, J = 7.9, 0.9 Hz, 2H), 7.11 (d, J = 8.8 Hz, 2H), 7.05-7.01 (m, 2H); 13C NMR
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(CD3CN, 100 MHz): δ 161.98, 155.70, 154.10, 152.18, 149.27, 148.56, 140.39, 138.51,
138.30, 132.37, 132.15, 132.02, 130.59, 130.13, 130.00, 129.28, 129.15, 127.22, 126.90,
125.75, 122.10; ESI MS calcd for C42H28N6Ru [M]+ 718.14, [M]2+ 359.07; found 718.3
[M]+, 359.2 [M]2+. Purity by HPLC: 99.9% by area. UV/Vis (CH3CN): λmax nm (ε M-1cm1

) 218 (78000), 338 (28400), 378 (19300), 440 (8300), 525 (8300).

[Ru(biq)2phen](PF6)2 (2n): Complex 2n was prepared by method 2, where purification of
the solid was carried out by flash chromatography (SiO2, MeCN and elution with 0.3%
KNO3 and 7% H2O) to give the pure complex. Yield: 102.3 mg (61.5%). 1H NMR
(CD3CN, 400 MHz): δ 9.10 (d, J = 8.8 Hz, 2H), 9.02 (d, J = 8.8 Hz, 2H), 8.84 (d, J = 9
Hz, 2H), 8.40 (d, J = 8.8 Hz, 2H), 8.32–8.29 (m, 4H), 8.18 (dd, J = 8.2, 1.1 Hz, 2H), 7.80
(2d, J = 8.2, 8.2 Hz, 2H), 7.70–7.67 (m, 4H), 7.53 (t, J = 7.5 Hz, 2H), 7.41 (d, J = 9 Hz,
2H), 7.24 (t, J = 7.5 Hz, 2H), 7.12–7.08 (m, 4H). 6.83 (t, J = 8.5 Hz, 2H);

13

C NMR

(CD3CN, 100 MHz): δ 161.35, 160.50, 152.70, 151.81, 150.23, 146.64, 140.26, 138.68,
137.79, 132.73, 130.44, 129.37, 129.52, 129.37, 129.23, 128.89, 128.75, 128.05, 127.44,
125.83, 125.39, 124.94, 122.50, 121.45; ESI MS calcd for C48H32N6Ru [M2+•PF6-]+
939.14, [M]2+ 397.09; found 939.1 [M2+•PF6-]+, 397.0 [M]2+. Purity by HPLC: 99.9% by
area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 217 (38100), 317 (19600), 361 (16400), 381
(17800), 479 (3600), 550 (5000).

[Ru(phen)2bnap](PF6)2 (2o): Prepared by method 1, where the purification of the solid
was carried out by flash chromatography (SiO2, MeCN and elution with 0.1% KNO3 and
7% H2O) to give the pure complex. Yield: 59.6 mg (29.7%). 1H NMR (CD3CN, 400
MHz): δ 8.85 (d, J = 8.8 Hz, 2H), 8.65 (d, J = 8.8 Hz, 2H), 8.53 (dd, J = 8.3, 1.3 Hz, 2H),
8.48 (dd, J = 8.2, 1.3 Hz, 2H), 8.37 (dd, J = 8.2, 1.9 Hz, 2H), 8.16–8.11 (m, 4H), 8.07
(dd, J = 5.3, 1.3 Hz, 2H), 7.86 (dd, J = 5.3, 1.3 Hz, 2H), 7.78 (dd, J = 4.2, 2.0 Hz, 2H),
7.59 (dd, J = 8.2, 5.3 Hz, 2H), 7.47 (dd, J = 8.3, 5.3 Hz, 2H), 7.40 (dd, J = 8.2, 4.2 Hz,
2H);

13

C NMR (CD3CN, 100 MHz): δ 163.30, 159.48, 154.77, 154.45, 153.64, 150.04,

149.38, 140.25, 139.37, 137.50, 137.08, 131.47, 131.10, 128.85, 128.21, 126.39, 125.67,
125.61, 125.51, 123.25; ESI MS calcd for C40H26N8Ru [M2+•PF6-]+ 865.09, [M]2+ 360.07;
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found 865.4 [M2+•PF6-]+, 360.0 [M]2+. Purity by HPLC: 99.9 % by area. UV/Vis
(CH3CN): λmax nm (ε M-1cm-1) 265 (71000), 345 (26800), 435 (9900), 575 (7600).
[Ru(dmphen)2bnap](PF6)2 (2p): Prepared by method 2, where the purification of the solid
was carried out by flash chromatography (SiO2, MeCN and elution with 0.5% KNO3 and
9% H2O) to give the pure complex. Yield: 93 mg (34%). 1H NMR (CD3CN, 400 MHz): δ
8.53 (d, J = 8.3 Hz, 2H), 8.41 (q, J = 8.6 Hz, 4H), 8.21 (dd, J = 8.3, 2.0 Hz, 2H), 8.16 (d,
J = 8.3 Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 2H), 7.70 (dd, J = 4.2, 2.0
Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.32–7.28 (m, 4H) 1.86 (s, 6H), 1.82 (s, 6H); 13C NMR
(CD3CN, 100 MHz): δ 169.76, 167.35, 164.61, 159.14, 153.51, 153.09, 151.68, 140.52,
139.68, 138.74, 137.63, 129.39, 129.36, 128.33, 127.91, 127.75, 126.97, 125.25, 125.20,
123.31, 26.45, 25.47; ESI MS calcd for C44H34N8Ru [M2+•PF6-]+ 921.15, [M]2+ 388.10;
found 920.9 [M2+•PF6-]+, 387.0 [M]2+. Purity by HPLC: 95% by area. UV/Vis (CH3CN):
λmax nm (ε M-1cm-1) 275 (45800), 350 (19200), 435 (6900), 585 (4900).
[Ru(biq)2bnap](PF6)2 (2q): Prepared by method 2, where the purification of the solid was
carried out by flash chromatography (SiO2, MeCN and elution with 0.1% KNO3 and 7%
H2O) to give the pure complex. Yield: 110 mg (63.6%). 1H NMR (CD3CN, 400 MHz): δ
8.67 (d, J = 8.8 Hz, 2H), 8.45–8.37 (m, 6H), 8.26 (d, J = 8.8 Hz, 2H), 8.13 – 8.10 (m,
4H), 8.01 (dd, J = 8.2, 1.3, 2H), 7.97 (d, J = 8.7 Hz, 2H), 7.77 (dd, J = 8.2, 1.1 Hz, 2H),
7.68 (d, J = 8.9 Hz, 2H), 7.62 (dd, J = 8.2, 4.2 Hz, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.45 (t, J
= 7.1 Hz, 2H), 7.31 (ddd, J = 8.1, 7.0, 1.0 Hz, 2H), 6.95 (ddd, J = 8.9, 7.0, 1.5 Hz, 2H),
6.58 (ddd, J = 8.8, 7.0, 1.4, 2H);

C NMR (CD3CN, 100 MHz): δ 164.41, 164.14,

13

154.63, 150.88, 141.92, 140.51, 140.06, 139.95, 132.53, 131.48, 130.60, 129.81, 129.70,
129.53, 127.37, 126.41, 126.07, 125.90, 122.62, 121.56, 121.39; ESI MS calcd for
C52H34N8Ru [M2+•PF6-]+ 872.19, [M]2+ 436.10; found 872.4 [M2+•PF6-]+, 436.2 [M]2+.
Purity by HPLC 96.1% by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 265 (79300), 340
(48800), 505 (7640), 575 (6600).
[Ru(bnap)3](PF6)2 (2r): Was a byproduct of a reaction to synthesize Ru(bnap)2Cl2. 1H
NMR (CD3CN, 400 MHz): δ 8.54 (q, J = 8.8 Hz, 12H), 8.30 (dd, J = 8.2, 2.0 Hz, 6H),
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7.46 (dd, J = 4.1, 1.2 Hz, 6H), 7.25 (dd, J = 8.1, 4.1 Hz, 6H);

13

C NMR (CD3CN, 100

MHz): δ 165.14, 159.30, 153.14, 139.63, 139.06, 124.83, 14.48, 121.98; ESI MS calcd
for C48H30N12Ru [M]+ 876.18, [M]2+ 438.09; found 875.8 [M]+ , 437.9 [M]2+. Purity by
HPLC: 99.9% by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 245 (74400), 345 (64300),
575 (8800).

[Ru(bpy)2(imid)Cl]PF6 (2s): [Ru(bpy)2Cl2]•2H2O (0.1464 g, 0.281 mmol) and imidazole
(0.259 g, 0.381 mmol) were added to 9 mL of 1:3 H2O:EtOH in a 15 mL pressure tube.
The mixture was heated to 80 °C for 1 hour. The reaction was cooled to room
temperature and with the addition of a saturated KPF6 solution a precipitate formed. The
precipitate was filtered and washed with deionized water and diethyl ether. Purification of
the solid was carried out by flash chromatography (neutral AlO3, 50% toluene/50%
MeCN). Yield: 153 mg (82.2%). 1H NMR (CD3CN, 400 MHz): δ 9.96 (d, J = 5.6 Hz,
1H), 8.45–8.42 (m, 2H), 8.34 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.27 (d, J =
8.05, 1H), 8.01 (q, J = 8.2 Hz, 2H), 7.88 (s, 1H), 7.84 (d, J = 5.5 Hz, 1H), 7.77 (t, J = 7.8
Hz, 2H), 7.68–7.64 (m, 2H), 7.55 (t, J = 6.6, 1H), 7.16–7.10 (m, 2H), 6.99 (s, 1H), 6.53
(s, 1H); 13C NMR (CD3CN, 100 MHz): δ 160.94, 159.87, 159.30, 158.86, 153.99, 153.93,
153.13, 153.10, 139.03, 136.69, 136.64, 136.41, 135.82, 128.78, 127.44, 127.32, 126.72,
124.45, 124.15, 123.89, 123.83; ESI MS calcd for C23H20ClN6Ru [M]+ 517.05; found
517.0 [M]+. Purity by HPLC: 99.7 % by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 295
(45000), 360 (7300), 515 (7400).
[Ru(bpy)2(py)Cl]PF6 (2t): Was prepared analogous to 2v. Yield: 80 mg (39.4%). 1H NMR
(CD3CN, 400 MHz): δ 9.95 (d, J = 5.5 Hz, 1H), 8.55 (d, J = 5.2 Hz, 1H), 8.48 (d, J = 8.1
Hz, 1H), 8.34 (d, J = 7.6 Hz, 2H), 8.25 (d, J = 8.0 Hz, 1H), 8.06 (q, J =8.3 Hz, 2H), 7.84–
7.72 (m, 6H), 7.64 (d, J = 5.4 Hz, 1H), 7.59 (t, J = 6.4 Hz, 1H), 7.24–7.13 (m, 5H); 13C
NMR (CD3CN, 100 MHz): δ 160.49, 159.45, 159.19, 158.90, 154.32, 154.03, 153.95,
153.16, 153.13, 138.01, 137.39, 137.23, 137.06, 136.40, 128.01, 127.93, 127.53, 126.92,
126.21, 124.69, 124.47, 124.19, 123.93; ESI MS calcd for C25H21ClN5Ru [M]+ 528.00;
found 527.9 [M]+. Purity by HPLC: 96.5 % by area. UV/Vis (CH3CN): λmax nm (ε M-1cm1

) 350 (11700), 500 (8400).
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[Ru(bpy)2(quinoline)Cl]PF6 (2u): was prepared by method 1, where purification of the
solid was carried out by flash chromatography (SiO2, MeCN and elution with 0.1%
KNO3 and 3% H2O) to give the pure complex. Yield: 62.8 mg (35%). 1H NMR (CD3CN,
400 MHz): δ 10.04 (d, J = 5.7 Hz, 1H), 8.62 (dd, J = 5.7, 0.6 Hz, 1H), 8.49 (d, J = 7.9
Hz, 2H), 8.36 (d, J = 8.0 Hz, 2H), 8.30 (d, J = 8.0 Hz, 1H), 8.24 (d, J = 7.9 Hz, 1H), 8.06
(td, J = 7.9, 1.4 Hz, 1H), 8.01 (td, J = 7.9, 1.5 Hz, 1H), 7.92–7.86 (m, 3H), 7.82–7.72 (m,
4H), 7.68 (t, J = 5.8 Hz, 2H), 7.62 (t, J = 6.2 Hz, 1H), 7.54 (ddd, J = 7.4, 5.8, 1.2 Hz,
1H), 7.24 (ddd, J = 7.4, 5.9, 1.3 Hz, 1H), 7.17 (ddd, J = 7.4, 5.8, 1.2 Hz, 1H); 13C NMR
(CD3CN, 100 MHz): δ 160.52, 159.46, 159.17, 158.92, 154.14, 154.00, 153.41, 153.13,
137.37, 137.21, 137.08, 136.43, 136.07, 133.15, 129.94, 129.58, 128.47, 128.00, 127.50,
127.41, 126.95, 124.71, 124.46, 124.18, 123.95, 122.96; ESI MS calcd for C29H23ClN5Ru
[M]+ 578.06; found 578.1 [M]+. Purity by HPLC: 95.1 % by area. UV/Vis (CH3CN): λmax
nm (ε M-1cm-1) 295 (82900), 360 (17700), 500 (13900).
[Ru(bpy)2(isoquinoline)Cl]PF6 (2v): Was prepared by method 2, where purification of the
solid was carried out by flash chromatography (SiO2, MeCN and elution with 0.4%
KNO3 and 12% H2O) to give the pure complex. Yield: 72.3 mg (62%). 1H NMR
(CD3CN, 400 MHz): δ 10.03 (d, J = 5.7 Hz, 1H), 8.61 (d, J = 5.6 Hz, 1H), 8.49 (d, J =
8.0 Hz, 1H), 8.30 (d, J = 8.1 Hz, 1H), 8.24 (d, J = 7.8 Hz, 1H), 8.06 (td, J = 7.9, 1.5 Hz,
1H), 8.00 (td, J = 7.7, 1.6 Hz, 1H), 7.93 – 7.87 (m, 3H), 7.84 – 7.72 (m, 7H), 7.67 (t, J =
5.0 Hz, 2H), 7.61 (d, J = 6.5 Hz, 1H), 7.54 (ddd, J = 7.4, 5.8, 1.3 Hz, 1H), 7.24 (ddd, J =
7.5, 5.9, 1.4 Hz, 1H), 7.17 (ddd, J = 7.4, 5.8 1.3 Hz, 1H); 13C NMR (CD3CN, 100 MHz):
δ 160.53, 159.49, 159.19, 158.94, 154.16, 15400, 153.42, 153.15, 138.86, 137.40, 137.24,
137.11, 136.47, 136.08, 133.16, 129.96, 129.60, 128.75, 128.49, 128.02, 127.53, 127.47,
127.43, 126.97, 124.71, 124.47, 124.20, 123.97, 122.99; ESI MS calcd for C29H23ClN5Ru
[M]+ 578.06; found 578.1 [M]+. Purity by HPLC: 96.3 % by area. UV/Vis (CH3CN): λmax
nm (ε M-1cm-1) 500 (8000).
[Ru(bpy)2(imid)2](PF6)2 (2w): Was prepared by method 1 using 2 eq of L’, where
purification of the solid was carried out by precipitation from acetone with diethyl ether
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to give the pure complex. Yield: 320 mg (80%). 1H NMR (CD3CN, 400 MHz): δ 8.93
(dq, J = 5.6, 0.7 Hz, 2H), 8.34 (d, J = 8.0 Hz, 2H), 8.26 (d, J = 8.0 Hz, 2H), 8.06 (td, J =
7.7, 1.5 Hz, 2H), 7.91 (dq, J = 5.7, 0.7 Hz, 2H), 7.85 (td, J = 7.9, 1.5 Hz, 2H), 7.67 (ddd,
J = 7.5, 5.7, 1.4 Hz, 2H), 7.47 (t, J = 1.2 Hz, 2H), 7.27 (ddd, J = 7.5, 5.7, 1.3 Hz, 2H),
7.06 (t, J = 1.5 Hz, 2H), 7.01 (s, 2H), 6.70 (t, J = 1.4 Hz, 2H);
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C NMR (CD3CN, 100

MHz): δ 159.18, 158.64, 153.57, 153.48, 139.13, 137.85, 137.52, 129.95, 128.26, 127.92,
124.58, 124.43, 119.50; ESI MS calcd for C26H24N8Ru [M2+•PF6-]+ 695.08, [M]2+ 275.06;
found 694.7 [M2+•PF6-]+, 274.7 [M]2+. Purity by HPLC: 98.1 % by area.

UV/Vis

(CH3CN): λmax nm (ε M-1cm-1) 290 (46900), 340 (7700), 490 (8000).
[Ru(bpy)2(py)2](PF6)2 (2x): Was prepared by method 1 using 2 eq of L’, where
purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.7% KNO3 and 11% H2O) to give the pure complex. Yield: 130 mg (70%).
1

H NMR (CD3CN, 400 MHz): δ 8.92 (d, J = 5.6 Hz, 2H), 8.36 (d, J = 7.9 Hz, 2H), 8.30–

8.26 (m, 6H), 8.13 (td, J = 7.9, 1.4 Hz, 2H), 7.94–7.89 (m = 4H), 7.85 (tt, J = 7.7, 1.5 Hz,
2H), 7.77 (ddd, J = 7.6, 5.7, 1.4 Hz, 2H), 7.36 (ddd, J = 7.4, 5.9, 1.3 Hz, 2H), 7.31–7.28
(m, 4H);

C NMR (CD3CN, 100 MHz): δ 158.65, 158.60, 154.62, 153.74, 153.40,
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139.10, 138.96, 138.65, 128.95, 128.64, 127.19, 125.03, 124.75; ESI MS calcd for
C30H26N6Ru [M2+•PF6-]+ 717.1, [M-py]2+ 246.6, [M-2 py]2+ 207.1, found 717.2 [M2+•PF6]+, 246.3 [M-py]2+, 206.9 [M-2 py]2+. Purity by HPLC: 99.9 % by area. UV/Vis
(CH3CN): λmax nm (ε M-1 cm-1) 240 (34000), 290 (56400), 335 nm (15800), 450 (1000).
trans-Ru(qpy)Cl2.3.5 H2O (2z) was prepared by literature method.10
trans-[Ru(qpy)(py)2](PF6)2 (2aa): To a suspension of Ru(qpy)Cl2.3.5 H2O (50 mg, 0.092
mmol) in EtOH:H2O (4:1) was added an excess of pyridine (741 µL, 9.20 mmol) under
N2. The resulting mixture was refluxed at 85 ºC overnight. After cooling the red solution
to R.T., 1–2 mL of a saturated aqueous KPF6 solution were added to obtain a red
precipitated that was extracted with CH2Cl2/CH3CN (3 x 10 mL). The organic phase was
purified by flash chromatography on SiO2 eluting at 80:20:0.1 acetonitrile/water/saturated
KNO3. The solvent was removed under vacuum, and the complex was converted to PF6salt. The product was obtained in 92% yield (74 mg) as a red solid. 1H NMR (CD3CN,
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400 MHz): δ 9.70 (dd, J = 6.4, 0.8 Hz, 2H), 8.57 (d, J = 8.4 Hz, 2H), 8.29 (d, J = 7.6 Hz,
2H), 8.20 (d, J = 8.0 Hz, 2H), 8.16–8.08 (m, 4H), 7.95–7.91 (m, 6H), 7.58–7.54 (m, 2H),
7.03 (t, J = 7.2 Hz, 2H);
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C NMR (CD3CN, 100 MHz): δ 160.49, 160.41, 159.22,

155.34, 152.16, 141.13, 138.94, 136.92, 130.52, 126.69, 126.28, 125.13, 125.07; ESI MS
calcd for C30H24N6Ru [M2+•PF6-]+ 715.07, [M]2+ 285.05, [M-py]2+ 245.54, [M-2 py]2+
206.02, found 715.2 [M2+•PF6-]+, 284.9 [M]2+, 245.4 [M-py]2+, 205.8 [M-2 py]2+. Purity
by HPLC: 99.9 % by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 290 (61100), 330
(32800), 350 nm (35800), 460 (5900), 530 (7000).

6.3.2 Chapter 3 compounds.

Figure 6.4: Example epoxide ring-opening reaction for modified phenanthroline ligands.
5-(2-sulfanylethan-1-ol)-1,10-phenanthroline (phenBME): In a 50 mL round bottom
flask 5,6-epoxy-5,6-dihydro-[1,10]phenanthroline (293 mg, 1.5 mmol) was added to 10
mL of dry methanol. In a vial, β-mercaptoethanol was added to 10 mL of 0.3 M sodium
methoxide in dry methanol (115 μL, 1.6 mmol). The contents of the vial was added to the
round bottom flask and allowed to stir at room temperature for 5 hours. Solvent was
removed under vacuum, 5 mL water was added and the mixture was used directly for the
complexation reaction. This ligand was not characterized prior to complexation.

5-thioglucose-1,10-phenanthroline (phenTG): 1-Thio-β-D-glucose sodium salt (261 mg,
1.2 mmol) was added to a vial with 8 mL of dry methanol to form a suspension. In a 25
mL round bottom flask 5,6-epoxy-5,6-dihydro-[1,10]phenanthroline (197 mg, 1.0 mmol)
was added to 8 mL of dry methanol. While stirring, the suspension of 1-Thio-β-Dglucose was added to the round bottom and let react overnight. The solid was filtered and
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washed with methanol to give the product. Yield: 159 mg (42%). 1H NMR (d6-DMSO,
400 MHz): δ 9.13 (dd, J = 4.2, 1.6 Hz, 1H), 9.06 (dd, J = 4.3, 1.7 Hz, 1H), 8.82 (dd, J =
8.4, 1.6 Hz, 1H), 8.39 (dd, J = 8.2, 1.7 Hz, 1H), 8.33 (s, 1H), 7.83 (dd, J = 8.4, 4.3 Hz,
1H), 7.77 (dd, J = 8.1, 4.3 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 3.73 (d, J = 11.3 Hz, 1H),
3.34–3.10 (m, 5H).

[Ru(bpy)2phenepox](PF6)2 (3a): Compound 3a was synthesized using method 1 and used
without further purification and characterization. Yield: 810 mg (92.4%). ESI MS calcd
for C32H24N6ORu [M]2+ 305.06; found 304.9 [M]2+. Purity by HPLC: 91.3 % by area.
UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 285 (64500), 450 (12100).
[Ru(biq)2phenepox](PF6)2 (3b): Compound 3b was synthesized using method 1 and was
used without further purification and characterization. Yield: 638 mg (78.8%). ESI MS
calcd for C48H32N6ORu [M]2+ 405.09; found 404.3 [M]2+. Purity by HPLC: 95.5 % by
area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 265 (86200), 325 (46000), 360 (35800), 380
(37800), 545 (10100).

[Ru(dmphen)2phenepox](PF6)2 (3c): Compound 3c was synthesized using method 1 and
was used without further purification and characterization. Yield: 750 mg (87.8%). ESI
MS calcd for C40H32N6ORu [M2+•PF6-]+ 859.13, [M]2+ 357.09; found 858.8 [M2+•PF6-]+,
357.1 [M]2+.

[Ru(bpy)2phenTG](PF6)2 (3d): Compound 3e was synthesized using method 1 and
purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.1% KNO3 and 13% H2O) to give the pure complex. Yield: 174 mg
(79.4%). 1H NMR (CD3CN, 400 MHz): δ 8.98 (ddd, J = 8.5, 4.1, 1.1 Hz, 1H), 8.56–8.45
(m, 6H), 8.13–8.05 (m, 3H), 8.04 (d, J = 4.6 Hz, 1H), 8.02–7.95 (m, 2H), 7.86 –7.80 (m,
2H), 7.76 (ddd, J = 8.5, 5.2, 1.6 Hz, 1H), 7.71 (dd, J = 8.3, 5.4 Hz, 1H), 7.57 (dt, J = 5.6,
0.7 Hz, 1H), 7.54–7.49 (m, 1H), 7.48–7.40 (m, 2H), 7.28–7.18 (m, 2H), 4.94 (d, J = 9.5
Hz, 1H), 3.80 (ddd, J = 11.9, 8.0, 2.5 Hz, 2H), 3.58 (ddd, J = 15.2, 11.9, 6.1 Hz, 2H),
3.50–3.41 (m, 2H);

C NMR (CD3CN, 100 MHz): δ 162.38, 161.52, 153.90, 153.68,

13

176

153.64, 152.85, 151.29, 14795, 147.34, 141.36, 138.14, 137.04, 133.81, 133.69, 131.58,
131.51, 130.86, 130.60, 130.44, 130.06, 130.03, 129.98, 129.94, 129.84, 129.74, 129.17,
127.25, 126.72, 126.43, 126.02, 123.60, 122.54, 87.43, 81.45, 79.03, 73.17, 70.96, 62.67;
ESI MS calcd for C38H24N6O5RuS [M]2+ 394.07; found 393.8 [M]2+. Purity by HPLC:
98.7% by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 285 (44900), 450 (11300).
[Ru(biq)2phenTG](PF6)2 (3e): Compound 3e was synthesized using method 1 and
purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.5% KNO3 and 9% H2O) to give the pure complex. Yield: 110 mg (90.3%).
1

H NMR (CD3CN, 400 MHz): δ 9.07 (d, J = 8.8 Hz, 2H), 9.00 (d, J = 8.8 Hz, 2H), 8.81

(dd, J = 8.8, 4.6 Hz, 2H), 8.71 (d, J = 8.4 Hz, 1H), 8.42–8.34 (m, 2H), 8.28 (d, J = 5.4
Hz, 1H), 8.23 (dd, J = 5.1, 1.9 Hz, 1H), 8.16 (d, J = 8.2 Hz, 3H), 7.95 (d, J = 3.1 Hz, 1H),
7.82–7.65 (m, 4H), 7.56–7.48 (m, 2H), 7.39 (dd, J = 8.9, 4.7 Hz, 2H), 7.30 – 7.21 (m,
2H), 7.12–7.02 (m, 4H), 6.89–6.77 (m, 3H), 4.51 (dd, J = 9.7, 4.8 Hz, 1H), 3.62 (d, J =
11.3 Hz, 3H), 3.51–3.31 (m, 3H);
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C NMR (CD3CN, 100 MHz): δ 158.31, 158.28,

158.02, 153.67, 153.29, 153.26, 153.08, 153.04, 153.01, 152.97, 148.79, 148.07, 138.92,
138.80, 137.11, 135.79, 135.71, 135.79, 135.71, 135.26, 153.02, 132.42, 132.30, 131.67,
131.63, 130.57, 130.29, 128.60, 128.48, 127.50, 126.99, 125.32, 125.29, 125.22, 87.88,
81.74, 79.63, 73.54, 71.09, 62.77; ESI MS calcd for C54H42N6O5RuS [M]2+ 494.10; found
494.1 [M]2+. Purity by HPLC: 95.7% by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1)
265 (43600), 330 (18900), 380 (16000, 480 (4100, 550 (4200).

[Ru(dmphen)2phenTG](PF6)2 (3f): Compound 3f was synthesized using method 1. Yield:
138 mg (68.6%). 1H NMR (CD3CN, 400 MHz): δ 8.76 (ddd, J = 8.2, 4.3, 1.5 Hz, 1H),
8.71 (dd, J = 8.3, 1.8 Hz, 2H), 8.33 (s, 1H), 8.30–8.22 (m, 5H), 8.11 (dd, J = 8.7, 1.5,
2H), 7.84–7.77 (m, 2H), 7.41–7.25 (m, 4H), 7.22 (dd, J = 8.4, 1.2 Hz, 2H), 4.81 (dd, J =
9.4, 5.8 Hz, 1H), 3.72 (dt, J = 11.9, 2.5 Hz, 2H), 3.43–3.17 (m, 4H), 1.97 (s, 3H), 1.96 (s,
3H) 1.68 (s, 3H), 1.65 (s, 3H); 13C NMR (CD3CN, 100 MHz): δ 169.78, 167.97, 169.91,
154.16, 153.85, 153.78, 150.43, 149.56, 149.51, 149.27, 149.23, 148.87, 148.83, 139.03,
137.63, 137.41, 136.11, 134.94, 134.79, 131.77, 131.10, 131.00, 130.77, 130.63, 128.49,
128.30, 128.22, 127.65, 127.59, 126.50, 125.99, 125.95, 87.96, 81.65, 79.25, 73.51,
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71.01, 62.70, 2980, 27.04, 26.97, 26.93; ESI MS calcd for C46H42N6O5RuS [M2+•PF6-]+
1037.16, [M]2+ 446.10; found 1036.8 [M2+•PF6-]+, 445.9 [M]2+. Purity by HPLC: 99.9%
by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 270 (78300), 465 (14300).
[Ru(biq)2phenBME](PF6)2 (3g): Compound 3g was synthesized using method 1 and
purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.3% KNO3 and 7% H2O) to give the pure complex. Yield: 68 mg (62%). 1H
NMR (CD3CN, 400 MHz): δ 9.07 (dd, J = 8.9, 5.6 Hz, 2H), 9.00 (dd, J = 8.9, 2.2 Hz,
2H), 8.82 (dd, J = 8.8, 6.6 Hz, 2H), 8.56 (d, J = 8.5 Hz, 1H), 8.39 (dd, J = 8.8, 3.2 Hz,
2H), 8.28 (d, J = 5.4 Hz, 1H), 8.17 – 8.13 (m, 4H), 7.78 (dd, J = 8.5, 5.5 Hz, 1H), 7.70
(dt, J = 8.3, 5.1 Hz, 4H), 7.55 – 7.50 (m, 3H), 7.37 (dd, J = 9.0, 4.8 Hz, 2H), 7.25 (ddd, J
= 7.9, 7.1, 4.1 Hz, 2H), 7.14 – 7.04 (m, 4H), 6.89 – 6.49 (m, 2H), 3.58 (t, J = 6.2 Hz, 2H),
3.07 (t, J = 6.2 Hz, 2H);
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C NMR (CD3CN, 100 MHz): δ 162.36, 161.55, 161.47,

153.87, 152.83, 152.70, 151.33, 151.26, 147.90, 141.31, 139.84, 139.72, 137.46, 137.34,
135.50, 133.79, 131.52, 130.84, 130.60, 130.42, 130.11, 129.97, 129.94, 129.89, 129.85,
129.48, 129.23, 129.15, 127.22, 126.69, 126.42, 126.11, 125.94, 124.59, 123.58, 123.53,
122.52, 122.49, 60.40, 36.30; ESI MS calcd for C50H36N6ORuS [M]2+ 435.09; found
434.8 [M]2+. Purity by HPLC: 99.9% by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1)
265 (78500), 330 (37300), 360 (31300, 380 (31400), 480 (7500), 550 (8500).

[Ru(dmphen)2phenBME](PF6)2 (3h): Compound 3h was synthesized using method 1 and
purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.3% KNO3 and 7% H2O) to give the pure complex. Yield: 124 mg (44%).
1

H NMR (CD3CN, 400 MHz): δ 8.71 (dd, J = 8.4, 2.5 Hz, 2H), 8.65 (dd, J = 8.3, 1.3 Hz,

1H), 8.28–8.22 (m, 5H), 8.11 (d, J = 8.8 Hz, 2H), 7.95 (s, 1H), 7.81 (dd, J = 8.4, 2.6 Hz,
2H), 7.39 (dd, J = 5.4, 1.3 Hz, 1H), 7.34–7.30 (m, 1H), 7.28–7.21 (m, 4H), 3.80 (t, J =
6.2 Hz, 2H), 3.30 (t, J = 6.2, 2H), 1.97 (s, 3H), 1.96 (s, 3H), 1.69 (s, 3H), 1.66 (s, 3H);
C NMR (CD3CN, 100 MHz): δ 169.76, 167.94, 154.18, 153.03, 150.44, 149.54, 149.30,
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149.24, 148.10, 139.02, 137.92, 137.63, 136.69, 134.89, 131.28, 131.10, 131.07, 131.00,
130.97, 130.72, 128.49, 128.30, 128.21, 127.64, 127.57, 126.52, 125.96, 125.18, 60.68,
36.52, 26.99, 26.84, 25.86, 25.85; ESI MS calcd for C42H36N6ORuS [M2+•PF6-]+ 919.13,
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[M]2+ 387.09; found 918.9 [M2+•PF6-]+, 387.0 [M]2+. Purity by HPLC: 98.9% by area.
UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 265 (53200), 355 (8500), 465 (12000).

Figure 6.5: Epoxide ring-opening reaction for direct complex modification.
[Ru(bpy)2phenamine](PF6)2 (3i): In a 50 mL round bottom flask 3a (402 mg, 0.448
mmol) was added to 10 mL of dry methanol. In a vial, mercaptoethylamine (122 mg, 1.07
mmol) was added to 10 mL of 0.3 M sodium methoxide in dry methanol. The contents of
the vial was added to the round bottom flask and allowed to stir at room temperature for 5
hours. The reaction was neutralized with 4M HCl and solvent was removed in vacuo.
Purification of the solid was carried out by flash chromatography (SiO2, MeCN and
elution with 0.7% KNO3 and 15% H2O) to give the pure complex. Yield: 410 mg
(95.4%). 1H NMR (CD3CN, 400 MHz): δ 8.86 (dd, J = 8.5, 1.2 Hz, 1H), 8.55–8.52 (m,
3H), 8.49 (dd, J = 8.3, 0.7 Hz, 2H), 8.26 (s, 1H), 8.13–8.07 (m, 3H), 8.04 (dd, J = 5.3, 1.3
Hz, 1H), 8.02–7.97 (m, 2H), 7.83 (dddd, J = 5.6, 4.2, 1.4, 0.7 Hz, 2H), 7.77 (dd, J = 8.5,
5.3 Hz, 1H), 7.73 (dd, J = 8.3, 5.2 Hz, 1H), 7.56 (dddd, J = 5.6, 3.5, 1.5, 0.7 Hz, 2H),
7.45 (ddt, J = 7.5, 5.8, 1.5 Hz, 2H), 7.24 (ddd, J = 7.5, 5.6, 1.3 Hz, 2H), 3.53 (t, J = 7.4
Hz, 2H), 3.31 (t, J = 6.8 Hz, 2H).
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C NMR (CD3CN, 100 MHz): δ 158.31, 158.27,

158.04, 153.88, 153.26, 153.06, 153.02, 149.08, 147.92, 138.95, 136.87, 134.86, 134.70,
131.65, 131.62, 128.63, 128.62, 128.52, 128.07, 127.64, 127.14, 125.34, 125.31, 125.25,
39.71, 30.55; ESI MS calcd for C34H29N7RuS [M]2+ 334.56; found 334.3 [M]2+. Purity by
HPLC: 94.8% by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 280 (59600), 450 (14700).
[Ru(biq)2phenamine](PF6)2 (3j): Compound 3j was synthesized analogous to 3i using 3b
as the starting Ru(II) complex. Purification of the solid was carried out by flash
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chromatography (SiO2, MeCN and elution with 0.5% KNO3 and 15% H2O) to give the
pure complex. Yield: 179 mg (42%). 1H NMR (CD3CN, 400 MHz): δ 9.08 (dd, J = 8.9,
7.6 Hz, 2H), 9.00 (dd, J = 8.8, 1.8 Hz, 2H), 8.84 (d, J = 8.8 Hz, 1H), 8.81 (d, J = 9.0 Hz,
1H), 8.53 (dd, J = 8.5, 0.7 Hz, 1H), 8.40 (t, J = 8.4 Hz, 2H), 8.30 (dd, J =5.4, 1.0 Hz,
1H), 8.25 (d, J = 8.2 Hz, 1H), 8.21 (dd, J = 5.5, 1.0 Hz, 1H), 8.17 (d, J = 8.1 Hz, 2H),
7.80 (dd, J = 8.5, 5.5 Hz, 1H), 7.76 (dd, J = 8.2, 5.5 Hz, 1H), 7.72–7.68 (m, 4H), 7.52 (t,
J = 7.2 Hz, 2H), 7.38 (d, J = 5.0 Hz, 1H), 7.36 (d, J = 5.0 Hz, 1H), 7.28–7.22 (m, 2H),
7.13 (d, J = 8.9 Hz, 1H), 7.10–7.05 (m, 3H), 7.03 (d, J = 8.8 Hz, 1H), 6.85 (ddd, J = 8.7,
7.1, 1.4 Hz, 1H), 6.80 (ddd, J = 8.7, 7.1, 1.4 Hz, 1H), 3.32 (t, J = 7.0 Hz, 2H), 3.26 (t, J =
7.2 Hz, 2H);

C NMR (CD3CN, 100 MHz): δ 162.39, 154.07, 153.33, 152.85, 151.39,
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151.26, 148.17, 146.88, 141.38, 139.88, 139.75, 137.75, 135.46, 134.39, 133.81, 131.59,
130.86, 130.61, 130.44, 130.02, 129.97, 129.93, 129.91, 129.51, 129.25, 129.15, 12738,
126.87, 126.42, 126.27, 126.14, 125.88, 123.60, 123.55, 122.56, 122.51, 39.36, 31.26,
29.89, 18.44; ESI MS calcd for C50H37N7RuS [M]2+ 434.60; found 434.5 [M]2+. Purity by
HPLC: 94.8% by area. UV/Vis (CH3CN): λmax nm (ε M-1 cm-1) 265 (75500), 330 (36800),
360 (30200), 380 (31500), 480 (7500), 550 (8600).

6.3.3 Chapter 4 compounds.
Dipyrido[3.2-a:2’,3’-c]phenazine (dppz) and [Ru(bpy)2dppz](PF6)2 (4a) were prepared by
literature methods.11 3,6-Dimethyl-dipyrido[3,2-a:2’,3’-c]phenazine (dmdppz): Dimethyldipyrido[3,2-a:2’,3’-c]phenazine was prepared by modification of literature methods
using 2,9-dimethylphendione (note the different numbering system; this is equivalent to
the 3,6 positions on dppz) instead of the starting material phendione.11a Yield: 0.9 g (65
%). 1H NMR (CDCl3, 400 MHz): δ 9.50 (d, J = 8.2 Hz, 2H), 8.31 (d, J = 6.6 Hz, 2H),
7.81 (d, J = 6.5, 2H), 7.63 (d, J = 8.2 Hz, 2H), 2.97 (s, 6H). ESI MS calcd for
C 20 H 14 N 4 [M•H]+ 311.12; found 311 [M•H]+.
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C NMR was not obtained due to poor

solubility of the free ligand.

11-Bromo-3,6-dimethyldipyrido[3,2-a:2',3'-c]phenazine (dmdppz-Br). The compound
was prepared by slight modification to a previously reported procedure.12 2,9-Dimethyl1,10-phenanthroline-5,6-dione (100 mg, 0.420 mmol) and 4-bromo-o-phenylenediamine
180

(88 mg, 0.471 mmol) were suspended in ethanol (4 mL) and refluxed at 80 °C for 4 h.
The resulting brown suspension was filtered and washed with cold ethanol. The product
was collected in 48% yield (79 mg) as a brown solid and used without further
purification.
[Ru(bpy)2phendione](PF6)2.13 [Ru(bpy)2Cl2]•2H2O (100 mg, 0.192 mmol) and 1,10phenanthroline-5,6-dione (55 mg, 0.262 mmol) were dissolved in ethanol (20 mL) and
refluxed at 80 °C for 2 h. The resulting yellow-brown mixture was cooled to room
temperature and precipitated with 3 mL of a saturated aqueous KPF6 solution. The
precipitate was filtered and washed with water and ether. The product was obtained in
85% yield (150 mg) as a brown solid.

1

H NMR (CD3CN, 400 MHz): δ 8.54–8.50 (m,

6H), 8.09 (tt, J = 7.8, 1.2 Hz, 4H), 7.94 (dd, J = 5.5, 1.2 Hz, 2H), 7.85–7.84 (m, 2H),
7.76–7.74 (m, 2H), 7.61 (2d, J = 7.8, 8.2 Hz, 2H), 7.45–7.41 (m, 4H); ESI MS
C32H22N6O2Ru: m/z calcd [M2+•PF6-]+ 769.08, [M]2+ 312.04, found 768.70 [M2+•PF6-]+,
312.10 [M]2+.

[Ru(bpy)2 dmdppz](PF6)2 (4b): [Ru(bpy)2Cl2]•2H2O (501 mg, 0.963 mmol) and 3, 6dimethyl-dipyrido[3,2-a:2',3'-c]phenazine (328 mg, 1.057mmol) were added to 16 mL
of degassed ethylene glycol in a 38 mL pressure tube. The mixture was heated at 150
°C with stirring and protected from light. After 16 hours the red solution was cooled to
room temperature and poured into 50 mL of distilled water. Addition of a saturated
aqueous KPF6 solution produced a deep red precipitate that was collected by vacuum
filtration and washed with dH2O (50 mL) and diethyl ether (50 mL). Purification of the
solid was carried out by flash chromatography on SiO2. Elution with saturated aq.
KNO3/H2O/CH3CN (5/15/80) gave the pure complex.

After column purification the

complex as the NO3- salt was dissolved in a minimal volume of water, and a saturated
aq. solution of KPF6 was added. The complex was extracted into CH2Cl2 and the solvent
removed under reduced pressure to give a deep red solid. Yield: 361 mg (37%). 1H NMR
(CD3CN, 400 MHz): δ 9.65 (d, J = 8.2 Hz, 2H), 8.52 (d, J = 8.4 Hz, 2H), 8.48–8.44 (m,
4H), 8.13–8.10 (m, 2H), 8.07–7.98 (m, 4H), 7.85 (d, J = 5.7 Hz, 2H), 7.79 (d, J = 8.3
Hz, 2H), 7.72 (d, J = 5.7 Hz, 2H), 7.32–7.27 (m, 4H), 2.09 (s, 6H);
181
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C NMR

(CD3CN, 100 MHz): δ 169.70, 158.66, 158.50, 154.15, 152.98, 152.74, 144.10,
140.44, 139.06, 138.86, 135.34, 133.30, 130.64, 129.66, 129.62, 128.56, 128.47,
125.63, 125.54, 26.47; ESI MS calcd for C40H30N8Ru [M2+•PF6-]+ 869.12, [M]+
724.16, [M]2+ 362.08; found 869.1 [M2+•PF6-]+, 723.3 [M]+, 362.1 [M]2+. Purity by
HPLC: 97% by area. UV/Vis (CH3CN): λmax nm (ε M-1cm-1) 284 (88,900), 325 (23,600),
352 (18,900), 450 (14,100).

Figure 6.6: Condensation reaction scheme for the synthesis of [Ru(bpy)2dppz-R]2+
derivatives.
[Ru(bpy)2dppz-Br](PF6)2 (4c):12 Complex 4c was synthesized following a procedure
reported for similar compounds.13 A solution of [Ru(bpy)2phendione](PF6)2 (68 mg,
0.074 mmol) and 4-bromo-o-phenylenediamine (18 mg, 0.096 mmol) in ethanol (8 mL)
was refluxed at 80 °C for 1 h. The resulting red mixture was cooled to room temperature,
diluted with water, filtered and washed with water and ether. Purification by flash
chromatography (silica, eluting at 80:20:0.1 acetonitrile/water/saturated KNO3) gave the
pure product. The solvent was removed under vacuum, and the complex was converted
to PF6- salt. The product was obtained in 96% yield (76 mg) as a crystalline red solid. 1H
NMR (CD3CN, 400 MHz): δ 9.62 (ddd, J = 8.2, 7.6, 1.2 Hz, 2H), 8.70 (d, J = 2.7 Hz,
1H), 8.55 (d, J = 8.2 Hz, 2H), 8.52 (d, J = 8.21 Hz, 2H), 8.37 (d, J = 9.0 Hz, 1H), 8.21
(dd, J = 9.0, 2.0 Hz, 1H), 8.18 (dt, J = 5.5, 1.6 Hz, 2H), 8.12 (td, J = 8.0, 7.8, 1.6 Hz, 2H),
8.02 (td, J = 8.0, 7.8, 1.6 Hz, 2H), 7.89 (ddd, J = 8.2, 5.5, 2.7 Hz, 2H), 7.86–7.84 (m,
2H), 7.73–7.72 (m, 2H), 7.47 (ddd, J = 7.5, 5.5, 1.2 Hz, 2H), 7.26 (ddd, J = 7.5, 5.9, 1.2
Hz, 2H);
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C NMR (CD3CN, 100 MHz): δ 158.28, 158.08, 155.12, 155.01, 153.23,

153.07, 151.81, 151.64, 144.12, 142.63, 141.77, 141.40, 139.10, 139.02, 136.83, 134.67,
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134.60, 132.73, 132.27, 131.73, 131.63, 128.73, 128.62, 128.58, 127.38, 125.44, 125.38;
ESI MS calcd for C38H25BrN8Ru: [M2+•PF6-]+ 919, [M]2+ 387.02, found 919.1 [M2+•PF6]+, 386.9 [M]2+. Purity by HPLC: 99.9% by area. UV/Vis in CH3CN, λmax nm (ε M-1 cm1

): 285 (107,400), 365 (21,100), 443 (18,700).

[Ru(bpy)2dmdppz-Br](PF6)2 (4d): A solution of [Ru(bpy)2Cl2]•2H2O (75 mg, 0.144
mmol) and dmdppz-Br (81 mg, 0.208 mmol) in ethylene glycol (8 mL) was stirred at 120
°C for 3 h. The resulting mixture was cooled and transferred to an Erlenmeyer flask with
water. The aqueous product was precipitated upon the addition of a saturated aqueous
KPF6 solution, filtered and washed with water and ether. Purification by flash
chromatography (silica, eluting at 85:15:0.1 acetonitrile/water/saturated KNO3) gave the
pure product. The solvent was removed under vacuum, and the complex was converted to
PF6- salt. The product was obtained in 65% yield (102 mg) as a crystalline red solid. 1H
NMR (CD3CN, 400 MHz): δ 9.60 (t, J = 8.2 Hz, 2H), 8.66 (dd, J = 2.2, 0.5 Hz, 1H),
8.52–8.45 (m, 4H), 8.34 (dd, J = 9.1, 0.5 Hz, 1H), 8.18 (dd, J = 9.1, 2.2 Hz, 1H), 8.07–
7.98 (m, 4H), 7.85–7.83 (m, 2H), 7.79 (dd, J = 8.3, 2.0 Hz, 2H), 7.71 (dq, J = 6.3, 0.7 Hz,
2H), 7.32–7.26 (m, 4H), 1.95 (s, 6H);
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C NMR (CD3CN, 100 MHz): δ 170.08, 169.97,

158.64, 158.48, 154.18, 154.16, 152.97, 152.93, 152.77, 144.28, 142.78, 140.98, 140.65,
139.09, 138.89, 136.45, 135.36, 135.31, 132.57, 132.15, 129.74, 129.33, 129.23, 128.61,
128.49, 126.97, 125.66, 125.56, 26.54, 26.52; ESI MS calcd for C40H29BrN8Ru:
[M2+•PF6-]+ 947.03, [M]2+ 401.04, found 946.8 [M2+•PF6-]+, 400.7 [M]2+. Purity by
HPLC: 99.9% by area. UV/Vis in CH3CN, λmax nm (ε

-1

M

cm-1): 285 (116,300), 365

(23,700), 443 (18,500).

The following complexes were prepared analogous to 4c using the corresponding
diamine in Table 6.2:

[Ru(bpy)2dppz-11-F](PF6)2 (4e). The product was obtained in 77% yield (102 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.61 (d, J = 8.2 Hz, 2H), 8.69 (s, 2H), 8.58 (d,
J = 8.2 Hz, 2H), 8.55 (d, J = 8.2 Hz, 2H), 8.21 (dd, J = 7.8, 1.2 Hz, 2H), 8.14 (td, J = 7.8,
1.6 Hz, 2H), 8.05 (td, J = 8.2, 1.6, 2H), 7.92 (dd, J = 8.2, 5.5 Hz, 2H), 7.87 (d, J = 5.5 Hz,
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2H), 7.75 (d, J = 5.5 Hz, 2H), 7.49 (ddd, J = 7.2, 5.9, 1.2 Hz, 2H), 7.29 (ddd, J = 7.2, 5.9,
1.2 Hz, 2H).
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C NMR (CD3CN, 100 MHz): δ 158.23, 158.03, 155.23, 153.22, 153.04,

151.81, 142.45, 142.03, 139.10, 139.01, 137.50, 134.64, 131.47, 131.24, 128.71, 128.67,
128.56, 125.42, 125.36; ESI MS calcd for C38H25FN8Ru: [M2+•PF6-]+ 859.08, [M]2+
357.06, found 858.4 [M2+•PF6-]+, 356.6 [M]2+. Purity by HPLC: 98.2% by area. UV/Vis
in CH3CN, λmax nm (ε M-1 cm-1): 280 (109,200), 380 (23,400), 440 (18,200).
[Ru(bpy)2dppz-11-Cl](PF6)2 (4f). The product was obtained in 69% yield (93 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.64 (ddd, J = 8.2, 4.7, 1.2 Hz, 2H), 8.58–8.46
(m, 6H), 8.22–8.19 (m, 2H), 8.16–8.09 (m, 3H), 8.05 (td, J = 7.8, 1.6 Hz, 2H), 7.92 (ddd,
J = 8.2, 5.5, 2.0 Hz, 2H), 7.88–7.86 (m, 2H), 7.76–7.74 (m, 2H), 7.50 (ddd, J = 7.2, 5.9,
1.2 Hz, 2H), 7.29 (ddd, 7.2, 5.9, 1.2 Hz, 2H).

C NMR (CD3CN, 100 MHz): δ 158.29,

13

158.09, 155.13, 155.00, 153.24, 153.08, 151.81, 151.63, 143.91, 142.45, 141.84, 141.32,
139.12, 139.04, 138.96, 134.67, 134.60, 134.35, 132.35, 131.73, 131.63, 129.27, 128.75,
128.62, 128.61, 125.46, 125.40; ESI MS calcd for C38H25ClN8Ru: [M2+•PF6-]+ 875.05,
[M]2+ 365.05, found 857.1 [M2+•PF6-]+, 364.6 [M]2+. Purity by HPLC: 96.9% by area.
UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 280 (103,500), 365 (19,200), 440 (18,000).
[Ru(bpy)2dppz-10-F](PF6)2 (4g).14 The product was obtained in 60% yield (79 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.65 (dt, J = 8.2, 1.6 Hz, 2H), 8.56 (d, J = 8.2,
2H), 8.53 (d, J = 8.2, 2H), 8.32 (dt, J = 8.6, 0.8 Hz, 1H), 8.20 (dt, J = 5.5, 1.6 Hz, 2H),
8.15–8.08 (m, 3H), 8.03 (td, J = 7.8, 1.6 Hz, 2H), 7.90 (ddd, J = 8.4, 5.3, 3.1 Hz, 3H),
7.87–7.83 (m, 2H), 7.74 (dq, J = 5.5, 0.8 Hz, 2H), 7.5 (ddd, J = 7.6, 5.7, 1.2 Hz, 2H),
7.27 (ddd, J = 7.9, 5.9, 1.2 Hz, 2H).
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C NMR (CD3CN, 100 MHz): δ 159.47, 15826,

158.06, 156.89, 155.16, 155.10, 153.22, 153.07, 151.84, 151.75, 144.50, 141.87, 140.96,
139.10, 139.02, 134.69 133.16, 133.08, 131.71, 131.65, 128.72, 128.63, 128.57, 126.74,
126.70, 125.43, 125.38, 116.78, 116.59; ESI MS calcd for C38H25FN8Ru: [M2+•PF6-]+
859.08, [M]2+ 357.06, found 859.0 [M2+•PF6-]+, 356.7 [M]2+. Purity by HPLC: 99.9% by
area. UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 285 (114,700), 360 (17,100), 440
(19,000).
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[Ru(bpy)2dppz-10-Cl](PF6)2 (4h). The product was obtained in 70% yield (94 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.71 (dd, J = 8.2, 1.2 Hz, 1H), 9.65 (dd, J =
8.2, 1.6 Hz, 1H), 8.58–8.52 (m, 4H), 8.44 (dd, J = 8.6, 1.2 Hz, 1H), 8.26 (dd, J = 7.4, 1.2
Hz, 1H), 8.21 (dd, J = 5.5, 0.8 Hz, 2H), 8.13 (td, J = 8.2, 1.6 Hz, 2H), 8.09–8.01 (m, 3H),
7.91 (ddd, J = 7.8, 5.9, 2.0, 2H), 7.88 – 7.86 (m, 2H), 7.76–7.73 (m, 2H), 7.48 (ddd, J =
7.2, 6.1, 0.8 Hz, 2H), 7.30–7.25 (m, 2H).

13

C NMR (CD3CN, 100 MHz): δ 158.27,

158.07, 155.17, 155.14, 153.25, 153.20, 153.06, 151.85, 151.81, 144.68, 141.75, 141.16,
140.39, 139.10, 139.03, 134.80, 134.75, 134.16, 133.28, 133.00, 131.76, 131.51, 130.01,
128.73, 128.68, 128.65, 128.59, 125.43, 125.38; ESI MS calcd for C38H25ClN8Ru:
[M2+•PF6-]+ 875.05, [M]2+ 365.05, found 874.6 [M2+•PF6-]+, 364.7 [M]2+. Purity by
HPLC: 99.2% by area. UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 285 (93,300), 362
(15,500), 440 (16100).

[Ru(bpy)2dppz-10-Br)(PF6)2 (4i). The product was obtained in 68% yield (80 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.71 (dd, J = 8.2, 1.2 Hz, 1H), 9.65 (dd, J =
8.2, 1.6 Hz, 1H), 8.57–8.52 (m, 4H), 8.47 (ddd, J = 8.0, 5.3, 1.2 Hz, 2H), 8.21 (dt, J =
5.1, 1.2 Hz, 2H), 8.15–8.11 (m, 2H), 8.05–7.99 (m, 3H), 7.93–7.89 (m, 2H), 7.87–7.85
(m, 2H) 7.76–7.73 (m, 2H), 7.48 (ddd, J = 6.7, 5.9, 0.8 Hz, 2H), 7.30–7.25 (m, 2H). 13C
NMR (CD3CN, 100 MHz): δ 158.26, 158.06, 155.13, 153.25, 153.20, 153.07, 153.05,
151.86, 151.81, 144.69, 141.78, 141.41, 141.21, 139.09, 139.01, 136.68, 134.85, 134.79,
133.84, 131.70, 131.46, 130.73, 128.72, 128.64, 128.57, 125.42, 125.36, 125.13; ESI MS
calcd for C38H25BrN8Ru: [M2+•PF6-]+ 919.0, [M]2+ 387.02, found 918.8 [M2+•PF6-]+,
386.7 [M]2+. Purity by HPLC: 99.9% by area. UV/Vis in CH3CN, λmax nm (ε M-1 cm-1):
285 (102,300), 365 (17,200), 440 (17,400).

[Ru(bpy)2dppz-11,12-F](PF6)2 (4j). The product was obtained in 77% yield (104 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.63 (dd, J = 8.2, 1.2 Hz, 2H), 8.56 (d, J = 7.8
Hz, 2H), 8.52 (d, J = 7.8, 2H), 8.32 (t, J = 9.8 Hz, 2H), 8.19 (dd, J = 5.5, 1.2 Hz, 2H),
8.13 (td, J = 7.8, 1.6 Hz, 2H), 8.03 (td, J = 7.8, 1.6 Hz, 2H), 7.91 (dd, J = 8.2, 5.5 Hz,
2H), 7.87–7.85 (m, 2H), 7.72 (dq, J = 5.9, 0.8 Hz, 2H), 7.47 (ddd, J = 7.2, 5.9, 1.2 Hz,
2H), 7.27 (ddd, J = 7.8, 5.7, 1.6 Hz, 2H).
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C NMR (CD3CN, 100 MHz): δ158.25,

158.06, 156.59, 156.40, 155.04, 154.00, 153.82, 153.20, 153.05, 151.57, 141.76, 141.70,
141.63, 141.27, 139.09, 139.00, 134.56, 131.51, 128.71, 128.59, 128.56, 125.42, 125.36,
116.14, 116.08, 116.01, 115.95; ESI MS calcd for C38H24F2N8Ru: [M2+•PF6-]+ 877.07,
[M]2+ 366.06, found 876.3 [M2+•PF6-]+, 365.8 [M]2+. Purity by HPLC: 99.9% by area.
UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 275 (84,300), 365 (19,300), 443 (16,600).
[Ru(bpy)2dppz-11,12-Cl](PF6)2 (4k).15 The product was obtained in 81% yield (112 mg)
as a red solid. 1H NMR (CD3CN, 400 MHz): δ 9.64 (d, J = 8.2 Hz, 2H), 8.53 (d, J = 8.3
Hz, 2H), 8.51 (d, J = 7.5 Hz, 2H), 8.17 (t, J = 5.5 Hz, 2H), 8,13–8.08 (m, 3H), 8.01 (t, J =
8.4 Hz, 2H), 7.96 (dd, J = 9.4, 2.7, 1H), 7.88 (ddd, 8.2, 5.4, 0.9 Hz, 2H), 7.85 (d, J = 5.1
Hz, 2H), 7.72 (d, J = 5.6 Hz, 2H), 7.47–7.43 (m, 2H), 7.25 (t, J = 6.7 Hz, 2H). 13C NMR
(CD3CN, 100 MHz): δ 164.02, 158.27, 158.06, 155.03, 154.80, 153.20, 153.06, 151.77,
151.44, 141.73, 141.40, 140.35, 139.07, 138.99, 134.71, 134.47, 133.53, 133.42, 131.84,
131.62, 128.72, 128.55, 125.42, 125.36, 124.73, 124.45, 113.66, 113.44; ESI MS calcd
for C38H24Cl2N8Ru: [M2+•PF6-]+ 909.01, [M]2+ 382.03, found 908.8 [M2+•PF6-]+, 382.6
[M]2+. Purity by HPLC: 99.9% by area. UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 280
(92,300), 360 (18,100), 443 (17,500).

[Ru(bpy)2dppz-11,12-Br](PF6)2 (4l). The product was obtained in 62% yield (94 mg) as a
red solid. 1H NMR (CD3CN, 400 MHz): δ 9.59 (dd, J = 8.2, 1.2 Hz, 2H), 8.85 (s, 2H),
8.58 (d, J = 8.2 Hz, 2H), 8.55 (d, J = 8.2 Hz, 2H), 8.21 (dd, J = 5.1, 1.2 Hz, 2H), 8.14 (td,
J = 8.2, 1.6 Hz, 2H), 8.05 (td, J = 7.4, 1.2 Hz, 2H), 7.91 (dd, J = 8.2, 5.5 Hz, 2H), 7.88–
7.86 (m, 2H), 7.76–7.74 (m, 2H), 7.49 (ddd, J = 7.8, 5.7, 1.6 Hz, 2H), 7.29 (ddd, J = 7.2,
5.9, 1.2 Hz, 2H).

13

C NMR (CD3CN, 100 MHz): δ 158.25, 158.06, 155.28, 153.23,

153.05, 151.86, 142.77, 142.06, 139.12, 139.04, 134.65, 134.58, 131.48, 129.84, 128.73,
128.70, 128.60, 125.44, 125.39; ESI MS calcd for C38H24Br2N8Ru: [M2+•PF6-]+ 996.91,
[M]2+ 425.98, found 997.6 [M2+•PF6-]+, 426.3 [M]2+. Purity by HPLC: 95.4% by area.
UV/Vis in CH3CN, λmax nm (ε M-1 cm-1): 285 (104,300), 385 (23,100), 440 (16,300).
6.4 Counter-ion exchange.
Prior to biological testing all compounds were converted to the Cl- salt.
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Method 1: The complex as the PF6- salt was dissolved in minimal acetone (1-2 mL) and
precipitated by the addition of a saturated acetone solution of t-butyl ammonium chloride.
The precipitate was filtered through a glass wool plug, washed with acetone, and eluted
with acetonitrile. The solvent was removed under reduced pressure to give the Cl- salt of
each complex.
Method 2: The PF6-- salts were converted to Cl- salts by dissolving 5–20 mg of product in
1–2 mL methanol.

The dissolved product was loaded onto an Amberlite IRA-410

chloride ion exchange column, eluted with methanol, and the solvent was removed in
vacuo.
6.5 Photophysical and photochemical studies.

6.5.1 General photoejection kinetics. Ruthenium compound was added to 3 mL of
dH2O in a cuvette for a final concentration to give the MLCT absorbance >0.2. The
sample was placed in a small box protected from ambient light covered with the
appropriate filter, and then irradiated with light and scans were taken after set time points
to monitor the process of ligand ejection until no change was observed. The normalized
change in absorbance was plotted to find the half-life of ejection using Prism software.

6.5.2 “Light switch” photoejection kinetics.

6.5.2.1 Pure solvents. Photoejection studies were conducted in 3 mL of CH2Cl2,
DMF, H2O, and D2O in a quartz cuvette with a final concentration to give the MLCT
absorbance >0.2. The sample was protected from ambient light and irradiated with
light and scans were taken at appropriate time points to monitor ligand ejection. The
normalized change in extinction coefficient was plotted against time to determine the
half-life of ejection using Prism software.
6.5.2.2 Solvent mixture photoejection studies. Photoejection studies of 4b (PF6- salt) in
acetonitrile/water mixtures were performed to determine the amount of water needed to
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provide a quenching eﬀect on photoejection. The PF6- salt was used to eliminate the
complication of the Cl- counterions acting as incoming ligands, competing with
acetonitrile as an incoming ligand. Acetonitrile percentages used in the mixtures were 1,
10, 20, 30, 40, 50, 90, and 99%. To study the eﬀects of polarity in solvents without
hydrogen-bonding capabilities, we tested dimethylformamide (DMF)/diethyl ether
mixtures using the Cl- salt of 4b. Ether percentages used in the mixtures were 10, 50, and
70%. Data for both sets of solvent mixtures were obtained and plotted in the same way
as described for the pure solvents.

6.5.2.3 Eﬀect of increased number of hydrogen-bonding groups. Photoejection studies
of 4b (Cl- salt) were performed in DMF in the presence of 1000x glucose, mannose, or
ribose with or without 1000x tetrabutylammonium chloride. Data for each sample were
obtained and plotted in the same way as described for the pure solvents.

6.5.2.4 Eﬀect of incoming ligand concentration. The eﬀect of incoming ligand
concentration (using the counterion as the incoming ligand, in competition with the
solvent, which is a poor ligand compared to Cl-) was investigated by determining the t1/2
of photoejection of 4b and 2e in samples that were prepared of the Ru(II) complexes
as the PF6- salts. These studies were performed in methylene chloride, methanol,
dimethylformamide, and dimethyl sulfoxide. To these solutions, 0x, 2x, 100x, or
1000x tetrabutylammonium chloride was added. In addition, the Ru(II) compounds as
the Cl- salts were tested in these solvents. In these cases, the Cl- acts as an incoming
ligand in competition with the solvent. Data for each sample were obtained and plotted in
the same way as described for the pure solvents.

6.5.2.5 Temperature dependence. To determine the activation energy barrier for ligand
loss, we performed photoejection studies of 4b with Cl- counterions in DMF or DMSO
with 1000x tetrabutylammonium chloride and 2e with Cl- counterions in DMF with
1000x tetrabutylammonium chloride at 60 and 85 °C in a water bath. Data for
sample were obtained and plotted in the same way as described for the pure solvents.
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each

6.5.2.6 Incoming ligand size eﬀect. Photoejection studies of 4b, 2e, and 2f with PF6- the
eﬀect of incoming ligand size on the photochemistry. The PF6- counterions were used to
ensure the nitrile solvents would act as the incoming ligand. Data were collected and
plotted as described for the pure solvents.

6.5.2.7 Biological molecules.
Method 1: Compound 4b was added to CT DNA (50 mM NaCl, 5 mM Tris, pH 7.0) in
a 400 μL quartz cuvette to give final concentrations of 200 μM nucleotides and 20 μM
4b; a 10:1 [Nu]:[Ru] ratio. This experiment was repeated for 15-mer oligonucleotide A
under the same conditions. Compound 4b was added to the annealed G-quadruplex (10
mM potassium phosphate, 100 mM KCl, pH 7.0) to give final concentrations of 40 μM
nucleotides and 20 μM 4b; a 2:1 [Nu]:[Ru] ratio. Compound 4b was added to BSA (50
mM NaCl, 5 mM Tris, pH 7.0) to give final concentrations of 20 μM BSA and 20 μM
4b, a 1:1 [BSA]:[Ru]. Spectra for each condition above were obtained and plotted in the
same manner as the pure solvents.
Method 2: The kinetics for ligand ejection for 4b and 4d (20 μM; Cl- counter-ions) in
Table 6.3 was determined in triplicate in a Greiner UV clear half-area 96-well plate.
Samples were measured in the presence of 100 μM of each biomolecule, with a final
volume of 50 μL. For DNA sequences the concentration is measured in [bp] and the ratio
of [Ru]:[bp] was 1:5. The well plate was positioned 12 inches below a 470 nm LED
array, and full spectra were collected after set time points of light exposure for a total of 8
hours. The normalized change in absorbance was plotted versus time to give the t1/2 of
ligand loss.

6.5.3 “Light switch” luminescence studies.
6.5.3.1 Pure solvents and solvent mixtures. Luminescence spectra (λex = 440 nm) were
collected in CH2Cl2 , DMF, H2 O, and D2 O with 5 μΜ compound 4a. Luminescence
spectra were also obtained for each solvent mixture described above with 5 μM
compound 1 (λex = 440 nm).
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6.5.3.2 Biological molecules. The emission of 4a, 4c, and 4e–4l were tested at 5 μM in
the presence of 25 μM of each biomolecule in Table 6.3 in triplicate in a Greiner
black/clear bottom 384-well plate. For DNA sequences the concentration is measured in
[bp] and the ratio of [Ru]:[bp] was 1:5. A final volume of 25 μL was used for all samples.
Data collection was performed with λex = 440 nm and λem = 550–750 nm.
Table 6.4: Protein, nucleosides, and DNA sequences tested.
Annealing
Biomolecule

Buffer

Temperature/

5'-3' fwd

5'-3' rev

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Time
Buffer

BSA

dA

dG

dT

dC

TGGT fwd

TGGT rev

50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0
50 mM NaCl, 5
mM Tris, pH 7.0

-

CCT CTC TGG
TTC TTC

GAA GAA

-

-

CCA GAG
AGG
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poly G

poly C

CT DNA

poly G poly C

poly GC

50 mM NaCl, 5
mM Tris, pH 7.0

50 mM NaCl, 5
mM Tris, pH 7.0

50 mM NaCl, 5
mM Tris, pH 7.0

GGG GGG
-

CCC CCC
-

-

CCC CCC
CCC CCC CC

-

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

10 min

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

10 min

poly GC

μM Co(NH3)6, 2

90 °C/

Z form

mM Tris,

10 min

pH 7.0

poly AT

-

GGG GGG GG

20 mM NaCl, 4

poly A poly T

GGG GGG

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

10 min

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

10 min
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-

-

GGG GGG

CCC CCC

GGG GGG

CCC CCC

GGG GGG GG

CCC CCC CC

GCG CGC

GCG CGC

GCG CGC

GCG CGC

GCG CGC GC

GCG CGC GC

GCG CGC

GCG CGC

GCG CGC

GCG CGC

GCG CGC GC

GCG CGC GC

AAA AAA

TTT TTT TTT

AAA AAA

TTT TTT TTT

AAA AAA AA

TT

ATA TAT ATA

ATA TAT

TAT ATA TAT

ATA TAT

AT

ATA TAT AT

TGGT

50 mM NaCl, 5

90 °C/

CCT CTC TGG

mM Tris, pH 7.0

10 min

TTC TTC

GAC TTA TCT
AB1-M

a

50 mM NaCl, 5

90 °C/

AGG GGT

mM Tris, pH 7.0

15 min

GAT AAG
CTG GTC

GAC TTA TCT
AB1-MMa

50 mM NaCl, 5

90 °C/

AGG GCT

mM Tris, pH 7.0

15 min

GAT AAG
CTG GTC

a

AB1-X (A)

AB1-X (C)a

AB1-X (G)a

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

15 min

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

15 min

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

15 min
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GAA GAA
CCA GAG
AGG
GAC CAG
CTT ATC
ACC CCT
AGA TAA
GTC
GAC CAG
CTT ATC
ACC CCT
AGA TAA
GTC

GAC TTA TCT

GAC CAG

AGG GRT

CTT ATC

GAT AAG

AXC CCT

CTG GTC R =

AGA TAA

abasic site

GTC X = A

GAC TTA TCT

GAC CAG

AGG GRT

CTT ATC

GAT AAG

AXC CCT

CTG GTC R =

AGA TAA

abasic site

GTC X = C

GAC TTA TCT

GAC CAG

AGG GRT

CTT ATC

GAT AAG

AXC CCT

CTG GTC R =

AGA TAA

abasic site

GTC X = G

AB1-X (T)a

50 mM NaCl, 5

90 °C/

mM Tris, pH 7.0

15 min

GAC TTA TCT

GAC CAG

AGG GRT

CTT ATC

GAT AAG

AXC CCT

CTG GTC R =

AGA TAA

abasic site

GTC X = T

GAC TTA TCT
B1-X (A)a

50 mM NaCl, 5

90 °C/

AGG G T GAT

mM Tris, pH 7.0

15 min

AAG CTG
GTC

GAC TTA TCT
a

B1-X (C)

50 mM NaCl, 5

90 °C/

AGG G T GAT

mM Tris, pH 7.0

15 min

AAG CTG
GTC

GAC TTA TCT
B1-X (G)a

50 mM NaCl, 5

90 °C/

AGG G T GAT

mM Tris, pH 7.0

15 min

AAG CTG
GTC

GAC TTA TCT
B1-X (T)a

50 mM NaCl, 5

90 °C/

AGG G T GAT

mM Tris, pH 7.0

15 min

AAG CTG
GTC
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GAC CAG
CTT ATC
AXC CCT
AGA TAA
GTC X = A
GAC CAG
CTT ATC
AXC CCT
AGA TAA
GTC X = C
GAC CAG
CTT ATC
AXC CCT
AGA TAA
GTC X = G
GAC CAG
CTT ATC
AXC CCT
AGA TAA
GTC X = T

50 mM NaCl, 5
triplex

mM Tris, 10 μM
MgCl2, pH 7.0

TTT TTT TTT
90 °C/

TTT TTT TTT

5 min

TTT TTT TTT
TTT

AAA AAA
AAA AAA
AAA AAA
AAA AAA
AAA AAA

TTA TTT TTA
5’-triplex

10 mM Kpi, 100

90 °C/

GGG TTA

mM KCl, pH 7.0

5 min

GGG TTA

-

GGG TT
TTA GGG TTA
3’-triplex

10 mM Kpi, 100

90 °C/

GGG TTA

mM KCl, pH 7.0

5 min

GGG TTA TTT

-

TT

i-motif

inter G-quad

10 mM Kpi, 100

90 °C/

mM KCl, pH 5.5

5 min

50 mM KCl, 5

90 °C/

mM Tris, pH 5.5

5 min

CCC TTA ACC
CTT ACC TTA

-

CCC T

TAG GGT TA

-

TGG GGT

c-myc G-quad

10 mM Kpi, 100

90 °C/

mM KCl, pH 7.0

10 min

GGG TGG
GGT GGG

-

TGG GGA
AGG

10 mM Napi, 100
Na+ G-quad

mM NaCl, pH
7.0

AGG GTT
90 °C/

AGG GTT

5 min

AGG GTT
AGG G

194

-

AGG GTT
K+ G-quad

10 mM Kpi, 100

90 °C/

AGG GTT

mM KCl, pH 7.0

5 min

AGG GTT

-

AGG G
TTA GGG TTA
wtTel26

10 mM Kpi, 100

90 °C/

GGG TTA

mM KCl, pH 7.0

5 min

GGG TTA

-

GGG TT
AAA GGG
Tel26

10 mM Kpi, 100

90 °C/

TTA GGG TTA

mM KCl, pH 7.0

5 min

GGG TTA

-

GGG AA

a

double G-

10 mM Kpi, 100

90 °C/

AGGG(TTAG

quad

mM KCl, pH 7.0

5 min

GG)7

-

Sequences that have been previously published.16

6.6 HPLC Analysis.
6.6.1 Purity. Each complex, as the Cl- salt, was diluted to 100 µM.

6.6.2 Ejected ligand. Complexes were prepared identical to purity analysis and irradiate
for 6x the half-life of ligand ejection. Ligands were dissolved in DMSO and diluted 10
fold into acetonitrile before injection.
6.6.3 Analysis of covalent adduct formation. The 15-mer oligonucleotide A (250 μM
nucleotide) was incubated with 500 μM 4b in the dark or was irradiated with >400 nm
light for 3 hours. Samples were then incubated at 37 °C overnight before HPLC analysis.
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The DNA duplex in the absence of compound was run as a reference. The K+ folded
telomeric G-quadruplex and intermolecular G-quadruplex (250 μM nucleotide
concentration) were incubated with 500 μM 4d either in the dark or under irradiated with
470 nm light for 3 hours. Samples were then incubated at 37 °C overnight before HPLC
analysis. The DNA in the absence of compound was run as a reference.

6.7 Crystallography. The compounds were known to be unstable with respect to light.
As a precaution, all crystal manipulations requiring exposure to light were conducted as
rapidly as possible. To this end, the crystal(s) were plunged directly into liquid nitrogen
and mounted using cryo-tongs17 initially developed for crystals of biological
macromolecules.

Single crystals of Compounds 2c–2e, 2g–2k, 2m, 2o, 2q, 3a, 3j, 4c, and 4d were grown
from methylene chloride or acetone by vapor diffusion of diethyl ether, THF, or hexanes,
the mounted in inert oil and transferred to the cold gas stream of the diffractometer. X-ray
diffraction data were collected at 90.0(2) K on a Bruker-Nonius X8 Proteum
diffractometer with graded-multilayer focused CuK(α) x-rays. Raw data were integrated,
scaled, merged and corrected for Lorentz-polarization effects using the APEX2
package.18 Corrections for absorption were applied using either SADABS or
TWINABS,19 and by XABS2.20 The structure was solved by direct methods (SHELXS97)20 and difference Fourier (SHELXL-97)21. Refinement was carried out against F2 by
weighted full-matrix least-squares (SHELXL-97)21, and assessed with the aid of an Rtensor.22 Hydrogen atoms were found in difference maps but subsequently placed at
calculated positions and refined using a riding model. Non-hydrogen atoms were refined
with anisotropic displacement parameters. Atomic scattering factors were taken from the
International Tables for Crystallography.23 Crystal data and relevant details of the
structure determinations are summarized below and selected geometrical parameters are
given in Appendix 2.
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Single crystals of Compound 2f, 2n were crystallized from acetone or methylene chloride
by vapor diffusion of diethyl ether, THF, or hexanes, mounted in inert oil and transferred
to the cold gas stream of the diffractometer. X-ray diffraction data were collected at
90.0(2) K on a Nonius κCCD diffractometer using MoK(α) x-rays. Raw data were
integrated, scaled, merged and corrected for Lorentz-polarization effects using the HKLSMN package.24 Corrections for absorption were applied using either SCALEPACK,24 or
SADABS,19 and by XABS2.20 The structure was solved by direct methods (SHELXS97)21 and difference Fourier (SHELXL-97).21 Refinement was carried out against F2 by
weighted full-matrix least-squares (SHELXL-97)21, with the aid of an R-tensor.22
Hydrogen atoms were found in difference maps but subsequently placed at calculated
positions and refined using a riding model. Non-hydrogen atoms were refined with
anisotropic displacement parameters. Atomic scattering factors were taken from the
International Tables for Crystallography.23 Crystal data and relevant details of the
structure determinations are summarized below and selected geometrical parameters are
given in Appendix 2.

6.8 Biological studies.

6.8.1 DNA Binding Studies.

6.8.1.1 Thermal DNA melts by circular dichroism. Compounds 4a–4d were incubated
with 25 μM K+ folded telomeric G-quadruplex and 50 μM intermolecular G-quadruplex at
a 2:1 [Ru]:[DNA bp] ratio in the dark. Samples of 4b and 4d were also irradiated with
470 nm light for 7 hrs in the presence of DNA. The DNA in the absence of compound
was used as the control. All samples were incubated at room temperature overnight.
Following incubation, samples were melted from 25–95 °C taking measurements every
5 °C and the CD signal was monitored from 220–320 nm. The normalized change in
ellipticity was plotted versus temperature to give the melting temperature (Tm). All
samples were run in duplicate.
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6.8.1.2 DNA binding constants. Absorbance binding titrations were performed for 4a–
4d in a half-area 96-well plate with 20 μM Ru(II) and a total volume of 150 μL. The
absorbance was measured after each DNA addition from 0–4.5 equivalents of DNA (CT
DNA, K+ G-quadruplex or intermolecular G-quadruplex). Samples were allowed to
equilibrate for 5 min prior to measuring the absorbance. The data was corrected for any
dilution of the Ru(II) complex during the titration. The maximum change was obtained at
a 2:1 [bp]:[Ru] ratio. The change in extinction coefficient was plotted versus CT DNA
concentration and Kb values were determined using Prism software.25
6.8.1.3 DNA binding stoichiometries. The binding stoichiometries were determined for
4a–4d with CT DNA, the K+ G-quadruplex, and the intermolecular G-quadruplex using
the method of continuous variation. Solutions of each complex and DNA were prepared
at 1 mM in the appropriate buffer (Table 6.4). The total concentration was kept constant at
80 μM while the [Ru] and [DNA] were varied from 0–1 mol fraction Ru(II) and 1–0 mol
fraction DNA. Samples were prepared in a half area 96-wel plate with a total volume of
100 μL. The Ru(II) only absorbance was measured prior to the addition of DNA. The
absorbance was adjusted for any dilution due to DNA addition. Following DNA addition
the samples were incubated for 15 min prior to measuring the absorbance. The change in
absorbance was plotted versus mol fraction of Ru(II) (χRu) to generate a Job plot. Linear
regression analysis was performed using Prism software.
6.8.2 DNA damage.
Ru (II) complexes were serially diluted 1:2 to give final concentrations of 0, 7.8, 15.6,
31.3, 62.5, 125, 250, and 500 μM of compound with 40 μg/mL of pUC19 plasmid in 10
mM phosphate buffer pH 7.4 in a 96 well plate. Dark control samples were removed prior
to light exposure. The samples were irradiate for one and three hours, aliquots were
removed and incubated in the dark overnight. DNA loading dye was added to the samples
prior to gel electrophoresis.

Control samples were generated to discriminate between single strand and double strand
breaks in the compound-plasmid reactions. To induce single strand breaks, 40 μg/mL of
pUC19 in 10 mM phosphate buffer, pH 7.4, was mixed with 5 μM Cu(OP)2 and the
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reaction was initiated upon the addition of 1 mM DTT and 1 mM H2O2. The reaction was
allowed to proceed at room temperature for 30 minutes. For the induction of double
strand breaks in pUC19 the restriction enzyme, EcoRI, was used according to the
manufacturer’s instructions, using 40 μg/mL of plasmid. The reaction was allowed to
proceed for 90 min at 37 °C and then stored at -20 °C.

Samples with pUC19 plasmid were resolved on a 1% agarose gel in Tris-acetate (TA)
buffer, with 0.3 μg of plasmid loaded per lane. The samples were run for 90 min at 100
mV followed by staining the gel with a solution of 500 ng/ml ethidium bromide in TA
buffer for 40 min. The gels were then destained in TA buffer for 30 min and digitally
imaged with the BioRad ChemiDoc System.

6.8.3 E. coli based assays. (Performed by Yang Sun)

6.8.3.1 E. coli culture maintenance. Escherichia coli BL21DE3 competent cells
transfected with PCW-ori plasmid containing Dendra2 gene (PCW-ori-Dendra2) were
cultured in Luria Broth (LB) rich medium at 37℃ with 180 rpm shaking. Dendra2 gene
was cloned into a PCW-ori plasmid modified to contain an N-terminal 6x histidine tag
with multiple restriction enzyme cloning sites.

6.8.3.2 Cytotoxicity determination. E. coli BL21DE3 cells transfected with PCW-oriDendra2 plasmid were plated in M63 minimal medium at 4 x 106 cells per well in 96 well
flat bottom transparent tissue culture treated plates (Greiner Bio One). Compounds were
dosed from 0–300 μM, followed by light irradiation with blue LED for a total light dose
of 30 minutes. The cells were incubated for 16 hours with the compounds, and cell
growth was determined by evaluation of cell density of measurement of optical density at
600 nm using SpectraMax Multiwell Plate Reader (Molecular Devices). The data were
then normalized with no treatment control being 100% and medium only being 0% and
fitted into a sigmoidal dose response model using Prism 6.02 to get IC50 values.
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6.8.3.3 Metal uptake in bacterial cells. E. coli BL21DE3 cells transfected with PCWori-Dendra2 plasmid were cultured in M63 minimal medium to and dosed with 20 µM
compounds or 20 μM of cisplatin. Cells treated with Ru complexes were irradiated with 7
J/cm2 blue filtered light (> 400 nm) for a total light dose of 3 minutes or protected from
light. Cells were then incubated for up to 24 hours. Cells were collected at 24 hours by
centrifugation at 8000 rpm for 5 minutes, the culture medium was separated for analysis,
and cells were washed twice with DPBS. Both cell content and medium were heated at
110℃ for 3 hours with 20% (v/v) HNO3. Following sample digestion, the metal content
was analyzed using a Varian 880Z AAS with single element hollow cathode lamps for
ruthenium and platinum (Agilent). All samples were analyzed in triplicate reading.

6.8.4 Cell survival assay. (Performed by Dr. David Heidary) Cytotoxicity was
determined in HL-60 (human promyelocytic leukemia) and A549 (human lung
carcinoma) cell lines. The cell lines were maintained in IMDM media (HL-60) or DMEM
media (A549) supplemented with 10% fetal bovine serum (FBS) and 50 U/mL
penicillin/streptomycin at 37 °C with 5% CO2. For cytotoxicity assays, the cells were
plated in Opti-mem supplemented with 1% FBS and 50 U/mL penicillin/streptomycin at
30,000 cells per well in Costar 96 well flat bottom clear tissue culture treated plates. The
compounds were dosed from 0 to 100 or 300 μM, incubated with the cells for 12 hours,
and irradiated for 3 minutes using a 410 W projector fitted with the blue cut-off filter or
the 470 nm LED at a distance of 12 inches from the lamp to the plate. The cells were then
incubated for 72 hours followed by the addition of Alamar Blue to determine viability.
Dark controls were run in parallel. The resulting fluorescence was measured with a
SpectraFluor Plus Plate Reader (Tecan). The data was fit to the equation for a sigmoidal
dose response using Prism Software.
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Appendix 1. Crystal Structure Data Tables and Figures.
Table S1.1: Crystal data for 2c–2k, 2m–2o, 2q, 3a, 3j, 4c and 4d.
Crystal Data

2c

2d/4a

2e

C38H32F12N8OP2Ru

C43H37C13F12N8+O1P2Ru

C32H28F12N6P2Ru

Red orange

Red orange

Red orange

0.08 x 0.06 x 0.04

0.22 x 0.10 x 0.02

0.12 x 0.10 x 0.02

Monoclinic

Triclinic

Monoclinic

Space group

P 21/c

C 2/c

Temperature (K)

90.0(2)

�
P1

90.0(2)

90.0(2)

Volume (Å )

3831.34(12)

4863.9(10)

6728.3(3)

a (Å)

18.9289(3)

17.115(2)

26.6937(6)

b (Å)

8.7226(2)

17.367(2)

9.8852(2)

c (Å)

24.7333(4)

17.373(2)

25.5089(6)

α (°)

90

81.255(8)

90

β (°)

110.248(1)

89.146(8)

91.6600(9)

γ (°)

90

72.459(7)

90

Z

4

4

8

1007.73

1175.67

887.61

ρcalcd (mg m-3)

1.747

1.606

1.753

μ (mm-1)

5.049

5.482

5.608

F000

2024

2362

3552

1.54178

1.54178

1.54178

1.102

1.109

1.056

Empirical formula
Crystal color
Crystal size (mm)
Crystal system

3

FW (g/mol)

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies (I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak and
hole (eÅ-3)

Full-matrix least-squares on F2
R1 = 0.0523
wR2 = 0.1330
48010

R1 = 0.0817
wR2 = 0.2333
62989

R1 = 0.0361
wR2 = 0.0984
47333

6955

17033

6149

0.898/-0.881

1.827/-1.210

1.730/-0.698
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Table S1.1 cont: Crystal data for 2c–2k, 2m–2o, 2q, 3a, 3j, 4c and 4d.
Crystal Data
Empirical formula
Crystal color
Crystal size (mm)

2f

2g

2h/4b

C34H28F12N6P2Ru

C40H36F12N8OP2Ru

C46H40F12N8P2Ru

Red orange

Red orange

Red orange

0.20 x 0.18 x 0.14

0.16 x 0.05 x 0.04

0.120 x 0.100 x
0.30

Crystal system

Monoclinic

Monoclinic

Monoclinic

C 2/c

P 21/n

P 21/n

90.0(2)

90.0(2)

150(2)

Volume (Å3)

6890.85(1)

3995.33(18)

8505.6(4)

a (Å)

26.2806(2)

9.6888(3)

14.5892(4)

b (Å)

9.8468(1)

12.8916(3)

38.7805(10)

c (Å)

26.6310(2)

32.0299(8)

15.4066(4)

α (°)

90

90

90

β (°)

90.8254(3)

92.9587(15)

102.636(1)

γ (°)

90

90

90

Z

8

4

8

FW (g/mol)

911.63

1035.78

1089.40

ρcalcd (mg m-3)

1.757

1.722

1.702

μ (mm )

0.651

4.860

5.590

F000

3648

2088

4363.4

0.71073

1.54178

1.54178

1.073

1.182

1.057

Space group
Temperature (K)

-1

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies (I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak and
hole (eÅ-3)

Full-matrix least-squares on F2
R1 = 0.0452
wR2 = 0.1195
77854

R1 = 0.0543
wR2 = 0.1655
43819

R1 = 0.0513
wR2 = 0.1339
99883

7896

7102

15055

1.693/-0.751

0.987/-0.765

1.381/-1.054
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Table S1.1 cont: Crystal data for 2c–2k, 2m–2p, 2r, 3a, 3j, 4c and 4d.
Crystal Data

2i

2j

2k

C46H48F12N6O2P2Ru

C54H60F12N6O3.5P2Ru

C415H364F108N72O12P18Ru9

Red orange

Red orange

Red orange

0.12 x 0.12 x 0.02

0.12 x 0.10 x 0.03

0.11 x 0.10 x 0.05

Monoclinic

Triclinic

Triclinic

C 2/c
90.0(2)

P1�

90.0(2)

P1�

90.0(2)

Volume (Å )

4479.2(4)

2743.76(10)

10563.1(3)

a (Å)

12.5870(6)

13.8077(3)

18.3127(3)

b (Å)

21.1648(8)

14.1056(3)

21.3286(4)

c (Å)

17.8587(10)

16.4476(3)

29.2640(6)

α (°)

90

72.902(1)

81.874(1)

β (°)

109.697(3)

66.930(1)

89.211(1)

γ (°)

90

71.675(1)

69.108(1)

Z

4

2

1

1107.91

1240.09

10070.85

ρcalcd (mg m-3)

1.643

1.501

1.583

μ (mm-1)

4.380

3.662

4.192

F000

2256

1272

5092

1.54178

1.54178

1.54178

1.042

1.094

1.025

Empirical formula
Crystal color
Crystal size (mm)
Crystal system
Space group
Temperature (K)
3

FW (g/mol)

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies
(I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak
and hole (eÅ-3)

Full-matrix least-squares on F2
R1 = 0.845
wR2 = 0.2164
26184

R1 = 0.0490
wR2 = 0.1202
37333

R1 = 0.0574
wR2 = 0.1472
139158

3944

9773

41744

2.158/-1.027

0.875/-0.866

2.093/-1.259
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Table S1.1 cont: Crystal data for 2c–2k, 2m–2p, 2r, 3a, 3j, 4c and 4d.
Crystal Data

2m

2n

2o

C87H62Cl6F24N12P4Ru2

C51H38F12N6OP2Ru

C40H29F12N8O1.5P2Ru

Dark red

Dark pink

Dark red

0.16 x 0.08 x 0.03

0.18 x 0.012 x 0.11

0.29 x 0.03 x 0.01

Monoclinic

Monoclinic

Triclinic

Space group

P 21/c

P21/n

Temperature (K)

90.0(2)

90.0(2)

P1�

90.0(2)

87083(3)

4681.82(6)

1964.35(12)

a (Å)

21.8129(4)

12.5876(1)

9.3070(3)

b (Å)

18.8565(4)

15.9629(1)

13.0364(5)

c (Å)

22.760(4)

23.7620(1)

17.7489(6)

α (°)

90

90

75.103(2)

β (°)

106.454(1)

101.403(4)

83.667(2)

γ (°)

90

90

70.783(2)

Z

4

4

2

2270.21

1141.88

1036.72

ρcalcd (mg m-3)

1.732

1.620

1.753

μ (mm-1)

6.148

0.499

4.957

F000

4536

2304

1038

1.54178

0.71073

1.54178

1.032

1.058

1.138

Empirical formula
Crystal color
Crystal size (mm)
Crystal system

3

Volume (Å )

FW (g/mol)

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies
(I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak
and hole (eÅ-3)

Full-matrix least-squares on F2
R1 = 0.0449
wR2 = 0.1213
118686

R1 = 0.0474
wR2 = 0.1164
103415

R1 = 0.0663
wR2 = 0.1494
22643

15730

10763

6648

0.947/-1.277

1.931/-0.656

1.151/-1.069
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Table S1.1 cont: Crystal data for 2c–2k, 2m–2p, 2r, 3a, 3j, 4c and 4d.
Crystal Data

2r

3a

3h

C52H34F12N8P2Ru

C34H28Cl4F12N6OP2Ru

C50H38F12N8O3P2RuS

Purple

Red orange

Dark pin k

0.12 x 0.08 x 0.02

0.10 x 0.09 x 0.03

0.20 x 0.08 x 0.05

Monoclinic

Triclinic

Monoclinic

P21/c

C2/c

90.0(2)

P1�

90.0(2)

90.0(2)

4729(2)

1977.54(11)

11628.2(4)

a (Å)

11.9999(3)

10.2004(3)

41.8560(8)

b (Å)

19.7237(5)

11.3813(6)

14.3022(3)

c (Å)

20.2544(5)

18.7104(5)

21.6006(4)

α (°)

90

102.015(1)

90

β (°)

99.409(1)

91.316(1)

115.939(1)

γ (°)

90

110.613(1)

90

Z

4

2

8

1161.88

1069.43

1221.95

ρcalcd (mg m-3)

1.632

1.796

1.396

μ (mm-1)

4.171

7.344

3.785

F000

2336

1064

4928

1.54178

1.54178

1.54178

1.228

1.047

1.058

Empirical formula
Crystal color
Crystal size (mm)
Crystal system
Space group
Temperature (K)
3

Volume (Å )

FW (g/mol)

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies
(I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak and
hole (eÅ-3)

Full-matrix least-squares on F2
R1 = 0.0378
wR2 = 0.0960
58019

R1 = 0.0374
wR2 = 0.1061
26444

R1 = 0.0402
wR2 = 0.1048
77197

8343

7079

10597

0.529/-0.794

0.963/-0.513

1.001/-0.1048
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Table S1.1 cont: Crystal data for 2c–2k, 2m–2p, 2r, 3a, 3j, 4c and 4d.
Crystal Data

4c

4d

C44H36BrF12N8O2P2Ru

C40H29BrF12N8P2Ru

Red orange

Red orange

0.17 x 0.10 x 0.08

0.24 x 0.21 x 0.18

Triclinic

Monoclinic

P1�

P21/c

90.0(2)

90.0(2)

2310.87(17)

4606.5(4)

a (Å)

9.3281(4)

10.7998(5)

b (Å)

13.0620(6)

12.6135(6)

c (Å)

19.8864(8)

34.0173(15)

α (°)

96.696(2)

90

β (°)

96.947(2)

96.2404(11)

γ (°)

103.634(2)

90

2

4

1179.73

1092.63

ρcalcd (mg m-3)

1.695

1.575

μ (mm-1)

5.280

1.364

F000

1178

2168

1.54178

0.71073

1.102

1.080

R1 = 0.0667
wR2 = 0.1540
29528

R1 = 0.0478
wR2 = 0.1261
74251

8159

10589

1.265/-1.341

0.874/-0.820

Empirical formula
Crystal color
Crystal size (mm)
Crystal system
Space group
Temperature (K)
3

Volume (Å )

Z
FW (g/mol)

Radiation (Å)
GOF
Data Refinement
Method
Final R indicies
(I>2σ(I))
No. refls collected
Unique refls
Largest diff. peak
and hole (eÅ-3)
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A

B

Figures S1.1: Thermal ellipsoid plots and atom labeling of 2c. (A) Clear labeling of
atoms; (B) side view to show absence of distortion. Ellipsoids are drawn to 50%
probability and hydrogen atoms are omitted for clarity.

Figures S1.2: Thermal ellipsoid plots and atom labeling of 2d. Ellipsoids are drawn to
50% probability and hydrogen atoms are omitted for clarity.
A

B

Figures S1.3: Thermal ellipsoid plots and atom labeling of 2e. (A) Clear labeling of
atoms; (B) side view to show presence of distortion created by the dmbpy ligand.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.
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A

B

Figures S1.4: Thermal ellipsoid plots and atom labeling of 2f. (A) Clear labeling of
atoms; (B )side view to show presence of distortion created by the dmphen ligand.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.
A

B

Figures S1.5: Thermal ellipsoid plots and atom labeling of 2g. (A) Clear labeling of
atoms; (B) side view to show absence of distortion from the dmdpq ligand. Ellipsoids are
drawn to 50% probability and hydrogen atoms are omitted for clarity.
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Figures S1.6: Thermal ellipsoid plots and atom labeling of 2h. Ellipsoids are drawn to
50% probability and hydrogen atoms are omitted for clarity.

A

B

Figures S1.7: Thermal ellipsoid plots and atom labeling of 2i. (A) Clear labeling of
atoms; (B )side view to show presence of distortion created by the dmphen ligands.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.

211

A

B

Figures S1.8: Thermal ellipsoid plots and atom labeling of 2j. (A) Clear labeling of
atoms; (B) side view to show presence of distortion created by the dmphen ligands.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.

B

A

Figures S1.9: Thermal ellipsoid plots and atom labeling of 2k. (A) Clear labeling of
atoms; (B) side view to show presence of distortion created by the dmphen ligands.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.
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A

B

Figures S1.10: Thermal ellipsoid plots and atom labeling of 2m. (A) Clear labeling of
atoms; (B) side view shows the 20o bend from horizontal of the biq ligand. Ellipsoids are
drawn to 50% probability and hydrogen atoms are omitted for clarity.
A

B

Figure S1.11: Thermal ellipsoid plots and atom labeling of 2n. (A) Ellipsoid plot (at
50% probability) of 2n (hydrogen atoms omitted for clarity) to show the numbering of
each atom. (B) capped stick overlay of 2n. In white the N(3)-N(4) biquinoline is
horizontal and in the blue the N(1)-N(2) biquinoline is horizontal to highlight the
different distortions of the two biquinoline ligands. Both biquinoline ligands have a 20°
bend from the ideal octahedral plan, but the N(3)-N(4) ligand has a 12° twist about the CC bond between the two quinolines while the N(1)-N(2) does not have this degree of
twist.
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A

B

Figures S1.12: Thermal ellipsoid plots and atom labeling of 2o. (A) Clear labeling of
atoms; (B) side view to show presence of lack of distortion created by the bnap ligand.
Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for clarity.

A

B

Figures S1.13: Thermal ellipsoid plots and atom labeling of 2q. (A) Clear labeling of
atoms; (B) side view to show presence of distortion created by both the biq and bnap
ligands. Ellipsoids are drawn to 50% probability and hydrogen atoms are omitted for
clarity.
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A

B

Figures S1.14: Thermal ellipsoid plots and atom labeling of 3a. (A) Clear labeling of
atoms; (B) side view to show absence of distortion created. Ellipsoids are drawn to 50%
probability and hydrogen atoms are omitted for clarity.

A

B

Figures S1.15: Thermal ellipsoid plots and atom labeling of 3j. (A) Clear labeling of
atoms; (B) side view to show presence of distortion created by the biq ligands. Ellipsoids
are drawn to 50% probability and hydrogen atoms are omitted for clarity.
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Figures S1.16: Thermal ellipsoid plots and atom labeling of 4c. Ellipsoids are drawn to
50% probability and hydrogen atoms are omitted for clarity.

Figures S1.17: Thermal ellipsoid plots and atom labeling of 4d. Ellipsoids are drawn to
50% probability and hydrogen atoms are omitted for clarity.
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Table S1.2: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2c.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C5-C6-N2
N1-Ru-N2-C6
N2-Ru-N1-C5
N3-C15-C16-N4
N3-Ru-N4-C16
N4-Ru-N3-C15

Selected Bond Lengths (Å)
2.065(5)
Ru-N4
2.071(5)
Ru-N5
2.066(5)
Ru-N6
Selected Bond Angles (°)
78.99(19)
N2-Ru-N6
97.70(19)
N3-Ru-N4
174.47(18)
N3-Ru-N5
86.27(18)
N3-Ru-N6
95.42(18)
N4-Ru-N5
89.16(18)
N4-Ru-N6
97.09(18)
N5-Ru-N6
94.39(18)
Selected Torsion Angles (°)
3.8(6)
N5-C25-C26-N6
-4.4(4)
N5-Ru-N6-C26
4.3(4)
N6-Ru-N5-C25
-1.9(7)
6.9(4)
-7.9(4)
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2.067(5)
2.061(5)
2.079(4)
172.01(18)
78.23(19)
175.12(17)
97.30(18)
97.98(17)
88.86(17)
79.45(18)

-2.1(7)
0.3(4)
-1.5(4)

Table S1.3: Selected bond lengths (Å), bond angles (°), and torsion angles (°) for 2d/4a
(B cation).

Ru-N1
Ru-N3
Ru-N5

Selected Bond Lengths (Å)
2.057(8)
Ru-N2
2.066(7)
Ru-N4
2.074(7)
Ru-N6

N1-Ru-N2
N1-Ru-N4
N1-Ru-N6
N2-Ru-N4
N2-Ru-N6
N3-Ru-N5
N4-Ru-N5
N5-Ru-N6

Selected Bond Angles (°)
78.6(3)
N1-Ru-N3
171.8(3)
N1-Ru-N5
95.9(3)
N2-Ru-N3
95.3(3)
N2-Ru-N5
170.7(3)
N3-Ru-N4
171.2(3)
N3-Ru-N6
95.1(3)
N4-Ru-N6
79.3(3)

N1-Ru-N2-C6
N1-C5-C6-N2
Ru-N2-C10-C9
Ru-N2-C6-C5
N3-Ru-N4-C16
N3-C15-C16-N4
Ru-N4-C20-C19
Ru-N4-C16-C15
N5-Ru-N6-C38
N5-C21-C38-N6
Ru-N6-C37-C36
Ru-N6-C38-C21

Selected Torsion Angles (°)
-3.4(7)
N2-Ru-N1-C5
2.2(13)
Ru-N1-C1-C2
177.0(7)
Ru-N1-C5-C6
1.7(11)
-2.4(6)
N4-Ru-N3-C15
-4.9(12)
Ru-N3-C11-C12
172.3(7)
Ru-N3-C15-C16
4.6(10)
4.0(6)
N6-Ru-N5-C21
-2.5(10)
Ru-N5-C22-C23
179.4(7)
Ru-N5-C21-C38
-2.2(9)
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2.055(7)
2.065(8)
2.072(7)

96.6(3)
90.6(3)
93.2(3)
93.1(3)
78.2(3)
94.9(3)
90.8(3)

4.5(6)
-177.5(7)
-5.0(11)
-3.4(7)
176.2(8)
2.8(10)
-5.3(5)
171.0(6)
5.8(8)

Table S1.4: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2e.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C6-C7-N2
N1-Ru-N2-C7
N2-Ru-N1-C6
N3-C17-C18-N4
N3-Ru-N4-C18
N4-Ru-N3-C17

Selected Bond Lengths (Å)
2.114(2)
Ru-N4
2.113(2)
Ru-N5
2.053(2)
Ru-N6
Selected Bond Angles (°)
78.26(9)
N2-Ru-N6
99.95(9)
N3-Ru-N4
178.60(9)
N3-Ru-N5
97.58(9)
N3-Ru-N6
85.02(9)
N4-Ru-N5
94.08(9)
N4-Ru-N6
101.97(9)
N5-Ru-N6
169.90(9)
Selected Torsion Angles (°)
2.94(4)
N5-C27-C28-N6
22.91(18)
N5-Ru-N6-C28
21.46(19)
N6-Ru-N5-C27
-6.1(3)
-9.71(19)
6.27(19)
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2.055(2)
2.062(2)
2.080(2)
91.91(9)
78.66(9)
95.72(9)
172.89(9)
82.41(9)
96.35(9)
78.49(9)

-1.6(4)
-7.66(19)
6.83(19)

Table S1.5: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2f.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C6-C7-N2
N1-Ru-N2-C7
N2-Ru-N1-C6
N3-C19-C20-N4
N3-Ru-N4-C20
N4-Ru-N3-C19

Selected Bond Lengths (Å)
2.116(2)
Ru-N4
2.121(3)
Ru-N5
2.048(3)
Ru-N6
Selected Bond Angles (°)
79.21(10)
N2-Ru-N6
96.96(10)
N3-Ru-N4
175.43(10)
N3-Ru-N5
98.32(9)
N3-Ru-N6
87.05(10)
N4-Ru-N5
92.77(9)
N4-Ru-N6
102.15(10)
N5-Ru-N6
170.40(10)
Selected Torsion Angles (°)
-0.7(4)
N5-C29-C30-N6
-11.8(2)
N5-Ru-N6-C30
11.5(2)
N6-Ru-N5-C29
4.0(4)
6.60(19)
-4.35(19)

220

2.064(2)
2.056(2)
2.074(2)
92.07(9)
78.65(10)
96.75(10)
174.22(9)
81.05(9)
97.24(9)
78.50(10)

-0.7(4)
2.43(19)
-2.84(19)

Table S1.6: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2g.

Ru-N1
Ru-N2
Ru-N5

Selected Bond Lengths (Å)
2.115(5)
Ru-N6
2.126(5)
Ru-N7
2.086(6)
Ru-N8

N1-Ru-N2
N1-Ru-N5
N1-Ru-N6
N1-Ru-N7
N1-Ru-N8
N2-Ru-N5
N2-Ru-N6
N2-Ru-N7

Selected Bond Angles (°)
79.3(2)
N2-Ru-N8
102.2(2)
N5-Ru-N6
90.5(2)
N5-Ru-N7
92.2(2)
N5-Ru-N8
170.9(2)
N6-Ru-N7
169.7(2)
N6-Ru-N8
92.2(2)
N7-Ru-N8
91.5(2)

Selected Torsion Angles (°)
N1-C6-C7-N2
-0.9(8)
N7-C31-C32-N8
N1-Ru-N2-C7
-1.4(5)
N7-Ru-N8-C32
N2-Ru-N1-C6
1.0(5)
N8-Ru-N7-C31
N5-C21-C22-N6
8.1(9)
N5-Ru-N6-C22
-0.6(5)
N6-Ru-N5-C21
5.2(5)
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2.052(5)
2.052(5)
2.075(6)
102.3(2)
77.6(2)
98.7(2)
77.9(2)
175.86(18)
98.5(2)
78.8(2)

5.3(9)
6.1(5)
-3.3(4)

Table S1.7: Selected bond lengths (Å), bond angles (°), and torsion angles (°) for 2h/4b
(A cation).

Ru-N1
Ru-N3
Ru-N5

N1-Ru-N2
N1-Ru-N4
N1-Ru-N6
N2-Ru-N4
N2-Ru-N6
N3-Ru-N5
N4-Ru-N5
N5-Ru-N6

N1-Ru-N2-C6
N1-C5-C6-N2
Ru-N2-C10-C9
Ru-N2-C6-C5
N3-Ru-N4-C16
N3-C15-C16-N4
Ru-N4-C20-C19
Ru-N4-C16-C15
N5-Ru-N6-C39
N5-C40-C39-N6
Ru-N6-C36-C35
Ru-N6-C39-C40

Selected Bond Lengths (Å)
2.056(4)
Ru-N2
2.061(4)
Ru-N4
2.096(4)
Ru-N6
Selected Bond Angles (°)
79.02(15)
N1-Ru-N3
171.75(15)
N1-Ru-N5
92.17(14)
N2-Ru-N3
96.19(15)
N2-Ru-N5
100.36(15)
N3-Ru-N4
99.89(15)
N3-Ru-N6
86.60(14)
N4-Ru-N6
78.68(15)
Selected Torsion Angles (°)
4.0(3)
N2-Ru-N1-C5
-0.5(6)
Ru-N1-C1-C2
-178.2(4)
Ru-N1-C5-C6
-3.1(5)
-0.1(3)
N4-Ru-N3-C15
-0.7(6)
Ru-N3-C11-C12
-178.2(4)
Ru-N3-C15-C16
0.4(5)
-15.1(3)
N6-Ru-N5-C40
1.9(6)
Ru-N5-C21-C22
172.1(4)
Ru-N5-C40-C39
12.1(5)
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2.065(3)
2.073(4)
2.112(4)

93.76(15)
98.29(14)
81.33(15)
177.14(14)
78.80(15)
174.04(14)
95.31(15)

-4.3(3)
175.1(4)
4.0(5)
-0.34(3)
-178.2(4)
0.7(5)
16.2(3)
-169.9(4)
-14.9(5)

Table S1.8: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2i.

Ru-N1
Ru-N2
Ru-N3

Selected Bond Lengths (Å)
2.106(6)
2.096(6)
2.067(6)

N1-Ru-N1
N1-Ru-N2
N1-Ru-N3
N2-Ru-N2

Selected Bond Angles (°)
178.4(3)
N2-Ru-N3
79.4(20)/101.7(2)
N3-Ru-N3
83.2(2)/95.5(2)
93.5(3)

N1-C6-C7-N2
N1-Ru-N2-C7
N2-Ru-N1-C6
N3-Ru-N3-C19

Selected Torsion Angles (°)
-2.1(9)
19.4(4)
-20.4(4)
2.3(4)
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94.0(2)/171.7(2)
78.9(3)

Table S1.9: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2j.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C5-C6-N2
N1-Ru-N2-C6
N2-Ru-N1-C5
N3-C17-C18-N4
N3-Ru-N4-C18
N4-Ru-N3-C17

Selected Bond Lengths (Å)
2.091(3)
Ru-N4
2.077(3)
Ru-N5
2.121(3)
Ru-N6
Selected Bond Angles (°)
79.29(12)
N2-Ru-N6
78.51(12)
N3-Ru-N4
94.16(12)
N3-Ru-N5
171.01(12)
N3-Ru-N6
98.62(12)
N4-Ru-N5
97.47(12)
N4-Ru-N6
173.26(11)
N5-Ru-N6
91.73(11)
Selected Torsion Angles (°)
4.2(5)
N5-C31-C32-N6
-2.0(2)
N5-Ru-N6-C31
4.2(3)
N6-Ru-N5-C32
4.5(5)
-17.3(2)
19.5(2)
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2.108(3)
2.107(3)
2.104(3)
81.91(12)
79.55(12)
103.26(11)
177.13(11)
94.83(11)
100.77(12)
79.58(11)

2.5(5)
15.5(2)
-14.2(2)

Table S1.10: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2k (A
cation).

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C6-C7-N2
N1-Ru-N2-C7
N2-Ru-N1-C6
N3-C20-C21-N4
N3-Ru-N4-C21
N4-Ru-N3-C20

Selected Bond Lengths (Å)
2.127(8)
Ru-N4
2.095(8)
Ru-N5
2.105(8)
Ru-N6
Selected Bond Angles (°)
80.4(3)
N2-Ru-N6
101.3(3)
N3-Ru-N4
179.0(3)
N3-Ru-N5
99.1(3)
N3-Ru-N6
83.8(3)
N4-Ru-N5
91.9(3)
N4-Ru-N6
100.5(3)
N5-Ru-N6
173.5(3)
Selected Torsion Angles (°)
-1.4(13)
N5-C33-C34-N6
-13.5(4)
N5-Ru-N6-C34
12.7(4)
N6-Ru-N5-C33
1.9(12)
16.7(8)
12.7(2)
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2.135(8)
2.083(7)
2.092(7)
94.9(3)
79.3(3)
94.5(3)
172.1(3)
80.0(3)
94.6(3)
78.6(3)

-0.8(13)
-4.9(1)
4.5(3)

Table S1.11: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2m .

Ru-N1
Ru-N2
Ru-N3

N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N3-Ru-N4-C24
N4-Ru-N3-C23
N4-C24-C23-N3
Ru-N3-C23-C24
Ru-N4-C24-C23
N5-Ru-N6-C36
N6-Ru-N5-C35
N5-C35-C36-N6
Ru-N5-C35-C36
Ru-N6-C36-C35

Selected Bond Lengths (Å)
2.112(3)
Ru-N4
2.095(3)
Ru-N5
2.063(3)
Ru-N6
Selected Bond Angles (°)
77.62(12)
N2-Ru-N6
96.15(12)
N3-Ru-N4
100.41(12)
N3-Ru-N5
171.15(12)
N3-Ru-N6
92.22(11)
N4-Ru-N5
99.15(12)
N4-Ru-N6
177.93(12)
N5-Ru-N6
99.29(12)
Selected Torsion Angles (°)
-6.2(2)
N1-Ru-N2-C10
6.3(2)
N2-Ru-N1-C9
0.2(5)
N1-C9-C10-N2
-5.5(4)
Ru-N1-C9-C10
5.2(4)
Ru-N2-C10-C9
Ru-N1-C1-C2
2.6(2)
Ru-N2-C18-C17
2.5(2)
C17-C18-C1-C2
-0.4(5)
-1.9(4)
2.5(4)
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2.056(3)
2.091(3)
2.091(3)

85.65(11)
80.35(12)
92.52(12)
171.08(12)
82.75(12)
95.11(12)
79.23(12)

-20.7(4)
17.6(2)
-5.6(5)
-12.3(4)
20.8(4)
21.1(5)
-25.9(5)
-4.40

Table S1.12: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2n.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-C9-C10-N2
N1-Ru-N2-C10
N2-Ru-N1-C9
Ru-N1-C9-C10
Ru-N2-C10-C9
Ru-N1-C1-C2
Ru-N2-C18-C17
C17-C18-C1-C2
N5-Ru-N6-C42
N6-Ru-N5-C41
N5-C41-C42-N6

Selected Bond Lengths (Å)
2.084(2)
Ru-N4
2.079(2)
Ru-N5
2.088(2)
Ru-N6
Selected Bond Angles (°)
77.93(10)
N2-Ru-N6
104.29(9)
N3-Ru-N4
176.23(9)
N3-Ru-N5
96.67(9)
N3-Ru-N6
82.28(9)
N4-Ru-N5
97.14(10)
N4-Ru-N6
104.89(10)
N5-Ru-N6
169.52(10)
Selected Torsion Angles (°)
2.7(4)
N3-Ru-N4-C28
-20.41(19)
N4-Ru-N3-C27
22.08(19)
N3-C27-C28-N4
-20.1(3)
Ru-N3-C27-C28
16.1(3)
Ru-N4-C28-C27
29.6(4)
Ru-N3-C9-C20
-20.7(4)
Ru-N4-C36-C35
4.48
C35-C36-C19-C20
-1.5(2)
1.7(2)
0.4(4)

Ru-N5-C41-C42
Ru-N6-C42-C41
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2.093(2)
2.105(3)
2.098(2)
91.42(10)
77.98(10)
92.89(9)
170.12(10)
80.14(9)
95.08(10)
78.87(10)

26.1(2)
-19.5(2)
12.1(4)
10.6(3)
-28.3(3)
-11.1(4)
36.5(4)
14.65
-1.7(3)
1.1(3)

Table S1.13: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2o.

Ru-N1
Ru-N2
Ru-N5

N1-Ru-N2
N1-Ru-N5
N1-Ru-N6
N1-Ru-N7
N1-Ru-N8
N2-Ru-N5
N2-Ru-N6
N2-Ru-N7
N1-Ru-N2-C9
N2-Ru-N1-C8
N1-C8-C9-N2
Ru-N1-C8-C9
Ru-N2-C9-C8
Ru-N1-C1-N3
Ru-N2-C16-N4
N7-Ru-N8-C34
N8-Ru-N7-C33
N7-C33-C34-N8

Selected Bond Lengths (Å)
2.100(5)
Ru-N6
2.105(5)
Ru-N7
2.070(5)
Ru-N8
Selected Bond Angles (°)
77.3(2)
N2-Ru-N8
96.1(2)
N5-Ru-N6
175.7(2)
N5-Ru-N7
99.9(2)
N5-Ru-N8
91.5(2)
N6-Ru-N7
92.9(2)
N6-Ru-N8
103.5(2)
N7-Ru-N8
173.9(2)
Selected Torsion Angles (°)
-2.7(4)
N5-Ru-N6-C22
5.5(1)
N6-Ru-N5-C21
5.0(4)
N5-C21-C22-N6
-7.4(0)
Ru-N5-C21-C22
-0.06(2)
Ru-N6-C22-C21
4.8(1)
-1.2(4)
-7.6(2)
6.9(8)
-1.0(4)

Ru-N7-C33-C34
Ru-N8-C34-C33
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2.084(5)
2.070(5)
2.072(5)

94.4(2)
79.7(2)
92.8(2)
170.5(2)
79.6(2)
92.7(2)
80.1(2)

7.2(3)
-6.6(5)
1.2(1)
5.1(2)
-6.8(3)

-5.4(8)
7.0(4)

Table S1.14: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 2q.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-Ru-N2-C10
N2-Ru-N1-C9
N1-C9-C10-N2
Ru-N1-C9-C10
Ru-N2-C10-C9
Ru-N1-C1-C2
Ru-N2-C18-C17
N5-Ru-N6-C45
N6-Ru-N5-C44
N5-C44-C45-N6
Ru-N5-C44-C45

Selected Bond Lengths (Å)
2.091(3)
Ru-N4
2.093(3)
Ru-N5
2.105(3)
Ru-N6
Selected Bond Angles (°)
77.96(10)
N2-Ru-N6
105.42(10)
N3-Ru-N4
175.09(10)
N3-Ru-N5
97.44(10)
N3-Ru-N6
80.24(10)
N4-Ru-N5
86.82(10)
N4-Ru-N6
105.57(10)
N5-Ru-N6
173.84(10)
Selected Torsion Angles (°)
-14.2(2)
N3-Ru-N4-C28
22.8(2)
N4-Ru-N3-C27
15.4(4)
N3-C27-C28-N4
-27.3(3)
Ru-N3-C27-C28
4.7(3)
Ru-N4-C28-C27
31.6(4)
Ru-N3-C19-C20
1.0(4)
Ru-N4-C36-C35
5.5(2)
5.8(2)
21.1(4)
-15.6(3)

Ru-N6-C45-C44
Ru-N5-C37-N7
Ru-N6-C52-N8
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2.093(3)
2.155(3)
2.143(3)
97.73(10)
78.40(10)
98.44(10)
173.45(10)
78.78(10)
95.77(10)
77.31(10)

24.3(2)
-13.2(2)
20.5(4)
1.0(3)
-31.0(3)
9.0(4)
37.2(4)
-15.3(3)
20.9(4)
21.4(4)

Table S1.15: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 3a.

Ru-N1
Ru-N2
Ru-N3
N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-Ru-N2-C6
N2-Ru-N1-C5
N1-C5-C6-N2
N3-Ru-N4-C16
N4-Ru-N3-C15
N3-C15-C16-N4

Selected Bond Lengths (Å)
2.052(3)
Ru-N4
2.065(3)
Ru-N5
2.062(3)
Ru-N6
Selected Bond Angles (°)
78.84(13)
N2-Ru-N6
95.03(11)
N3-Ru-N4
172.45(11)
N3-Ru-N5
97.59(11)
N3-Ru-N6
88.73(11)
N4-Ru-N5
93.98(11)
N4-Ru-N6
97.99(12)
N5-Ru-N6
170.67(11)
Selected Torsion Angles (°)
-8.2(2)
N5-Ru-N6-C26
5.0(1)
N6-Ru-N5-C25
-5.8(5)
N5-C25-C26-N6
8.2(1)
5.8(9)
4.2(4)
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2.062(3)
2.064(3)
2.079(3)
92.15(12)
78.27(11)
94.93(11)
173.33(11)
86.56(11)
98.27(11)
79.08(11)

0.9(3)
0.6(1)
2.8(5)

Table S1.16: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 3j.

Ru-N1
Ru-N2
Ru-N3

N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5
N1-Ru-N2-C10
N2-Ru-N1-C9
N1-C9-C10-N2
Ru-N1-C9-C10
Ru-N2-C10-C9
Ru-N1-C1-C2
Ru-N2-C18-C17
N5-Ru-N6-C42
N6-Ru-N5-C41
N5-C41-C42-N6

Selected Bond Lengths (Å)
2.117(3)
Ru-N4
2.106(2)
Ru-N5
2.090(3)
Ru-N6
Selected Bond Angles (°)
78.21(10)
N2-Ru-N6
106.02(10)
N3-Ru-N4
174.55(9)
N3-Ru-N5
95.06(10)
N3-Ru-N6
77.83(10)
N4-Ru-N5
90.28(10)
N4-Ru-N6
105.91(10)
N5-Ru-N6
172.41(11)
Selected Torsion Angles (°)
-13.1(7)
N3-Ru-N4-C28
23.5(4)
N4-Ru-N3-C27
19.5(9)
N3-C27-C28-N4
-29.8(6)
Ru-N3-C27-C28
1.6(1)
Ru-N4-C28-C27
36.3(2)
Ru-N3-C19-C20
8.4(2)
Ru-N4-C36-C35
4.4(9)
-3.9(4)
1.0(5)

Ru-N5-C41-C42
Ru-N6-C42-C41
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2.098(3)
2.089(2)
2.089(3)

95.76(10)
77.76(10)
95.01(10)
173.44(9)
80.59(9)
98.04(10)
79.24(10)

20.4(9)
-13.8(4)
12.4(1)
5.6(6)
-23.9(2)
-2.8(7)
32.1(4)
2.8(6)
-4.4(2)

Table S1.17: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 4c.

Ru-N1
Ru-N2
Ru-N3

N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5

N1-C5-C6-N2
Ru-N2-C6-C5
Ru-N1-C5-C6
N3-C15-C16-N4
Ru-N4-C16-C15
Ru-N3-C15-C16

Bond Lengths (Å)
2.071(5) Ru-N4
2.076(5) Ru-N5
2.073(5) Ru-N6
Bond Angles (°)
78.5(2) N2-Ru-N6
97.9(2) N3-Ru-N4
174.36(18) N3-Ru-N5
96.39(18) N3-Ru-N6
87.6(2) N4-Ru-N5
86.89(18) N4-Ru-N6
96.49(19) N5-Ru-N6
174.4(2)
Torsion Angles (°)
-8.8(9) N5-C25-C26-N6
7.9(8) Ru-N6-C26-C25
5.5(8) Ru-N5-C25-C26
-1.0(7)
-2.6(6)
4.1(6)
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2.064(5)
2.063(4)
2.072(5)

98.05(18)
79.05(19)
96.08(18)
173.22(18)
88.70(18)
95.71(19)
79.38(18)

-1.0(7)
0.7(6)
0.7(6)

Table S1.18: Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 4d.

Ru-N1
Ru-N2
Ru-N3

N1-Ru-N2
N1-Ru-N3
N1-Ru-N4
N1-Ru-N5
N1-Ru-N6
N2-Ru-N3
N2-Ru-N4
N2-Ru-N5

N1-C5-C6-N2
Ru-N2-C6-C5
Ru-N1-C5-C6
N3-C15-C16-N4
Ru-N4-C16-C15
Ru-N3-C15-C16

Bond Lengths (Å)
2.071(3) Ru-N4
2.056(3) Ru-N5
2.054(3) Ru-N6
Bond Angles (°)
78.62(12) N2-Ru-N6
96.59(12) N3-Ru-N4
173.25(12) N3-Ru-N5
93.63(18) N3-Ru-N6
87.1(3) N4-Ru-N5
82.19(11) N4-Ru-N6
95.60(11) N5-Ru-N6
171.90(16)
Torsion Angles (°)
1.9(5) N5-C26-C27-N6
6.8(4) Ru-N6-C27-C26
-9.6(4) Ru-N5-C26-C27
5.9(5)
0.6(4)
-9.6(4)
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2.055(3)
2.109(4)
2.120(5)

99.06(17)
79.04(12)
101.23(14)
176.3(3)
92.28(17)
97.4(3)
77.98(15)

-2.7(9)
-10.8(9)
14.8(7)

Appendix 2. Additional Figures and Tables.
A2.1 Chapter 2 Additional Figures and Tables.

Figure S2.1.1: Plots of HPLC analysis of the purity of compounds 2m and 2n and the
ligand ejected after exposure to light. A: 1,10-phenanthroline; B: 2,2’-biquinoline; C:
compound 2m before light activation; D: compound 2m after activation; E: compound
2n before light activation; F: compound 2n after activation. Insets show the UV/Vis
spectra corresponding to the elution peaks
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Figure S2.1.2: Thermal exchange studies of 2s in the presence of different aqueous
media. (A) Water, (B) 1 x PBS, (C) Opti-mem supplemented with 1% FBS, and (D) CT
DNA. Initial scan (t=0, blue line) and final scan (t=15 hr, red line).
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Figure S2.1.3: Thermal exchange studies of 2t in the presence of different aqueous
media. (A) Water, (B) 1 x PBS, (C) Opti-mem supplemented with 1% FBS, and (D) CT
DNA. Initial scan (t=0, blue line) and final scan (t=15 hr, red line).
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Figure S2.1.4: Thermal exchange studies of 2u in the presence of different aqueous
media. (A) Water, (B) 1 x PBS, (C) Opti-mem supplemented with 1% FBS, and (D) CT
DNA. Initial scan (t=0, blue line) and final scan (t=15 hr, red line).
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Figure S2.1.5: Thermal exchange studies of 2v in the presence of different aqueous
media. (A) Water, (B) 1 x PBS, (C) Opti-mem supplemented with 1% FBS, and (D) CT
DNA. Initial scan (t=0, blue line) and final scan (t=15 hr, red line).
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Figure S2.1.6: Photoejection kinetics of 2s–2v in 1 x PBS and in the presence of CT
DNA. Insets show the change in absorbance versus time. (A) 2s in 1 x PBS, (B) 2s with
CT DNA, (C) 2t in 1 x PBS, (D) 2t with CT DNA, (E) 2u in 1 x PBS, (F) 2u with CT
DNA, (G) 2v in 1 x PBS, and (H) 2v with CT DNA.
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Figure S2.1.7: Photoejection kinetics of 2w and 2x in 1 x PBS and in the presence of CT
DNA. Insets show the change in absorbance versus time. (A) 2w in 1 x PBS, (B) 2w with
CT DNA, (C) 2x in 1 x PBS, and (D) 2x with CT DNA.
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Figure S2.1.8: Photoejection kinetics of 2s – 2x in acetonitrile. Insets show the change in
absorbance versus time. (A) 2s, (B) 2t, (C) 2u, (D) 2v, (E) 2w, and (F) 2x.
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Figure S2.1.9: BL21 dose response curves in the dark (A) and following irradiation (B).
Cisplatin (black, ), 2s (blue, ), 2t (red, ), 2u (green, ), 2v (orange, ), 2w
(purple, ), and 2x (pink,).

A

B

C

D

Figure S2.1.10: Thermal exchange of 2y followed by UV/Vis absorption spectroscopy in
different aqueous solutions. (A) water, (B) 1 x PBS, (C) opti-mem with 1% FBS, and (D)
50 mM NaCl, 5 mM Tris at pH 7.0; where the blue line is t = 0 min and the red line is t =
15 hr. Inset shows the change in absorbance as a function of time fit to a one phase decay
equation with Prism software.
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Figure S2.1.11: Thermal exchange of 2x followed by UV/Vis absorption spectroscopy in
different aqueous solutions. (A) water, (B) 1 x PBS, (C) opti-mem with 1% FBS, and (D)
50 mM NaCl, 5 mM Tris at pH 7.0; where the blue line is t = 0 min and the red line is t =
15 hr.
A

B

C

D

Figure S2.1.12: Thermal exchange of 2z followed by UV/Vis absorption spectroscopy in
different aqueous solutions. (A) water, (B) 1 x PBS, (C) opti-mem with 1% FBS, and (D)
50 mM NaCl, 5 mM Tris at pH 7.0; where the blue line is t = 0 min and the red line is t =
15 hr.
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D

Figure S2.1.13: Thermal exchange of 2aa followed by UV/Vis absorption spectroscopy
in different aqueous solutions. (A) water, (B) 1 x PBS, (C) opti-mem with 1% FBS, and
(D) 50 mM NaCl, 5 mM Tris at pH 7.0; where the blue line is t = 0 min and the red line is
t = 15 hr.
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Table S2.1.1: Half-lives of thermal exchange and DNA binding for 2y.
t1/2 (min)

Δabs @ 500nm

53 ± 3

0.085 ± 0.008

1 x phosphate buffer saline (PBS)

33.4 ± 0.2

0.083 ± 0.005

opti-mem with 1% FBS

12.8 ± 0.3

0.05 ± 0.02

50 mM NaCl, 5 mM Tris, pH 7.0

48 ± 1

0.13 ± 0.02

bovine serum albumin (BSA)

30 ± 4

0.08 ± 0.02

adenosine (dA)

49 ± 3

0.177 ± 0.002

thymidine (dT)

47 ± 1.3

0.12 ± 0.01

guanosine (dG)

51 ± 5

0.12 ± 0.02

cytidine (dC)

50 ± 3

0.141 ± 0.005

calf thymus (CT) DNA

44 ± 2

0.10 ± 0.04

25 ± 3 (62%)

0.11 ± 0.02

Condition
water

poly A poly Ta

228 ± 6
poly G poly Ca

14.9 ± 0.5 (72%) 0.084 ± 0.008
750 ± 80

poly ATa

24.8 ± 0.8 (63%) 0.126 ± 0.004
270 ± 14

poly GCa

17 ± 3 (98%)

0.09 ± 0.01

>900
β-mercaptoethanol (BME)

39.9 ± 0.3

0.11 ± 0.04

53 ± 3

0.14 ± 0.01

23.3 ± 0.6

0.115 ± 0.002

phenol

52 ± 3

0.148 ± 0.009

cysteamine

60 ± 15

0.16 ± 0.02

acetic acid

72 ± 10

0.19 ± 0.04

acetonitrile

53 ± 4

0.14 ± 0.01

ethanol (EtOH)
imidazole

a

Oligonucleotides were fit to a two phase decay. The percent of the fast phase is reported

in parentheses.
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Table S2.1.2: Δabs of thermal exchange and DNA binding for 2x.
Condition

Δabs @ 450 nm

water

0.0025 ± 0.0005

1 x phosphate buffer saline (PBS)

0.015 ± 0.001

opti-mem with 1% FBS

0.021 ± 0.009

50 mm NaCl, 5 mm Tris, pH 7.0

0.013 ± 0.008

bovine serum albumin (BSA)

0.012 ± 0.005

adenosine (dA)

0.028 ± 0.009

thymidine (dT)

0.035 ± 0.003

guanosine (dG)

0.03 ± 0.01

cytidine (dC)

0.034 ± 0.007

calf thymus (CT) DNA

0.02 ± 0.01

poly A poly T

0.001 ± 0.0005

poly G poly C

0.035 ± 0.003

poly AT

0.001 ± 0.0005

poly GC

0.001 ± 0.0003

β-mercaptoethanol (BME)

0.041 ± 0.004

ethanol (EtOH)

0.035 ± 0.003

imidazole

0.038 ± 0.003

phenol

0.015 ± 0.005

cysteamine

0.039 ± 0.007

acetic acid

0.02 ± 0.01

acetonitrile

0.041 ± 0.006
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Table S2.1.3: Δabs of thermal exchange and DNA binding for 2z.
Δabs @ 345 nm

Condition
water

0.19 ± 0.02

1 x phosphate buffer saline (PBS)

0.13 ± 0.02

opti-mem with 1% FBS

0.011 ± 0.003

50 mM NaCl, 5 mM Tris, pH 7.0

0.089 ± 0.005

bovine serum albumin (BSA)

0.16 ± 0.08

adenosine (dA)

0.11 ± 0.01

thymidine (dT)

0.08 ± 0.01

guanosine (dG)

0.093 ± 0.003

cytidine (dC)

0.11 ± 0.01

calf thymus (CT) DNA

0.08 ± 0.01

poly A poly T

0.12 ± 0.01

poly G poly C

0.15 ± 0.01

poly AT

0.10 ± 0.01

poly GC

0.122 ± 0.004

β-mercaptoethanol (BME)

0.019 ± 0.003

ethanol (EtOH)

0.11 ± 0.01

imidazole

0.15 ± 0.01

phenol

0.10 ± 0.02

cysteamine

0.05 ± 0.02

acetic acid

0.12 ± 0.03

acetonitrile

0.061 ± 0.002
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Table S2.1.4: Δabs of thermal exchange and DNA binding for 2aa.
Δabs @ 325 nm

Condition
water

0.07 ± 0.03

1 x phosphate buffer saline (PBS)

0.06 ± 0.01

opti-mem with 1% FBS

0.05 ± 0.02

50 mm NaCl, 5 mm Tris, pH 7.0

0.06 ± 0.01

bovine serum albumin (BSA)

0.019 ± 0.007

adenosine (dA)

0.057 ± 0.004

thymidine (dT)

0.053 ± 0.006

guanosine (dG)

0.04 ± 0.01

cytidine (dC)

0.08 ± 0.01

calf thymus (CT) DNA

0.02 ± 0.005

poly A poly T

0.033 ± 0.005

poly G poly C

0.056 ± 0.007

poly AT

0.025 ± 0.009

poly GC

0.015 ± 0.007

β-mercaptoethanol (BME)

0.08 ± 0.01

ethanol (EtOH)

0.061 ± 0.001

imidazole

0.080 ± 0.004

phenol

0.029 ± 0.007

cysteamine

0.08 ± 0.01

acetic acid

0.050 ± 0.005

acetonitrile

0.08 ± 0.01

245

A2.2 Chapter 4 Additional Figures and Tables.
Table S2.2.1: Full data table for the photophysics of 4a and photochemistry of 4b in
pure solvents.
Counter-ion

λem (nm),
4a[a]

Area,
4a[a]

t1/2 (min),
4b

Dichloromethane

Cl-

596

7.08 x 107

0.5 ± 0.05

Acetonitrile

PF6-

618

2.63 x 107

1.6 ± 0.1

Butyronitrile

PF6-

614

5.59 x 107

6.4 ± 0.2

Benzonitrile

PF6-

603

2.52 x 107

10.9 ± 0.6

Dimethylformamide

Cl-

638

1.20 x 107

25 ± 2

Dimethyl sulfoxide

Cl-

629

5.70 x 106

80 ± 10

Methanol

Cl-

614

3.22 x 106

5.8 ± 0.1

Ethanol

Cl-

611

2.71 x 107

1.23 ± 0.01

1-propanol

Cl-

608

3.39 x 107

1.02 ± 0.06

1-butanol

Cl-

613

3.15 x 107

0.96 ± 0.03

1-hexanol

Cl-

622

3.05 x 107

1.93 ± 0.03

1-octanol

Cl-

624

2.78 x 107

2.11 ± 0.06

1-decanol

Cl-

625

2.42 x 107

3.9 ± 0.2

iso-butanol

Cl-

610

9.16 x 106

2.1 ± 0.1

sec-butanol

Cl-

614

1.19 x 107

2.3 ± 0.1

tert-butanol

Cl-

624

7.95 x 106

2.3 ± 0.1

Ethylene glycol

Cl-

630

3.88 x 105

110 ± 20

Glycerol

Cl-

No emission

No emission

DNE[b]

Water

Cl-

No emission

No emission

>480[c]

[a] Uncorrected values. [b] Did not eject (DNE). [c] t1/2 of water was estimated because
photodecomposition was incomplete after 12 hours of irradiation.
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Table S2.2.2: Luminescence area and λmax of 4c.
Ratio to

Ratio to

buffer[b]

duplex[c]

81 ± 10

1.0

0.2

623

86 ± 10

1.1

0.2

dA

618

65 ± 6

0.8

0.1

dG

618

68 ± 7

0.8

0.1

dT

619

63 ± 2

0.8

0.1

dC

622

73 ± 8

0.9

0.2

CT DNA

624

470 ± 10

5.8

1.0

poly G poly C

621

850 ± 40

10.5

1.8

poly GC

617

990 ± 10

12.3

2.1

poly GC Z form

621

740 ± 20

9.1

1.6

poly A poly T

630

670 ± 30

8.3

1.4

poly AT

631

400 ± 50

4.9

0.9

TGGT

621

420 ± 7

5.2

0.9

cruciform

625

470 ± 20

5.9

1.0

hairpin match

624

450 ± 10

5.6

1.0

hairpin mismatch

620

460 ± 30

5.7

1.0

triplex

620

2400 ± 100

30.2

5.2

Na+ G-quad

628

620 ± 10

7.6

1.3

inter G-quad

614

6600 ± 100

81.6

14.1

i-motif

611

3000 ± 200

37.5

6.5

c-myc G-quad

618

2440 ± 50

30.1

5.2

K+ G-quad

626

1990 ± 70

24.5

4.2

AB1-M

619

480 ± 30

6.0

1.0

AB1-MM

628

680 ± 21

8.4

1.5

AB1-X (A)

622

470 ± 10

5.9

1.0

λmax (nm)

Area

Buffer

618

BSA

Condition[a]
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Table S2.2.2 cont: Luminescence area and λmax of 4c.
AB1-X (C)
622
550 ± 20
6.8

1.2

AB1-X (T)

622

440 ± 40

5.4

0.9

B1-X (A)

625

620 ± 10

7.7

1.3

B1-X (C)

620

790 ± 20

9.8

1.7

B1-X (G)

600

540 ± 10

6.7

1.2

B1-X (T)

623

490 ± 50

6.0

1.0

[a] For full experimental details see Chapter 6. [b] The luminescence area with the
biomolecule compared to buffer alone. [c] The luminescence area with the biomolecule
compared to CT DNA.
Table S2.2.3: Comparison of t1/2 values of 4d.
Ratio to

Ratio to

buffer[c]

duplex[d]

330 ± 80

1.0

0.3

Condition[a]

t1/2 (min)

Buffer[b]
[b]

BSA

-

-

0.2

[b]

dA

600 ± 100

0.5

0.1

dG[b]

300 ± 100

1.1

0.3

dT[b]

170 ± 20

1.9

0.5

dC[b]

200 ± 50

1.7

0.4

CT DNA

90 ± 7

3.7

1.0

poly G poly C

100 ± 8

3.2

0.9

poly GC

127 ± 7

2.6

0.7

poly GC Z form

110 ± 10

2.9

0.8

poly A poly T

110 ± 20

3.0

0.8

poly AT

220 ± 20

1.5

0.4

TGGT

65 ± 5

5.0

1.4

cruciform

74 ± 2

4.4

1.2
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hairpin
Table S2.2.3
match cont: Comparison
110 ± 10 of t1/2 3.1
values of 4d.
0.8

hairpin mismatch

96 ± 7

3.4

0.9

triplex

260 ± 30

1.2

0.3

Na+ G-quad

215 ± 3

1.5

0.4

inter G-quad

74 ± 8

4.4

1.2

i-motif

158 ± 4

2.1

0.6

c-myc G-quad

60 ± 4

5.4

1.5

K G-quad

27 ± 2

11.8

3.2

AB1-M

79 ± 8

4.1

1.1

AB1-MM

87 ± 13

3.7

1.0

AB1-X (A)

250 ± 30

1.3

0.3

AB1-X (C)

240 ± 30

1.4

0.4

AB1-X (G)

170 ± 30

1.9

0.5

AB1-X (T)

120 ± 15

2.6

0.7

B1-X (A)

120 ± 16

2.6

0.7

B1-X (C)

110 ± 20

3.0

0.8

B1-X (G)

95 ± 10

3.4

0.9

B1-X (T)

82 ± 5

4.0

1.1

+

[a] For full experimental details see Chapter 6. [b] Photodecomposition was extremely
slow and incomplete after 8 hours of light exposure, therefore the t1/2 values are not for a
complete reaction. [c] The t1/2 with the biomolecule compared to buffer alone. [d] The
t1/2 with the biomolecule compared to CT DNA.
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Table S2.2.4: Luminescence area and λmax of 4a with G-quadruplex DNA.
Condition[a]
Buffer
inter
c-myc
Na+[e]
K+[e]

λmax (nm)

Area

- [d]

99 ± 4
5900 ± 100
3210 ± 50
1250 ± 70
4100 ± 200

608
610
617
614

Ratio to
buffer[b]
1.0
59.6
32.4
12.6
41.4

Ratio to
duplex[c]
0.1
4.4
2.4
1.0
3.1

[a] For full experimental details see Chapter 6. [b] The luminescence ratio with the
specified biomolecule compared to buffer. [c] The luminescence area with the specified
biomolecule compared to CT DNA. [d] No emission peak was observed. [e] Human
telomeric sequence folded in the presence of the indicated cation.

Table S2.2.5: Comparison of t1/2 values of 4b with G-quadruplex DNA.
Condition[a]

t1/2 (min)

Buffer
inter
c-myc
Na+[e]
K+[e]

210 ± 5[d]
36 ± 5
34 ± 4
70 ± 6
33 ± 4

Ratio to
buffer [b]
1.0
5.8
6.1
3.0
6.4

Ratio to
duplex[c]
0.2
1.2
1.3
0.6
1.4

[a] For full experimental details see Chapter 6. [b] The t1/2 ratio with the specified
biomolecule compared to buffer. [c] The t1/2 with the specified biomolecule compared to
CT DNA. [d] Photodecomposition was extremely slow and incomplete after 8 hours of
light exposure; therefore the t1/2 values are not for a complete reaction. [e] Human
telomeric sequence folded in the presence of the indicated cation.
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Table S2.2.6: Melting temperatures (°C) determined by circular dichroism.

Mixed-Hybrid
Condition
DNA only

Tm (°C)

Intermolecular
G-quadruplex
Tm (°C)

64.7 ± 0.5

61.5 ± 0.3

4c

70 ± 3

74 ± 1

4d, dark

69 ± 1

79.4 ± 0.8

65.1 ± 0.6

75.5 ± 0.9

74 ± 1

73.1 ± 0.6

4b, dark

73.0 ± 0.9

74.8 ± 0.5

4b, hν

66.0 ± 0.5

71.7 ± 0.7

4d, hν
4a
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A

B

C

D

E

F

Figure S2.2.1: HPLC chromatograms of 4d reacted in the presence of the telomeric
mixed-hybrid G-quadruplex. Black(−): DNA only, blue (– –): 4d reacted with the mixedhybrid G-quadruplex in the dark, red (--): 4d irradiated in the presence of the mixedhybrid G-quadruplex, and green (– –): 2,2’-bipyridine (bpy). (A) Full HPLC
chromatograms (7.5 min = bpy, 9–10 min = DNA, 20 min = unreacted 4d, 39 min =
DNA with the same absorption profiles as the 10 min region). (B) DNA region of the
HPLC chromatograms showing decreased signal and shifted retention time for both dark
and irradiated samples. The association of 4d causes this through either non-covalent
(dark) or covalent (light) interaction with the DNA. (C) Full and (D) zoomed UV/Vis
absorption traces of DNA peaks showing the covalent attachment of Ru(II) when
irradiated with light. (E) Ru(II) region of the HPLC chromatograms showing a decrease
in 4d following irradiation. (F) UV/Vis absorption profile for 4d. The dmdppz-Br ligand
is not visible in the light activated sample, either due to insolubility or it is retained with
the DNA. The absence of the 2,2’-bipyridine in the light activated samples is evidence for
the selective ejection of the dmdppz-Br ligand.
252

A

B

C
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Figure S2.2.2: HPLC chromatograms of 4d reacted in the presence of the intermolecular
G-quadruplex. Black(−): DNA only, blue (– –): 4d reacted with the intermolecular Gquadruplex in the dark, red (--): 4d irradiated in the presence of the intermolecular Gquadruplex, and green (– –): 2,2’-bipyridine. (A) Full HPLC chromatograms (7.5 min =
bpy, 9–10 min = DNA, 21 min = unreacted 4d). (B) DNA region of the HPLC
chromatograms showing decreased signal and shifted retention time for both dark and
irradiated samples. The association of 4d causes this through either non-covalent (dark)
or covalent (light) interaction with the DNA. (C) UV/Vis absorption traces of DNA peaks
showing no covalent attachment of Ru(II) when reacted in the dark. (D) UV/Vis
absorption traces of DNA peaks showing covalent attachment of Ru(II) when irradiated
with light (red (– –)), unreacted photoejected 4d (red (−)), and unreacted DNA (red (--)).
The absorption profile of 4d (green) is overlaid to show that the photoproduct with DNA
is not the parent complex. (E) Ru(II) region of the HPLC chromatograms and (F) UV/Vis
absorption profile for 4d. The dmdppz-Br ligand is not visible in the light activated
sample, either due to insolubility or it is retained with the DNA. The absence of the 2,2’bipyridine in the light activated samples is evidence for the selective ejection of the
dmdppz-Br ligand.
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A

B

C

D

Figure S2.2.3. Luminescence area (left), fold change as compared to buffer (middle), and
fold change as compared to CT DNA (right) of the 11-substituted complexes. (A) 4a, (B)
4e, (C) 4f, (D) 4c . The conditions, from left to right, are buffer, BSA, and nucleosides
(black); single strand DNA (blue); duplex DNA (red); damaged duplex DNA (green);
triplex DNA (purple); i-motif and G-quadruplex DNA (orange). Note: biomolecules are
ordered as they appear in Table 6.4.
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A

B

C

Figure S2.2.4. Luminescence area (left), fold change as compared to buffer (middle), and
fold change as compared to CT DNA (right) of the 10-substituted complexes. (A) 4g, (B)
4h, (C) 4i. The conditions, from left to right, are buffer, BSA, and nucleosides (black);
single strand DNA (blue); duplex DNA (red); damaged duplex DNA (green); triplex
DNA (purple); i-motif and G-quadruplex DNA (orange). Note: biomolecules are ordered
as they appear in Table 6.4.
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A

B

C

Figure S2.2.5. Luminescence area (left), fold change as compared to buffer (middle), and
fold change as compared to CT DNA (right) of the 11, 12-substituted complexes. (A) 4j,
(B) 4k, (C) 4i. The conditions, from left to right, are buffer, BSA, nucleosides (black);
single strand DNA (blue); duplex DNA (red); damaged duplex DNA (green); triplex
DNA (purple); i-motif and G-quadruplex DNA (orange). Note: biomolecules are ordered
as they appear in Table 6.4.
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Table S2.2.7. Slopes and linear correlation coefficients for Figure 4.31.
Slope

R2

4a

1.09 ± 0.14 0.95

4c

0.67 ± 0.11 0.92

4d

0.86 ± 0.16 0.92

4b

1.13 ± 0.24 0.89

4e

0.39 ± 0.08 0.90

4f

0.75 ± 0.12 0.93

4g

0.84 ± 0.20 0.86

4h

0.76 ± 0.13 0.92

4i

1.05 ± 0.24 0.87

4j

0.36 ± 0.11 0.77

Table S2.2.8. Linear correlation coefficients and slopes for Figure 4.34.
2

Slope

R

4a

0.37 ± 0.28

0.98

4c

0.09 ± 0.03

0.80

4d

0.15 ± 0.06

0.65

4b

0.20 ± 0.06

0.81

4e

0.21 ± 0.03

0.95

4f

0.47 ± 0.05

0.97

4g

0.68 ± 0.08

0.96

4h

0.08 ± 0.06

0.40

4i

0.24 ± 0.08

0.75

4j

0.07 ± 0.01

0.92
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Figure S2.2.6. Linear correlation of the 10-substituted series slopes with the substituent
atomic radius. Slope = luminescence area as a function of the number of guanosines. R2 =
0.94.

258

VITA
Erin Melissa Wachter

Personal Information
Place of Birth: Lexington, KY U.S.A.

Education
Saint Vincent College
Latrobe, PA U.S.A.
Bachelors of Science in Chemistry (2010)

University of Kentucky
Lexington, KY U.S.A.
Doctoral Studies (2010–2016)
Advisor: Dr. Edith C. Glazer

Awards and Scholarships
Nietzel Visiting Distinguished Faculty Program Award – Spring 2016
ACS Division of Inorganic Chemistry Travel Award for National Meeting – Spring 2016
Outstanding Graduate Student Research Award – Spring 2015
Research Challenge Trust Fund Fellowship – 2012–2013 and 2014–2015
Additional Fellowship funded by the Research Challenge Trust Fund – 2011–present
Nominated nationally for P.E.O. Scholar Award – October 2014
Naff Symposium poster competition – 1st place – May 2012
Nominated for A&S Outstanding Teaching Award – Spring 2012
Kentucky Excellence Fellowship – 2010–2011 academic year

Publications
Submitted or in preparation

259

E. Wachter, D. Moyá,, E. C. Glazer, Combining a Ru(II) “Building Block” and Rapid
Screening Approach to Identify DNA Structure-Selective “Light Switch” Compounds.
Manuscript in revision.

E. Wachter, A. Zamora, D. K. Heidary, J. Ruiz, E. C. Glazer, Geometry Matters: Inverse
Cytotoxic Relationship for cis/trans-Ru(II) Polypyridyl Complexes from cis/trans[PtCl2(NH3)2]. Manuscript in revision.
A. Zamora, C. A. Denning, E. Wachter, D. K. Heidary, J. Ruiz, E. C. Glazer,
Ruthenium-Caged P450 Inhibitors for Dual Antitumor Activity. Manuscript in
preparation.

A. Zamora, S. A. Pérez, E. Wachter, G. Barone, M. Vera, D. K. Heidary, V. Rodríguez,
V. Fernandez-Espín, C. Janiak, E. C. Glazer, J. Ruiz, Selective “Light-Switch” of
Organoplatinum(II) Complexes to AT Rich B-DNA Sequences. Manuscript in
preparation.

E. Wachter, B. S. Howerton, Y. Sun, D. K. Heidary, S. Parkin, E. C. Glazer, StructureActivity Relationship of Ruthenium(II) Polypyridyl Complexes as Potential Phototherapy
Agents. Manuscript in preparation.

Published – Undergraduate collaborators are underlined
E. Wachter, D. Moyá, S. Parkin, E. C. Glazer, Ruthenium Complex “Light Switches”
that are Selective for Different G-quadruplex Structures. Chemistry – A European
Journal, 2016, 22, 550-559. Inside Back Cover

A. Hidayatullah, E. Wachter, D. K. Heidary, S. Parkin, E. C. Glazer, Photoactive Ru(II)
Complexes With Dioxinophenanthroline Ligands Are Potent Cytotoxic Agents.
Inorganic Chemistry, 2014, 53, 10030-10032.

260

E. Wachter, E. C. Glazer, Mechanistic Study on the Photochemical “Light Switch”
Behavior of [Ru(bpy)2dmdppz]2+. Journal of Physical Chemistry A, 2014, 118, 1047410486.

E. Wachter, B. S. Howerton, E. C. Hall, S. Parkin, E. C. Glazer, A New Type of DNA
“Light Switch”: A Dual Photochemical Sensor and Metalating Agent for Duplex and Gquadruplex DNA. Chemical Communications, 2014, 50, 311-313.

E. Wachter, D. K. Heidary, B. S. Howerton, S. Parkin, E. C. Glazer, Light-Activated
Ruthenium Complexes Photobind DNA and Are Cytotoxic in the Photodynamic Therapy
Window. Chemical Communications, 2012, 48, 9649-9651.

Presentations
E. Wachter, Ana. Zamora, Y. Sun, D. K. Heidary, E. C. Glazer, Structural Features that
Influence Photochemical Reactivity and Phototherapeutic Activity of Ru(II) Polypyridyl
Complexes, Oral presentation at: 250th American Chemical Society National Meeting:
March 13-18; San Diego, Ca.

E. Wachter, D. Moyá, E. C. Glazer, Using a Ru(II) Building Block and a Rapid
Screening Approach to Identify Nucleic Acid Selective “Light Switch” Compounds, Oral
presentation at: 250th American Chemical Society National Meeting: March 13-18; San
Diego, Ca.

E. Wachter, D. Moyá, S. Parkin, E. C. Glazer, Developing Sequence and Structure
Selective Ru(II) “Light Switches” for Nucleic Acids, Poster presented at: 2015 Gordon
Research Conference : Nucleosides, Nucleotides and Oligonucleotides; 2015 June 28–
July 3; Newport, RI.

E. Wachter, A. Effinger, Y. Sun, D. K. Heidary, E. C. Glazer, Functionalizing
Photoreactive Ru(II) Polypyridyl Complexes to Target Cancer Cells, Poster presented at:
2015 Pharmaceutics Graduate Student Research Meeting (PGSRM); Lexington, KY.
261

E. Wachter, D. Moyá, S. Parkin, E. C. Glazer, Developing “Light Switches” for Nucleic
Acids, Oral presentation at: 2015 Ohio Photochemical Society Conference (OoPS);
Oregon, OH.

E. Wachter, A. Effinger, S. Parkin, E. C. Glazer, Increasing Synthetic Diversity of
Ru(II) Polypyridyl Complexes for Phototherapy, Poster session presented at: 249th
American Chemical Society National Meeting; 2015 March 22–26; Denver, CO.

E. Wachter, D. Moyá, E. C. Glazer, A High-Throughput Screening Approach to Identify
Selective Ru(II) Agents for Therapeutically Relevant DNA Sequences, Poster session
presented at 2015 Naff Symposium; Lexington, KY.

E. Wachter, S. Parkin, E. C. Glazer, Determining the Photosubstitution Mechanism of
Ru(bpy)2dmdppz: A Photochemical “Light-Switch” and DNA Metalating Agent, Poster
session presented at: 2014 Naff Symposium; Lexington, KY.

E. Wachter, S. Parkin, E. C. Glazer, Determining the Photosubstitution Mechanism of
Ru(bpy)2dmdppz: A Photochemical “Light-Switch” and DNA Metalating Agent, Poster
session presented at: 2014 Ohio Photochemical Society Conference (OoPS); Oregon, OH.

E. Wachter, B. Howerton, S. Beavin, A. Hidyatullah, J. Archer, S. Parkin, E. Glazer,
Photochemical Studies of a Strained Ruthenium(II) Polypyridyl Complex, Poster session
presented at: 2013 Naff Symposium; Lexington, KY.

E. Wachter, B. Howerton, D. Heidary, S. Parkin, E. Glazer, Ruthenium Complexes for
Photodynamic Therapy That Absorb Red Light. Poster session presented at: 2012 Naff
Symposium; Lexington, KY.

262

E. Wachter, B. Howerton, D. Heidary, S. Parkin, E. Glazer, Ruthenium Complexes for
Photodynamic Therapy That Absorb Red Light. Poster session presented at: 243rd
American Chemical Society National Meeting; 2012 March 25–29; San Diego, CA.

263

